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The human pregnancy is a unique immunological process. The foetus is 
tolerated and nourished through the complex yet transient organ, 
placenta, which bears the genetic fingerprint of the developing baby. The 
process of placentation is different in humans and large primates in 
comparison to other mammals. Human placentation involves several 
waves of invasion, whereby the placenta is deeply attached to layers of 
the uterine wall, through the mucosal lining of the uterus, the decidua and 
into the underlying muscle, the myometrium. In order for adequate but 
not inappropriate depth of placentation to occur, the maternal immune 
system must be fine-tuned to tolerate yet control the invasive trophoblast 
cells, which originate in the placenta.  
 
When placentation is successful, the endothelial cells lining the uterine 
arteries that feed the placenta will be replaced by the endovascular 
trophoblast cells. Maternal circulation to the placenta is activated at the 
end of the first trimester. Thereafter the remodelled spiral arteries 
supply a high-flow, low-resistance placental circulation.  
 
Pre-eclampsia is a common vascular disease of the human pregnancy. 
Pre-eclampsia, particularly in its severe form, is intrinsically linked to 
failure of deep-placentation. While pre-eclampsia has long been known 
to have a familial, i.e. genetic component, the genes contributing to the 
disease have not been well characterised thus far.  
 
This thesis addresses the question of effects of complement system in 
pre-eclampsia by comparing pre-eclamptic women to non-pre-eclamptic 
controls using several methods. Using immunofluorescence and 
immunohistochemistry, placental tissues were stained for one 
angiogenic receptor and nine components of the complement system to 
determine the localisation and extent of complement activation, and on 
the other hand, complement regulation in placentae from pre-eclamptic 
and healthy pregnancies. In two candidate gene studies, the variants 
within coding regions and flanking sequences surrounding exons of a key 
complement regulator, membrane cofactor-protein (CD46) gene 
(MCP/CD46) and activator, complement component 3 gene (C3) were 
explored in women with a history of severe pre-eclampsia and non-pre-
eclamptic controls. The candidate gene studies were done by Sanger 
sequencing alone (MCP), and a combination of Sanger sequencing and 
sequenom genotyping (C3). Finally, using a targeted exomic sequencing 
approach we studied known candidate genes in pre-eclampsia to identify 
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low-frequency variants in the Finnish population that may predispose to 
or protect from pre-eclampsia. We combined pre-eclamptic patients from 
the FINNPEC (Finnish genetics of pre-eclampsia consortium) and the 
national FINRISK studies to characterise health consequences of the most 
important variants that associate to pre-eclampsia. 
 
While we did not find a genetic association to pre-eclampsia in the 
membrane bound complement regulator, MCP, we found three out of 
forty-three observed single nucleotide polymorphisms to be associated 
with pre-eclampsia in the C3. Furthermore, a section of tight linkage 
disequilibrium was identified within the C3 that depending on the 
sequence context, may predispose to, or protect from pre-eclampsia. We 
have also provided a description of localisation and presence of the key 
complement factors in placentae from healthy and pre-eclamptic 
placentae. Most recently, the first maternal genetic association of the fms 
related tyrosine kinase 1 gene (FLT1) coding for an anti-angiogenetic 
marker soluble fms-like tyrosine kinase 1 elevated in pre-eclampsia was 
discovered. Two SNPs within the FLT1 protect women from not only pre-
eclampsia, but also from heart failure in later life.  
 
The work presented in this thesis sheds light to some of the many 
inherited traits that contribute to the aetiology of pre-eclampsia. The 
results present a first genetic association to pre-eclampsia in C3 and they 
may provide a maternal genetic link between angiogenesis process 
during pregnancy and heart failure in later life. The crucial effect of the 
complement system for the successful pregnancy is demonstrated by 
genetic association as well as comparative localisation of complement 










Raskausaika on ainutlaatuinen immunologinen tapahtuma ihmisen 
elinkierrossa. Sikiötä ravitsee monimutkainen mutta väliaikainen elin, 
istukka, joka edustaa perimältään sikiön geneettistä sormenjälkeä. 
Istukan tehtävä on myös ylläpitää toleranssia äidin 
immuunipuolustuksessa lapsen kudosten suojelemiseksi. Istukan 
muodostuminen eli plasentaatio eroaa ihmisten ja muiden suurten 
kädellisten sekä muiden nisäkkäiden välillä. Ihmisen plasentaatiossa 
toistuvat istukkasolujen invaasioprosessit varmistavat, että elin 
kiinnittyy äidin kohdunseinämään limakalvokerrosten alle aina 
kohdunalaiseen lihaskudokseen asti. Jotta istukan kiinnittyminen ulottuu 
oikealle tasolle, riittävän syvälle, mutta ei liian syvälle, äidin 
immuunipuolustuksen pitää olla virittynyt siten, että istukan invasoivia 
trofoblastisoluja siedetään ja kontrolloidaan samanaikaisesti.  
 
Istukkaa ruokkivat kohdun kierteiset spiraalivaltimot. Plasentaation 
onnistuessa kohdun valtimoiden sisäseiniä päällystävät endoteelisolut 
korvaantuvat endovaskulaarisilla trofoblastisoluilla. Äidin verenkierto 
alkaa ruokkia kasvavaa istukkaa ensimmäisen raskauskolmanneksen 
lopulla, jolloin muovaantuneet spiraalivaltimot takaavat runsaan mutta 
matalapaineisen verenkierron istukkaan.  
 
Pre-eklampsia on yleinen monitekijäinen raskaudenaikainen 
verisuonisairaus. Etenkin vaikea pre-eklampsia liittyy keskeisesti 
syväplasentaation ilmiöön. Pre-eklampsian tiedetään esiintyvän 
suvuittain, joten perintötekijöillä on tärkeä osa taudin puhkeamisessa, 
mutta suurinta osaa pre-eklampsialle altistavista geeneistä ei vielä 
tunneta.  
 
Väitöskirjassani käsittelen useaa menetelmää hyödyntäen luontaisen 
immunipuolustuksen komplementtijärjestelmän merkitystä pre-
eklampsiataudissa vertailemalla pre-eklamptikkoäitejä ja äitejä, joilla ei 
ole ollut pre-eklampsiadiagnosia. Istukkakudosleikkeitä värjättiin 
immunofluoresenssi ja immunohistokemiallisin menetelmin yhtä 
angiogeneettistä reseptoria ja yhdeksää komplementtitekijää 
tunnistavilla vasta-aineilla. Tutkimuksen tarkoituksena oli määritellä 
komplementtiaktivaation sijainti ja laajuus istukkakudoksessa ja 
toisaalta kuvata komplementilta suojaavien tekijöiden ilmeneminen pre-
eklampsiaistukassa ja terveessä istukassa. Kahdessa 
kandidaattigeenitutkimuksessa kuvattiin koodaavien alueiden ja niitä 
ympäröivien geenialueiden perimänvaihtelua keskeisessä komplementin 
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säätelijässä MCP/CD46 ja toisaalta aktivaattorissa C3. 
Kandidaattigeenitutkimuksissa vertailtiin vaikeaan pre-eklampsiaan 
sairastuneiden äitien perimänvaihtelua sellaisten äitien geeneihin, joilla 
pre-eklampsiadiagnosia ei ole. Kandidaattigeenitutkimukset suoritettiin 
Sanger-sekvensointimenetelmällä MCP-geenitutkimuksessa ja Sanger-
sekvensointia ja Sekvenomgenotyyppausta yhdistämällä C3-
geenitutkimuksessa. Hyödyntämällä kohdennettua 
eksomisekvensointimenetelmää tutkimme myös muita tunnettuja 
kandidaattigeenejä pre-eklampsiataudissa tunnistaaksemme harvinaisia 
perimänvaihtelun muotoja suomalaisessa väestössä, jotka liittyvät pre-
eklampsiatautiin. Yhdistimme FINNPEC (Finnish genetics of pre-
eclampsia consortium) aineistoon ja FINRISKI-tutkimukseen kirjattujen 
potilaiden tietoja kuvataksemme pre-eklampsiaan liittyvien 
perimänvaihteluiden yhteyttä sairastavuuteen taudin jälkeen.  
 
MCP-geenistä ei löydetty pre-eklampsiaan liittyviä perimänvaihtelun 
muotoja, mutta C3-geenissä kuvatusta neljästäkymmenestä kolmesta 
pistemutaatiosta kolmen todettiin liittyvän pre-eklampsiaan. Lisäksi C3-
geenin keskivaiheilla kuvattiin sekvenssialue, jossa on vahva 
kytkentäepätasapaino. Riippuen alueen emäsjärjestyksestä, sen todettiin 
joko altistavan tai suojaavan pre-eklampsiataudilta. Viimeisimpänä 
kuvattiin ensimmäistä kertaa äidin perinnöllinen suojaava tekijä FLT1-
geenistä, joka koodaa verisuonien muodostukseen liittyvää tekijää sFlt-1, 
jonka lisääntyneen määrän verenkierrossa tiedetään liittyvän pre-
eklampsiariskiin. Kahden pistemutaation FLT1-geenissä todettiin 
suojaavan paitsi pre-eklampsialta, myös sydämen vajaatoiminnalta.  
 
Väitöskirjassani esittelemä tutkimus lisää ymmärrystä monista 
perintötekijöistä, jotka liittyvät pre-eklampsiataudin kehittymiseen. 
Tuloksissa kuvataan ensimmäistä kertaa perinnöllinen yhteys pre-
eklampsiataudin ja C3 geenin välillä. Toisaalta äidin 
verisuontenmuodostusta säätelevän tekijän osalta osoitetaan 
perinnöllinen yhteys raskaudenaikaisen terveyden ja vähentyneen 
sydämen vajaatoimintaan sairastuvuuden välillä. 
Komplementtijärjestelmän keskeinen merkitys terveessä raskaudessa 
käy ilmi sekä perintötekijöiden kautta että kudosvärjäystutkimuksen 
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The integrity of human organism, as any living being, is maintained and 
ensured by a functional immune system. The purpose of immune system 
is to discriminate between self- and non-self structures, to provide 
defensive mechanisms against pathogens, and to maintain health of the 
organism by clean up of debris and unwanted articles. The human 
immune system may be divided into innate and adaptive arms. Innate 
immune system is the evolutionarily ancient first line of defence, which 
recognises unwanted structures and initiates immune response. 
Adaptive immune system develops throughout the course of the 
individual’s life to provide specific defence against a variety of pathogens.  
 
The second classification that is widely used to describe the immune 
system is the division between humoral and cellular immunity. The 
innate and adaptive immune systems have components from both 
categories. Humoral immunity is comprised of activating or inhibiting 
proteins that circulate in the plasma and serum or are formed in tissues 
to activate the immune system. Cellular immunity refers to cell-mediated 
immunity, such as recognition of antigenic peptides, and activation of 
cells in the adaptive immune system by antigen presenting cells.  
 
Pregnancy presents an exceptional challenge to the immune system. The 
developing foetus and placenta are genetic allografts that may be 
recognised as foreign by the maternal immune system. For this reason, 
numerous immunosuppressive processes take place in the maternal 
immune system during pregnancy to protect the developing foetus. 
Breakdown of any of these protective mechanisms may result in adverse 
pregnancy outcomes. In order for placentation to be successful, the foetal 
cells must evade the maternal immune system to survive and invade into 
the maternal tissues. The purpose of trophoblast invasion is to ensure 
sufficient blood flow by anchoring the placenta deep into the maternal 
tissue and to improve maternal blood flow to the uterus in a process 
known as spiral artery remodelling. 
 
In this thesis work, I have explored the maternal innate humoral immune 
system in pre-eclampsia, a common vascular disease of the pregnancy. I 
also searched for genetic associations among known candidate genes 





Complement system is an ancient part of innate immunity, which consists 
of cell surface bound and freely circulating proteins that interact in a 
cascade of activation and regulation. Complement system has the 
capacity to discriminate between self and non-self cells and particles and 
thereby maintain tolerance or activate adaptive immunity. Complement 
activation can lead to inflammation, cell death, and tissue destruction. 
The component C3 is at the core of the complement system. It can be 
activated by three different pathways of the complement system. C3 can 
also become spontaneously activated in the human serum. 
 
To protect own tissues from complement-mediated destruction and 
death, interaction between tissues and the complement system must be 
carefully regulated. While soluble inhibitors are important in controlling 
complement activation, the cells of the human body are also protected by 
surface-bound regulators of the complement system. One of these potent 
regulators is the membrane co-factor protein (MCP, cluster of 
differentiation 46/CD46). The gene coding for this protein, MCP has 
previously been implicated in pre-eclampsia. As a part of this study, we 
explored the association of genetic polymorphisms of MCP to pre-
eclampsia. 
 
Complement components can be visualised in the placenta. Of particular 
interest is the possible deposition, coating, and localisation of 
complement activators and regulators on the maternal-foetal interface, 
the syncytiotrohoblast cell layer, which circumferentially lines the foetal 
tissues facing the maternal blood flow in the intervillous space of the 
placenta.  
 
In this thesis, I will discuss the role of the complement system in pre-
eclampsia. I hypothesise that in a subset of pre-eclamptic patients, 
particularly those with the severe or early-onset disease, over-activation 
or lack of regulation of the complement system may predispose these 
patients to pre-eclampsia. Pre-eclampsia being a complex genetic disease, 
heritable predisposition within genes coding for components of the 
complement system are mostly studied. To address the multifactorial 
aspect of the disease, candidate genes with previously suggested 
association to pre-eclampsia from other pathways are also studied. While 
genetic association studies of the maternal complement system and other 
candidate genes are at the core of the study, foetal complement system is 
studied in immunohistochemistry, and C4 copy number variations in both 
foetal and maternal samples are also assessed.  
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2.  REVIEW OF THE LITERATURE 
 
2.1 Pre-eclampsia - disease of many symptoms and 
few explanations 
Pre-eclampsia was first described by the Greek philosopher and surgeon 
Hippocrates, who described the grand-mal seizures inflicting a 
previously healthy expecting mother as surprising as lightning. The 
diagnostic separation of pre-eclampsia from hysteria or epilepsy was 
established throughout the 16th century (Schlembach 2003).  
 
 
“--- we now have all the essential facts bearing on the aetiology of 
eclampsia, and that they resemble the pieces of a jig-saw puzzle and 
only need to be assembled in proper sequence to provide an 
acceptable explanation of eclampsia, including its onset two or three 
days after delivery.” 
F.J. Browne, 1958 
 
 
Pre-eclampsia was branded as a disease of theories over half a century 
ago (Jeffcoate 1966). The label has stood the test of time (Figure 1) 
(Broughton Pipkin & Rubin 1994, Mignini et al. 2006, Widmer et al. 2007, 
Dennis & Castro 2014). Pre-eclampsia is a complex multifactorial disease 
with a variable spectrum of symptoms. The key diagnostic criteria used 
worldwide are new-onset proteinuria combined with elevated blood 
pressure during the second half of the pregnancy. Subjective symptoms 
that may or may not appear include headaches, vision impairment, 
nausea, oedema, and abdominal pain. 
 
The systemic nature and aetiological contribution of the placenta to the 
disease was identified already in the beginning of the last century 
(Holland 1909). Nutritional and microbial triggers were previously at the 
centre of the research, and immunological mechanisms and hypertensive 
predisposition have been under investigation since early days. Familial 
predisposition to pre-eclampsia was recognised early (Chesley et al. 
1968). With the development of molecular biomedical research, genetic 














Figure 1.  Theories of pre-eclampsia. While the underlying cause is debated 
on, in majority of the cases the underlying mechanistic problem in 
pre-eclampsia is inadequate trophoblast invasion resulting in 
impaired placentation. Together with other factors, the result is 
systemic endothelial dysfunction, which most often manifests as 
hypertension and proteinuria during the second half of the 
pregnancy resulting in the diagnosis of pre-eclampsia. 
 
2.2 Burden of pre-eclampsia 
Pre-eclampsia is a serious complication of human pregnancy. It affects 3–
5% of pregnancies in all ethnic groups. The onset and clinical course of 
pre-eclampsia is unpredictable. Pre-eclampsia is a leading cause of 
pregnancy related morbidity and mortality worldwide. The burden of 
pre-eclampsia on the healthcare system is mainly focused at the maternal 
and foetal mortality in developing countries and at the complications 
related to prematurity of the infants born from pre-eclamptic 
pregnancies in the Western world. Pre-eclampsia increases perinatal 
mortality five-fold attributing to 10-19% of maternal deaths worldwide 
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(Lain & Roberts 2002, Duley 1992, World Health Organization 2005). In 
the developing countries pre-eclampsia leads to approximately 50 000 
maternal deaths annually (World Health Organization 2005). It can lead 
to multi-organ dysfunction and, rarely, to a life-threatening convulsive 
condition, eclampsia (Roberts et al. 2003). Presently, delivery of the 
placenta remains the only cure for pre-eclampsia. The aetiology of pre-
eclampsia is still largely unknown. Key features of pre-eclampsia include 
vascular impairment, systemic endothelial disturbance, and placental 
disruption and dysfunction. 
 
2.3 Diagnosis and definition 
Pre-eclampsia is a complex multifactorial disease with a variable 
spectrum of symptoms. The key criteria used worldwide are new-onset 
proteinuria combined with elevated blood pressure during the second 
half of the pregnancy, or new onset pre-eclampsia-associated findings in 
the absence of proteinuria (American College of Obstetricians and 
Gynecologists & Task Force on Hypertension in Pregnancy 2013, 
Tranquilli et al. 2014). Pre-eclampsia-associated findings include 
thrombocytopenia, renal insufficiency, impaired liver function, 
pulmonary oedema and cerebral or visual symptoms (American College 
of Obstetricians and Gynecologists & Task Force on Hypertension in 
Pregnancy 2013). The variability of symptoms reflects the likelihood that 
pre-eclampsia is not a single disease, rather resembling a syndrome 
(Roberts & Escudero 2012, Myatt & Roberts 2015). For the benefit of 
research, further classification of pre-eclampsia patients is commonly 
performed according to the specific symptoms and timeline of the 
disease.  
 
According to severity of symptoms and onset of the disease or delivery 
time, pre-eclampsia may be classified into further sub-phenotypes of 
severe or non-severe pre-eclampsia and early or late onset pre-
eclampsia. After the studies in this thesis were initiated, the International 
Society for the Study of Hypertension in Pregnancy (ISSHP) released new 
guidelines for diagnosing pre-eclampsia. According to the ISSHP 2014 
guidelines, pre-eclampsia may be diagnosed in a hypertensive patient in 
absence of proteinuria, if one or more criteria are met from a list 
including maternal organ dysfunction (elevated liver enzymes, 
haematological complications, renal insufficiency, and neurological 
symptoms) and uteroplacental dysfunction (Kallela et al. 2016, Tranquilli 
et al. 2014). Furthermore, according to the ISSHP 2014 
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recommendations, due to the unpredictability of the disease, in clinical 
practice all patients should be treated as potentially severe pre-
eclamptics (Tranquilli et al. 2014). This study treated disease onset 
before 34 weeks of pregnancy as early-onset pre-eclampsia, which is in 
accordance to the ISSHP 2014 recommendations (Tranquilli et al. 2014).  
2.3.1 Vascular impairment 
Increased resistance in uterine arteries can be detected in Doppler 
ultrasound already in the early second trimester of pregnancy in women 
who will develop pre-eclampsia later in their pregnancy (Harrington et 
al. 1996). Vascular impairment caused by pre-eclampsia is mirrored in 
later life by increased risk of cardiovascular disease (CVD) (Irgens et al. 
2001, Sattar & Greer 2002, Bellamy et al. 2007).  
2.3.2  Systemic endothelial disturbance 
Endothelial disturbance results in disruption of the blood vessel barrier 
as well as altered function of the endothelial cells. Several of the typical 
findings in pre-eclampsia are due to endothelial dysfunction including 
damage of the glomeruli, activation of the coagulation cascade, and 
oedema (Roberts et al. 1989).  
Systemic endothelial disturbance is reflected in some of the more 
uncommon end-points of severe pre-eclampsia. It is poorly understood 
which pre-eclampsia sufferers will develop life-threatening 
complications. Such complications may affect the central nervous system 
resulting in seizures and eclampsia, or the liver resulting in diagnosis of 
haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome. 
Rarely, function of the heart and lungs may also be compromised as a 
result of complicated pre-eclampsia. 
2.3.3  Placental disruption  
Placental disruption and dysfunction is particularly associated with the 
early-onset and severe pre-eclampsia phenotypes. In 20% of early-onset 
cases inadequate trophoblast invasion is associated with hypoxia 
(Huppertz 2008). Notably, the pre-eclamptic placenta has been observed 
to be immature in its structure. In early-onset pre-eclampsia, inadequate 
trophoblast invasion in the early stages of placentation leads to 
incomplete spiral artery remodelling causing poor placental 
development and oxidative stress in later pregnancy (Figure 2.) 
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(Khodzhaeva et al. 2015). Inefficiency of trophoblast invasion to 
myometrium and resulting inadequate spiral artery remodelling is not 
unique to pre-eclampsia, but it is most common in severe pre-eclampsia 
(Meekins et al. 1994). 
 
Furthermore, inadequate remodelling of the spiral arteries creates 
turbulent and constrained blood flow to the intervillous space (Roth et al. 
2017). The irregular blood flow increases not only the physical strain on 
the placental tissue causing shedding of the syncytiotrophoblast and the 
subcellular material within, but also the deficiency of nutrient supply to 
the foetus (Pijnenborg et al. 2006).  
 
 
Figure 2. A microscopy image (magnification 200x) of HE stained placenta at 
week 19 shows extravillous trophoblasts (EVT) migrating into the 
decidua invading the maternal tissue. The EVT are pointed out with 
black arrows and they have a round to oval dark nuclei and they 
penetrate between the round lighter shaded decidual cells. Similar 
EVT migration trails are seen in the decidua of placentae at week 8 in 
the event of the first invasive phase. Courtesy of B. Huppertz, 

























2.3.4 Development of the disease 
The main phenomena listed above constitute pre-eclampsia and interact 
to aggravate the disease. Vascular impairment will promote placental 
dysfunction by increasing physical shear and tear to the placental tissue 
due to turbulent and forceful blood flow from the constricted spiral uteral 
arteries (Figure 3) (Roth et al. 2017). Disruption of the placental tissue 
releases subcellular material such as cell-free foetal DNA (cffDNA) as well 
as syncytial fragments into the maternal blood (Roth et al. 2017). Excess 
foetal material released into the maternal blood stream may contribute 
to systemic endothelial dysfunction and inflammation and predict the 
onset of severe complications such as HELLP (Swinkels et al. 2002).  
 
 
Figure 3.  Early-onset pre-eclamptic placenta (wk 34) showing the typical 
syncytial disruption, where the syncytium is no longer even and 
encapsulating the villus circumferentially but instead the syncytium is 
shredded and bursting (black arrow) to release sub-cellular material 
into the maternal circulation. Another typical feature of the pre-
eclamptic syncytium is the syncytial knot (red arrow) that is a cluster 
of nuclei that may be shed into the intravillous space. DAPI (4',6-





2.4 Evolutionary perspective - human 
predisposition to pre-eclampsia 
2.4.1  Evolution of placentation 
Pre-eclampsia is a disease that only affects humans and larger primates 
(Crosley et al. 2013). It is known that among non-human mammals, only 
great apes (gibbon, gorilla, chimpanzee, orang-utan) share some of the 
key features of human placentation, such as varying depth of trophoblast 
invasion, the consequent spiral artery remodelling, and the presence of 
intravillous space (Carter & Pijnenborg 2011, Gundling & Wildman 
2015). Studying the shared mechanisms of the deep placentation among 




because many severe 
obstetric pathologies 
are related to an 
erroneous level of 
placentation depth 
(Brosens et al. 2011). 
It has been 
suggested that the 
development of 
bipedal posture in 
hominid evolution 
had several 
consequences to the 
reproductive 
process resulting 
ultimately in deep 
placentation (Figure 
4.). The upright stature resulted in modification of the female pelvis to 
initially enable the upright stance and later to accommodate for the 
increased brain size of the infant through unique rotating birthing 
mechanism (Fischer & Mitteroecker 2015, Rosenberg & Trevathan 2007). 
The increase in cognitive ability resulting from larger brain size led to 
improved foraging efficiency of early hominids. Adequate foraging 
efficiency allowed for the increase in nutrient transfer to the foetus, 
which is enabled by deep placentation.  
Figure 4. Interactions between processes 




The evolutionarily unique placentation process is mirrored in the 
molecular fingerprint of the placenta as well as the genetic constitution 
on which the process of placentation develops (Crosley et al. 2013, Elliot 
& Crespi 2015). Only hominids (orang-utan, gorilla, chimpanzee and 
human) have galectin cluster in chromosome 19. Furthermore, galectin-
13 (pp13) is unique to Old World monkeys and apes, which have intense 
spiral artery remodelling by the invasive trophoblast (Pijnenborg et al. 
2011a, Pijnenborg et al. 2011b). Since pp13 may be a novel player in 
introducing and maintaining maternal tolerance to the semi-allogeneic 
foetus, it is a possible link between deep placentation, pre-eclampsia and 
immunogenetic complexity (Than et al. 2014, Pijnenborg et al. 2011a). 
 
There is ample evidence that the depth and efficiency of placentation are 
at a co-evolutionary deadlock (Wells 2015). This phenomenon is known 
as the Red Queen hypothesis of an evolutionary arms race (Pijnenborg et 
al. 2008). The Red Queen hypothesis states, that evolutionary arms race 
leads to an endpoint, where due to competing improvement, each 
counterpart succeeds as well as they did in the beginning (Van Valen 
1973). The conflicting selection pressures behind the co-evolutionary 
process of placentation are derived from the foetus aspiring for a deeper 
placentation and more nutrients to be transferred and the mother 
keeping her physiological homeostasis in check and restricting the 
amount of nutrients invested in rearing offspring. 
2.4.2 Pre-eclampsia – an evolutionary paradigm 
Pre-eclampsia affects all human populations worldwide with comparable 
frequency, usually approximately 3% of pregnancies (Roberts et al. 
2011). However, Vietnam and Niger have an exceptionally low rate of 
pre-eclampsia of approximately 1.1% (Bilano et al. 2014). In comparison, 
African-American and certain Latin American populations have at least 
double the incidence, when compared to populations of European origin 
(Bilano et al. 2014, Breathett et al. 2014). While some of the variation can 
be explained by availability of antenatal care, over- or under- reporting 
of the cases, or the obesity epidemic, there seem to be underlying 
differences in pre-eclampsia incidence between populations at the global 
level. 
 
Pre-eclampsia belongs unquestionably to the leading causes of 
reproductive failure in humans. Therefore, it is surprising that in the 
quest to understand and describe the disease pathogenesis, evolutionary 
causes and consequences have received relatively limited attention. 
Heritability is the ratio of genetic variance to the sum of genetic and 
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environmental variance noted as h2, which can have a value between 0 
(non-heritable trait) to 1 (100% heritable trait). By the rules of natural 
selection, a heritable (h2> 0.55) predicament leading to decreased 
reproductive success, such as pre-eclampsia, is expected to disappear 
from the population, unless a counteracting balancing selection process 
is at work (Cnattingius et al. 2004, Brown et al. 2013).  
 
A growing body of evidence suggests that pre-eclampsia associates with 
vascular and metabolic diseases that typically manifest later in life 
(Ramsay et al. 2003, Christensen et al. 2017, Bokslag et al. 2017). While 
epidemiologically relevant, these disease associations after the prime 
reproductive age offer little in terms of evolutionary evidence for the 
development and maintenance of pre-eclampsia as a constant 
phenomenon in the human population. 
 
2.4.3 Human reproduction – an evolutionary challenge 
Humans typically have a very tight fit between the maternal pelvic form 
and size and the size of the baby. At the core of the evolutionary seesaw 
of pregnancy is the size of the baby (Figure 5.). While maintaining a viable 
robust offspring, it is advantageous for the mother to produce as small 
offspring as possible, due to larger metabolic demands and increased 
risks during childbirth related to rearing larger infants (Fischer & 
Mitteroecker 2015). In contrast, it is advantageous for the offspring to 
extract as much nutrients as possible through the placenta while still 
securing a safe birth. Large birth size will store nutrients and support 
neurological development. This parent-offspring conflict (POC) is 
reflected in the expression of paternally and maternally imprinted genes 
during pregnancy. Recent theories suggest that the size of the baby is 
mostly influenced by the environmental factors, i.e. the metabolic 
signalling from the mother in order to compensate for intergenerational 
shifts in pelvic structure due to changes in ecological conditions and 
nutritional status (Wells 2015). 
Reduced size of the baby combined with signalling to induce elevated 
maternal blood pressure may be an evolutionary response to ischemic 
uteroplacental circulation (Espinoza 2012). Indeed, POC has been shown 
to act as a selection pressure via timing of pregnancy induced 
hypertension or gestational hypertension (GH) (Hollegaard et al. 2013). 
Early onset GH is beneficial for the offspring reducing early mortality and 
risks in later life, while GH during later trimesters is deleterious 
increasing these risks to the level of co-occurrence of GH with pre-






Figure 5. Suggested relationship between pregnancy complications (in red) 
along an evolutionary axis of balancing selection by immunogenetic 
and physiological characteristics. Green arrows indicated various 
selection pressures. KIR AA genotype is more frequently observed 
in survivors than fatal cases of Ebola virus (Wauquier et al. 2010), 
and they are also over-represented in patients with pre-eclampsia 
(Yu et al. 2014). HLA-C has been likewise implicated in hepatitis C 
virus (HCV) infections and pre-eclampsia. This study indicates, that 
complement components C1q (Lokki et al. 2014), C3 (Lokki et al. 
2017) , and C4 (Lokki et al. 2014)  play a part in healthy pregnancy. 
OB: obstetric, IUGR: intra-uterine growth restriction, PE: pre-
eclampsia, SA: small for age. Blue – immunogenetic characteristics 
of an individual, Red – pathological endpoint, Green – evolutionary 
process.  
 
The reproductive fitness of an individual is based on a combination of its 
immunogenetic characters and the physiological restrains of the 
pregnancy and childbirth. The balancing selection possibly via 
immunological mechanisms proposed here contains a paradoxical 
phenomenon of protection from severe viral infections while pre-
disposing the individual to pre-eclampsia and intra-uterine growth 
restriction (IUGR) (Parham & Moffett 2013). There are suggestions that 
genes linked to tuberculosis and leishmaniosis may be novel candidate 
genes for pre-eclampsia susceptibility via numerous biological pathway 
analyses (Elliot & Crespi 2015). Similar balancing selection is observed in 
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the trade-off between resistance to malaria and morbidity from sickle-
cell anaemia. 
 
2.5 Maternal genetic association to pre-eclampsia 
 
“The strongest aetiological factors in toxaemia lie in the maternal organism.” 
Vara, Timonen & Lokki, 1965  
 
 
It has been recognised since the era pre-dating genetic research that 
maternal, foetal, and environmental factors all play a part in development 
of pre-eclampsia (Vara et al. 1965). Genetic association studies have 
addressed questions of maternal impaired immunotolerance and 
angiogenic imbalance for the last twenty years (Broughton Pipkin 1999). 
Twin studies have shown pre-eclampsia to be approximately 50% 
heritable (Salonen Ros et al. 2000). 
 
Family linkage studies have identified several regions of maternal genetic 
association. Susceptibility loci in chromosome 2 have been indicated in 
Icelandic, Australian, New Zealander, and Finnish patients (Arngrimsson 
et al. 1999, Moses et al. 2000, Laivuori et al. 2003, Laasanen et al. 2003). 
Other candidate loci have been located in chromosomes 10, 9, 3, and 15 
(van Dijk et al. 2005, Laivuori et al. 2003, Lachmeijer et al. 2001). Thus 
far, detailed studies of genes associated with the indicated chromosomal 
loci, have rarely resulted in confirmation of genetic association to pre-
eclampsia (Kivinen et al. 2007, Kaartokallio et al. 2016, Peterson et al. 
2009). 
 
Genome-wide association studies have identified few susceptibility 
regions for pre-eclampsia. (Zhao et al. 2012, Johnson et al. 2012). Due to 
small sample sizes, convincing candidate genes have not been identified. 
Candidate gene studies have found variants that associate to pre-
eclampsia in several genes in the maternal genome, but most of the 
candidate genes’ associations have not been replicated. Among 
associating candidate genes are several genes that contribute to the 
development of the disease through numerous pathways including 
thrombosis, endothelial function, vasoactive proteins, oxidative stress, 




Examples of candidate genes in pre-eclampsia include Corin (Atrial 
natriuretic peptide-converting enzyme), a gene that is abundantly 
expressed in the heart. Corin contributes to the risk of pre-eclampsia in 
Caucasian women with population-specific variants (Stepanian et al. 
2014). The activin receptor genes type 1 and 2 (ACVR1C, ACVR2A) have 
been the subject of several candidate gene studies. While association to 
pre-eclampsia was indicated for ACVR2A in a Norwegian study, the 
results were not replicated in the Finnish population (Roten et al. 2009, 
Lokki et al. 2011). Two single nucleotide polymorphisms (SNPs) 
(rs13406336 and rs4556933) in ACVR1C have been considered as 
candidate SNPs previously, but they were not associated to pre-eclampsia 
in a Norwegian population (Roten et al. 2009).  
 
A large meta-analysis of candidate genes in pre-eclampsia from 542 
genetic association studies found associating variants in or near several 
candidate genes (Buurma et al. 2013). These included the angiotensin-
converting enzyme (ACE), with potential to affect the regulation of blood 
pressure and blood volume, the lipoprotein lipase (LPL), which may 
contribute to endothelial cell dysfunction if the gene function is 
compromised, and cytotoxic T-lymphocyte associated protein 4 (CTLA4), 
which plays an important role in the negative regulation of T-cell 
proliferation and activation (Buurma et al. 2013). ACE, angiotensinogen 
(AGT) and angiotensin II receptor type 1 (AGTR1) were also verified as 
associating candidate genes in a second meta-analysis, which combined 
the data from 192 independent genetic association studies (Staines-Urias 
et al. 2012).  
 
2.5.1  Finnish population genetics 
Genetics of the Finnish population are unique among Europeans 
(Lundmark et al. 2008). The Finnish population structure provides an 
exceptional opportunity to study rare enriched variants that contribute 
to the risk of complex diseases (Lim et al. 2014). The structure of Finnish 
genetics is attributed to repetition of strong founder effects caused by 
bottleneck events (Nevanlinna 1972). Over centuries, fluctuations of 
internal migration created regional isolated populations in rural parts of 
the country, which remained surprisingly intact into the 20th century 
(Peltonen et al. 1999). Furthermore, geographic isolation has resulted in 
the enrichment of deleterious rare and low-frequency variants that are 
rare or absent in other populations (Kere 2001, Lim et al. 2014). This 
phenomenon is mirrored in what has been described as the Finnish 
disease heritage; a selection of 36 rare hereditary diseases (Norio 2003, 
Polvi et al. 2013). On the other hand, due to effects of negative sampling 
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and genetic drift, Finland has an unusually low incidence of certain 
genetic diseases such as cystic fibrosis, which has a ten-fold larger 
incidence in other Caucasian populations in comparison to the Finns 
(Kere et al. 1989).  
 
2.6 Cellular immunity in pre-eclampsia 
The predominant non-trophoblast cell population in the placenta is the 
Hofbauer cells (HC), which express the typical macrophage markers such 
as CD68 (Joerink et al. 2011). The HC polarise towards the alternative M2 
phenotype, which are suggested to be involved in homeostasis, parasite 
killing, tumour promotion, tissue remodelling among other processes. 
While the exact role of the HC remains unknown, their numbers in HELLP 
syndrome are increased, likely reflecting the increased inflammation in 
the affected placentae (Evsen et al. 2013). Concordantly, a decrease in 
C3aR in the HC pre-eclamptic placentae may indicate the failure to clear 
the excess of activated complement thereby aggravating the sterile 
inflammation locally as immune complexes build up, which ensues in 
development of the disease (Lim & Lappas 2012).  
 
In the pre-eclamptic pregnancy, the immune cell populations in the 
maternal tissue, the decidua, are altered. B cells and CD4+ CD29+ T-cells 
are increased as well as CD4+CD45RO+ memory T-cells and CD8+S6F1+ 
and CD8+CD28+ cytotoxic T-cells, while CD4+CD45RA+ T-cells are 
decreased. This results in over-production of immune complexes and 
autoantibodies (Matthiesen et al. 1995, Matthiesen et al. 1999, Wilczynski 
et al. 2003). CD4+CD25high and CD3+FoxP3+ Treg cells are decreased in 
comparison to normal pregnancies, which may result in loss of maternal 
tolerance to the foetus in pre-eclamptic pregnancies (Sanguansermsri & 
Pongcharoen 2008, Sasaki et al. 2007). 
  
In pre-eclampsia, the population of natural killer t-cells (NKT) is also 
increased in comparison to a healthy pregnancy resulting in a shift 
towards Th1-type immune response (Borzychowski et al. 2005). The 
cytokine environment created by Th1-type immune response is known 
to be incompatible with a healthy pregnancy (Zhou et al. 2013, van den 






2.7 Complement system in pre-eclampsia 
The semi-allograft foeto-placental unit poses a unique challenge to the 
maternal immune system. Immunological mechanisms in pre-eclampsia 
may involve a non-classical-type incompatibility (Redman & Sargent 
2010a). Maintaining clearance by complement and phagocytes, and 
controlling the potentially destructive effects of complement on the 
placenta and foetal tissues, are of central importance for a healthy 
pregnancy.  
2.7.1 Complement activation 
Complement system is an integral part of innate immunity. Complement 
system has several important roles. These include lysis of microbes by 
the membrane attack complex (MAC), opsonisation of complement 
activating structures by complement components C3b, C4b, and C1q, 
chemotaxis by C3a and especially C5a, clearance of immune complexes by 
C3b, C4b and CR1, initiating and supporting the adaptive immune 
response, and initiation, intermediation, and enhancement of immune 
reactions by increasing capillary permeability, inducing smooth muscle 
contraction, and releasing immune mediators from mast cells. Altogether 
the complement system comprises more than 40 different components 
including receptors and regulators. Its activation pathway consists of 
approximately 20 components that interact in a progressive cascade to 
instigate terminal pathway activation. Complement activation proceeds 
by three distinct pathways in a step-wise enzymatic cleavage of the 
activating components which produce chemoattractants or 
anaphylatoxic fragments to be released (Figure 6.). 
The classical pathway (CP) is activated when the C1 complex binds to the 
target cell leading to activation of complement components C4, C2 and 
finally cleavage of complement component C3 and formation of the C5 
convertase which initiates terminal pathway (TP) activation (Walport 
2001a). C1q binds to apoptotic cells, immune complexes, gram-negative 
bacteria, some viruses, and the surface-attached C-reactive protein (CRP).  
The lectin pathway (LP) of complement activation is analogous to the 
classical pathway. The lectin pathway is activated by mannan-binding 
lectin (MBL) binding to microbes with sugars such as mannose groups on 
the surface structures. Certain fungi including Candida and Aspergillus 
and a limited number of bacteria, for example certain strains of 
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Salmonella also bind MBL. Ficolins are the newest discovery in the 
complement system, they opsonise certain bacteria and yeast, and 
activate complement via the lectin pathway analogously to MBL 
(Matsushita & Fujita 2001, Endo et al. 2011). With the mannan binding 
lectin serine peptidase 1 and 2 (MASP1 and MASP2) proteins, MBL or 
ficolins may form an activator complex similar to C1 in the CP also leading 
to deposition of C4 and C2 and the formation of the C3 convertase C4b2a. 
The alternative pathway (AP) is among most evolutionarily ancient 
immune defence mechanisms. It has the capacity to discriminate between 
self and non-self surfaces and particles. In AP activation, C3b is covalently 
bound to cell surfaces and thereafter either inactivated by soluble or 
surface bound complement regulators, or activated by default. Failing 
inhibition, AP activation will be accelerated by activation of the AP in the 
amplification loop where C3bBb convertases will activate more native C3 
molecules to C3b to opsonise the target cell surface. During activation, 
Factor D (FD) will cleave C3b-bound Factor B (FB) to Ba and Bb. Together 
with C3b, Bb will form the C3 convertase C3bBb. AP activation will lead 
to the C5 cleavage and MAC formation as the final result of TP activation. 
MAC formation will result in cell death and tissue destruction. The 
surfaces lacking protective regulatory components and thereby 
promoting alternative pathway activation include fungi, viruses and 
certain bacteria (Walport 2001a).  
Among the most potent surface bound regulators of the complement 
system is the membrane co-factor protein (MCP, CD46). The MCP is coded 
by CD46, which is located in the 1q32.2 within a genomic region called 
the Regulators of Complement Activation (RCA) gene cluster in the 
proximity of several other genes that produce complement regulators 
(Holers et al. 1985). The 43 kb CD46 is composed of 14 exons. At least 59 
amino acid changing mutations are known in the CD46 Seven of these 
polymorphisms are not related to atypical haemolytic uremic syndrome 
(aHUS), which is a serious disease of the kidneys caused by tissue 
destruction resulting from un-controlled complement attack in the 
kidney vascular walls and on blood cells (Liszewski & Atkinson 2015, 
Meri 2013). 
 
The functional region of MCP consists of four complement control protein 
(CCP) domains linked to a 34-amino-acid signal peptide. Thereafter, an 
alternatively spliced region for O-glycosylation, a segment of unknown 
function, a transmembrane domain, and one of several alternative splice 






Figure 6. Complement system can be activated by alternative pathway 
(green), classical pathway (yellow) or lectin pathway (blue). They all 
lead to activation of the terminal pathway (orange) by formation of 
C5 convertases. The most important complement inhibitors are 
shown in bright red. Factor H (FH) and C4b binding protein (C4bp) 
are the most important soluble regulators of early pathways of 
complement activation. FH is particularly important in acting as a 
cofactor for the inactivation of C3b by factor I in the alternative 
pathway, while C4bp is primarily active in the classical pathway of 
complement activation. The triangular regulators are surface bound 
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inhibitors. C5a and C3a are potent anaphylatoxins with the capacity 
to increase vascular permeability and recruit immune cells to the site 
of complement activation, as well as in participating in the induction 
of the adaptive immune response. MAC – membrane attack 
complex, CLU – clusterin, VTN – vitronectin, MCP – membrane 
cofactor protein, DAF – decay accelerating factor, MBL – mannose-
binding lectin, MASP - mannan-binding lectin serine peptidase, FCN 
– ficolin, C1inh – complement component 1 inhibitor, CR1 – 
complement receptor 1, FI – factor I, FB – factor B, FD – factor D 
Other surface bound complement regulators are decay accelerating 
factor (DAF, CD55) and protectin (CD59). MCP facilitates the inactivation 
of complement components C3b and C4b by Factor I (FI), whereas DAF 
promotes the decay of the C3 convertase enzymes. In addition to the 
surface bound CD59 soluble proteins vitronectin (VTN; S-protein) and 
clusterin (CLU) control the terminal pathway. Important regulators of 
complement system are listed in Table 1 (Zipfel & Skerka 2009).  
 
Table 1. Regulators of complement activation (modified from Zipfel & Skerka 
2009). 
 
Regulator Location Main target Notes 
Factor H soluble C3b, C3bBb FH 
FHL-1 soluble C3b, C3bBb FH-like protein 1 
Properdin soluble C3bBb Positive regulator 
CR1 surface-bound C3b, C4b CD35 
CR2 surface-bound C3dg, C3d CD21 
CR3 surface-bound iC3b CD11b/CD18 
CR4 surface-bound iC3b CD11c/CD18 
CRIg surface-bound C3b,iC3b VSIG4 
MCP surface-bound C3b, C4b 
CD46, membrane 
cofactor protein 
DAF surface-bound C4b2a, C3bBb 
CD55, decay accelerating 
factor 
C4bp soluble C4b2a  
Carboxyl-peptidase N soluble C3a, C5a Inactivates C3a and C5a 
C1INH soluble C1s, C1r, MASPs  
FHR-1 soluble C3b?, C5? FH-related protein 1 
Clusterin soluble C5b-9 SP40,40, ApoJ 
Vitronectin soluble C5b-9 S-protein 
Protectin surface-bound C5b-8, C5b-9 CD59 
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2.7.2 Complement in the placenta  
Complement belongs to the first line of defence in the circulation and 
tissues. Extra-villous trophoblast cells invading into maternal tissues 
must be sufficiently protected from the maternal complement system 
(Redman & Sargent 2005, Regal et al. 2017). A second site in the need of 
protection from complement activation is on the syncytiotrophoblast, 
which is the foetal surface that is constantly exposed to maternal blood 
(Figure 7). Complement activation will result in the release of 
anaphylatoxins and chemotaxins with the potential to cause 
inflammation, vascular leakage and thrombosis. Unregulated 
complement activation may also result in tissue damage characterised by 
inflammatory lesions, and increased apoptosis on the placental villi (Ito 
et al. 2015, Rampersad et al. 2008).  
 
The crucial role of complement for the healthy pregnancy is reflected in 
recurrent pregnancy loss, where mutations in complement regulatory 
genes have been reported (Mohlin et al. 2013). Furthermore, recurrent 
miscarriage and pre-eclampsia are both characterised by excessive 
complement activation (Denny et al. 2012). 
The incompatibility between maternal immune system and placental 
cells may disrupt the balance of complement activation and regulation. 
This can contribute to the pathogenesis of pre-eclampsia (Girardi 2017). 
In discordant cases, complement attack may compromise placental cells 
if their protection fails. Complement activation may occur spontaneously 
(Meri 2016). Alternatively, antibodies or exposed tissue structures may 
act as the trigger. Several factors may potentially cause incompatibility 
between complement attack and regulation. First, excess of burden or 
abnormal function of the complement may limit its capacity to perform 
the necessary waste disposal function. Consequently, placental material 
cannot be properly cleared and accumulation may occur in maternal 
tissues such as in the lungs or blood vessels of kidneys causing 
inflammation and vascular damage. Secondly, antibodies, tissue 
degradation products, or insufficient regulation of complement activity 








Figure 7.  Schematic representation of the maternal-foetal interface and its immunological players (green). The placental villi 
are shown in the right side of the image. The syncytiotrophoblast is formed by the cytotrophoblast cells that in the 
early stages of the pregnancy create a double layer on the villi, in term pregnancy the cytotrophoblasts are scarce 
and the apical and basal membrane of the fused syncytium is the border between maternal and foetal circulation. 
The villi are anchored to the decidua by trophoblast columns (TC), which flatten and disappear during the course of 
the pregnancy fusing the anchoring villi to the decidua, which is shown on the left side of the figure. Invading 
trophoblast cells will encounter maternal complement system (C) in the decidua, and in the intervillous space. 
Successful trophoblast invasion will extend to the vascular layers of myometrium, and invade the uterine spiral 
arteries, where endovascular trophoblast cells (EvTC) will replace endothelial cells (E) causing remodulation and 
relaxation of the spiral artery to allow for non-turbulent high volume low pressure circulation into the intervillous space. 
Interstitial trophoblast cells (ITC) will remain in the maternal tissue creating tolerance of the foetal tissue in the 
maternal immune system. Hofbauer cells (HC) are the predominant immune cell population in the villi throughout 
placental development. The decidual immune cell population consists of macrophages (M), natural killer cells (NK), 
and other populations of T-cells (T). Tolerance inducing Treg and Breg cells in particular are essential for a healthy 




2.7.3 Complement disturbance in pregnancy 
Complement has been studied in pre-eclampsia extensively (Gilbert et al. 
2012, Girardi 2017, Regal et al. 2017). Hypertensive disorders of 
pregnancy with compromised placental perfusion can result from 
excessive activation of the complement system, or alternatively from 
deficiencies in complement function not allowing the adequate 
development and perfusion of the uteroplacental unit (Regal et al. 2015). 
The larger body of evidence points towards over activation of the 
complement system (Derzsy et al. 2010). Complement activators have 
been shown to be elevated in early-onset severe pre-eclampsia and late-
onset severe pre-eclampsia (He et al. 2016). However, the results of 
complement studies are conflicting. Studies in support of over activation 
of the alternative pathway often report an excess of factor B (FB) and its 
activation products in the patient sera (Lynch et al. 2008, Hoffman et al. 
2013), but the role of FB is not clear (Derzsy et al. 2010).  
 
Disturbed complement activity can predispose to infections or to an 
immuno-inflammatory syndrome, which resembles systemic lupus 
erythematosus (SLE). SLE is associated with inadequate clearance of 
debris by the classical pathway (Walport 2001b). Such syndromes are 
likely to aggravate during pregnancy. This is possibly due to greater 
clearance requirement caused by shedding of material with placental 
origin. Furthermore, patients with SLE or antiphospholipid syndrome 
have an increased risk for adverse foetal outcomes and hypertensive 
disorders of pregnancy (Gilbert et al. 2012). On the other hand, 
inadequate regulation of the complement system can lead to catastrophic 
consequences such as the aHUS and other forms of thrombotic 
microangiopathy (TMA) (Meri 2013). In TMA, complement attacks 
against endogenous tissue structures such as endothelial cells and blood 
cells causing vascular damage and kidney failure. Pregnancy can act as a 
trigger of TMA syndromes. 
 
2.8 Fms-like tyrosine kinase 1 (sFlt1) – An anti-
angiogenic marker  
Among the most promising lines of recent research into aetiology of pre-
eclampsia is the investigation of the role of angiogenesis in the 
pathophysiology of pre-eclampsia (Agarwal & Karumanchi 2011). Two of 
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the best documented increases in anti-angiogenic factors are seen in 
soluble endoglin (sEng), a transforming growth factor-β1 and -β3 
receptor, and soluble fms-like tyrosine kinase 1 (sFlt1) a splice variant of 
vascular endothelial growth factor receptor 1 (VEGFR1) (Levine et al. 
2006). SFlt1 is a known anti-angiogenic marker of pre-eclampsia that is 
predominately expressed by the trophoblast cells. VEGFR1 is coded by 
fms related tyrosine kinase 1 gene (FLT1). Multiple isoforms of VEGFR1 
exist, and the soluble forms have been implicated in pre-eclampsia. The 
extracellular parts of the protein are encoded by the first 13 of 30 exons. 
Intracellular parts coded by the latter half of the gene are not included in 
the soluble VEGFR1. The protein in its entirety consists of seven 
immunoglobulin (Ig)-like domains in an extracellular ligand-binding 
region, a transmembrane segment and a cytoplasmic region containing a 
tyrosine kinase (TK) domain (Shibuya 2001). Endothelial tissue 
throughout the body produces VEGFR1. 
 
An excess of VEGFR1 of placental origin has been recorded in pre-
eclampsia (Maynard et al. 2003). While prediction of pre-eclampsia has 
proven difficult, the best results have been obtained by observing the 
ratio of sFlt1 to placental growth factor (PlGF) (Zeisler et al. 2016). SFlt1 
levels typically correlate with the severity of pre-eclampsia (Levine et al. 
2004), but conflicting views persist in relation to the normalisation of 
sFlt1 levels in pre-eclampsia. Previously, sFlt1 levels were considered to 
normalise after the birth of the placenta (Levine et al. 2004, Levine & 
Karumanchi 2005). However, recently it was shown that in some patients 
sFlt1 levels may remain elevated in women with a history of pre-
eclampsia even after healthy endothelium is restored (Tuzcu et al. 2015). 
2.8.1  Role of VEGFR1- mediated angiogenesis in placentation 
VEGFR1 is essential for survival through its capacity to negatively 
regulate the levels of VEGF. Internalisation and signalling of functional 
VEGF receptors enhances angiogenic growth of blood vessels (Boulanger 
2016). VEGFR1 also binds PlGF thereby limiting its availability and 
proliferation of the placental tissue. VEGFR1 has been shown to be 
expressed at the site of implantation, where blocking the VEGFR1 had 
immunomodulary effects i.e. reducing the recruitment of macrophages to 
the uterus, although pregnancy itself was not compromised by the anti-
VEGFR1 treatment in a murine model (Douglas et al. 2014). Furthermore, 
by continuous blocking of VEGFR1, angiogenesis of the implantation site 






2.8.2  sFlt1, PE, and comorbidity 
Pre-eclampsia is associated with increased risk of non-communicable 
diseases in later life. Women with a history of pre-eclampsia have at least 
double the risk of a future cardiovascular CVD in comparison to healthy 
controls, and the risk increases with severity of the disease (Ray et al. 
2005, Bellamy et al. 2007). The heightened risk of coronary artery 
calcification is detectable three decades after the index pregnancy (White 
et al. 2016). Moreover, an increased risk for stroke (Bushnell et al. 2014) 
and type 2 diabetes has been observed after a pre-eclamptic pregnancy 
(Weissgerber & Mudd 2015). 
 
For healthy circulation to persist, sustaining angiogenesis is paramount. 
Cardiovascular morbidity is observed accordingly in association with 
anti-angiogenic treatment (Abdel-Qadir et al. 2017). The driver of the 
cardiac dysfunction in pre-eclampsia is likely mediated by anti-
angiogenic factors (Shahul et al. 2016). Pre-eclampsia also increases the 
risk of peripartum cardiomyopathy, and it has been suggested that sFlt1 
may be toxic to the heart. Increased levels of sFlt1/sVEGFR1 are 
associated with peripartum cardiomyopathy with correlating levels of 
sFlt1 and symptom severity (Damp et al. 2016). Higher levels of sFlt1 are 
also recorded in heart failure after myocardial infarction in absence of 
pregnancy (Onoue et al. 2009). In heart failure concurrent with 
pregnancy, extreme sFlt1 levels are also observed (Wu et al. 2017). 
During the time period of 1-10 years after pre-eclampsia, 3.6-fold 
increase in risk of heart failure is associated with pre-eclampsia (Wu et 
al. 2017). Severe pre-eclampsia bears the largest risk for cardiomyopathy 
in later life in comparison to GH (second largest risk) or moderate pre-
eclampsia (smallest risk) (Behrens et al. 2016). 
2.8.3  sFlt1 - evolutionary context  
While pre-eclampsia is a primate-specific disease, sFlt1 is conserved in 
vertebrates across avian and mammalian classes. The major contributor 
to sFlt1 load in human pregnancy is the recently evolved isoform sFlt1-
e15. Overexpression of the primate specific isoform sFlt1-e15a is also 
associated with pre-eclampsia, suggesting that this novel isoform 
harbours thus far unexplained fitness advantages (Thomas et al. 2009). 
Assuming that sFlt1 is pathogenic, it is thereby possible that in non-
primate mammals’ pregnancy-associated pathologies, the rise in sFlt1 
does not exist. On the other hand, it is also possible that the sFlt1 in 
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humans has evolved specific functions, patterns of expression, or 
regulatory mechanisms that are essential for development of pre-
eclampsia (Brown et al. 2013).  
 
sFlt1 has been implicated to have an anti-inflammatory function (Yano et 
al. 2006). It is also expressed on inflammatory cells (Luttun et al. 2002). 
In areas of Africa where, Plasmodium falciparum is endemic, first 
pregnancies share a particular risk of not only pre-eclampsia but also of 
placental malaria (Muehlenbachs et al. 2008). Interestingly, it has been 
shown, that in placental malaria the foetal tissue will express an excess of 
sFlt1 apparently in an attempt to regulate the maternal inflammatory 
response thereby reducing the rate of spontaneous abortions 
(Muehlenbachs et al. 2006). Consequently, positive selection on a genetic 
variant with capacity to resist placental malaria may have influenced 
allele frequencies within the general population enough to introduce a 
novel risk to pre-eclampsia (Brown et al. 2013). Further evidence of the 
immunological interactions of VEGFR1 come from a murine model, where 
increase in complement activation resulted in increased levels of VEGRF1 
(Girardi et al. 2006). It was confirmed that monocytes can be stimulated 
to express an excess of VEGFR1 when exposed to complement activation 
products C3a and C5a in vitro (Girardi et al. 2006). 
 
2.9 Animal studies in pre-eclampsia 
In studies of pregnancy complications, most invasive research techniques 
and many clinical trials are impossible to carry out safely during 
pregnancy. This makes the concept of animal model studies enticing. 
Indeed, rats and mice have been used to reproduce particular symptoms 
of the syndrome-like pre-eclampsia using numerous methods. For 
example: an injection of an adenovirus carrying sFlt1 to pregnant mice 
recapitulates hypertension and foetal growth restriction (Lu et al. 2007). 
This model has been used to study the VEGF and PlGF pathways in pre-
eclampsia pathology, the connection of sFlt1 increase to the well-
documented increase in CVD risk in later life and even the beneficial effect 
of CO in pre-eclampsia (Mateus et al. 2011, Venditti et al. 2014, Pruthi et 
al. 2015). The role of sFlt1 in pre-eclampsia pathogenesis was originally 
confirmed in Sprague-Dawley rats using a similar protocol (Maynard et 
al. 2003). Recently, a second mouse model of late-onset pre-eclampsia 
has been developed with the overexpression of human sFlt1-e15a (Szalai 




Another area of recent advances in pre-eclampsia studies via animal 
models is the molecular mechanisms to mitigate vascular pathologies in 
the pre-eclamptic placenta using reduced uterine perfusion pressure 
(RUPP) rats or chemically created pre-eclampsia-like state of decreased 
vasodilation in BALB/c mice (Morton et al. 2015, Motta et al. 2015).  
 
Some of the most compelling evidence of the link connecting innate 
immunological mechanisms to onset of pre-eclampsia comes from animal 
studies. Already in 2000, regulation of C3 was shown to be crucial for a 
successful pregnancy in a revered experiment using Crry-/- and C3-/- 
mice (Xu et al. 2000). One of the most complete models for pre-eclampsia 
is reproduced in pregnant C1q-deficient (C1q -/- -strain) mice (Singh et 
al. 2011). Activation of the alternative pathway of the complement 
system has been shown to be crucial in development of hypertension in 
the RUPP rats (Lillegard et al. 2013). Furthermore, blocking of activation 
of the complement system in known areas of complement activation will 
prevent maternal features of pre-eclampsia in DBA/2-mated CBA/J mice 
(Qing et al. 2011). 
 
A serum-based pregnancy-specific C57BL/6 IL-10−/− mouse model that 
closely mirrors pre-eclampsia is created by a single administration of 
human pre-eclampsia serum (Kalkunte et al. 2010). These mice mimic 
many of the symptoms of pre-eclampsia including placental hypoxic 
injury and increased sFlt1 and endoglin levels thus confirming the role of 
immunological pathways in aetiology of the disease (Kalkunte et al. 
2010). 
 
It is noteworthy, however, that development of pre-eclampsia is 
intrinsically linked to insufficiency of deep placentation unique to the 
higher primates (Burton et al. 2015). For example, in the RUPP model, 
compromised blood flow mimicking conditions during pre-eclampsia is 
created by mechanically blocking blood flow via the uterine arteries using 
clips fitted inside pregnant rats in a surgical procedure. While similar 
pregnancy complications to mild pre-eclampsia and GH are consequently 
recreated, the RUPP model does not reflect the systemic endothelial 
dysfunction typical of severe pre-eclampsia or its rare complications 
(Balta et al. 2011).  
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3. AIMS AND OBJECTIVES 
 
 
In this study, I assessed the role of complement system and candidate 
genes in pre-eclampsia.  
 
The specific aims were:  
 
1) Assess the genetic role of C3 in severe pre-eclampsia.  
2) Assess the genetic role of MCP in severe pre-eclampsia. 
3) Describe complement components’ expression and 
deposition on the placenta tissue of normal pregnancy, late-
onset pre-eclampsia and early-onset pre-eclampsia.  
4) Evaluate the role of genetic polymorphisms in candidate 


























4. MATERIALS AND METHODS 
 
This study was conducted at the Departments of Medical and Clinical 
Genetics and Bacteriology and Immunology, and at Immunobiology 
Research Program, and at Institute for Molecular Medicine Finland in the 
University of Helsinki. Laboratory studies for Study IV were conducted in 
collaboration with Institute for Molecular Medicine Finland and School of 
Medicine, Washington University in St. Louis, MO, USA. Statistical analysis 
for Study IV were conducted in collaboration between Institute for 
Molecular Medicine Finland and Broad Institute, MA, USA.  
 
This study consists of four case-control studies of pre-eclampsia in the 
Finnish population. Controls were defined as non-pre-eclamptic 
singleton pregnancies. Pre-eclampsia presents with variable symptoms 
at different time points during the second half of the pregnancy. 
Hypertension and proteinuria were compulsory symptoms of pre-
eclampsia according to the definitions available during the recruitment 
years of the included studies. The convulsive state, eclampsia, is usually 
but not always preceded by pre-eclamptic symptoms. Neurodamage, 
kidney damage, foetal demise, and death are severe complications of pre-
eclampsia. In some cases, typically associated with HELLP syndrome, 
liver failure is seen. HELLP is often preceded by pre-eclampsia diagnosis, 
but may also occur without hypertension and proteinuria. 
 
4.1  Definitions of pre-eclampsia sub-phenotypes 
In this study, we used guidelines from the FINNPEC study to determine 
the subphenotypes of patients with pre-eclampsia (Jääskeläinen et al. 
2016). Early vs. late onset pre-eclampsia may be defined by either the 
time of diagnosis or delivery. In study I, we used the time point of 
diagnosis earlier or later than 34+0 pregnancy weeks to define early and 
late onset pre-eclampsia. The diagnostic criteria for patients in each study 












g/L or per 24h sample 
 (repeated dipstick reading) 
Diagnosis week Study where used 
Early-onset pre-eclampsia ≥ 140  ≥ 90  ≥ 0.3 (≥ 1+)  < 34+0 I 
Late-onset pre-eclampsia ≥ 140  ≥ 90  ≥ 0.3 (≥ 1+)  > 34+0 I 
Severe pre-eclampsia ≥ 160  ≥ 110  ≥ 5  na II and III 
Non-severe pre-eclampsia ≥ 140  ≥ 90  ≥ 0.3 (≥ 1+)  na I and IV 
Controls < 140 < 90 none na I - IV 
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4.2 Study subjects  
4.2.1 FINNPEC 
This study is part of larger pre-eclampsia research consortium, Finnish 
Genetics of Pre-eclampsia Consortium (FINNPEC). In three of the studies 
presented here, we have used exclusively samples from the FINNPEC 
cohort (Jääskeläinen et al. 2016). In Study III, control individuals from the 
FINNPEC cohort were combined with patients from the Helsinki study 
cohort, because in the beginning of the study the review of the FINNPEC 
hospital records of the patient group were still ongoing. In FINNPEC, DNA 
samples and clinical data have been collected from all university hospitals 
in Finland (Helsinki, Turku, Tampere, Kuopio and Oulu) beginning in 
2008. First and third trimester serum and placental samples after 
delivery, including 9-site biopsies for transcriptome studies, have been 
collected from a subset. The inclusion criteria for pre-eclampsia are in 
accordance to standard criteria based on hypertension and new onset 
proteinuria occurring after 20 weeks of gestation (ACOG Committee on 
Obstetric Practice 2002). Hypertension is defined as systolic blood 
pressure of 140 mmHg or more, and/or a diastolic blood pressure of 90 
mmHg or more after 20 weeks of gestation. Proteinuria is defined as the 
urinary excretion of ≥0.3g protein in a 24h specimen, or 0.3g/l, or in the 
absence of concurrent quantitative measurement, at least a ‘2+’ or more, 
or two ‘1+’ proteinuria dipstick readings with no evidence of the urinary 
tract infection. Pre-eclampsia is considered severe if blood pressure is 
≥160/110mmHg, or proteinuria exceeds 5g/24h, or subjective symptoms 
such as cerebral or visual disturbances or abdominal pain appear. 
Intrauterine growth restriction/placental insufficiency is defined as birth 
weight below -2SD and/or umbilical artery resistance ≥+2SD according 
to gestational age specific standards (IUGR) (Acharya et al. 2005) without 
known aetiology unrelated to the aims of the present project (e.g. 
congenital malformation syndromes and chromosomal defects). The 
women with multiple pregnancy and maternal age less than 18 years are 
excluded. All diagnoses were confirmed by an independent double jury 
consisting of a research nurse i.e. midwife and a medical doctor i.e. 
resident or specialist in gynaecology and obstetrics using the customised 





Figure 8.  The diagnostic chart used by midwife/resident double jury in the 
FINNPEC procedure.  
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4.2.2  The Finnish population-based pre-eclampsia cohort 
The Finnish population-based pre-eclampsia cohort consists of 248 pre-
eclamptic women and 679 controls identified and recruited from 100,000 
consecutive pregnant women from the National Hospital Discharge 
Register. While the pre-eclampsia group followed diagnostic criteria 
described in Table 2., the control group consisted of uncomplicated 
pregnancies and women with non-pre-eclamptic pregnancy 
complications at comparable proportion to the general population. The 
cohort is described in detail elsewhere (Hiltunen et al. 2009). 
4.2.3 Southern Finland pre-eclampsia study 
The Southern Finland pre-eclampsia study cohort consists of 113 women 
who had had pre-eclamspia in at least one previous pregnancy and 103 
controls with at least one normotensive pregnancy. The cohort consists 
of previously healthy women of Finnish origin who lived in Southern 
Finland without a history of renal or autoimmune history. The cohort has 
been described in detail previously (Laivuori et al. 2000).  
4.2.4  FINRISK 
FINRISK is a large Finnish population survey for the purpose of study of 
risk factors on chronic, noncommunicable diseases. The study was 
initiated in 1972, but for this study, we used the comprehensive National 
Hospital Discharge Register covering years 1992 to 2007 to identify pre-
eclamptic cases and control pregnancies within the FINRISK study. The 
FINRISK study is described in detail online a. 
4.2.5  Patient selection in Studies I-IV 
For Study I, placental samples were chosen preferentially from FINNPEC 
patients with severe and early-onset pre-eclampsia, with previous 
diagnosis of an immunological disorder as an exclusion criterion. We 
divided the pre-eclampsia patients in early- and late-onset groups 
according to the weeks of gestation at diagnosis (early-onset < 34 weeks 
of gestation, late-onset ≥ 34 weeks of gestation). Two patients had HELLP 
syndrome. Chronic hypertension (an elevated blood pressure that 
predated the pregnancy or detected before mid-pregnancy) was 
observed in one person in every study group. One patient of the late-onset 
pre-eclampsia group had celiac disease and one patient of the early-onset 
pre-eclampsia group had thrombophilia, (Factor II mutation). 
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In Study II, 95 severe pre-eclamptic women with severe proteinuria 
(minimum 5 g/L) and 190 controls were selected from the FINNPEC 
cohort. Patients and controls had similar BMI, but control women were 
slightly older (29 vs. 30.8 years p=0.003) and less often primiparous 
(100% vs. 45%) (p<0.001). 
In Study III, a combination of samples from the three study cohorts, the 
FINNPEC cohort, the Finnish population-based pre-eclampsia cohort and 
Southern Finland pre-eclampsia study, were used.  
In the SNP genotyping two datasets (the Finnish population-based pre-
eclampsia cohort and Southern Finland pre-eclampsia study) were used 
with a total of 259 women with pre-eclampsia and 426 control women. 
32 patients from the Southern Finland pre-eclampsia study were selected 
for the Sanger sequencing and replication was done with the severe pre-
eclampsia patients (N=95) from Study II, results were compared against 
controls from the FINNPEC cohort (N=95). In sequenom genotyping, we 
used 960 severe pre-eclamptic women and 705 controls from the 
FINNPEC cohort to increase the sample size in 14 SNPs within the gene. 
In Study IV, geographically matched patients (N=500) and controls 
(N=190) from the FINNPEC cohort were studied. The patients were non-
obese (BMI < 30 kg/m2) without known immunological diagnoses. 
Genotypes from 122 women with a history of pre-eclampsia from the 
national FINRISK cohort were added as cases. Their diagnoses were 
verified using The International Classification of Diseases (ICD) codes 
from the Care Register for Health Care. Furthermore 1905 parous women 
without a history of pre-eclampsia were included as controls. For the final 
association analyses, we combined genotypes from sequenced FINNPEC 
and FINRISK cohorts, which combined totalled 615 cases and 2094 
controls. 
 
4.3  Ethical considerations 
All subjects provided a written informed consent in accordance with the 
Declaration of Helsinki. All study subjects were at least 18 years of age 
and had sufficient Finnish or Swedish skills to understand the sampling 
protocol and study questionnaire. Study protocols were approved by the 
local Ethical Committees: for the FINNPEC study, ethical approval has 
been obtained from the Coordinating Ethics Committee, Hospital District 
of Helsinki and Uusimaa, for the Finnish population-based pre-eclampsia 
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cohort was approved by the ethics committee of the Finnish Red Cross 
Blood Service and by the Ministry of Social Affairs and Health and for 
Southern Finland pre-eclampsia study was approved by the Ethics 
Committee of the Department of Obstetrics and Gynaecology at Helsinki 
University Central Hospital. Analyses were done using coded data sheets 
to ensure anonymity of the patients and traceability to primary database 
if necessary. The FINRISK ethical approvals are available online b.  
 
4.4  Laboratory methods 
4.4.1 Immunohistochemistry (Study I) 
Placental tissue studies were done using unfixed 5 µm cryo sections from 
placenta tissue samples removed from the middle of the organ. Placental 
samples of approximately 1 cm square cylinders were frozen within two 
hours after the delivery in liquid nitrogen using nested isopropanol 
mediated protocol to minimize complement shedding during sample 
handling. After initial 20-minute freezing at the nested isopropanol 
container, cryotubes were stored at -80 °C until tissue sectioning using a 
cooled cryotome. Haematoxylin and eosin (HE) stain was done for all 
placental sections. All stainings had a mock negative control along the 
staining (I antibody omitted) and standard immunofluorescent staining 
protocol was followed using a darkened humidity chamber at RT for 
incubations. The classical, alternative and terminal complement 
pathways were evaluated using the antibodies listed in Table 3. 
4.4.2  DNA extraction (Studies I-IV) 
DNA was mostly extracted from 10 ml EDTA whole blood stored at-20C° 
(after initial freezing period at-80C° aimed to prevent formation of icicles 
resulting in molecular degradation) using Chemagic Magnetic Separation 
Module I (Chemagen, PerkinElmer, Baesweiler, Germany) automatic DNA 
extraction protocol as provided by the manufacturer.  
DNA for some samples was extracted using standard phenol-chloroform 
extraction protocol from 10 ml EDTA whole blood samples. Extracted 






Table 3.  Primary antibody dilutions and types according to role in the 
complement system. 
 
Role Name Dilution / Source* Type 
Classical pathway   
regulator Cabp 1:200 / The Binding Site Sheep pAb 
component C1q 1:1000 / DAKO Rabbit pAb 
component C4c 1:400 / DAKO Rabbit pAb 
activator CRP 1 µg/ml / Fitzgerald Goat pAb 
Alternative pathway   
regulator Factor H 1:400 / Calbiochem Goat pAb 
component C3c 1:1000 / DAKO Rabbit pAb 
component C3d 1:1000 / DAKO Rabbit pAb 
Classical and alternative pathways 
regulator MCP (CD46) 1 µg/ml / IBGRL Mouse mAb 
regulator Bric 230 (CD55) 1 µg/ml / IBGRL Mouse mAb 
regulator CR1 1 µg/ml / AbD Serotec Mouse mAb 
Terminal pathway   
regulator Bric 229 (CD59) 1 µg/ml / IBGRL Mouse mAb 
component C9 1:400 / Quidel Goat pAb 
Pre-eclampsia   
indicator s-Endoglin 2 µg/ml / Santa Cruz Goat pAb 
 
*DAKO, Glostrup, Denmark; The Binding Site, Birmingham, UK; Fitzgerald Industries 
International, North Acton, MA, USA; Calbiochem, Merck KGaA, Darmstadt, Germany; 
Quidel Corporation, San Diego, CA, USA; IBGRL The International Blood Group Reference 
Laboratory, Bristol, UK; AbD Serotec, Oxford, UK; Santa Cruz Biotechnology, Inc., Dallas, 
TX, USA. 
pAb, polyclonal antibody; mAb, monoclonal antibody. 




4.4.3  SNP genotyping (Studies II and IV) 
An Illumina sequenom custom made SNP array was designed by Dr. Ville 
Holmberg (University of Helsinki). The SNP selection for the array was 
based on known SNPs in genes coding for components of the complement 
system that have been cited in literature to have pathological 
associations. In quality control analysis, all SNPs passed the missingness 
test with at least 80% genotyping success. Twenty-one SNPs failed the 
frequency test Minor allele frequency (MAF) < 0.05 and the remaining 72 
SNPs entered the association analyses. A second Sequenom iPLEX 
genotyping was done to increase the sample size of 14 SNPs observed in 
C3 Sanger sequencing. On both occasions, the assay design and the 
genotyping were performed with Sequenom MassArray system at the 
FIMM Technology Centre, University of Helsinki. The Technology Centre 
performed routine quality control steps to ensure high quality of the 
genotyping. 
4.4.4  Sanger sequencing (Studies II-III) 
Following the manufacturer’s protocol, PCR was carried out using Mytaq 
(Bioline, London, UK) or AmpliTaq Gold (Thermo Fisher Scientific, 
Waltham, MA USA) polymerase enzymes with manufacturers’ buffer. The 
primers used in Sanger sequencing are listed in Table 4. Purification of 
PCR products was done with ExoSAP-IT (GE Healthcare Life Science, UK) 
shrimp phosphatase alkaline product. The purified DNA fragments were 
sequenced according to manufacturer’s protocol using Big Dye 
Terminator v3.1 Cycle enzyme and buffer (Applied Biosystems, Carlsbad, 
CA, USA). The final sequencing reaction product was purified and 
analysed at FIMM sequencing core facility by Performa DTR v3 
filterplates (Edge BioSystems, Gaithersburg, MD, USA) and ABI3730xl 





Table 4. The primers used for Sanger sequencing in this study. The capitalised font refers to forward strand and non-




Gene Region Left primer Right primer Amplicon Size 
CD46 promoter CCGAATTCCCGGAAACTATT CCGGAGAAGGAGTACAGCAG 561 
CD46 exon 1 TCGGTTTCTCTGCTTTCCTC AGAGAACCCTGTCCCCAAAC 265 
CD46 exons 2-3 TTCCCAAACAAACCAAAAGC CCCTTATTTCCTCTAAGGAGCA 877 
CD46 exon 4 GTGGAAAGGCACAGCAGATT GGGTGTAAAGGAGGCAAAAA 398 
CD46 exon 5 TTGACAAATTTATTGAAGACACAGAA CAGGAGGAGGAAGCACATACA 392 
CD46 exon 6 TTGCATTCCATTCCTTGTCTC TCTAAAATGAACAGCAACAACAA 348 
CD46 exons 7-8 AACTCCCAAGTGGTTGATCTTC CAAATGTCCTCCCTCCTTTC 385 
CD46 exon 9 TTGATAAGGCCCTGGTGAAT CACGCTGTGCACACATACC 180 
CD46 exon 10 AAGGGATTTTCTACAAAGGTGAA TGTTTGGGCACCTCATAAAA 240 
CD46 exons 11-12 TCTGGAGATCCATGTGTTCAA ACTGAAGCTGCACAAAAGCA 730 
CD46 exon 13 TGCTACTCGTTTCTTTTTGGTTT AGCAAAGGGAACAGGAATGT 299 
CD46 exon 14.1 CCAGGTTGGTGGCTCATTAC TTTTTATGCACAAGAGCCAAA 679 
CD46 exon 14.2 TCTTTGTAAAGAAAGTGGCTTGAA GCCAAGGCAATGTAAATGGA 658 
CD46 exon 14.3 AGTCTTGTTGTTTTCCCAAAGA GAATTCCTGTTTGTTCTCCTCAA 694 
CD46 exon 14.4 TTGGGCCAAAGAAACATTG GATGGGCCCAATTAGAAACA 700 
C3 Promoter GGGAGCCTCCTTGGAAAATA AGCCCTGTTTGTGGGTAGAG 852 
C3 Exon1 CTGCTCACTCCTCCCCATC AAATGTCTGCTTCCACCCC 200 
C3 Exon2 GAGGACTGGCGTCTCACATC ggaggggctcaggaggag 328 
 
 
C3 Exon3-4 CAAGATCCGGAAGCTGGAC TTGCCTCTCCTAAGCCTGTG 446 
C3 Exon5-7 AGCTGAGAGGCTAAGCCCAG GTCTTCACCTGGTCCCTCAC 579 
C3 Exon8-9 GGAGATCCCATTCTCCAGG CTTCTGACCTGGTCTCCCC 450 
C3 Exon10-11 GGAGGTCTAATCCTGAGGGG GAACCCCTGTACCGTCTTCC 479 
C3 Exon12-13 caccaattcccaggtctcag agacagttgagagacagagaggg 807 
C3 Exon14 CATCCCAGGCACTCCTCTC CTCCAGTCCCACCCACCTC 299 
C3 Exon15-16 GTGGGGTCATTTGGGAAGAG TCCCCTCCTCCCTCTCTG 652 
C3 Exon17 GAAGTCCTCCCTGGGGTC TCCCTCCTCAGACAGGAGTC 357 
C3 Exon18-19 ccaactcctggcctcaag ATGACACTCAGACACCCTGG 630 
C3 Exon20-21 AAGAGCTGAGACCCAGGAGC GAAGACCAGGAGCCCTCTC 583 
C3 Exon22-23 TGCTGACCATCTGTGTGTCTG ATGAGATGGAATTTGGCTCC 420 
C3 Exon24 AACCCTTTTCACGCCACC GGGATCTTAGGGGAGGGATG 344 
C3 Exon25-26 CTGTCCCCTCTCTGCACC CTCTCGTGTTCATCCTGCG 726 
C3 Exon27 GATGACTGCCATGTGTGGAC CAAGGTGGCTGTGCTCTG 222 
C3 Exon28-29 TCCTTACTAACGTGACAGCAATG CTAGGAGGCCAGTGGGAAG 906 
C3 Exon30-33 GATGTCCCAGCTCTGATTTG ACTTGGAAAGTACTGAATATCATGG 954 
C3 Exon34-35 TCCTTGTCCAGGAACAGACC CAGCCAGATAGAGGTCAGGG 423 
C3 Exon36 CCCAAGACAATGCTGGACTC CCCCACAATTCATATATACCTGG 246 
C3 Exon37-38 TGGTCTTTGGAGGGAGGC CAACCACACCTACCACCCAC 504 
C3 Exon39-41 GTGCCCCTCATGGTCAAC GGCAAAGAACTCCAGACACG 697 
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4.4.5  Microsatellite analysis (Study III) 
GF100472 is a (CA)n repeat polymorphism in the promoter area of C3 
gene. Size of the (CA)n repeat was determined by fragment analysis. The 
are of CA-repeats was amplified by PCR using forward primer with FAM 
–label and non-labelled reverse primer in PCR conditions of an initial 
denaturation at 95°C for 10 minutes, followed by 32 amplification cycles 
of 95°C for 30 seconds, 67°C for 30 seconds and 72°C for 50 seconds and 
final extension at 72°C for 7 minutes. The primer used were FAM-
ATGGGAGGAAGACCACCTTT/forward and 
CCCCTCACTTACCCTTGTCA/reverse, which produced fragments of 245-
259 nucleotides. FIMM Sequencing Laboratory determined the sizes of 
the amplified fractions with an automated capillary sequencer ABI3730xl 
DNA Analyzer (Applied Biosystems). GeneScan 500 LIZ Size Standard 
(Applied Biosystems) was applied to size the fragment data. The number 
of CA repeats was verified with Gene Mapper v4.0 software (Applied 
Biosystems). 
4.4.6  C4 gene quantification (Study I) 
The normal gene number for C4A and C4b is considered to be two copies 
of each, although it is not uncommon to find 0-4 copies of either gene in a 
healthy individual. In an attempt to correlate the C4 deposition observed 
in the placentae with the functional C4 genes, C4A and C4B gene copy 
numbers and a silencing C4A mutation were analysed using a previously 
published protocol (Paakkanen et al. 2012). In essence, a real-time 
quantitative polymerase chain reaction with a specified concentration 
range approach was used to obtain numbers of C4 and to detect 
deficiencies due to CTins, which renders the affected C4A non-functional. 
An individual with 0-1 copies of C4A or C4B or with the insertion 
polymorphism within the C4A is considered deficient in C4.  
4.4.7  Targeted exome sequencing (Study IV) 
Targeted exome sequencing was performed at Washington University 
School of Medicine, St. Louis, MO, USA. Genomic DNA was prepared into 
libraries using in-house protocols and enzymes from Enzymatics 
(Beverly, MA) were used (Triebwasser 2015). In sequence capture by 
hybridisation, manufacturer’s recommendations were modified to add 
longer blocking oligos containing 7bp inosine segment to enable 
promiscuous pairing with different index sequences (Roche SeqCap 
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Hybridization and Wash Kit No. 05634261001). Captured DNA was 
washed and eluted after hybridisation following the manufacturer’s 











ACE AGTR1 ERAP2 JAG1 ROCK2 AGT rs699  
ACVR1 AGTR2 ESRRG KDR SOD1 AGT rs4762  
ACVR1B ANGPT1 F13A1 KIAA1239 SOD2 AGTR1 rs5186  
ACVR1C ANGPT2 FLT1 KIAA1462 STOX1 APOE rs429358  
ACVR2A ANGPT3 FLT4 LCT STOX2 CTLA4 rs231775  
ACVR2B ANGPT4 FN1 LIPA SWAP70 ESRRG rs17686866 
ACVRL1 ANTXR1 GPR98 LMCD1 TGFB1 IFLTD1 rs10743565 
ADAM10 Cdkn1c HEY1 LPL TGFB2 IL10 rs1800896  
ADAM12 COMMD7 HEY2 LRRFIP1 TGFB3 KIAA1239 rs1426409 
ADAM15 COMT IFLTD1 MAGI1 TGFBR1 LMCD1 rs9831647 
ADAM17 CORIN IL10 MME TGFBR2 LPL rs1800590  
ADAM19 CTLA4 INHA NODAL TGFBRAP1 LPL rs268  
ADAM28 DEF6 INHBA NOS3 TIE1 near IL-10 rs1800871 
ADAM8 DGKE INHBB NOTCH2 TIE2 near IL-10 rs1800896 
ADAM9 EDN1 INHBC PDGFD TNF NOS3 rs61722009 
ADAMTS7 EDN2 INHBE PDXDC1 VEGFA NOS3 rs2070744  
ADM EHD3 IP6K1 PGF VEGFB NOS3 rs1799983  
ADM2 EHD4 ITGA2 PSG11 VEGFC VEGFA rs3025039 









4.4.8  Epidemiological study of FLT1 variants (Study IV) 
Two SNPs within FLT1 that were found to have the strongest associations 
to pre-eclampsia were also compared to predefined epidemiological 
diagnoses derived from national health care registries. The analysis used 
imputed genotypes of 11,257 women from the FINRISK population 
cohort using a joint panel of Finnish whole genome sequences and 1000 
Genomes phase I reference with a high imputation confidence (info 
metric > 0.97) (1000 Genomes Project Consortium et al. 2012, Chheda et 
al. 2017). Logistic regression (SNPTEST v2.5.2, EM algorithm) was used 
as the preliminary association test which was further confirmed with 
Fisher’s exact test given the rarity of variants and several diagnoses. No 
multiple testing corrections to estimates were performed due to the 
explorative nature of this part of the analysis. Individuals with heart 
failure were identified using codes I50, 4289X, and 42700 in Finnish ICD-
10, ICD-9, and ICD-8, respectively.  
 
4.5  Bioinformatic methods 
Sequencing primers were designed using Primer 3 and GenomeTester 
softwares (Rozen & Skaletsky, Andreson et al. 2006). The discovered 
single nucleotide polymorphisms were verified using SNPper and NCBI 
databases (Riva & Kohane 2002). VEP, HSF 2.4.1 and rnaSNP were used 
for in silica functional studies of intronic studies (Desmet et al. 2009, 
McLaren et al. 2010, Sabarinathan et al. 2013). Additionally, SIFT and 
PolyPhen2 were used to predict functional consequences of exonic SNPs 
(Kumar et al. 2009, Adzhubei et al. 2010).  
4.5.1  Statistical methods (Studies I-IV) 
Basic statistics including fisher’s exact, χ2 and independent-samples t-test 
to compare means of clinical characteristics between patients and 
controls were done using IBM SPSS statistics version 22 (IBM corp.) 
In image quantification, an independent-samples t-test for analysing the 
significance of differences between means of values obtained from 
patient groups and controls was carried out for key statistical parameters 
including sum and mean. Same steps were repeated for the high-intensity 
analyses. Log10 transformation was used to normalise the image capture 
data. Normality was controlled by Shapiro–Wilk W test. (Study I) 
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Fisher’s exact test was used to analyse for differences between 
segregation of C4 deficiencies between groups of patients, and 
independent-samples t-test was used to assess the association of C4 
deficiencies, and immunohistochemistry fluorescence sum and mean 
values. (Study I) 
Plink software was used in genetic association analyses (Purcell et al. 
2007). Additional association analyses including 10 000 x permutation 
testing and haplotype analysis were conducted in Haploview (Barrett et 
al. 2005). Data were analysed using PlinkSeq, Plink (Purcell et al. 2007) 
and R. Kaviar (Glusman et al. 2011), SNPper (Riva & Kohane 2002) and 
VEP Build 37 was used in additional annotations (McLaren et al. 2010). 
Loss of function (LoF) analyses were conducted for each gene with 
associating variants in silico by the Loss of Function – tool c. he following 
annotations were calculated: LoF score < 0.2 is probably damaging, LoF 
score 0.2-0.7 is possibly damaging, LoF score < 0.7 is benign.  
In candidate complement gene studies, MAF and HWE values were 
observed for cases and controls separately, and also separately for 
samples from different cohorts. Sites with >5% missing data or departure 
from Hardy-Weinberg equilibrium in controls (p<0.05) resulted in 
exclusion of the variant from association analyses (Studies II and III). In 
Sequenom genotyping data for Study III, 11 individuals were removed 
due to >10% failed genotyping. Three individuals were excluded due to 
unresolved discrepancy in genotyping results. 
Study IV combined data from two cohorts and several genotyping 
methods. Quality control before meta-analysis included removal of 
singleton and monomorphic variants, removal of sites with >10% missing 
data in the targeted sequencing or a significant departure from Hardy-
Weinberg equilibrium in controls (p<0.001). The combined dataset was 
analysed using Fisher’s exact test of genetic association. The analysis was 
carried out in two phases: low frequency and rare variants (MAF<10%) 
and common variants (MAF>10%) were analysed separately. After 
quality control, 622 variants (443 variants with MAF<10% and 179 
variants with MAF>10%) were included in the combined primary 
association analysis. Of these, 201 were in considered to be in putatively 
functional categories (missense, nonsense, or splice region variants) and 
421 were in likely benign categories (synonymous, intronic, and 
intergenic). (Study IV) 
From results of the association test, the two SNPs with strongest 
associations were further compared to 672 predefined diagnoses derived 
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from national health care registries using imputed genotypes of 11,257 
women from the National FINRISK cohort. Genotypes were imputed 
using a combined panel of Finnish whole genome sequences and 1000 
Genomes phase I reference with a high imputation confidence (info 
metric > 0.97) (1000 Genomes Project Consortium et al. 2012, Chheda et 
al. 2017). Associations were calculated using logistic regression 
(SNPTEST v2.5.2, EM algorithm) and then further confirmed with Fisher’s 
exact test given the rarity of variants and several diagnoses. Due to the 
explorative nature of this part of the analysis, no multiple testing 
corrections to estimates were performed. (Study IV) 
4.5.2  Relative extended homozygosity haplotype (Study III) 
The discovered haplotype was subjected to Relative Extended 
Homozygosity Haplotype (EHH) based tests using REHH program. The 
analysis determines the evolutionary selection pressures contributing to 
the extent of the haplotype. REHH analysis uses the ancestral allele of a 
tagging SNP, here rs2287847 (Gautier & Vitalis 2012). REHH was 
conducted in R following the developer’s instructions to compare extent 
of the associated haplotype in cases and controls.  
 
4.6  Imaging (Study I) 
Fluorescent microscopy images were captured using Olympus DP 
Manager (ver. 2.2.1.195) and Olympus DP Controller (ver. 2.2.1.227) 
image capture softwares with Olympus BX51 fluorescence microscope 
camera. 
ImageJ 1.46 and Fiji-win32 software packages were used in 
immunofluorescent image quantification analyses (Abramoff et al. 2004). 
Background autofluorescence commonly introduces false positive 
readings to immunofluorescence images, so in order to correct for 
autofluorescence, using negative controls as samples, mean intensity +1 
SD (X+σ) was determined to be 7 at 20 ms exposure and 15 at 50 ms 
exposure times. Using an image specific zero threshold, several 
parameters of fluorescence intensity were recorded to differentiate 
between patterns of fluorescence as well as intensity. Sum was defined as 
mean intensity * area of positive fluorescence in pixels (X*σ).  
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The high-intensity area quantification used a black-and-white rendering 
of the original fluorescent image. Using the black-and-white image as a 
reference, a threshold was set at 75% positive fluorescence, where after 
the percentage and pixel count of the positive area is used as a 
quantification to be compared between patient groups.  
For quantification of the areas of most interest i.e. areas of high-intensity 
fluorescence, the top 75% proportion of fluorescence histogram was 
determined for each image using ImageJ 1.46 software and the calculated 
maximum fluorescence value. The calculated 75% minimum value was 
used as a cut-off point creating representative and comparable images of 
high-intensity regions. Thereafter, Pearson-correlation of high-intensity 
proportions across different stainings was calculated independently for 
each patient group. Positive correlations were interpreted as two 
components being observed in the same sample, while negative 




5. RESULTS AND DISCUSSION 
 
 
Complement system is a key contributor to development of pre-
eclampsia. Excess complement activation causes and aggravates sterile 
inflammation and endothelial dysfunction (Hertle et al. 2014), which is 
typically seen in pre-eclampsia. The role of complement mediated 
inflammation seems to be particularly prominent in severe pre-
eclampsia (Burwick et al. 2013). Deposits of complement component C4 
have been observed in renal biopsies of pre-eclamptic women providing 
a link between complement activation and renal dysfunction, an 
important diagnostic characteristic of pre-eclampsia (Penning et al. 
2015). Other immunological mechanisms with adverse consequences for 
the systemic endothelium may include neutrophil extracellular trap 
(NET) formation by neutrophils as a consequence of activation of 
maternal leukocytes (Laresgoiti-Servitje 2013).  
 
Inflammation during pre-eclampsia has varied systemic consequences. 
Endothelial dysfunction may be caused by shedding of foetal trophoblast 
membranes from the syncytium of the pre-eclamptic placenta (Smarason 
et al. 1993). Oxidative stress and inflammation among other mechanisms 
interact to contribute to endothelial dysfunction (Steyers & Miller 2014). 
 
The results of this study combine case-control data from candidate gene 
studies using several methods of sequencing and immunohistochemistry 
to pinpoint association to pre-eclampsia in the Finnish population. We 
have explored genes of complement components C3, C4, and CD46. 
Additionally, we studied localisation and quantity of ten components of 
the complement system and the anti-angiogenic factor sEng in placentae 
from pre-eclamptic pregnancies and non-pre-eclamptic women. Finally 
results from candidate genes from several biological pathways known to 
associate with pre-eclampsia were studied in a targeted exome 
sequencing study. Complement components were the subject of Studies 
I-III, anti-angiogenic factors were studied in Studies I and IV, and other 
candidate genes in Study IV. Before the results are discussed topic-wise, 





5.1 Complement genotyping (III) 
We hypothesised that genetic variants within genes coding for the 
complement system may associate to pre-eclampsia. As complement 
system is comprised of 40 activating and regulating components, which 
are coded for by at least 41 genes (total C4 is coded by two genes: C4A 
and C4B), we approached the hypothesis by selecting previously 
described loci within key components of the complement system to 
pinpoint a possible gene of interest for closer study.  
Seventeen genes coding components of the complement system or 
known candidate genes for pre-eclampsia were genotyped for selected 
SNPs using the Sequenom platform. In 64/72 SNPs, no differences were 
observed between 259 pre-eclamptic women and 426 non-pre-eclamptic 
controls. 72/93 SNPs had minor allele frequency of >0.05. These were 
included in the analyses. 685/720 individuals had genotyping success of 
>90% and these were included in the analyses. Of the analysed SNPs 
listed in Table 6, preliminary analyses revealed possible associations in 
Ficolins 1 and 2, Factor H, C3 and Factor B (data not shown). The sample 
size available at the time the study was initiated limited the power of our 
analysis. It is possible that true associations within the remaining genes 
may be discovered using a larger sample size of well characterised 
patients and controls. When association analyses were controlled for 
multiple testing, the most significant results mapped to C3. The 
permutation procedure reduced the significant p-values to two SNPs in 
C3 (rs2230205; p=0.032 and rs2230204; p=0.005), and therefore only 
results concerning C3 are discussed hereafter. 
Two haploblocks with significant association to pre-eclampsia were 
discovered in C3 by experimental haploblock creation of three 
neighbouring SNPs (Table 7). In conditional haplotype analyses between 
rs2230204 and rs2230205 the previous was found most likely to have 
independent effect (χ2=5.1, df=1, p=0.0239). Rs2230204 and 
rs22302045 are synonymous SNPs located in exon 14 of the C3, in the 
middle of the gene. They were found to be in linkage disequilibrium. To 
explore the genetic architecture of C3 and look for possible associating 
variants to severe pre-eclampsia, the exons and selected introns as well 
as regulatory regions were sequenced in patients with severe pre-






Table 6.  The analysed polymorphisms listed by chromosome, gene symbol 
and rs identifier.  
 
Chromosome Gene RSID Chromosome Gene RSID 
1 MASP2 RS2273347 9 FCN2 RS17549193 
1 MASP2 RS1033638 9 FCN2 RS7851696 
1 MASP2 RS1782455 9 FCN1 RS1071583 
1 MASP2 RS12711521 9 FCN1 RS2274845 
1 MASP2 RS3765900 9 FCN1 RS2989722 
1 FCN3 RS4970521 9 FCN1 RS10858293 
1 FCN3 RS10794501 9 FCN1 RS10117466 
1 THBS3 RS35154152 9 FCN1 RS10120023 
1 THBS3 RS914615 9 FCN1 RS2989727 
1 CFH RS800292 10 MBL2 RS5030737 
1 CFH RS1061147 10 MBL2 RS1800450 
1 CFH RS2274700 10 MBL2 RS7096206 
1 CFH RS1329428 10 MBL2 RS11003125 
3 MASP1 RS698090 11 SERPING1 RS3758918 
3 MASP1 RS698092 11 SERPING1 RS1005510 
3 MASP1 RS3105782 11 SERPING1 RS1557522 
3 MASP1 RS1357134 11 SERPING1 RS4926 
3 MASP1 RS850307 13 FLT1 RS9554314 
3 MASP1 RS6783637 13 FLT1 RS7326277 
3 MASP1 RS7624953 13 FLT1 RS7993418 
5 THBS4 RS3813667 13 FLT1 RS2296189 
5 THBS4 RS423906 15 THBS1 RS2228261 
6 CFB RS641153 15 THBS1 RS2292305 
6 CFB RS537160 19 C3 RS17030 
6 CFB RS541862 19 C3 RS10402876 
6 CFB RS4151658 19 C3 RS423490 
6 CFB RS2072633 19 C3 RS366510 
6 THBS2 RS7382711 19 C3 RS2230205 
6 THBS2 RS12178180 19 C3 RS2230204 
9 FCN2 RS3124952 19 C3 RS1047286 
9 FCN2 RS3811140 20 THBD RS1042580 
9 FCN2 RS7865453 20 THBD RS1042579 
9 FCN2 RS17514136 23 CFP RS1048118 
9 FCN2 RS3128624 23 CFP RS8177079 
9 FCN2 RS7037264 23 CFP RS909523 
9 FCN2 RS12684723    
 
 
Table 7. Two experimental haploblocks with predisposing and protective associations to pre-eclampsia. F_A: frequency of 







Haplotype F_A F_U χ2 df P-value SNPs Effect 
GGT 0.181 0.235 5.707 1 0.017 RS10402876|RS423490|RS366510 protective 
CGT 0.415 0.345 6.634 1 0.010 RS10402876|RS423490|RS366510 predisposing 
CTC 0.279 0.352 7.87 1 0.005 RS2230205|RS2230204|RS1047286 protective 
TCC 0.229 0.181 4.644 1 0.031 RS2230205|RS2230204|RS1047286 predisposing 
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5.2 C3 Sequencing (III) 
The results from above described complement gene study led us to the 
hypothesis that genetic variants within the C3 may associate to pre-
eclampsia. To explore this hypothesis, sequencing of C3 was done using 
Sanger sequencing and Sequenom iplex. C3 is the central component of 
complement activation. Unfunctioning C3 or complete deficiency of the 
protein increases susceptibility to encapsulated pyogenic bacteria being 
potentially fatal and therefore rare (Lokki & Colten 1995). There are less 
than 30 confirmed cases of C3 deficiency and interestingly several cases 
with gain-of-function mutations described worldwide (Grumach & 
Kirschfink 2014). However, variants in C3 associate to autoimmune 
diseases and aHUS among other diseases. 
Sanger sequencing of C3 exons, flanking regions, and selected introns 
revealed a functional haplotype of 16 SNPs spanning the functionally 
critical sections in the middle of the gene. The region covered by the 
haploblock on the protein structure is indicated by blue square in Figure 
9. Rs423490 is included in the experimental haploblock associating to, 
and protecting from pre-eclampsia (Table 7) as well as in the actual 
haplotype discovered by Sanger sequencing (Table 8), but Sanger 
sequencing did not reveal a single SNP association at this locus. The three 
SNPs with most robust associations to severe pre-eclampsia are also 
located within the haploblock further supporting its functional 
significance. 
Regulatory regions, such as promoter or the pre-promoter microsatellite 
region known to associate to temporal lobe epilepsy and seizures did not 
yield significant associations to pre-eclampsia (Jamali et al. 2010). 
However, these results should be treated suggestive rather than 
conclusive due to small sample size in these analyses. 
 
Table 8.  Summary of findings in complement component 3 gene sequencing 
project. The p- values in parentheses are not conclusive due to small 
MAF and/or sample size in this location. Only statistically significant 
















6677978 rs17030    
6679349 rs344555    
6681980 rs7951    
6682103 rs45532534    
6686410 rs11666133    
6686493 rs2241391   (0.044) 
6686567 rs11665922    
6686648 rs237554    
6690602 rs3745568    
6690629 rs375600369    
6693152 rs10414623 C C  
6693229 rs2241390 C T  
6693262 rs11569492 C T  
6693306 rs2241389 C T  
6693376 rs389404 C T  
6694388 rs385791 C C  
6696331 rs2287848 C T 0.041 
6696485 rs2287847 G G  
6696546 rs2287846 C G  
6696586 rs2287845 T C 0.038 
6697395 rs423490 C C  
6697611 rs77063881 G G  
6697818 rs366510 A C 0.039 
6702146 rs428453 C G  
6702235 rs432823 G A  
6702444 rs11569450 C C  
6702489 rs200046246    
6702587 rs406514    
6707655 rs558232596    
6707902 rs144432231    
6709693 rs2230205    
6709837 rs2230204    
6710771 rs2230203    
6710937 rs10411506    
6713164 rs11085197    
6713251 rs1047286    
6713280 rs2230201    
6714024 rs11569571    
6718376 rs2230199    
6719442 rs190390034   (0.005) 
6720709 rs11569569    
6720961 rs183805948   (0.017) 
6721227 rs146998274    
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Using the ancestral allele of SNP rs2287845, the extent of selection 
pressure on the haploblock structure was evaluated using the REHH 
analysis. The analysis revealed that the controls hold tighter haploblock 
structures than women with severe pre-eclampsia. The tight haploblock 
suggests that the structure is indeed due to a positive evolutionary 
selection pressure. Selection pressures were slightly relaxed in pre-
eclamptic women suggesting a loosened force of active selection. It is 
possible that the observed selection pressure in pre-eclamptic women is 
the force of selection past, i.e. remnants of the selection pressure 
previously active on the haplotype. It is also possible that the genetic 
haplostructure of severe pre-eclamptics reflect a distinct selection 




Figure 9.  The C3 domain structure in relation to the associating single SNPs. 
Together with CUB (complement C1r/C1s, Uegf, Bmp1) and TED (thio-
ester containing) domains, the α’NT forms the functional region 
containing the critical binding sites for factor B as well as inhibitors 
CR1 and factor H causing activation or deactivation of C3. The 
extent of the associating haplotype is shown in the blue square. 
 
The mechanism of haplotype association to severe pre-eclampsia is 
unclear, but the effect may be due to functional or regulatory attributes 
of this region. Functional changes in C3 may affect the extravillous 
trophoblasts’ capacity to evade complement activation by C3 binding 
thereby compromising deep placentation and spiral artery remodelling. 
Excess complement activation may also be involved in a later stage of pre-
eclampsia influencing severity of symptoms such as inflammation and 
hypertension (Lillegard et al. 2013).  
 
The results of this study indicate that parallel to mice, C3 also plays a 
central role in the healthy pregnancy in humans (Xu et al. 2000). The 
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complement system has been indicated in some cases of a related 
condition, HELLP syndrome, a rare condition which is considered to be a 
complication of severe pre-eclampsia. By the inhibitor drug treatment 
eculizumab, which targets C5, a patient suffering from HELLP was able to 
extend her pregnancy until a safer time to secure a healthy delivery 
(Burwick & Feinberg 2013). The results of this study indicate that an 
earlier point within complement activation pathways, C3 may also be a 
plausible target for drug development. With further confirmation of these 
results, a combination of C3 polymorphisms may also be incorporated 
into a genetic predictor tool to detect those patients who are most at risk 
of developing severe pre-eclampsia.  
 
5.3  Complement in placenta (I) 
We hypothesized that excess or unregulated complement activation may 
be detectable within the placenta tissue of pre-eclamptic patients. 
Furthermore, localisation and quantity of complement components in 
relation to tissue integrity in a healthy and pre-eclamptic placenta may 
be observed in the placenta by immunohistochemistry.  
Nine components of the complement system were studied alongside with 
sEng to pinpoint localization of complement components in the placenta 
tissue and to assess, whether their quantity or localisation is associated 
to pre-eclampsia. The studied components were selected to represent the 
key activators and regulators of components from classical (C1q, C4c, 
C4bp, DAF, and MCP), alternative (C3c, C3d, FH, MCP), and terminal (C9 
and CD59) pathways of complement activation. C3c was considered to 
indicate a general indicator of complement activation, while C3d was 
considered to be an indicator of chronic and specific C3 deposition on the 
placenta tissue. 
Complement components were visualised on the placenta tissue using 
immunofluorescence staining of placental sections from pre-eclamptic 
and healthy pregnancies. Intensity of fluorescence was measured by sum 
amount as well as mean of total intensity. Associations of intensity 
readings between groups are given in table 9 according to the component 
where association was discovered. Furthermore, the high intensity areas 
thought to represent the functionally most significant areas of 
complement deposition, were correlated against each other and 
significant correlations between groups are given in table 10. Negative 
result of Pearson’s r signifies that in the given group, the two components 
 
 65 
are negatively correlated, while positive results signify that the more 
there is of one component, the more there will be of the second one. 
 
Table 9. Significant associations of t-test analysis between diagnostic 
groups. Both mean and sum of intense fluorescence areas were 
analysed and compared against all diagnostic groups. Early – early 
onset pre-eclampsia, late – late onset pre-eclampsia, PE – pre-
eclampsia, s-Endoglin – soluble endoglin, C1q – complement 
component 1q, df – degrees of freedom.  
   
Association Test t-test p-value df 
C1q 
early/late Sum 2.273 0.046 10 
early/late Mean 3.614 0.005 10 
late/control Sum 2.793  0.015 13 
late/control Mean 2.993 0.01 13 
s-Endoglin 
PE/control Sum 2.008 0.059 19 
PE/control Mean 2.463 0.023 19 
early/control Sum 1.524 0.150 14 
early/control Mean 1.815 0.091 14 
late/control Sum 1.842 0.090 12 
late/control Mean 2.825 0.015 12 
 
S-Eng was used as a positive control in this study, because it is known to 
stain circumferentially on the placenta (Gu et al. 2008). Furthermore, s-
Eng is increased in pre-eclampsia in comparison to healthy pregnancies 
(Venkatesha et al. 2006). Due to small sample size and inaccuracy of the 
semi-quantification protocol, we were not able to corroborate the 
correlation between s-Eng and pre-eclampsia severity (Leanos-Miranda 
et al. 2017), but our results are in accordance with other studies who did 
not differentiate late- and early-onset pre-eclampsia by levels of endoglin 
expression (Sitras et al. 2009, Nishizawa et al. 2007). The significant 
association between s-Eng deposition in pre-eclamptic and controls in 
Table 9 (mean p-value=0.023) proves that the semi-quantification of 
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immunohistochemistry stainings may reveal trends in placental 
deposition and allows for comparison between pre-eclamptics and 
controls.  
The association of C1q deposition in Table 9. between early-onset and 
late-onset pre-eclampsia and on the other hand between late-onset pre-
eclampsia and controls reveals the role of complement-mediated 
housekeeping function in pre-eclampsia. It is likely, that activation of 
classical pathway of complement system signifies here the increase in 
demand for debris clearance which is associated with break-down of 
syncytiotrophoblast integrity, which is typical in pre-eclampsia. In our 
data, this is particularly seen in the case of late-onset pre-eclampsia, 
where C1q is most abundant. In conclusion, the association between 
complement and pre-eclampsia here is most likely due to the effects of 
the disease rather than being the underlying cause of it. That being said, 
activation of complement pathways will serve to induce and maintain 
inflammatory response in the placenta.  
Correlation between quantification results of different complement 
components in the same placentae point were used to point us towards 
the active complement pathways. When a negative correlation between 
an activator of an early pathway and an activator of a terminal pathway 
component is observed, it is interpreted as successful regulation of 
complement activation. 
The role of the complement in pre-eclamptic and control placentae is 
further clarified by the significant correlations in Table 10. The more C3b 
deposition there is, the more endoglin is also observed indicating an 
association between C3 and early-onset pre-eclampsia. Controls typically 
have more of the membrane bound inhibitors DAF and MCP, but this 
correlation is absent in pre-eclamptic placentae. Interestingly, in late-
onset pre-eclampsia the activation of classical pathway (C4) is correlated 
with activation of terminal pathway (C9) even in the presence of strong 
correlation between the soluble regulator C4bp and C4. Another 
indication of classical pathway in the late-onset pre-eclampsia is the 
negative correlation between C1q and soluble regulator FH. FH is known 
to bind independently and compete with C1q in apoptotic surfaces and 





Table 10.  The significant correlations of complement component among 
diagnostic groups (PE - pre-eclampsia).  
 




Early-onset PE C1q C9 −0.878 0.009 
Early-onset PE DAF C4 0.824 0.023 
Late-onset PE C4 C9 0.921 0.026 
Late-onset PE C4bp C4    0.962 0.009 
Control C4bp MCP −0.659 0.038 
Alternative pathway 
Early-onset PE C3b/iC3b s-Eng 0.829 0.021 
Control FH C9 0.671 0.034 
Classical and alternative pathways 
Late-onset PE C1q FH −0.932 0.021 
Control DAF MCP 0.634 0.049 
 
 
The results of this study indicate that components of the complement 
system are present in a specific pattern on the placenta. The most typical 
pattern of localisation was circumferentially on the syncytiotrophoblast, 
which is effectively the maternal-foetal interface (data not shown). 
Placenta during pregnancy must be carefully protected by inhibitors of 
complement activation from complement mediated tissue destruction 
and cell death (Buurma et al. 2012). An example of failed complement 
regulation is shown in an immunofluorescent overlay staining of a 
paraffin fixed placental sample in Figure 10. In comparison of the images, 
it is observed that in the region, where coverage of FH is not adequate, 
complement activation likely through amplification loop (green in panel 




Figure 10.  In panel (A) the red stains soluble 
complement inhibitor factor H. The 
black region marked with m is the 
intervillous space between villi and 
the blue is DAPI staining of the nuclei. 
In panel (B) the green stain is 
complement component C3d, which 
indicates chronic complement 
activation. In panel (C) the yellow 
regions are co-stained, both C3 and 
FH are deposited in these areas.  
v – vessel, foetal blood flow   




The results and study design from Study I are summarised in Figure 11. 
The localisation and pattern of complement deposition differ between 
pre-eclamptic and control placentae, but we cannot conclusively 
differentiate between functional differences in different diagnostic 
groups, or the effect of tissue disruption, known to be associated with 
pre-eclampsia, on the pattern of complement component deposition. The 
correlation of C9 indicating MAC deposition with the classical pathway 
activating components C4 in the patient groups may be indicative of 
breakdown of complement regulation and/or uncontrolled classical 
pathway activation in pre-eclampsia. In controls, the soluble regulator 
factor H, correlated with C9 indicating a healthy regulation of 
complement activation in these placentae. Furthermore, the control 
placentae are well protected by correlating amounts of surface-bound 
regulators DAF and MCP.  
 
5.4 C4 deficiencies in pre-eclampsia (I) 
Complement component C4 is coded by two genes, C4A and C4B, with 
partially overlapping functions. Typically, an individual may have 
between zero and four copies of both genes, although zero copies of both 
genes resulting in complete C4 deficiency are very rare (Lokki & Colten 
1995). This study was based on the hypothesis that the copy number 
variation observed within the genes coding for C4 may associate to pre-
eclampsia. Results of this study suggest that deficiencies in C4 may 
predispose to pre-eclampsia. C4A or C4B deficiencies were found almost 
twice as often in early-onset pre-eclampsia patients than in healthy 
controls (Table 11). C4A deficiencies are observed in 16% of general 
population in Finland (Wennerstrom et al. 2013). C4A deficiencies were 
found in 40% (2/5) of pre-eclampsia mothers with late-onset disease and 
43% (3/7) of pre-eclampsia mothers with early-onset disease. None were 
observed in the controls (n=7). Because of the small number of samples, 
the difference was on the borderline statistically significant (p=0.055 
Fisher’s exact two-sided test). Only two individuals had total C4 
deficiency (total C4A deficiency in one control mother and total C4B 









Table 11.  Frequency of C4A and C4B gene deficiency in diagnostic groups 
and controls. 
 









C4A or C4B 
deficiency 
maternal 0.667 0.714 0.600 0.375 
foetal 0.700 0.667 0.750 0.500 
C4A deficiency 
maternal 0.417 0.429 0.400 0 
foetal 0.300 0.333 0.250 0.375 
C4B deficiency 
maternal 0.333 0.286 0.400 0.375 






The genetic analyses in Study I showed that C4A deficiency was more 
frequent in pre-eclamptic women than controls. Although the results 
were not conclusive due to small sample size, it would seem that C4 
deficiencies are more of importance in maternal than foetal genotype. 
Furthermore, the copy number of C4 seems to decrease with the severity 
of pre-eclampsia symptoms. C4A deficiencies have previously been linked 
to autoimmune diseases (Samano et al. 2004). The patients in this study 
did not suffer from diagnosed autoimmune diseases. The high incidence 
of C4A deficiency in pre-eclampsia supports the importance of classical 




Figure 11.  The components of complement system studied in 
Study I are mostly located in the alternative and 
classical pathways of complement activation. The 
main results of the placenta study are indicated by 
bold dark green arrows. C4 was studied using 
genetic and immunohistochemistry methods, others 





5.5  Sequencing of MCP (CD46) (II) 
MCP has the capacity to regulate both alternative and classical pathways 
of complement activation by binding to C3b or C4b, and acting as a co-
factor to the inactivator enzyme Factor I. MCP is a widely expressed type 
1 membrane bound protein. The gene MCP is located in the regulators of 
complement activation (RCA) gene cluster in chromosome 1 in proximity 
of genes for numerous other complement inhibiting components (Holers 
et al. 1985, Liszewski et al. 1991). In this study, fifteen SNPs were 
discovered, including three novel variants. The SNPs are listed in Table 
12 according to their location on the gene. None of the SNPs were 
associated to pre-eclampsia with severe proteinuria. 
 
A disease of the kidney, aHUS, can be caused by mutations in the MCP 
(Manchester et al. 1995, Richards et al. 2003, Fremeaux-Bacchi et al. 
2006, Fang et al. 2008). Proteinuria is one of the defining symptom of pre-
eclampsia, but its extent can vary 10-fold between patients. For this 
project, pre-eclamptic women with severe proteinuria were selected, 
because renal dysfunction due to uncontrolled complement activation 
was suspected to be the underlying link between pre-eclampsia and 
kidney diseases.  
 
To investigate whether sequence variations in the CD46 promoter, splice 
sites and exome might predispose Finnish women to pre-eclampsia we 
sequenced these areas within the MCP gene in pre-eclamptic women with 
severe proteinuria and in non-pre-eclamptic controls. A larger cohort of 
controls was used in this study, to increase the power of the analysis in 
the relevant region of the gene, because A304V (rs35366573) was 
previously shown to be associated with pre-eclampsia (Salmon et al. 
2011).  
 
The results of this study do not corroborate the previously reported 
association of A304V to severe pre-eclampsia (Salmon et al. 2011). We 
observed a high MAF of approximately 6% in both cases and controls and 
we also found one control individual, who was homozygous to 304*V. The 
other functional SNP K32N (rs150429980) located in CCP 1 was found in 
one heterozygous case and one heterozygous control and thereby results 






Table 12.  Fifteen single nucleotide polymorphism (SNPs) discovered in Sanger sequencing of membrane cofactor protein gene 
(MCP). The number of individuals that passed quality control is given in N cases and N controls. 
 
 MAF cases MAF controls N cases N controls Function 
Promoter 
rs2796268 0.453 0.457 95 94 regulatory 
rs41266397 0.069 0.074 95 95 regulatory 
Exonic 
rs150429980 0.005 0.005 95 94 ex2 / K32N 
rs12126088 0.011 0.000 95 94 ex4 / synonymous 
rs41258244 0.069 0.074 95 94 ex5 / synonymous 
rs35366573 0.058 0.061 95 188 ex11 / A304V 
Intronic 
rs2724374 0.247 0.200 95 95 close to ex8 
NewSNP1 0.000 0.005 92 97 close to ex13 
NewSNP2 0.005 0.000 95 94 cytoplasmic tail 
NewSNP3 0.005 0.000 95 187 cytoplasmic tail 
rs7144 0.452 0.457 95 94 cytoplasmic tail 
rs14374 0.053 0.021 95 95 cytoplasmic tail 
rs185457983 0.000 0.005 95 94 cytoplasmic tail 
rs193023975 0.005 0.000 95 94 cytoplasmic tail 
rs1237 0.069 0.042 95 95 cytoplasmic tail 
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It is possible, however, that MCP plays a part in a particular subtype of 
pre-eclampsia, due to the heterogeneous nature of the disease. 
Regulators of complement activation may be particularly important on 
the foetal tissue, but also in controlling inflammation and preventing 
tissue destruction on the placental bed. Severe pre-eclampsia has been 
previously linked with elevated levels of alternative pathway activation 
in the mother (Hoffman et al. 2014). 
 
5.6  Maternal FLT1 variants protect from pre-
eclampsia (IV) 
Dysregulation of angiogenesis is among the most promising hypotheses 
of study to the pre-eclampsia pathophysiology over the last 15 years 
(Levine et al. 2004). A high ratio of sFlt1 to PlGF is considered a promising 
biomarker for prediction of pre-eclampsia (Villa et al. 2013, Sunderji et 
al. 2010, Sahai et al. 2017). We hypothesised that genetic variants in the 
FLT1 may associate to pre-eclampsia.  
We found four SNPs to be associated to pre-eclampsia in the Flt1 (Table 
13). Two of the variants, rs35832528 and rs141440705, were protective 
while the others, rs148588802 and rs61763183, were predisposing. 
Rs148588802 is rare, and rs61763183 is associated at a borderline level 
only, so these results should be treated with caution. 
Among the observed associating variants in FLT1, rs141440705 causing 
R54S is more likely of functional importance, because it results in a polar 
change (positive->neutral) within the immunoglobulin -like domain 1, 
one of the functional domains of the protein (Christinger et al. 2004). On 
the other hand, rs141440705 is located in the last nucleotide of exon 3. 
Therefore, the variant potentially affects splicing as well as the coded 
amino acid sequence.  
In study IV we provide further evidence on the link between pre-
eclampsia and heart failure. The results suggest that those FLT1 variants 
that protect from pre-eclampsia also protect from heart failure (Table 
14). 
The anti-angiogenic FLT1 is a tempting candidate gene for the suspected 
link between pre-eclampsia and increased risk for CVD in later life. FLT1 
has been indicated in coronary artery disease in a genome wide 
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association study as well as in a follow-up study indicating association to 
long-term cardiovascular events (Lee et al. 2013, Lee et al. 2016). The 
circulating sFlt1 levels are higher in pregnant, in comparison to non-
pregnant women. From serum, increased levels of sFlt1 are indicated in 
both pre-eclampsia and in peripartum cardiomyopathy. In both diseases, 
high levels of sFlt1 correlate with severity of symptoms (Damp et al. 
2016). Pre-eclampsia may increase the risk of peripartum 
cardiomyopathy (Hilfiker-Kleiner et al. 2015). It has been suggested that 
sFlt1 may be toxic to the heart thereby contributing to the development 
of peripartum cardiomyopathy in susceptible women (Shahul et al. 
2016). In heart failure during pregnancy, extreme sFlt1 levels in at least 
the 95th percentile have been reported (Rhee et al. 2011). Independent 
from pregnancy, heart failure after myocardial infarction is also reflected 
in extreme levels of sFlt1 (Onoue et al. 2009). 
 
In a meta-analysis of results from seven studies, it was shown that an 
increase of 3.6-fold in risk of heart failure is associated with a history of 
pre-eclampsia, predominantly during 1-10 years after pre-eclampsia (Wu 
et al. 2017). Cardiac dysfunction in predisposed pre-eclamptics is likely 
mediated by antiangiogenic factors (Shahul et al. 2016). High sFlt1 is also 
linked to impaired renal function, heart failure, and early mortality in 
patients with chronic kidney disease (Di Marco et al. 2015). The role of 
the sFlt1 in proteinuria and glomerular endotheliosis was established in 
the beginning of the last decade, but given the importance of proteinuria 
and hypertension to the diagnosis of pre-eclampsia, the specific 
mechanisms have received unexpectedly little attention in the last 
decade, while the role of sFlt1 in hypertension has been more widely 
studied (Maynard et al. 2003). 
Further research is required to assess the interaction between genetic 
variants of FLT1, and their consequences to the development of the 
symptoms related to pre-eclampsia. Specifically, the immunological and 
renal effects of sFlt1 warrant further investigation. It is likely that future 
research will tie these effects to the widely reported increased risk of 
heart failure in later life. In support of this theory, the results of this study 
indicate that FLT1 variants that protect from pre-eclampsia may also 
protect from heart failure. In susceptible patients, angiogenic imbalance 
may link pre-eclampsia to later life cardiovascular morbidity. The 
research to the possibility of blocking sFlt1 production or development 
of neutralising antibodies against angiogenic proteins may in the future 
provide therapeutic benefit for individuals with genetic predisposition 
(Thadhani 2010, Maynard & Karumanchi 2011). The results of this study 
add to the toolbox of genetic markers that may been soon used to 
determine a patient’s risk of these serious diseases.  
 
 




Table 14.  E982A and R54S in fms related tyrosine kinase 1 gene (FLT1) protect from heart disease as examined across registry-
derived disease endpoints.  
 




Count with minor 
allele 
ncases/ncontrols 
Consequence (distance from 
exon, base pairs) 
 
rs35832528 
2.49E-4 0.387 (0.205 - 0.678) 0.010 14/122 missense variant, E982A 
 
rs141440705 
0.003 0.442 (0.233 - 0.779) 0.010 14/106 missense variant, R54S 
 
rs148588802 
0.038 10.328 (0.829 - 540.960) 0.002 3/1 intron variant (+40) 
 
rs61763183 








rs35832528 E952A 0.007 0.368 0.164-0.830 301/10956 
rs141440705 R54S 0.007 0.340 0.140-0.826 297/10960 
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5.7  Candidate gene associations (IV) 
We hypothesised that genes not coding for components of the 
complement system may also contribute to the patients’ predisposition 
to pre-eclampsia, which is known to be a multifactorial disease. In 
addition to the FLT1 association to pre-eclampsia described above, 
associating variants were found in twenty-three other candidate genes. 
The candidate genes were selected to represent key pathways that have 
a suspected link to pre-eclampsia. These include common immunological 
genes, genes with previously reported or suspected association to pre-
eclampsia or related pregnancy complications, and genes linked to 
susceptibility to cardiovascular disease, or belonging to suspected 
pathways of importance such as angiogenesis. Genes coding for factors of 
the coagulation cascade and components of the complement system were 
excluded from this study to be later analysed separately. The significant 
results of the association studies are listed in Table 15. The most 
promising candidate genes with associating variants are discussed below.  
Corin codes for a member of the type II transmembrane serine protease 
class of the trypsin superfamily that is predominantly expressed in 
cardiac tissue (Yan et al. 1999). Through cleavage of atrial natriuretic 
peptide (ANP) Corin regulates blood pressure (Yan et al. 2000, Li et al. 
2017). Corin also likely plays an important role in the regulation of CVDs 
(Hooper et al. 2001). Recent evidence has shown that corin-ANP 
autocrine function in the kidney may regulate sodium homeostasis 
suggesting, that local corin function may also be an underlying cause in 
kidney diseases (Li et al. 2017). In pre-eclampsia, association with corin 
has been previously indicated with two population-specific variants 
having similar odds ratios of approximately 2.5 in intronic SNPs to what 
we found in exonic variants rs61759670 and rs61760500 (Stepanian et 
al. 2014). Corin may have an important role in trophoblast invasion and 
spiral artery remodelling (Cui et al. 2012, Kaitu'u-Lino et al. 2013) and 
immunohistochemistry stainings show over-expression in a subset of 
decidual cells from pregnancies with foetal growth restriction in 
comparison to healthy pregnancies (Miyazaki et al. 2016).  
 
 Activin A receptor type 1 (ACVR) and type 1C (ACVR1C) belong to the 
transforming growth factor signalling molecule receptor group. Previous 
results from rs13406336 and rs4556933 in ACVR1 and ACVR1C have 
been inconclusive. They were studied as potential candidate SNPs, but no 
significant association to pre-eclampsia was established in a Norwegian 
population (Roten et al. 2009). The result in this study indicates a likely 




Table 15. The list of variants with possible associations to pre-eclampsia. 


















rs61758484 CORIN 0.003 2.658 (1.320 - 5.261) 0.013 
non-coding transcript 















rs80338240 JAG1 0.010 0.256 (0.051 - 0.806) 0.004 intron variant (-11) Notch signalling 
rs147998709 GPR98 0.011 13.757 (1.360 - 675.490) 0.003 intron variant (+24) 
Development of central 
nervous system. 
rs2290843 ADAM12 0.011 0.726 (0.561 - 0.932) 0.071 
synonymous variant, 
T326T 









rs147942437 ADAM28 0.012 5.181 (1.226 - 24.998) 0.004 
missense variant, 
L449P 




















rs13406336 ACVR1 0.013 2.423 (1.129 - 5.062) 0.011 
missense variant, 
A15G 
Apoptosis pathway, cell 





rs142436579 ADAM28 0.014 0.366 (0.129 - 0.852) 0.005 
missense variant, 
R219S 
A disintegrin and 
metalloprotease 
domain-family 








rs201756397 FLT4 0.014 Inf (1.283 - Inf) 0.001 
synonymous variant, 
E926E 
Receptor for VEGFC 
and VEGFD. 
Lympahgiogenesis. 
rs80069610 GPR98 0.016 2.499 (1.122 - 5.411) 0.010 
synonymous variant, 
V1101V 
Development of central 
nervous system. 








rs4556933 ACVR1C 0.019 0.847 (0.735 - 0.976) 0.323 
synonymous variant, 
F38F 






















rs41302834 GPR98 0.022 3.451 (1.031 - 11.557) 0.007 
missense variant, 
D1944N 
Development of central 
nervous system. 
rs3736061 FLT4 0.023 0.803 (0.665 - 0.973) 0.135 
synonymous variant, 
L252L 
Receptor for VEGFC 
and VEGFD. 
Lympahgiogenesis. 
rs3741849 PZP 0.039 1.309 (1.004 – 1.696) 0.068 
synonymous variant, 
K563K, splice region 
variant 
Proteinase inhibitor, 
highly expressed in late 
pregnancy serum. 
rs34307240 LCT 0.026 2.201 (1.038 - 4.515) 0.010 
missense variant, 
D106E 
Hydrolase activity and 
lactase activity, 
galactose metabolism. 








rs2228048 TGFBR2 0.029 0.672 (0.459 - 0.963) 0.030 
synonymous variant, 
N354N 
A member of the 
Ser/Thr protein kinase 
family and the TGFB 





0.032 4.311 (0.926 - 21.758) 0.005 
missense variant, 
R229Q 
INHBA Antisense RNA 
1 
rs1466360 ADAM12 0.033 1.152 (1.010 - 1.315) 0.414 intron variant (+30) 





























rs140593977 TREX1 0.034 3.448 (0.920 - 12.928) 0.004 
downstream gene 
variant (-44) 
3' exonuclease activity. 
DNA repair. Immune 
system. 
rs1466361 ADAM12 0.034 1.152 (1.010 - 1.316) 0.414 intron variant (-46) 






















rs1554286 IL10 0.037 1.203 (1.009 - 1.438) 0.153 intron variant (+18) 
T-cell growth inhibitory 




















rs2453040 NOTCH2 0.037 0.818 (0.676 - 0.992) 0.141 intron variant (-45) 
Cell-cell signalling. 
Angiogenesis. 




Hydrolase activity and 
lactase activity, 
galactose metabolism. 




Signalling in embryonic 
vascular development. 
rs200071734 FLT4 0.040 10.114 (0.811 - 529.805) 0.002 
missense variant, 
V157M 
Receptor for VEGFC 
and VEGFD. 
Lympahgiogenesis. 




surface interactions at 
the vascular wall. 
rs368518386 FLT4 0.046 5.581 (0.799 - 61.819) 0.003 intron variant (-43) 
Receptor for VEGFC 
and VEGFD. 
Lympahgiogenesis. 
rs3736062 FLT4 0.046 1.547 (0.988 - 2.374) 0.024 
synonymous variant, 
Y531Y 
Receptor for VEGFC 
and VEGFD. 
Lympahgiogenesis. 
rs7830 NOS3 0.049 0.877 (0.769 - 1.002) 0.434 intron variant (+11)  
Angiogenesis. Produces 
NO, vascular smooth 
cell relaxation, mediates 
angiogenesis in 




Nitric oxide synthase 3 (NOS3) synthesises nitric oxide (NO), which is a 
reactive free radical that has a role as a biologic mediator in several 
processes, including antimicrobial and anti-tumoural activities and 
neurotransmission. Association of NOS3 has been investigated in several 
studies and a haplotype including rs7830 was found to protect women 
from pregnancy hypertension and pre-eclampsia (Muniz et al. 2012). 
However, the association has not been confirmed in meta-analyses 
(Staines-Urias et al. 2012, Buurma et al. 2013). Indeed, Staines-Urias et 
al. found indication that reported associations of NOS3 and other genes 
to pre-eclampsia might be due to reporting bias, where results are 
reported selectively (Staines-Urias et al. 2012). Other variants in NOS3 
are associated with susceptibility to coronary spasm (Chang et al. 2003). 
Alternative splicing and alternative promoters result in multiple 
transcript variants of NOS3. It is possible that similarly to FLT1, only some 
of the isoforms of NOS3 are relevant in the context of pre-eclampsia 
thereby making result comparison between studies and data 
interpretation challenging when information about individual SNP 
position and studied isoforms is not reported.  
 
Interleukin 10 is an anti-inflammatory cytokine that is most often linked 
to inflammation suppressing Th2 type immunity (Spellberg & Edwards 
2001). The role of interleukin 10 (L-10 in pre-eclampsia has been 
demonstrated by a murine model of IL-10 deficit mice (Kalkunte et al. 
2010). We found rs1554286 to associate to pre-eclampsia (p=0.037). 
This SNP belongs to an intronic haplotype, which strongly predisposes 
women of Bahraini Arab population to idiopathic recurrent miscarriages 
(Qaddourah et al. 2014). The association results from Study IV support 
the hypothesis that recurrent miscarriages and pre-eclampsia may share 
common immunological aetiology (Redman & Sargent 2010b, Robertson 
et al. 2003).  
 
The results discussed here concern non-adjusted significance testing 
from a targeted exomic sequencing. While some of the results may be 
false positives, the results corroborate several known associations 
between adverse pregnancy outcomes and candidate genes. 
Furthermore, the statistical framework of the targeted exome sequencing 
supports validity of the results: the tail of the p-value distribution of 
benign variants was as expected (0 results with p<0.001 (expected ≤ 1) 
and 2 results with p<0.01 (expected ≤ 4.2)). Concerning the 201 
putatively functional variants, one had p<0.001 (alpha=0.05) compared 
to the 0/421 observed among benign variants. Statistical confounders 
such as stratification would be indicated by inflated p-values, which were 
not observed in this study. Further studies into regulatory mechanisms 
and haploblock structures within these genes may reveal the true 
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functional association underlying these individual preliminary 
associations. 
 
5.8 Limitations of the study 
In Study I, foetal and maternal components of the complement system 
were not in all cases distinguishable, and foetal genotypes of C4 genes 
were studied alongside the maternal genes in this small group of patients. 
The laboratory methods of this study were completed before most of the 
foetal DNA of the FINNPEC cohort became available. Therefore, the other 
genetic association studies were concerned with only the maternal 
genotype. It is obvious that especially in immunological studies the 
compatibility of maternal and foetal genotypes and functional pathways 
is important. The same is true for studies of sFlt1, which is known to be 
largely of placental origin during pregnancy.  
 
A core problem in placental studies is the fact that the complications 
underlying defective placentation most likely take place in the early 
second or even first trimester during the two phases of trophoblast 
invasion. In study of the post-partum placenta the data is always limited 
to the condition and structure of the placenta after the processes of later 
pregnancy and birth. Therefore, conclusions concerning disease 
aetiology drawn from this material must be conservatively interpreted. 
However, pathophysiological study of the immunological components in 
the placenta may serve as a fingerprint of processes that led to the disease 
development. At the very least, they will describe the immunological 
stress the placenta was subjected to at the time of birth.  
 
Candidate gene studies are often balanced on rigorousness of data and 
sample size and the labour and finances available. These problems can to 
a degree be overcome by next generation sequencing methodology, such 
as the targeted exome sequencing in Study IV. However, our sequencing 
gene studies with limited sample sizes have shown that sequencing has 
benefits such as coverage of the intronic, splicing, and regulatory regions. 
When sequencing protocols can be adjusted individually for each 
amplicon, even technically challenging genomic regions can be analysed. 
While statistically limited, the data from sequencing studies is 
comprehensive and allows for a holistic approach to data analysis 
including exploration of the haploblock structures spanning across 




This study is concerned with candidate genes in pre-eclampsia and 
different aspects of humoral innate immunity. Immunological processes 
function systemically and locally in an intertwined web of interactions 
between humoral and cellular immunity as well as innate and adaptive 
immunity. While humoral innate immunity and complement system is 
the first line of defence with specific role of self-nonself detection, I have 
not explored possible cellular immunological contributors or down-
stream immunological processes within adaptive immunity that may also 
have an important role in aetiology of pre-eclampsia. 
 
This study was done in Finnish patients and controls. Pre-eclampsia is a 
complex disease whose aetiology may vary between populations. Finland 
has a unique population history, and consequently, particularly non-
common loss-of-function alleles are overrepresented in the Finnish 
population (Lim et al. 2014). It is beneficial if several populations are 
studied in pursuit of global factors of complex diseases. 
 
This study did not explore functional consequences of the genetic 
findings. Mechanistic validation would add weight to the associations 
described in this study. 
 
5.9  Future perspectives 
5.9.1  Future of pre-eclampsia research 
The results of this study give rise to several important research questions. 
Replication of the protective variants in FLT1 is of particular interest in 
other populations but also in Finnish samples of children born from pre-
eclamptic pregnancies. The structure and genomic context of FLT1 is 
poorly understood and warrants further research.  
 
Candidate genes within the complement system should be further 
studied, as only two genes of the complement system were sequenced as 
part of this study. Likewise, the C4 genotyping in different disease sub-
phenotypes is an important next step.  
 
Replication of our results in ethnically diverse sample cohorts will show, 
if the associations found are unique to Finnish population. In either case, 
detailed research of the candidate genes with associating variants may 
eventually pinpoint the associating element and function of the candidate 
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proteins in pathophysiology of pre-eclampsia.  
 
Functional studies to explore the underlying mechanism of genetic 
association are required to validate the genetic associations found here.  
5.9.2  Therapeutic suggestions 
The role of sFlt1 in the aetiology of pre-eclampsia remains enigmatic. 
However, it is plausible from this and other studies, that sFlt1 plays an 
important role in at least aggravation of pre-eclampsia. Removal of sFlt1 
out of the maternal serum could be one possible way of treatment to 
restore angiogenic balance in pre-eclamptic patients (Schrey-Petersen & 
Stepan 2017). Neutralising antibodies may also be explored to prevent 
the effects of excess sFlt1 in the maternal circulation. 
Eculizumab was one of the first drug that inhibits complement activation 
and was used to treat a pre-eclamptic patient with HELLP with success 
(Burwick & Feinberg 2013). Eculizumab targets the terminal pathway of 
complement activation. While supporting the effect of complement 
activation in pre-eclampsia pathogenesis, the results of this study did not 
address the effect terminal pathway of complement activation 
specifically and therefore recommendations concerning use of 
Eculizumab in treatment of pre-eclampsia warrants further studies.  
 
The results of this study suggest, that with further research, it may be 
possible to identify a more specific upstream target within the 
complement system that may, in suitable patients, be influenced with 
therapeutics. This would prevent the release of anaphylatoxins which are 
released as complement cascade advances and thereby limit the 
inflammatory response effectively. 
 
Increasing knowledge of the particular traits enriched in the Finnish 
population may also open avenues for development of personalised risk 








Pre-eclampsia is a complex disease which is reflected in its 
immunogenetic foundation. Immunological health of the pregnancy is 
constituted by a network of interacting immunological processes of 
maternal and foetal origins (Parham & Moffett 2013). Identifying the 
appropriate pathways in targeting treatment for any pre-eclamptic 
woman requires more studies of the immunogenetic framework while 
keeping in mind the evolutionary consequences of the findings. The 
human pregnancy and birth can be seen as a life-history bottleneck 
(Brown et al. 2013). The study of the maternal and foetal implications of 
reproductive complications opens a unique opportunity to broaden our 
understanding of the human evolutionary process (Brown et al. 2013). 
  
This study adds to the growing body of evidence, which indicates that 
processes within the innate immunity play a central role in development 
of pre-eclampsia. Furthermore, our findings support the hypothesis that 
recurrent miscarriages and pre-eclampsia may share common 
immunological aetiology (Redman & Sargent 2010b, Robertson et al. 
2003). The immunological connection between pre-eclampsia and 
miscarriage warrants further study by replication of our results in 
suitable cohorts of consisting of patients with reproductive failure. 
The results in of this study highlight the importance of careful sub-
phenotyping in pre-eclampsia research. It is likely that the patient pool is 
comprised of individuals with varying aetiological determinants, but who 
present with similar symptoms of proteinuria and hypertension in the 
second half of the pregnancy. Therefore, careful phenotyping should be 
at the core of research studies on pre-eclampsia. When comparing results 
to previous studies, it is essential that the interpretation is adjusted to the 
phenotype of the studies in question. Moreover, in any future study 
designs standardised data collection should be at the core of data 
collection. It is of paramount importance that studies be compared and 
replicated in well-characterised and compatible patient samples.  
Pregnancy brings about tremendous changes in the body fluid volume 
and distribution. Fundamentally, pre-eclampsia is a disease that reflects 
an underlying failure in regulating vascular and hemodynamic changes in 
pregnancy, which may be due to dysregulation of immunological 
processes and the consequential loss of tolerance to the allogenic foeto-




The work presented here underlines the great potential of genetic studies 
in prediction, diagnosis, and treatment of pre-eclampsia. In the field of 
complex disease genetics, the recent technological advances allowing for 
more cost-effective and detailed analysis of the genome hold great 
promise. However, hypothesis based candidate studies, when 
undertaken using a carefully characterised and representative pool of 
patients, still have the potential to produce important advances towards 
a better understanding of the enigma that is pre-eclampsia. The results of 
this study may open novel avenues for treatment development in pre-
eclampsia as well as tools for identifying the pool of patients that is most 
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 ⇔≡↓↑↔″≡±↔ °≠ ∠←↔≡↔↑∂…← ±≈ ¬ƒ±≡…°≥°÷ƒ⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂ ±≈ ⋅≡≥←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ ⇐≡±↔↑≥ ⋅°←↓∂↔≥⌠
⋅≡≥←∂±×∂⌠ ∧∂±≥±≈⌠  ∧∂±±∂←• √±←↔∂↔♠↔≡ ≠°↑ °≥≡…♠≥↑ ≡≈∂…∂±≡⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈
⌡ ∂±×≡↑∂〉≥°××∂⇓•≡≥←∂±×∂〉≠∂
⇒←↔↑…↔
∉↑≡≡…≥″↓←∂ ∂←  …°″″°± ≈∂←°↑≈≡↑ °≠ ↓↑≡÷±±…ƒ …•↑…↔≡↑∂∞≡≈ ƒ ≡±≈°↔•≡≥∂≥ ≈ƒ←≠♠±…↔∂°±〉
√↔ ″ƒ ≡ ≥∂≠≡∫↔•↑≡↔≡±∂±÷ ≠°↑ ↔•≡ ″°↔•≡↑ ±≈ ≠≡↔♠← ∂± ←≡♥≡↑≡ …←≡←〉 ⇔ƒ←↑≡÷♠≥↔∂°± °≠ ↔•≡ …°″∫
↓≥≡″≡±↔ ←ƒ←↔≡″ •← ≡≡± ←♠÷÷≡←↔≡≈ ↔° ↓↑≡≈∂←↓°←≡ ♦°″≡± ↔° ↓↑≡≡…≥″↓←∂〉 ⇐°″↓≥≡″≡±↔ ∂←
↓↑↔ °≠ ↔•≡ ∂±±↔≡ ±≈ ≈↓↔∂♥≡ ∂″″♠±≡ ←ƒ←↔≡″← ±≈ ↓°↔≡±↔∂≥≥ƒ …↓≥≡ °≠ …♠←∂±÷ ∂±≠≥″∫
″↔∂°± ±≈ ↔∂←←♠≡ ≈″÷≡〉 ≡″↑±≡ …°≠…↔°↑ ↓↑°↔≡∂± ⇐∉ ⇐⇔ ∂← ″°±÷ ↔•≡ ↓°↔≡±↔
…°″↓≥≡″≡±↔ ↑≡÷♠≥↔°↑← ↔•↔ •♥≡ ↑≡…≡±↔≥ƒ ≡≡± ≥∂±×≡≈ ↔°  ←≡♥≡↑≡ ≠°↑″ °≠ ↓↑≡≡…≥″↓←∂ ♦∂↔•
°↑ ♦∂↔•°♠↔ ± ♠±≈≡↑≥ƒ∂±÷ ♠↔°∂″″♠±≡ ↓•≡±°↔ƒ↓≡〉 ♠↔↔∂°±← ∂± ⇐⇔ ↓↑≡≈∂←↓°←≡ ↔° ↔•↑°″∫
°↔∂… ″∂…↑°±÷∂°↓↔•ƒ ♦∂↔• ≡±≈°↔•≡≥∂≥ …≡≥≥ ≈ƒ←≠♠±…↔∂°±〉 ⊄•≡ ≡♣°″≡ °≠ ⇐⇔♦≡↑≡ ←≡∫
→♠≡±…≡≈ ∂±  ∧∂±±∂←• ♦°″≡± ♦∂↔• ←≡♥≡↑≡ ↓↑≡≡…≥″↓←∂〉 ¬≡±≡↔∂… ♥↑∂↔∂°±← ≈∂←…°♥≡↑≡≈ ∂±
↔•≡ ≠♠≥≥ ≡♣°″≡ ♦≡↑≡ …°″↓↑≡≈ ↔° ↔•°←≡ °←≡↑♥≡≈ ∂±  …°±↔↑°≥ ♦°″≡± ♦•° ≈∂≈ ±°↔ ≈≡♥≡≥°↓
↓↑≡≡…≥″↓←∂〉 ⇑≡…♠←≡ ⇒⊃ ↑← ♦← ←←°…∂↔≡≈ ♦∂↔• ↓↑≡≡…≥″↓←∂ ∂± °±≡ ↓↑≡∫
♥∂°♠← ←↔♠≈ƒ⌠ ♦≡ ←≡→♠≡±…≡≈ ↔•≡ ↔↑±←″≡″↑±≡ ↑≡÷∂°± ∂±…≥♠≈∂±÷ ↔•≡ ⇒⊃ ♥↑∂±↔ ±≈ ↓↑↔
°≠ ↔•≡ …ƒ↔°↓≥←″∂… ↔∂≥ ∂±  ≈≈∂↔∂°±≥ …°±↔↑°≥←〉 ∪≡ ≈∂≈ ±°↔ ≈∂←…°♥≡↑ ±ƒ ←←°…∂↔∂°± ≡↔♦≡≡±
⇒⊃ °↑ °↔•≡↑⇐⇔ ⊂∇∉← ±≈ ↓↑≡≡…≥″↓←∂〉 ⊄•∂← ←↔♠≈ƒ ≈≡←…↑∂≡←  …↑≡≠♠≥≥ƒ …•↑…↔≡↑∫
∂∞≡≈ …°•°↑↔ °≠ ←≡♥≡↑≡≥ƒ ↓↑≡≡…≥″↓↔∂… ∧∂±±∂←• ♦°″≡± ±≈ ≠°♠±≈ ±° ↓°↔≡±↔∂≥≥ƒ ↓↑≡≈∂←↓°←∂±÷
♥↑∂±↔← ∂± ⇐⇔〉 ⋅°♦≡♥≡↑⌠ ∂↔ ∂← ↓°←←∂≥≡ ↔•↔ °↔•≡↑ ÷≡±≡↔∂… …°″↓°±≡±↔← °≠ ↔•≡ …°″↓≥≡″≡±↔
←ƒ←↔≡″ ″ƒ ≠≠≡…↔ ↔•≡ ↓↔•°÷≡±≡←∂← °≠ ←≡♥≡↑≡ ↓↑≡≡…≥″↓←∂ ±≈ ↑≡≥↔≡≈ ≈∂←≡←≡←〉
√±↔↑°≈♠…↔∂°±
∉↑≡≡…≥″↓←∂ ∂←  …°″″°±  ≈∂←°↑≈≡↑ °≠ ↓↑≡÷±±…ƒ〉 √↔ ∂±…↑≡←≡← ↓≡↑∂±↔≥ ″°↑↔≥∂↔ƒ
≠∂♥≡∫≠°≥≈ ⊗ℜ〉 ⊄•≡ °±←≡↔ ±≈ …≥∂±∂…≥ …°♠↑←≡ °≠ ↓↑≡≡…≥″↓←∂ ∂← ♠±↓↑≡≈∂…↔≥≡〉 √↔ °≠↔≡± ±≡∫
…≡←←∂↔↔≡← ↓↑≡↔≡↑″ ≈≡≥∂♥≡↑ƒ⌠ ♦•∂…• …↑↑∂≡← ↔•≡ ↑∂←× ≠°↑ …°″↓≥∂…↔∂°±← °≠ ↓↑≡″↔♠↑∂↔ƒ〉
∉∠⊂ ∠∇∨ ≤ ⇔∠√∑〉ñ∝°♠↑±≥〉↓°±≡〉 ∧≡↑♠↑ƒ ⌠   ñ 

∠∉∨∇ ⇒⇐⇐∨⊂⊂
⇐∂↔↔∂°±∑ °××∂ ⇒√⌠ ⇒≥↔°∫⊃∂≥∝×∂±≡± ⊄⌠ ≡↑∂ ⊂⌠
∂♥♠°↑∂ ⋅⌠  ¬≡±≡↔∂… ⇒±≥ƒ←∂← °≠ ≡″↑±≡
⇐°≠…↔°↑ ∉↑°↔≡∂± ⇐⇔ °≠ ↔•≡ ⇐°″↓≥≡″≡±↔ ⊂ƒ←↔≡″
∂± ∪°″≡± ♦∂↔• ±≈ ♦∂↔•°♠↔ ∉↑≡≡…≥″↓↔∂…
∉↑≡÷±±…∂≡←〉 ∉°⊂ ∠∇∨ ∑ ≡〉
≈°∂∑〉ñ∝°♠↑±≥〉↓°±≡〉
⇒…≈≡″∂… ∨≈∂↔°↑∑ ⇒±±≡ ⇐↑°ƒ⌠ ∈♠≡≡±← ⊇±∂♥≡↑←∂↔ƒ⌠
⇐⇒∇⇒⇔⇒
⊆≡…≡∂♥≡≈∑ ⊂≡↓↔≡″≡↑ ⌠ 
⇒……≡↓↔≡≈∑ ∏±♠↑ƒ ⌠ 
∉♠≥∂←•≡≈∑ ∧≡↑♠↑ƒ ⌠ 
⇐°↓ƒ↑∂÷•↔∑ ϖ  °××∂ ≡↔ ≥〉 ⊄•∂← ∂← ± °↓≡±
……≡←← ↑↔∂…≥≡ ≈∂←↔↑∂♠↔≡≈ ♠±≈≡↑ ↔•≡ ↔≡↑″← °≠ ↔•≡
⇐↑≡↔∂♥≡ ⇐°″″°±← ⇒↔↔↑∂♠↔∂°± ∂…≡±←≡⌠ ♦•∂…• ↓≡↑″∂↔←
♠±↑≡←↔↑∂…↔≡≈ ♠←≡⌠ ≈∂←↔↑∂♠↔∂°±⌠ ±≈ ↑≡↓↑°≈♠…↔∂°± ∂± ±ƒ
″≡≈∂♠″⌠ ↓↑°♥∂≈≡≈ ↔•≡ °↑∂÷∂±≥ ♠↔•°↑ ±≈ ←°♠↑…≡ ↑≡
…↑≡≈∂↔≡≈〉
⇔↔ ⇒♥∂≥∂≥∂↔ƒ ⊂↔↔≡″≡±↔∑ ⇔↔ ↑≡ ♥∂≥≥≡ ≠↑°″
↔•≡ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ⋅↑↔″± √±←↔∂↔♠↔≡ ≠°↑
↑≡←≡↑…•≡↑← ♦•° ″≡≡↔ ↔•≡ …↑∂↔≡↑∂ ≠°↑ ……≡←← ↔°
…°±≠∂≈≡±↔∂≥ ≈↔〉 ⊄•≡ ≈↔ °≠ ↔•∂← ←↔♠≈ƒ ″ƒ ≡
↑≡→♠≡←↔≡≈ ≠↑°″ ⇒←←°…〉 ∉↑°≠〉 ⋅±±≡≥≡ ∂♥♠°↑∂
•±±≡≥≡〉≥∂♥♠°↑∂⇓•≡≥←∂±×∂〉≠∂〉
∧♠±≈∂±÷∑ ⊄•≡ ∧√∇∇∉∨⇐ ←↔♠≈ƒ ♦← ←♠↓↓°↑↔≡≈ ƒ
∏±≡ ±≈ ⇒↔°← ∨↑××° ∧°♠±≈↔∂°±⌠ ∉;∂♥∂××∂ ±≈
⊂×↑∂ ⊂°•≥≡↑÷ ∧°♠±≈↔∂°±⌠ ⇒…≈≡″ƒ °≠ ∧∂±≥±≈⌠
⊆≡←≡↑…• ∧♠±≈← °≠ ↔•≡ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ⊂↓≡…∂≥
←↔↔≡ ←♠←∂≈ƒ ≠°↑ ⋅≡≥↔• ⊂…∂≡±…≡← ∨⊃∠ ≠♠±≈∂±÷ ↔
⋅≡≥←∂±×∂ ±≈ ⊇♠←∂″ ⋅°←↓∂↔≥ ⇔∂←↔↑∂…↔⌠ ↔•≡ ∇↔∂°±≥
∉↑≡≡…≥″↓←∂ ∂← ≥←° ←←°…∂↔≡≈ ♦∂↔• ± ∂±…↑≡←≡≈ ↑∂←× °≠ …↑≈∂°♥←…♠≥↑ ≈∂←≡←≡ ∂± ≥↔≡↑ ≥∂≠≡
°≠ °↔• ↔•≡ ″°↔•≡↑ ±≈ ↔•≡ ≠≡↔♠← ⊗⌠ℜ〉 ⇒≥↔•°♠÷• ↔•≡ ≈∂←≡←≡ °↑∂÷∂±↔≡← ≡↑≥ƒ ∂± ↓↑≡÷±±…ƒ⌠
↔•≡ ≈≡≠∂±∂±÷ ←ƒ″↓↔°″←⌠ ±≡♦≥ƒ∫°±←≡↔ •ƒ↓≡↑↔≡±←∂°± ±≈ ↓↑°↔≡∂±♠↑∂⌠ ≈≡♥≡≥°↓ ∂± ↔•≡ ≥↔↔≡↑
•≥≠ °≠ ↓↑≡÷±±…ƒ〉 ⇐♠↑↑≡±↔≥ƒ⌠ ±° ↑≡≥∂≥≡ ↓↑≡≈∂…↔∂♥≡ ↔≡←↔ ≠°↑ ↓↑≡≡…≥″↓←∂ ∂← ×±°♦± ±≈ ±°
…♠↑≡ °↔•≡↑ ↔•± ≈≡≥∂♥≡↑ƒ ∂← ♥∂≥≥≡〉
⊄•≡ …°″↓≥≡″≡±↔ ←ƒ←↔≡″ ∂← ± ∂±↔≡÷↑≥ ↓↑↔ °≠ ↔•≡ ∂±±↔≡ ∂″″♠±≡ ←ƒ←↔≡″ …°±←∂←↔∂±÷ °≠
↓•ƒ≥°÷≡±≡↔∂…≥≥ƒ ±…∂≡±↔ ↓↑°…≡←←≡← °≠ ↓↔•°÷≡± ↑≡…°÷±∂↔∂°± ±≈ ←≡≥≠∫ñ±°±∫←≡≥≠∫
≈∂←…↑∂″∂±↔∂°±〉 √±  ±°↑″≥ ↓↑≡÷±±…ƒ ↔•≡ …°″↓≥≡″≡±↔ ←ƒ←↔≡″ ≡…°″≡← …↔∂♥↔≡≈ ↔  ≥°♦
≥≡♥≡≥ ⊗ℜ〉 ⇒…↔∂♥↔∂°± °≠ ↔•≡ ↔≡↑″∂±≥ …°″↓≥≡″≡±↔ ↓↔•♦ƒ ≥≡≈← ↔° ≠°↑″↔∂°± °≠ ↔•≡ ″≡″∫
↑±≡ ↔↔…× …°″↓≥≡♣ ⇒⇐ ±≈ ↓°←←∂≥≡ ≈≡←↔↑♠…↔∂°± °≠ ↔•≡ ↔↑÷≡↔ …≡≥≥〉 ⇐°″↓≥≡″≡±↔ …±
≡ …↔∂♥↔≡≈ ♥∂ ↔•↑≡≡ ∂±≈≡↓≡±≈≡±↔ ↓↔•♦ƒ←〉 ⊄•≡ ≥≡…↔∂± ↓↔•♦ƒ ∉ ∂← …↔∂♥↔≡≈ ƒ ″±∫
±°←≡∫∂±≈∂±÷ ≥≡…↔∂± ⇑ ±≈ ƒ ≠∂…°≥∂±←〉 √↔ •← ↓↑≡♥∂°♠←≥ƒ ≡≡± ←↔♠≈∂≡≈ ∂± ←←°…∂↔∂°±
♦∂↔• ↓↑≡≡…≥″↓←∂ ♦∂↔• …°±↔↑≈∂…↔°↑ƒ ↑≡←♠≥↔← ⊗⌠ℜ〉 ⊄•≡ …≥←←∂…≥ ↓↔•♦ƒ ⇐∉ ∂← …↔∂♥↔≡≈
ƒ ↔•≡ ⇐∫↑≡…↔∂♥≡ ↓↑°↔≡∂± ⇐⊆∉ °↑ ƒ ∂″″♠±≡ …°″↓≥≡♣≡←⌠ ←♠…• ← ±↔∂°≈∂≡← °♠±≈ ↔°
″∂…↑°≡← °↑ ♠↔°±↔∂°≈∂≡← °♠±≈ ↔° ←≡≥≠∫±↔∂÷≡±←〉 ⊄•≡ ↑°≥≡ °≠  ″∂…↑°∂≥ ↔↑∂÷÷≡↑ ≠°↑ ∂±∫
≠≥″″↔∂°± ≈♠↑∂±÷ ↓↑≡÷±±…ƒ ←  …♠←↔∂♥≡ ÷≡±↔ ∂± ↓↑≡≡…≥″↓←∂ •← ≡≡± ↔•≡ ←♠∝≡…↔ °≠
 ≥≡±÷↔•ƒ ≈≡↔≡⌠ ♦•≡↑≡ ±° ≈≡≠∂±∂↔∂♥≡ …°±…≥♠←∂°±← •♥≡ ƒ≡↔ ≡≡± …•∂≡♥≡≈ ⊗ℜ〉 ⇒± ∂″↓°↑∫
↔±↔ ↑°≥≡ ≠°↑ ↔•≡ ≥↔≡↑±↔∂♥≡ ↓↔•♦ƒ ⇒∉ °≠ …°″↓≥≡″≡±↔ ∂± ±°↑″≥ ↓↑≡÷±±…ƒ ♦← ←♠÷∫
÷≡←↔≡≈ ƒ ±∂″≥ ←↔♠≈∂≡← °♥≡↑  ≈≡…≈≡ ÷°⌠ ♦•≡± ⇐↑↑ƒ⌠ ↔•≡ ≠♠±…↔∂°±≥ ″♠↑∂±≡ •°″°≥°÷♠≡
°≠ •♠″± …°″↓≥≡″≡±↔ ∂±•∂∂↔°↑← ″≡″↑±≡ …°≠…↔°↑ ↓↑°↔≡∂± ⇐∉ ±≈ ≈≡…ƒ ……≡≥≡↑↔∫
∂±÷ ≠…↔°↑ ⇔⇒∧⌠ ♦← ×±°…×≡≈ °♠↔ …♠←∂±÷ ∂±≠≡↑↔∂≥∂↔ƒ ≈♠≡ ↔° ≥↔≡↑±↔∂♥≡ ↓↔•♦ƒ …↔∂♥↔∂°±
⊗ℜ〉 ⊆≡…≡±↔≥ƒ⌠ ∂↔ ♦← ←•°♦± ↔•↔ ± ≡≥≡♥↔≡≈ ≥≡♥≡≥ °≠ ≥↔≡↑±↔∂♥≡ ↓↔•♦ƒ …↔∂♥↔∂°± °……♠↑←
≥←° ∂± •♠″± ↓↑≡÷±±…∂≡←⌠ ♦•≡↑≡ ←≡♥≡↑≡ ↓↑≡≡…≥″↓←∂ ≈≡♥≡≥°↓← ⊗ℜ〉 ⇒…↔∂♥↔∂°± °≠ ↔•≡
…°″↓≥≡″≡±↔ ←ƒ←↔≡″ ″♠←↔ ≡ ↑∂÷°↑°♠←≥ƒ ↑≡÷♠≥↔≡≈ ∂± °↑≈≡↑ ≠°↑ ±°↑″≥ ↓≥…≡±↔↔∂°± ↔°
°……♠↑ ±≈ ≠°↑ ↔•≡ ↓≥…≡±↔ ↔° ≡ ↓↑°↔≡…↔≡≈ ≠↑°″ ↔∂←←♠≡ ≈≡←↔↑♠…↔∂°±⌠ ↔•↑°″°←∂← ±≈ ±↔∂±∫
÷∂°÷≡±∂… ≠…↔°↑← ⊗⌠ℜ〉 ⇐∉ ∂←  ♦∂≈≡≥ƒ ≡♣↓↑≡←←≡≈ …°″↓≥≡″≡±↔ ↑≡÷♠≥↔°↑ ↔•↔ ∂±•∂∂↔←
⇒∉⌠ ∉ ±≈ ⇐∉〉 √↔ ∂±≈← ↔° °↔• ⇐ ⇒∉ ±≈ ⇐ ⇐∉ ±≈ …↔← ←  …°≠…↔°↑ ≠°↑ ↔•≡∂↑ ∂±∫
…↔∂♥↔∂°± ƒ ↔•≡ ⇐ñ⇐ ∂±…↔∂♥↔°↑ ≡±∞ƒ″≡ ≠…↔°↑ √ ⊗⌠ℜ〉 ⇐∉ ∂←  ↔ƒ↓≡  ″≡″↑±≡
°♠±≈ ↓↑°↔≡∂± …°±←∂←↔∂±÷ °≠ ± ∂±↔↑…≡≥≥♠≥↑ ↔∂≥ ↑≡÷∂°± ♦∂↔• ←≡♥≡↑≥ ♥↑∂±↔ ←↔↑♠…↔♠↑≡← ⊗ℜ
 ←∂±÷≥≡ ↔↑±←″≡″↑±≡ ∫•≡≥∂…≥ ↑≡÷∂°±⌠  ←•°↑↔ ↑≡÷∂°± °≠ ♠±×±°♦± ≠♠±…↔∂°± ⊇⌠  …°≥≥↑
⊂⊄∉∫ ↑∂…• ↑≡÷∂°± ♦∂↔• ←≡♥≡↑≥ ♥↑∂±↔ ←↔↑♠…↔♠↑≡←⌠ ±≈ ≠∂±≥≥ƒ ≠°♠↑ ≡♣↔↑…≡≥≥♠≥↑ ⇐°″↓≥≡∫
″≡±↔ ⇐°±↔↑°≥ ∉↑°↔≡∂± ⇐⇐∉ ≈°″∂±← …↑↑ƒ∂±÷ ↔•≡ …°≠…↔°↑ …↔∂♥∂↔ƒ ∧∂÷〉  ⊗⌠ℜ〉
⇐∉ ∂← ≡±…°≈≡≈ ƒ ⇐⇔ ≥°…↔≡≈ ∂± ↔•≡ ⊆≡÷♠≥↔°↑← °≠ ⇐°″↓≥≡″≡±↔ ⇒…↔∂♥↔∂°± ÷≡±≡
…≥♠←↔≡↑ °± …•↑°″°←°″≡ →〉〉 ⇒↓↑↔ ≠↑°″ ∂↔← ↑°≥≡ ←  …°″↓≥≡″≡±↔ ∂±•∂∂↔°↑ °± …≡≥≥
″≡″↑±≡← ⇐∉ …± …↔ ←  ↑≡…≡↓↔°↑ ≠°↑ …≡↑↔∂± ↓↔•°÷≡±← ←♠…• ← ↔•≡ ″≡←≥≡← ♥∂↑♠←
∨≈″°±←↔°± ←↔↑∂± ⊗ℜ⌠ •♠″± •≡↑↓≡←♥∂↑♠←  ⊗ℜ ±≈ ∇≡∂←←≡↑∂ ÷°±°↑↑•°≡≡ ⊗ℜ〉 ⇐∉
•← ≥←° ≡≡± ←♠÷÷≡←↔≡≈ ↔° •♥≡ ↑°≥≡ ∂± ↔•≡ ≠≡↑↔∂≥∂∞↔∂°± °≠ ↔•≡ •♠″± ≡÷÷ ⊗ℜ〉 ∇°↔≥ƒ⌠
←≡♥≡↑≥ ″♠↔↔∂°±← °↔• ∂± ↔•≡ ⇐⇐∉← ← ♦≡≥≥ ← ∂± ↔•≡ ↔↑±←″≡″↑±≡ ↑≡÷∂°± ↑≡ ≥∂±×≡≈ ↔°
↔ƒ↓∂…≥ •≡″°≥ƒ↔∂… ♠↑≡″∂… ←ƒ±≈↑°″≡ ⋅⊇⊂ ⊗⌠ℜ〉∪•∂≥≡ ♦≡ ∂±∂↔∂↔≡≈ °♠↑ ←↔♠≈∂≡← °± ↔•≡
⇒∉ ↑≡÷♠≥↔°↑ƒ ÷≡±≡← ∂± ↓↑≡≡…≥″↓←∂⌠ ⇐∉ ″°±÷ °↔•≡↑ …°″↓≥≡″≡±↔ ↑≡÷♠≥↔°↑← ↑≡…≡∂♥≡≈
…°±←∂≈≡↑≥≡ ↔↔≡±↔∂°± ← ↓°↔≡±↔∂≥ ↔↑÷≡↔ ≠°↑ ″♠↔↔∂°±← ∂± ↓↑≡≡…≥″↓←∂ ⊗ℜ〉
∪≡ •ƒ↓°↔•≡←∂∞≡≈ ↔•↔ ♥↑∂↔∂°± ∂± …°″↓≥≡″≡±↔ ↑≡÷♠≥↔∂°± ″∂÷•↔ ≡ °±≡ ♠±≈≡↑≥ƒ∂±÷ ↑≡←°±
≠°↑ ←≡♥≡↑≡ ↓↑≡≡…≥″↓←∂ ∂± ↓↔∂≡±↔← ♦•° ≈≡♥≡≥°↓≡≈ •≡♥ƒ ↓↑°↔≡∂±♠↑∂〉 ⊄•≡ °∝≡…↔∂♥≡ °≠ ↔•∂←
←↔♠≈ƒ ♦← ↔° ∂±♥≡←↔∂÷↔≡ ♦•≡↔•≡↑ ←≡→♠≡±…≡ ♥↑∂↔∂°±← ∂± ↔•≡ ⇐⇔ ↓↑°″°↔≡↑⌠ ←↓≥∂…≡ ←∂↔≡← ±≈
≡♣°″≡ ↑≡ ↓↑≡←≡±↔ ∂± ∧∂±±∂←• ♦°″≡± ♦∂↔• ±≈ ♦∂↔•°♠↔ ↓↑≡≡…≥″↓←∂〉 ⇑≡…♠←≡ ⇒⊃
↑← ♦← ←←°…∂↔≡≈ ♦∂↔• ↓↑≡≡…≥″↓←∂ ∂± °±≡ ↓↑≡♥∂°♠← ←↔♠≈ƒ ⊗ℜ⌠ ♦≡ ←↔♠≈∂≡≈ ↔•∂←
♥↑∂±↔ ∂±  ≥↑÷≡↑ ÷↑°♠↓ °≠ …°±↔↑°≥←〉
⇐∉ ∂± ∉↑≡≡…≥″↓↔∂… ∉↑≡÷±±…∂≡←
∉∠⊂ ∠∇∨ ≤ ⇔∠√∑〉ñ∝°♠↑±≥〉↓°±≡〉 ∧≡↑♠↑ƒ ⌠   ñ 
¬↑≈♠↔≡ ⊂…•°°≥ °≠ ⇐≥∂±∂…≥ √±♥≡←↔∂÷↔∂°± ⇐√¬⊂⌠
∇°♥° ∇°↑≈∂←× ∧°♠±≈↔∂°±⌠ ∧∂±±∂←• ∧°♠±≈↔∂°± ≠°↑
∉≡≈∂↔↑∂… ⊆≡←≡↑…•⌠ ∨″∂≥ ⇒≥↔°±≡± ∧°♠±≈↔∂°±⌠ ±≈
⊂∂÷↑∂≈ ∏♠←6≥∂♠← ∧°♠±≈↔∂°±〉 ⊄•≡ ≠♠±≈≡↑← •≈ ±° ↑°≥≡
∂± ←↔♠≈ƒ ≈≡←∂÷±⌠ ≈↔ …°≥≥≡…↔∂°± ±≈ ±≥ƒ←∂←⌠ ≈≡…∂←∂°±
↔° ↓♠≥∂←•⌠ °↑ ↓↑≡↓↑↔∂°± °≠ ↔•≡ ″±♠←…↑∂↓↔〉
⇐°″↓≡↔∂±÷ √±↔≡↑≡←↔←∑ ⊄•≡ ♠↔•°↑← •♥≡ ≈≡…≥↑≡≈
↔•↔ ±° …°″↓≡↔∂±÷ ∂±↔≡↑≡←↔← ≡♣∂←↔〉
≡↔•°≈←
⊂⊄⊇⇔∅ ∉∠∉⊇⇒⊄√∠∇
⊄•≡ ↓↑↔∂…∂↓±↔← ↑≡  ←♠÷↑°♠↓ °≠ ↔•≡ ∧√∇∇∉∨⇐ ⊄•≡ ∧∂±±∂←• ¬≡±≡↔∂…← °≠ ∉↑≡≡…≥″↓←∂ ⇐°±∫
←°↑↔∂♠″ ←↔♠≈ƒ …°•°↑↔〉 ⇑↑∂≡≠≥ƒ⌠ ↔ ↔•≡ ↔∂″≡ °≠ ↓♠≥∂…↔∂°±⌠ ↔•≡ …°•°↑↔ …°″↓↑∂←≡←  ♦°″≡± ≈∂∫
÷±°←≡≈ ♦∂↔• ↓↑≡≡…≥″↓←∂ ∂± ↔•≡∂↑ ←∂±÷≥≡↔°± ↓↑≡÷±±…ƒ ±≈  ♦°″≡± ♦∂↔•°♠↔ ↓↑≡≡…≥″↓←∂
←ƒ″↓↔°″← ∂± ↔•≡∂↑ ←∂±÷≥≡↔°± ↓↑≡÷±±…ƒ ↔•≡ …°±↔↑°≥ ÷↑°♠↓〉 ∉↑≡≡…≥″↓←∂ ♦← ≈≡≠∂±≡≈ ← •ƒ∫
↓≡↑↔≡±←∂°± ±≈ ↓↑°↔≡∂±♠↑∂ °……♠↑↑∂±÷ ≠↔≡↑  ♦≡≡× °≠ ÷≡←↔↔∂°±〉 ⋅ƒ↓≡↑↔≡±←∂°± ♦← ≈≡≠∂±≡≈ ← 
←ƒ←↔°≥∂… ≥°°≈ ↓↑≡←←♠↑≡  ″″⋅÷⌠ ±≈ñ°↑  ≈∂←↔°≥∂… ≥°°≈ ↓↑≡←←♠↑≡  ″″⋅÷〉 ∉↑°↔≡∂±∫
♠↑∂ ♦← ≈≡≠∂±≡≈ ← ↔•≡ ♠↑∂±↑ƒ ≡♣…↑≡↔∂°± °≠ 〉 ÷ ↓↑°↔≡∂± ∂±  ∫•°♠↑ ←↓≡…∂″≡±⌠ °↑ 〉÷ñ⌠ °↑
 ↑≡≈∂±÷ °± ≈∂↓←↔∂…× ∂±  ↑±≈°″ ♠↑∂±≡ ≈≡↔≡↑″∂±↔∂°± ↔ ≥≡←↔ ↔♦∂…≡ ♦∂↔• ±° ≡♥∂≈≡±…≡ °≠ 
♠↑∂±↑ƒ ↔↑…↔ ∂±≠≡…↔∂°±〉 √±↔↑♠↔≡↑∂±≡ ÷↑°♦↔• ↑≡←↔↑∂…↔∂°± √⊇¬⊆ ♦← ≈≡≠∂±≡≈ ← ∂↑↔• ♦≡∂÷•↔
≡≥°♦∫ ⊂⇔ ……°↑≈∂±÷ ↔° ↔•≡ ∧∂±±∂←• ←↔±≈↑≈← ⊗ℜ〉
∧°↑ ↔•∂← ←↔♠≈ƒ ♦≡ ←≡≥≡…↔≡≈  ←♠←≡↔ °≠  ↓↑∂″∂↓↑°♠← ♦°″≡± ♦∂↔• ←≡♥≡↑≡ ↓↑≡≡…≥″↓←∂ 
←ƒ←↔°≥∂… ≥°°≈ ↓↑≡←←♠↑≡  ″″⋅÷ °↑  ≈∂←↔°≥∂… ≥°°≈ ↓↑≡←←♠↑≡  ″″⋅÷ °↑ ↓↑°↔≡∂±♠↑∂
 ÷ ↓↑°↔≡∂± ∂±  ∫•°♠↑ ←↓≡…∂″≡±〉 ⇑≡…♠←≡ ↔•≡ ↓↑°″∂±≡±↔ ″♠↔↔∂°±← °≠ ⇐⇔ ↑≡ ×±°♦± ↔°
←←°…∂↔≡ ♦∂↔• ≈∂←°↑≈≡↑← ∂±♥°≥♥∂±÷ ×∂≈±≡ƒ ≠♠±…↔∂°±⌠ ♦≡ ∂±…≥♠≈≡≈ ↓↑≡≡…≥″↓↔∂… ♦°″≡± ♦∂↔•
•≡♥ƒ ↓↑°↔≡∂±♠↑∂ ∂± ↔•∂← ←↔♠≈ƒ〉 ⊄•≡ƒ •≈ ±° ♠↔°∂″″♠±≡ ≈∂←≡←≡←〉 ⊄♦≡±↔ƒ∫←∂♣ ↓↔∂≡±↔← 
∧∂÷ 〉 ⊄•≡ ←…•≡″↔∂… ←↔↑♠…↔♠↑≡ °≠ ↔•≡ ″≡″↑±≡ …°≠…↔°↑ ↓↑°↔≡∂± ⇐⇔〉 ⊄•≡ ↓°←∂↔∂°±← °≠ ↔•≡ ″∂±°
…∂≈ …•±÷∂±÷ ←∂±÷≥≡ ±♠…≥≡°↔∂≈≡ ↓°≥ƒ″°↑↓•∂←″← ≈≡←…↑∂≡≈ ∂± ⊂≥″°± ≡↔ ≥〉 ⊗ℜ ±≈ ∂± ↔•∂← ←↔♠≈ƒ ↑≡ ≈≡↓∂…↔≡≈〉
√±←↓∂↑≡≈ ƒ ∧±÷ ≡↔ ≥〉 ⊗ℜ〉
≈°∂∑〉ñ∝°♠↑±≥〉↓°±≡〉〉÷
⇐∉ ∂± ∉↑≡≡…≥″↓↔∂… ∉↑≡÷±±…∂≡←
∉∠⊂ ∠∇∨ ≤ ⇔∠√∑〉ñ∝°♠↑±≥〉↓°±≡〉 ∧≡↑♠↑ƒ ⌠   ñ 
•≈ ≡↑≥ƒ∫°±←≡↔ ↓↑≡≡…≥″↓←∂ ≈∂÷±°←∂← ≡≠°↑≡  ♦≡≡×← °≠ ÷≡←↔↔∂°±〉 ⇒ …°±↔↑°≥ ÷↑°♠↓ …°″∫
↓↑∂←≡≈  ♦°″≡± ↑±≈°″≥ƒ ←≡≥≡…↔≡≈ ≠↑°″ ↔•≡ °↑∂÷∂±≥ …°±↔↑°≥ ÷↑°♠↓〉 ∇°±≡ °≠ ↔•≡ …°±↔↑°≥←
•≈ ♠↔°∂″″♠±≡ ≈∂←≡←≡←〉 ⊄•≡ …≥∂±∂…≥ …•↑…↔≡↑∂←↔∂…← °≠ ↔•≡ ↔♦° ÷↑°♠↓← ↑≡ ←•°♦± ∂± ⊄≥≡ 〉
∨⊄⋅√⇐⊂ ⊂⊄⇒⊄∨∨∇⊄
⇒≥≥ ←♠∝≡…↔← ↓↑°♥∂≈≡≈  ♦↑∂↔↔≡± ∂±≠°↑″≡≈ …°±←≡±↔ ±≈ ↔•≡ ∧√∇∇∉∨⇐ ←↔♠≈ƒ ↓↑°↔°…°≥ ♦← ↓∫
↓↑°♥≡≈ ƒ ↔•≡ …°°↑≈∂±↔∂±÷ ∨↔•∂…← ⇐°″″∂↔↔≡≡ °≠ ↔•≡ ⋅°←↓∂↔≥ ⇔∂←↔↑∂…↔ °≠ ⋅≡≥←∂±×∂ ±≈ ⊇♠←∂″
↓≡↑″∂↔ ±♠″≡↑ ñ∨ñ〉
⇒⇑∠⊆⇒⊄∠⊆∅∨⊄⋅∠⇔⊂
⇔∇⇒ ♦← ≡♣↔↑…↔≡≈ ≠↑°″  ″≥ ∨⇔⊄⇒ ♦•°≥≡ ≥°°≈ ←↔°↑≡≈ ↔∫⇐ο ≠↔≡↑ ∂±∂↔∂≥ ≠↑≡≡∞∂±÷ ↓≡↑∂°≈
↔∫⇐ο ↔° ↓↑≡♥≡±↔ ≠°↑″↔∂°± °≠ ∂…∂…≥≡← ±≈ ″°≥≡…♠≥↑ ≈≡÷↑≈↔∂°± ♠←∂±÷ ⇐•≡″÷∂… ÷±≡↔∂…
⊂≡↓↑↔∂°± °≈♠≥≡ √ ⇐•≡″÷≡±⌠ ∉≡↑×∂±∨≥″≡↑⌠ ⇑≡←♦≡∂≥≡↑⌠ ¬≡↑″±ƒ ♠↔°″↔∂… ⇔∇⇒ ≡♣↔↑…∫
↔∂°± ↓↑°↔°…°≥ ← ↓↑°♥∂≈≡≈ ƒ ↔•≡ ″±♠≠…↔♠↑≡↑〉 ∨♣↔↑…↔≡≈ ⇔∇⇒ ♦← ♠←≡≈ ↔ ≠∂±≥ …°±…≡±↔↑∫
↔∂°±← °≠  ±÷ ñ ≥ ±≈  ±÷ ñ ≥〉
∨♣°″∂… ←≡→♠≡±…∂±÷ ∂±…≥♠←∂♥≡ °≠ ≠≥±×∂±÷ ∂±↔↑°±∂… ↑≡÷∂°±← ♦← …↑↑∂≡≈ °♠↔ ♠←∂±÷  ↓∂↑← °≠
↓↑∂″≡↑← ← ≥∂←↔≡≈ ∂± ⊂ ⊄≥≡〉 ∉↑°″°↔≡↑ ↑≡÷∂°±  ↓ ♠↓←↔↑≡″ °≠ ≡♣°±  ♦← ≥←° ←≡→♠≡±…≡≈〉
∉↑∂″≡↑← ♦≡↑≡ ≈≡←∂÷±≡≈ ±≈ ↔≡←↔≡≈ ƒ ♠←∂±÷ ∉↑∂″≡↑ ±≈ ¬≡±°″≡⊄≡←↔≡↑ ←°≠↔♦↑≡← ⊗⌠ℜ〉 ∉⇐⊆
♦← …↑↑∂≡≈ °♠↔ ♠←∂±÷ ƒ↔→ ⇑∂°≥∂±≡⌠ °±≈°±⌠ ⊇ ↓°≥ƒ″≡↑←≡ ≡±∞ƒ″≡ ±≈ ♠≠≠≡↑ ≠°≥≥°♦∂±÷
↔•≡ ″±♠≠…↔♠↑≡↑← ↓↑°↔°…°≥〉 ∉⇐⊆ ↓↑°≈♠…↔← ♦≡↑≡ ↓♠↑∂≠∂≡≈ ♠←∂±÷ ∨♣°⊂⇒∉∫√⊄ ¬∨ ⋅≡≥↔•…↑≡ ∂≠≡
⊂…∂≡±…≡⌠ ⊇ ←•↑∂″↓ ↓•°←↓•↔←≡ ≥×≥∂±≡ ↓↑°≈♠…↔ ±≈ ↔•≡ ↓♠↑∂≠∂≡≈ ⇔∇⇒ ≠↑÷″≡±↔← ♦≡↑≡ ←≡∫
→♠≡±…≡≈ ƒ ⇑∂÷ ⇔ƒ≡ ⊄≡↑″∂±↔°↑ ♥〉 ⇐ƒ…≥≡ ≡±∞ƒ″≡ ±≈ ♠≠≠≡↑ ⇒↓↓≥∂≡≈ ⇑∂°←ƒ←↔≡″←⌠ ⇐↑≥←≈⌠
⇐⇒⌠ ⊇⊂⇒ ≠°≥≥°♦∂±÷ ↔•≡ ″±♠≠…↔♠↑≡↑← ↓↑°↔°…°≥〉 ⊄•≡ ←≡→♠≡±…∂±÷ ↑≡…↔∂°± ↓↑°≈♠…↔ ♦← ↓♠↑∂≠∂≡≈
ƒ ∉≡↑≠°↑″⇔⊄⊆ ♥ ≠∂≥↔≡↑↓≥↔≡← ∨≈÷≡ ⇑∂°⊂ƒ←↔≡″←⌠ ¬∂↔•≡↑←♠↑÷⌠ ⇔⌠ ⊇⊂⇒ ±≈ ±≥ƒ∞≡≈
♠←∂±÷ ⇒⇑√♣≥ …↓∂≥≥↑ƒ ≡≥≡…↔↑°↓•°↑≡←∂← ←≡→♠≡±…≡↑ ⇒↓↓≥∂≡≈ ⇑∂°←ƒ←↔≡″←⌠ ⇐↑≥←≈⌠ ⇐⇒⌠ ⊇⊂⇒〉
⊄•≡ ↑♦ ≈↔ ♦← ±≥ƒ∞≡≈ ♠←∂±÷ ⊂≡→♠≡±…•≡↑  ←°≠↔♦↑≡ ⇒↓↓≥∂≡≈ ⇑∂°←ƒ←↔≡″←⌠ ⇐↑≥←≈⌠ ⇐⇒⌠
⊇⊂⇒ ±≈ ↔•≡ ≈≡↔≡…↔≡≈ ↓°≥ƒ″°↑↓•∂←″← ♦≡↑≡ ♥≡↑∂≠∂≡≈ ♠←∂±÷ ⊂∇∉↓≡↑ ⊗ℜ ±≈ ∇⇐⇑√ ≈↔←≡←〉
⊂⊄⇒⊄√⊂⊄√⇐⇒ ∨⊄⋅∠⇔⊂
⇐⇔ ←≡→♠≡±…∂±÷ ↑≡←♠≥↔← ♦≡↑≡ ±≥ƒ∞≡≈ ≠°↑ ≈∂←≡←≡ ←←°…∂↔∂°± ∂± ∉√∇ ⊗ℜ〉 ⇒←←°…∂↔∂°± ƒ
∂±≈∂♥∂≈♠≥ ⊂∇∉← ±≈ ←←°…∂↔∂°± ∂± ↔≡↑″← °≠ ≈∂≠≠≡↑≡±↔ ÷≡±°↔ƒ↓∂… ″°≈≡≥← ♦≡↑≡ ≡♥≥♠↔≡≈ ƒ ∧∂←•∫
≡↑← ∨♣…↔ ↔≡←↔〉 ⊄•≡ ≠♠±…↔∂°±≥∂↔ƒ °≠ ″∂±° …∂≈ …•±÷∂±÷ ⊂∇∉← ♦← ≡♥≥♠↔≡≈ ♠←∂±÷ ∉°≥ƒ∉•≡±∫
⊗ℜ ±≈ ⊂√∧⊄ ⊗ℜ〉 √± ⊂√∧⊄⌠ ←…°↑≡← 〉 °↑ ←°″≡↔∂″≡← 〉 ↑≡ …°±←∂≈≡↑≡≈ ∂±≈∂…↔∂°± °≠ 
≈≡≥≡↔≡↑∂°♠← ″♠↔↔∂°± ⊗ℜ〉 ⇒± ∂±≈≡↓≡±≈≡±↔ ♥≥♠≡← ↔∫↔≡←↔ ♦← ♠←≡≈ ↔° …°″↓↑≡ ″≡±← °≠ …≥∂±∂…≥
…•↑…↔≡↑∂←↔∂…← ≡↔♦≡≡± ↓↔∂≡±↔← ±≈ …°±↔↑°≥← ∂± √⇑ ⊂∉⊂⊂ ←↔↔∂←↔∂…← ♥≡↑←∂°±  √⇑ …°↑↓〉〉
⊆≡←♠≥↔←
⇒ ↔°↔≥ °≠  ⊂∇∉← ⊄≥≡ ⌠ ∂±…≥♠≈∂±÷ ↔•↑≡≡ ±°♥≡≥ °±≡← ⊄≥≡ ⌠ ♦≡↑≡ °←≡↑♥≡≈ ∂±⇐⇔〉 ⊄•≡ ≥∫
≥≡≥≡← ±≈″∂±°↑ ≥≥≡≥≡ ≠↑≡→♠≡±…∂≡← ⇒∧ ∂± ↓↔∂≡±↔← ±≈ …°±↔↑°≥← ↑≡ ↓↑≡←≡±↔≡≈ ∂± ⊄≥≡ 〉 ⋅≡↔≡↑°∫
∞ƒ÷°←∂↔ƒ ≠°↑ ↔•≡ ⇒⊃ ♥↑∂±↔ ↑← ♦← °←≡↑♥≡≈ ∂±  ñ °≠ …←≡← ±≈  ñ
 °≠ …°±↔↑°≥← ∠⊆  〉⌠ ⇐√  〉⌠ 〉〉 √± ≈≈∂↔∂°±⌠ °±≡ …°±↔↑°≥ ♦← •°″°∞ƒ÷°♠← ≠°↑
⇒⊃〉 ⇒⊃ ♦← ↓↑≡≈∂…↔≡≈ ↔° ≡ ≡±∂÷± ∉°≥ƒ↓•≡± ←…°↑≡ 〉ñ ±≈ ↔°≥≡↑↔≡≈ ⊂∂≠↔∑ 〉〉
⊄•≡ ∇ ♥↑∂±↔ ↑←⌠ ± ″∂±° …∂≈ …•±÷≡ ∂± ↔•≡ ≠♠±…↔∂°±≥ ↓↑↔ °≠ ↔•≡⇐∉″°≥≡∫
…♠≥≡⌠ ∂± ↔•≡ ″°←↔ ″≡″↑±≡ ≈∂←↔≥ ⇐⇐∉⌠ ♦← °←≡↑♥≡≈ ∂±  •≡↔≡↑°∞ƒ÷°♠← ≠°↑″ ∂± °±≡ ↓↔∂≡±↔ ±≈ ∂±
°±≡ …°±↔↑°≥ ∠⊆  ⌠  ⇐√  〉⌠ 〉⌠ ⊂ ⊄≥≡〉 ∇♦← ″∂♥≥≡±↔≥ƒ ↓↑≡≈∂…↔≡≈ ↔° ≡
↓↑°≥ƒ ≈″÷∂±÷ ∉°≥ƒ↓•≡± ←…°↑≡ 〉ñ⌠ ←≡±←∂↔∂♥∂↔ƒ 〉⌠ ←↓≡…∂≠∂…∂↔ƒ 〉 °↑ ↓°←←∂≥ƒ ↔°≥≡↑↔≡≈
⇐∉ ∂± ∉↑≡≡…≥″↓↔∂… ∉↑≡÷±±…∂≡←
∉∠⊂ ∠∇∨ ≤ ⇔∠√∑〉ñ∝°♠↑±≥〉↓°±≡〉 ∧≡↑♠↑ƒ ⌠   ñ 
⊄≥≡ 〉 ⇐≥∂±∂…≥ …•↑…↔≡↑∂←↔∂…← °≠ ↔•≡ ←↔♠≈ƒ ↓°↓♠≥↔∂°±〉
⊂≡♥≡↑≡ ↓↑≡≡…≥″↓←∂ ±   ⇐°±↔↑°≥← ±   ⇔∂≠≠≡↑≡±…≡ ≡↔♦≡≡± ↓↔∂≡±↔←
±≈ …°±↔↑°≥←≡± ⊂⇔ ∇  ≡± ⊂⇔ ∇ 
⇒÷≡ ƒ≡↑← 〉 〉 〉 〉 ↓  〉
⇑°≈ƒ ″←← ∂±≈≡♣ ×÷ 〉 〉 〉 〉 ∇⊂
∉↑∂″∂↓↑     ↓  〉
∨↑≥ƒ∫°±←≡↔ ↓↑≡≡…≥″↓←∂ ≈∂÷±°←≡←  ♦≡≡×← °≠ ÷≡←↔↔∂°±    ↓  〉
⊂ƒ←↔°≥∂… ≥°°≈ ↓↑≡←←♠↑≡ ″″⋅÷  〉  〉 ↓  〉
⇔∂←↔°≥∂… ≥°°≈ ↓↑≡←←♠↑≡ ″″⋅÷  〉  〉 ↓  〉
∉↑°↔≡∂±♠↑∂ ÷⌠ ∫•°♠↑ ←↓≡…∂″≡± 〉 〉 ⌡
¬≡←↔↔∂°±≥ ≈∂≡↔≡←     ↓  〉
∉↑≡∫÷≡←↔↔∂°±≥ ≈∂≡↔≡← ↔ƒ↓≡  ≈∂≡↔≡←    ∇⊂
∉↑≡∫÷≡←↔↔∂°±≥ •ƒ↓≡↑↔≡±←∂°±     ∇⊂
¬≡←↔↔∂°±≥ •ƒ↓≡↑↔≡±←∂°±    ↓  〉
∪≡≡×← °≠ ÷≡←↔↔∂°± ↔ ≈≡≥∂♥≡↑ƒ 〉 〉 〉 〉 ↓  〉ξ
∉↑≡↔≡↑″ ∂↑↔• ≈≡≥∂♥≡↑ƒ ≡≠°↑≡  ♦≡≡×← °≠ ÷≡←↔↔∂°±    〉 ↓  〉
⇑∂↑↔•♦≡∂÷•↔ ÷  〉  〉 ↓  〉ξ
√±↔↑♠↔≡↑∂±≡ ÷↑°♦↔• ↑≡←↔↑∂…↔∂°± ∫ ⊂⇔     ↓  〉
⊄•≡  ←♠÷↑°♠ °≠ …°±↔↑°≥← ≈∂≈ ±°↔ ≈∂≠≠≡↑ ←↔↔∂←↔∂…≥≥ƒ ≠↑°″ ↔•≡  …°±↔↑°≥ ↓°°≥〉 ⊄•≡ ←∂÷±∂ …±…≡ ≥≡♥≡≥ ∂← 〉〉
∇⊂±°↔ ←∂÷±∂ …±↔
ξ ∨→♠≥ ♥↑∂±…≡← ±°↔ ←←♠″≡≈
⌡ ∠±≡ ∂±≈∂♥∂≈♠≥ 〉 ∂± ↔•≡ …°±↔↑°≥ ÷↑°♠↓ •≈ ÷≡←↔↔∂°±≥ ↓↑°↔≡∂±♠↑∂〉
 ⊄∫↔≡←↔
 ±±∫∪•∂↔±≡ƒ ⊇ ↔≡←↔
≈°∂∑〉ñ∝°♠↑±≥〉↓°±≡〉〉↔
⊄≥≡ 〉 ⊄•≡ °←≡↑♥≡≈ ←∂±÷≥≡ ±♠…≥≡°↔∂≈≡ ↓°≥ƒ″°↑↓•∂←″← ⊂∇∉← ±≈ ″∂±°↑ ≥≥≡≥≡ ≠↑≡→♠≡±…∂≡← ⇒∧ ∂± ↔•≡ ÷≡±°↔ƒ↓≡≈ …←≡← ±≈ …°±↔↑°≥←〉
⇐⋅⊆ ⊂∇∉ ⇒∧ …←≡← ⇒∧ …°±↔↑°≥← ∇ …←≡← ∇ …°±↔↑°≥← °…↔∂°±
 ↑← 〉 〉   ↓↑°″°↔≡↑
 ↑← 〉 〉   ↓↑°″°↔≡↑
 ↑← 〉 〉   ≡♣°±  ∇
 ↑← 〉 〉   ≡♣°±  ←ƒ±°±ƒ″°♠←
 ↑← 〉 〉   ≡♣°±  ←ƒ±°±ƒ″°♠←
 ↑← 〉 〉   ∂±↔↑°±∂…
 ↑← 〉 〉   ≡♣°±  ⇒⊃
 ∇≡♦⊂∇∉ 〉 〉   ∂±↔↑°±∂…
 ∇≡♦⊂∇∉ 〉 〉   …ƒ↔°↓≥←″∂… ↔∂≥
 ∇≡♦⊂∇∉ 〉 〉   …ƒ↔°↓≥←″∂… ↔∂≥
 ↑← 〉 〉   …ƒ↔°↓≥←″∂… ↔∂≥
 ↑← 〉 〉   …ƒ↔°↓≥←″∂… ↔∂≥
 ↑← 〉 〉   …ƒ↔°↓≥←″∂… ↔∂≥
 ↑← 〉 〉   …ƒ↔°↓≥←″∂… ↔∂≥
 ↑← 〉 〉   …ƒ↔°↓≥←″∂… ↔∂≥
≈°∂∑〉ñ∝°♠↑±≥〉↓°±≡〉〉↔
⇐∉ ∂± ∉↑≡≡…≥″↓↔∂… ∉↑≡÷±±…∂≡←
∉∠⊂ ∠∇∨ ≤ ⇔∠√∑〉ñ∝°♠↑±≥〉↓°±≡〉 ∧≡↑♠↑ƒ ⌠   ñ 
⊂∂≠↔∑ 〉〉 ∠±≡ ±≡♦ ⊂∇∉♦← ≥°…↔≡≈ ±≡↑ ≡♣°± ⌠ ≡∂±÷ °←≡↑♥≡≈ ∂± °±≡ …°±↔↑°≥〉 ⊄♦° °≠ ↔•≡ ±≡♦
⊂∇∉← ♦≡↑≡ ≥°…↔≡≈ ∂± ≡♣°± 〉 ⇑°↔• ♦≡↑≡ °←≡↑♥≡≈ °±…≡ ∂±  ≈∂≠≠≡↑≡±↔ ↓↔∂≡±↔ ∧∂÷〉 ⌠ ⊄≥≡ 〉
⇔∂←…♠←←∂°±
√± ↔•∂← ←↔♠≈ƒ ♦≡ ≈∂≈ ±°↔ ≠∂±≈ ±ƒ ←≡→♠≡±…≡ ♥↑∂±↔← ∂± ↓↑°″°↔≡↑←⌠ ≡♣°″≡← ±≈ ≠≥±×∂±÷ ↑≡÷∂°±←
°≠ ⇐⇔ ←←°…∂↔≡≈ ♦∂↔• ↓↑≡≡…≥″↓←∂〉 ∉↑≡≡…≥″↓←∂ ∂← ×±°♦± ↔° ≡  …≥∂±∂…≥≥ƒ ♥↑∂≥≡ ±≈ ≡↔∂∫
°≥°÷∂…≥≥ƒ •≡↔≡↑°÷≡±≡°♠← ≈∂←≡←≡ ⊗ℜ〉 ∉↑≡≡…≥″↓↔∂… ↓↔∂≡±↔← ♦∂↔• •≡♥ƒ ↓↑°↔≡∂±♠↑∂ ♦≡↑≡ ←≡≥≡…↔∫
≡≈ ≠°↑ ↔•≡ ↓↑°∝≡…↔⌠ ≡…♠←≡ ←≡♥≡↑≥ ↓↑≡♥∂°♠← ←↔♠≈∂≡← ↓°∂±↔≡≈ ↔°♦↑≈← ≠♠±…↔∂°±≥ ↓↑°≥≡″← °≠ ↔•≡
×∂≈±≡ƒ ∂± ←←°…∂↔∂°± ♦∂↔• …°″↓≥≡″≡±↔ …↔∂♥↔∂°± ±≈ ↓↑↔∂…♠≥↑≥ƒ ♦∂↔• ⇐⇔″♠↔↔∂°±←⌠ ←
°←≡↑♥≡≈ ∂± ⋅⊇⊂ ⊗⌠⌠⌠ℜ〉 ⊄•≡ ←∂″∂≥↑ ±≡↓•↑°≥°÷∂…≥ ←ƒ″↓↔°″← ≡↔♦≡≡± ⋅⊇⊂ ±≈ ↓↑≡∫
≡…≥″↓←∂ ≥≡≈ ♠← ↔° ↓♠↑←♠≡  …°″″°± …♠←≡ ↔° ↔•≡←≡ ↔♦° …°±≈∂↔∂°±←〉
√±↔≡↑≡←↔∂±÷≥ƒ⌠ ⊂≥″°± ±≈ …°∫♦°↑×≡↑← ↑≡↓°↑↔≡≈ ⇐⇔″♠↔↔∂°±← ← ÷≡±≡↔∂… ≈≡≠≡…↔← ←←°…∂↔≡≈
♦∂↔• ↓↑≡≡…≥″↓←∂ ⊗ℜ〉 √± ↔•≡ ∉⊆∠√⊂⊂∨ …°•°↑↔ …°±←∂←↔∂±÷ °≠  ↓↑≡÷±±↔ ↓↔∂≡±↔← ♦∂↔• ←ƒ←↔≡″∫
∂… ≥♠↓♠← ≡↑ƒ↔•≡″↔°←♠← ⊂∨ ±≈ñ°↑ ±↔∂↓•°←↓•°≥∂↓∂≈ ±↔∂°≈ƒ ⇒∉ ⇒ ←ƒ±≈↑°″≡ ↔•≡ƒ ≠°♠±≈
± ∂±…↑≡←≡ ≠↑°″ 〉 ↔°  ∂± ⇒⊃ •≡↔≡↑°∞ƒ÷°←∂↔ƒ ∂± ♦°″≡±⌠ ♦•° ≈≡♥≡≥°↓≡≈ ↓↑≡≡…≥″↓←∂〉
⊄•≡ƒ ↑≡↓≥∂…↔≡≈ ↔•≡∂↑ ≠∂±≈∂±÷ ∂±  ♦°″≡± ♦∂↔• ↓↑≡≡…≥″↓←∂ ±≈ñ°↑ ↔•≡⋅∨∉ •≡″°≥ƒ←∂←⌠ ≡≥≡∫
♥↔≡≈ ≥∂♥≡↑ ≡±∞ƒ″≡←⌠ ≥°♦ ↓≥↔≡≥≡↔ …°♠±↔ ←ƒ±≈↑°″≡ ±≈  …°±↔↑°≥← ♦∂↔•°♠↔ ♠↔°∂″″♠±≡ ≈∂←≡←≡
⊗ℜ〉 √± ↔•≡  ↓↔∂≡±↔←⌠ ⊂≥″°± ≡↔ ≥〉 °←≡↑♥≡≈  •∂÷•≡↑ ⇒∧ ″∂±°↑ ≥≥≡≥≡ ≠↑≡→♠≡±…ƒ 〉 ↔•±
♦•↔ ♦← ←≡≡± ∂± ≡↔•±∂…≥≥ƒ ±≈ ÷≡°÷↑↓•∂…≥≥ƒ ″↔…•≡≈ …°±↔↑°≥← 〉⌠ ∂±…≥♠≈∂±÷  •°″°∞ƒ÷°♠←
∂±≈∂♥∂≈♠≥ ⊗ℜ〉 ∠♠↑ ↑≡←♠≥↔← ♦∂↔•  ≥↑÷≡↑ ←↔♠≈ƒ ↓°↓♠≥↔∂°± ≈° ±°↔ ←♠↓↓°↑↔ ↔•≡ ↓↑≡♥∂°♠←≥ƒ ↑≡↓°↑↔≡≈
≠∂±≈∂±÷←〉 √± ↔•≡ ↓↑≡←≡±↔ ←↔♠≈ƒ⌠ ⇒⊃ ♥↑∂±↔ ♦← ≡→♠≥≥ƒ ↓↑≡♥≥≡±↔ ∂± ↔•≡ ↔♦° ÷↑°♠↓←〉 ∧♠↑↔•≡↑∫
″°↑≡⌠ ♦≡ ≈∂←…°♥≡↑≡≈ ± ∂±≈∂♥∂≈♠≥ •°″°∞ƒ÷°♠← ≠°↑ ⇒⊃ ″°±÷ ↔•≡ •≡≥↔•ƒ …°±↔↑°≥←〉 ⇒∧ ≠°↑
⇒⊃♦← 〉 ∂±  ∧∂±±∂←• ∂±≈∂♥∂≈♠≥← °≠ ↔•≡ ⊂√⊂♠ ⊂≡→♠≡±…∂±÷ ∂±∂↔∂↔∂♥≡ ⊂♠°″∂ ≈↔ ↑≡∫
←°♠↑…≡ ♦♦♦〉←∂←♠↓↑°∝≡…↔〉≠∂〉 ∪•∂≥≡ ∇⇐⇑√ ↑≡↓°↑↔← •≡↔≡↑°∞ƒ÷°←∂↔ƒ ∂± ≈∂≠≠≡↑≡±↔ ↓°↓♠≥↔∂°±← ↔° ↑±÷≡
≡↔♦≡≡± ⌠ ♦∂↔• ⇒∧ °≠ 〉〉⌠ ↔•≡ •∂÷•≡←↔ ♥≥♠≡← ≡∂±÷ ↑≡…°↑≈≡≈ ∂± ∨♠↑°↓≡± ↓°↓♠≥∫
↔∂°±←⌠ °♠↑ ↑≡←♠≥↔ ↔°÷≡↔•≡↑ ♦∂↔• ↔•≡ ⊂√⊂♠ ≈↔ ←♠÷÷≡←↔←⌠ ↔•↔ ± ≡♥≡± •∂÷•≡↑ ⇒∧ ∂← ↔ƒ↓∂…≥ °≠ ↔•≡
÷≡±≡↑≥ ∧∂±±∂←• ↓°↓♠≥↔∂°±〉 √± ≥∂÷•↔ °≠ ↔•∂← ≡♥∂≈≡±…≡ ∂↔ ←≡≡″← ♠±≥∂×≡≥ƒ ↔•↔ ↔•≡ ∂±…↑≡←≡ ∂± ⇒∧
≠↑°″ 〉 ÷≡±≡↑≥ ↓°↓♠≥↔∂°± °↑ 〉 •≡≥↔•ƒ ÷≡°∫≡↔•±∂…≥≥ƒ ″↔…•≡≈ ↓↑≡÷±±↔ …°±↔↑°≥← ↔°
〉 ∉⊆∠√⊂⊂∨♦∂↔• ↓↑≡≡…≥″↓←∂ °↑ 〉 ⊇↔• ⊂≡♥≡↑≡ ↓↑≡≡…≥″↓←∂ñ⋅∨∉ …°•°↑↔ ≥°±≡
♦°♠≥≈ ≡↑ ≠♠±…↔∂°±≥ …°±←≡→♠≡±…≡← ≠°↑ ↔•≡ ≈≡♥≡≥°↓″≡±↔ °↑ ↓↑°÷↑≡←←∂°± °≠ ↓↑≡≡…≥″↓←∂⌠ ← ↓↑≡♥∂∫
°♠←≥ƒ ←♠÷÷≡←↔≡≈ ⊗ℜ〉 ∧♠↑↔•≡↑″°↑≡⌠ ↓↑≡≡…≥″↓←∂ ≡∂±÷  •≡↔≡↑°÷≡±°♠← ≈∂←≡←≡⌠ ≈∂≠≠≡↑≡±↔ ←♠↔ƒ↓≡←
←♠…• ← ⋅∨∉″ƒ ±°↔ ≡ …°″↓↔∂≥≡ ∂± ≡↔∂°≥°÷∂…≥ …°″↓↑∂←°±〉 ∠♠↑ ≈↔ ←≡↔ •≈ ±° ↓↔∂≡±↔←
♦∂↔• ←≡♥≡↑≡ ∂″″♠±°≥°÷∂…≥ ≈∂÷±°←≡← ←♠…• ← ⊂∨〉 ⊄•≡ ↓↔∂≡±↔← ♦∂↔• ←≡♥≡↑≡ ↓↑≡≡…≥″↓←∂ ≠↑°″
↔•≡ ←↔♠≈ƒ ƒ ⊂≥″°± ≡↔ ≥〉 ↑≡ …°″↓↑≥≡ ↔° °♠↑ ≈↔ ←≡↔ ⊗ℜ〉
⇒⊃ ♥↑∂±↔ ∂← ≥°…↔≡≈ ∂± ↔•≡ ↔↑±←″≡″↑±≡ ↑≡÷∂°± °≠ ↔•≡ ″°≥≡…♠≥≡ ∧∂÷〉 〉 ⊄•≡ ↓°←←∂≥≡
≠♠±…↔∂°±≥ ↑°≥≡ ∂← ↔•♠← ±°↔ ≈∂↑≡…↔≥ƒ ↑≡≥↔≡≈ ↔° ∂±↔≡↑…↔∂°± ♦∂↔• ⇐ ±≈ ⇐⌠ ♦•∂…• ↑≡ ×±°♦±
↔° ∂±≈ ↔° ≡♣↔↑…≡≥≥♠≥↑ ⇐⇐∉ ↑≡÷∂°±←〉 ⊄•≡ ″≡…•±∂←″ °≠ ≈≡…↑≡←≡≈ ≥↔≡↑±↔∂♥≡ ↓↔•♦ƒ ↑≡÷♠≥∫
↔∂°± ←←°…∂↔≡≈ ♦∂↔• ⇒⊃ ∂← ↔•♠← ±°↔ …≥≡↑ ⊗⌠ℜ〉 ∪≡ ≈∂≈ ±°↔ ≠∂±≈ ∂±≈∂…↔∂°± °≠ ≈∂←≡←≡
⊄≥≡ 〉 ⇔≡↔∂≥← °≠ ↔•≡ ±≡♦ ←∂±÷≥≡ ±♠…≥≡°↔∂≈≡ ↓°≥ƒ″°↑↓•∂←″← ⊂∇∉←〉
⊂∇∉ √⇔ ⇒≥≥≡≥≡  ⇒≥≥≡≥≡  ¬≡±°″∂… ↓°←∂↔∂°±⌡
∇≡♦⊂∇∉ ¬ ⇒ 
∇≡♦⊂∇∉ ¬ ⇐ 
∇≡♦⊂∇∉ ⇒ ¬ 
⌡ ……°↑≈∂±÷ ↔° ♠∂≥≈ ¬⊆⇐•〉↓
≈°∂∑〉ñ∝°♠↑±≥〉↓°±≡〉〉↔
⇐∉ ∂± ∉↑≡≡…≥″↓↔∂… ∉↑≡÷±±…∂≡←
∉∠⊂ ∠∇∨ ≤ ⇔∠√∑〉ñ∝°♠↑±≥〉↓°±≡〉 ∧≡↑♠↑ƒ ⌠   ñ 
↑≡≥↔≡≈±≡←← °≠ ⇒⊃ ∂± °♠↑ ∂°∂±≠°↑″↔∂…← ±≥ƒ←≡← ∂±  ″∝°↑∂↔ƒ °≠ ↔•≡ ↔↑±←…↑∂↓↔←⌠ ∂〉≡〉 ←↓≥∂…≡
♥↑∂±↔← ∂±…≥♠≈≡≈ ∂± ↔•≡ ←°≠↔♦↑≡ ±≥ƒ←≡←〉
⊂≥″°± ≡↔ ≥〉 ≠°♠±≈ ∇ ∂±  ↓↔∂≡±↔ ≠≠≡…↔≡≈ ƒ ⊂∨♦∂↔•  •∂←↔°↑ƒ °≠ ↑≡↓≡↔≡≈ ↓↑≡÷±±…ƒ ≥°←←⌠
≠≡↔≥ ≈≡↔• ±≈ ↓↑≡≡…≥″↓←∂〉 ⊄•∂← ″∂±° …∂≈ ←♠←↔∂↔♠↔∂°± ≠↑°″ ←∂… ≥ƒ←∂±≡ ↔° ±≡♠↔↑≥ ←↓↑÷∂±≡
…♠←≡←  ♣ ≈≡…↑≡←≡ ∂± ↔•≡ ⇐ …≥≡♥÷≡ ↓↑°″°↔∂±÷ …↔∂♥∂↔ƒ °≠⇐∉ ⊗ℜ〉 √± °♠↑ ″↔≡↑∂≥ ∇
♦← °←≡↑♥≡≈ ∂±  •≡↔≡↑°∞ƒ÷°♠← ≠°↑″ ∂± °±≡ ↓↑≡≡…≥″↓↔∂… ↓↔∂≡±↔ ±≈ °±≡ …°±↔↑°≥〉 ⊂√⊂♠ ↑≡↓°↑↔← ↔•≡
⇒∧ °≠ ∇ ↔° ≡ 〉 ∂±  ∧∂±±∂←• ∂±≈∂♥∂≈♠≥←〉 √± ↔•≡ ∂°∂±≠°↑″↔∂…← ±≥ƒ←≡← ↔•≡ ↓°←←∂≥≡
≠♠±…↔∂°±≥ ≡≠≠≡…↔← °≠ ∇♦≡↑≡ …°±↔↑°♥≡↑←∂≥〉 ∪•∂≥≡ ⊂√∧⊄ ↓↑≡≈∂…↔≡≈ ∇ ↔° ≡ ↔°≥≡↑↔≡≈⌠ ∉°≥ƒ∫
↓•≡± ↓↑≡≈∂…↔≡≈ ∂↔ ↔° •♥≡ ≈≡≥≡↔≡↑∂°♠← …•±÷≡← ≠°↑ ↔•≡ ↓↑°↔≡∂± ≠♠±…↔∂°± ∂± ≥≥ ♥∂≥≥≡ ↔↑±←…↑∂↓↔←〉
∉↑≡≡…≥″↓←∂ ≡∂±÷  …≥∂±∂…≥≥ƒ ♥↑∂≥≡ ±≈ •≡↔≡↑°÷≡±≡°♠← ≈∂←≡←≡⌠ ∂↔ ∂← ≥♦ƒ←  …•≥≥≡±÷≡ ↔°
↓∂±↓°∂±↔ ± ←←°…∂↔∂°± ↔° ≥∂±× ←∂±÷≥≡ ÷≡±≡ ♥↑∂±↔ ↔°  ↓↑↔∂…♠≥↑ ←♠↓•≡±°↔ƒ↓≡〉 ⊄•≡ ″∂←←∂±÷ ←∫
←°…∂↔∂°± ≡↔♦≡≡±⇐⇔″♠↔↔∂°±← ±≈ ↓↑≡≡…≥″↓←∂ ″ƒ ≥←° ≡ ↔↔↑∂♠↔≡≈ ↔° ∂±…°″↓≥≡↔≡ ↓≡±≡∫
↔↑±…≡ °≠ …°″↓≥≡″≡±↔ ″♠↔↔∂°±← ∂± ↓↑≡≡…≥″↓←∂〉 ∧♠↑↔•≡↑″°↑≡⌠ ↔•≡ ″♠≥↔∂≠…↔°↑∂≥ …×÷↑°♠±≈ ∂←
±°↔•≡↑ ≥∂×≡≥ƒ ≡♣↓≥±↔∂°± ≠°↑ ″∂←←∂±÷ ←←°…∂↔∂°± ∂±  …°″↓≥≡♣ ≈∂←≡←≡ ≥∂×≡ ↓↑≡≡…≥″↓←∂〉 ⊄•≡
↓↑≡←≡±↔ ←↔♠≈ƒ ≈°≡← ±°↔ ……°♠±↔ ≠°↑ ↔•≡ ≡≠≠≡…↔ °≠ ≈∂←≡←≡ ←↓≡…∂≠∂… ∂←°≠°↑″← ∂± ↓↑≡≡…≥″↓←∂〉 ∪•∂≥≡
←≡♥≡↑≥ ←↓≥∂…∂±÷ ∂←°≠°↑″← °≠ ⇐⇔ •♥≡ ≡≡± ×±°♦± ↔° ≡♣∂←↔ ≠°↑  ≥°±÷ ↔∂″≡ ↑≡…≡±↔ ♦°↑× ←♠÷÷≡←↔←
 ≈∂←≡←≡ ←↓≡…∂≠∂… ↑°≥≡ ≠°↑ ↔•≡ °……♠↑↑≡±…≡ °≠ ⇐⇔ ∂←°≠°↑″← ⊗ℜ〉 ∨♣°±←  ±≈  …°≈≡ ≠°↑ ↔•≡
≥↑÷≡ …ƒ↔°↓≥←″∂… ↔∂≥ ←≡…↔∂°± °≠ ↔•≡″°≥≡…♠≥≡⌠ ♦•∂…• ∂← ♥↑∂≥ƒ ∂±…≥♠≈≡≈ °↑ ←↓≥∂…≡≈ °♠↔ ≠↑°″ ↔•≡
≠♠±…↔∂°±≥ ∂←°≠°↑″← °≠ ↔•≡ ↓↑°↔≡∂± ∧∂÷〉  ⊗ℜ〉 ⊄•≡ ≠♠±…↔∂°±≥ ≡≠≠≡…↔← °≠ ↔•≡ ±≡♦ ⊂∇∉← ≈∂←…°♥≡↑≡≈
∂± ↔•≡←≡ ≡♣°±← ≠♠±≈″≡±↔≥≥ƒ ≈≡↓≡±≈ °± ♦•≡↔•≡↑ ↔•≡ƒ ↑≡ ∂±…≥♠≈≡≈ ∂± ↔•≡ ∂←°≠°↑″ ∂± →♠≡←↔∂°±〉
⇒← ≈∂←…♠←←≡≈ °♥≡⌠ ↔•≡ …°″↓≥≡″≡±↔ ←ƒ←↔≡″ •← ± ≡←←≡±↔∂≥ ↑°≥≡ ∂± ↓↑≡÷±±…ƒ〉 ⊄•≡ °♥≡↑↑∂≈∫
∂±÷ •ƒ↓°↔•≡←∂← ∂← ↔•↔ ≡♣…≡←←∂♥≡ ±≈ ♠±…°±↔↑°≥≥≡≈ …↔∂♥↔∂°± °≠ ↔•≡ ″↔≡↑±≥ …°″↓≥≡″≡±↔ ←ƒ←∫
↔≡″ …°″↓↑°″∂←≡← ↔•≡ ↓≥…≡±↔ ±≈ ♠≥↔∂″↔≡≥ƒ ↔•≡ ≠≡↔♠← ⊗⌠ℜ〉 ⇒……°↑≈∂±÷≥ƒ⌠ ∂↔ ∂← ±°↔ ≥∂×≡≥ƒ ↔•↔
″≥≠♠±…↔∂°±∂±÷ ″↔≡↑±≥ ⇐∉⌠ ≡∂±÷  …≡≥≥∫°♠±≈ ↑≡÷♠≥↔°↑ °≠ ↔•≡ …°″↓≥≡″≡±↔ ←ƒ←↔≡″⌠ ♦°♠≥≈
•♥≡  ≠♠±≈″≡±↔≥ ≡≠≠≡…↔ °± ↔•≡ ∂±↔≡÷↑∂↔ƒ °≠ ↔∂←←♠≡← °≠ ≠≡↔≥ °↑∂÷∂± ←♠…• ← ↔•≡ ↓≥…≡±↔〉 ↔≡↑∫
±≥ …↔∂♥↔°↑← ±≈ ≠≡↔≥ ↑≡÷♠≥↔°↑← ↑≡ ↔•≡ ″°↑≡ °♥∂°♠← ″°≥≡…♠≥≡← °≠ ∂±↔≡↑≡←↔ ∂± ≠♠↔♠↑≡ ←↔♠≈∂≡←〉
√± ↔•∂← ←↔♠≈ƒ ♦≡ •♥≡ ≡♣↓≥°↑≡≈ ↔•≡ ÷≡±≡↔∂… ↓°≥ƒ″°↑↓•∂←″ °≠ ⇐⇔ ∂± ↓↑≡≡…≥″↓←∂〉 ⊄•↑≡≡
±°♥≡≥ ↑↑≡ ♥↑∂±↔← ♦≡↑≡ ≈∂←…°♥≡↑≡≈ ♠↔ ±≡∂↔•≡↑ ↔•≡ƒ ±°↑ °↔•≡↑ ↓°≥ƒ″°↑↓•∂←″← °≠ ∂±↔≡↑≡←↔ ♦≡↑≡
←←°…∂↔≡≈ ♦∂↔• ←≡♥≡↑≡ ↓↑≡≡…≥″↓←∂〉 ⊂↔♠≈∂≡← °± ≠♠±…↔∂°±≥ ⇐⇔ ∂←°≠°↑″← ∂± ↓↑≡≡…≥″↓←∂ ″ƒ
↓↑°♥∂≈≡ ≠♠↑↔•≡↑ ∂±←∂÷•↔ ∂±↔° ↔•≡ ↓°←←∂≥≡ ↑°≥≡ °≠ ⇐∉ ±≈ …°″↓≥≡″≡±↔∫″≡≈∂↔≡≈ ∂±∝♠↑ƒ ∂± ↔•≡
↓↔•°÷≡±≡←∂← °≠ ←≡♥≡↑≡ ↓↑≡≡…≥″↓←∂〉
∧∂÷ 〉 ⊄•≡ ←≡→♠≡±…≡← °≠ ↔•≡ ±≡♦≥ƒ ≈∂←…°♥≡↑≡≈ ⊂∇∉← ±≡↑ ≡♣°±  ±≈ ∂± ≡♣°±  °≠ ↔•≡ ⇐⇔〉 ∉±≡≥ ⇒∑ ∇≡♦ ⊂∇∉ ¬ñ⇒ •≡↔≡↑°∞ƒ÷°↔≡ ↔°↓ ±≈ ⇒ñ⇒
•°″°∞ƒ÷°↔≡ °↔↔°″〉 ∉±≡≥ ⇑∑ ∇≡♦ ⊂∇∉ ¬ñ⇐ •≡↔≡↑°∞ƒ÷°↔≡ ↔°↓ ±≈ ⇐ñ⇐ •°″°∞ƒ÷°↔≡ °↔↔°″〉 ∉±≡≥ ⇐∑ ∇≡♦ ⊂∇∉ ⇒ñ¬ •≡↔≡↑°∞ƒ÷°↔≡ ↔°↓ ±≈ ¬ñ¬
•°″°∞ƒ÷°↔≡ °↔↔°″〉
≈°∂∑〉ñ∝°♠↑±≥〉↓°±≡〉〉÷
⇐∉ ∂± ∉↑≡≡…≥″↓↔∂… ∉↑≡÷±±…∂≡←
∉∠⊂ ∠∇∨ ≤ ⇔∠√∑〉ñ∝°♠↑±≥〉↓°±≡〉 ∧≡↑♠↑ƒ ⌠   ñ 
⊂♠↓↓°↑↔∂±÷ √±≠°↑″↔∂°±
⊂ ⊄≥≡〉 ⊇←≡≈ ↓↑∂″≡↑←〉
⇔∠⇐∩
⊂ ⊄≥≡〉 ⇒←←°…∂↔∂°± ← ≈≡↔≡↑″∂±≡≈ ƒ ∧∂←•≡↑← ≡♣…↔〉
⇔∠⇐∩
⇒…×±°♦≥≡≈÷″≡±↔←
∧√∇∇∉∨⇐ …°±↔…↔ ∂±≠°↑″↔∂°±∑ •±±≡≥≡〉≥∂♥♠°↑∂⇓•≡≥←∂±×∂〉≠∂
⊄•≡ ∧√∇∇∉∨⇐ ⇐°↑≡ √±♥≡←↔∂÷↔°↑ ¬↑°♠↓ …°±←∂←↔← °≠
⋅±±≡≥≡ ∂♥♠°↑∂⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂ ±≈ ⋅≡≥←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ ⇐≡±↔↑≥ ⋅°←↓∂↔≥⌠ ⋅≡≥∫
←∂±×∂⌠ ∧∂±≥±≈〉
⊂≡↓↓° ⋅≡∂±°±≡±⌠ ⇔≡↓↑↔″≡±↔ °≠ ∠←↔≡↔↑∂…← ±≈ ¬ƒ±≡…°≥°÷ƒ⌠ ♠°↓∂° ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥⌠
±≈ ⊇±∂♥≡↑←∂↔ƒ °≠ ∨←↔≡↑± ∧∂±≥±≈⌠ ♠°↓∂°⌠ ∧∂±≥±≈
∨≡↑° ∝±↔∂≡⌠ ⇔≡↓↑↔″≡±↔ °≠ ⇐•↑°±∂… ⇔∂←≡←≡ ∉↑≡♥≡±↔∂°±⌠ ⇔∂≡↔≡← ∉↑≡♥≡±↔∂°± ⊇±∂↔⌠
∇↔∂°±≥ √±←↔∂↔♠↔≡ ≠°↑ ⋅≡≥↔• ±≈ ∪≡≥≠↑≡⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈⌠ ±≈ ⇐•∂≥≈↑≡±← ⋅°←↓∂↔≥⌠ ⋅≡≥∫
←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ ⇐≡±↔↑≥ ⋅°←↓∂↔≥ ±≈ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈
∏♠• ≡↑≡⌠ ⇔≡↓↑↔″≡±↔ °≠ ⇑∂°←…∂≡±…≡← ±≈ ∇♠↔↑∂↔∂°±⌠ ↑°≥∂±←× √±←↔∂↔♠↔≡↔⌠ ⋅♠≈≈∂±÷≡⌠ ⊂♦≡∫
≈≡±⌠ ∧°≥×•;≥←± √±←↔∂↔♠↔≡ °≠ ¬≡±≡↔∂…←⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈⌠ ±≈ ⇔≡↓↑↔″≡±↔ °≠ ≡≈∂…≥ ¬≡±≡↔∂…←⌠
⋅↑↔″± √±←↔∂↔♠↔≡⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈
↔∝ ∂♥∂±≡±⌠ ∪≡≥≥…°″≡ ⊄↑♠←↔ ⊂±÷≡↑ √±←↔∂↔♠↔≡⌠ ∪≡≥≥…°″≡ ⊄↑♠←↔ ¬≡±°″≡ ⇐″↓♠←⌠ ⋅∂±♣∫
↔°±⌠ ⇐″↑∂≈÷≡⌠ ⊇
⇒±±≡≥∂ ∉°♠↔⌠ ⇔≡↓↑↔″≡±↔ °≠ ⇐•∂≥≈↑≡±⌠ ∅°♠±÷ ↓≡°↓≥≡ ±≈ ∧″∂≥∂≡←⌠ ∇↔∂°±≥ √±←↔∂↔♠↔≡ ≠°↑
⋅≡≥↔• ±≈ ∪≡≥≠↑≡⌠ ∠♠≥♠⌠ ∧∂±≥±≈
⊄•≡ ⊂≡→♠≡±…∂±÷ √±∂↔∂↔∂♥≡ ⊂♠°″∂ ⊂√⊂♠ ↓↑°∝≡…↔ ♦♦♦〉←∂←♠↓↑°∝≡…↔〉≠∂ ∂← ± ∂±↔≡↑±↔∂°±≥ …°≥∫
≥°↑↔∂°± ≡↔♦≡≡± ↑≡←≡↑…• ÷↑°♠↓← ∂″∂±÷ ↔° ♠∂≥≈ ↔°°≥← ≠°↑ ÷≡±°″∂… ″≡≈∂…∂±≡〉 ⊄•≡←≡ ÷↑°♠↓←
↑≡ ÷≡±≡↑↔∂±÷ ♦•°≥≡ ÷≡±°″≡ ±≈ ♦•°≥≡ ≡♣°″≡ ←≡→♠≡±…≡ ≈↔ ≠↑°″ ∧∂±±∂←• ←″↓≥≡← ±≈ ↓↑°∫
♥∂≈≡ ≈↔ ↑≡←°♠↑…≡← ≠°↑ ↔•≡ ↑≡←≡↑…• …°″″♠±∂↔ƒ〉 ≡ƒ ÷↑°♠↓← °≠ ↔•≡ ↓↑°∝≡…↔ ↑≡ ≠↑°″ ⊇±∂♥≡↑←∂∫
↔∂≡← °≠ ∨←↔≡↑± ∧∂±≥±≈⌠ ∠♠≥♠ ±≈ ⋅≡≥←∂±×∂ ±≈ ⊄•≡ √±←↔∂↔♠↔≡ ≠°↑ ⋅≡≥↔• ±≈ ∪≡≥≠↑≡⌠ ∧∂±≥±≈⌠
♠±≈ ⊇±∂♥≡↑←∂↔ƒ⌠ ⊄•≡ ∪≡≥≥…°″≡ ⊄↑♠←↔ ⊂±÷≡↑ √±←↔∂↔♠↔≡⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ∠♣≠°↑≈⌠ ⊄•≡ ⇑↑°≈ √±←↔∂∫
↔♠↔≡ °≠ ⋅↑♥↑≈ ±≈ √⊄⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ∂…•∂÷±⌠ ∪←•∂±÷↔°± ⊇±∂♥≡↑←∂↔ƒ ∂± ⊂↔〉 °♠∂←⌠ ±≈
⊇±∂♥≡↑←∂↔ƒ °≠ ⇐≥∂≠°↑±∂⌠ °← ⇒±÷≡≥≡← ⊇⇐⇒〉 ⊄•≡ ↓↑°∝≡…↔ ∂← …°°↑≈∂±↔≡≈ ∂± ↔•≡ √±←↔∂↔♠↔≡ ≠°↑
°≥≡…♠≥↑ ≡≈∂…∂±≡ ∧∂±≥±≈ ↔ ↔•≡ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂〉
⊂♠←±±≡•↔;≥;⌠ ♠…ƒ ⇐•↓″±⌠ ±≈ ⊆∂∂↔↔ ≡•↔∂±≡± ↑≡ ↔•±×≡≈ ≠°↑ ↔≡…•±∂…≥ ←←∂←↔±…≡〉
⇒♠↔•°↑ ⇐°±↔↑∂♠↔∂°±←
⇐°±…≡∂♥≡≈ ±≈ ≈≡←∂÷±≡≈ ↔•≡ ≡♣↓≡↑∂″≡±↔←∑ ⇒√〉 ∉≡↑≠°↑″≡≈ ↔•≡ ≡♣↓≡↑∂″≡±↔←∑ ⇒√〉 ⇒±≥ƒ∞≡≈ ↔•≡
≈↔∑ ⇒√ ⊄⇒⊃〉 ⇐°±↔↑∂♠↔≡≈ ↑≡÷≡±↔←ñ″↔≡↑∂≥←ñ±≥ƒ←∂← ↔°°≥←∑ ⋅ ⊂〉 ∪↑°↔≡ ↔•≡ ↓↓≡↑∑ ⇒√
⊄⇒⊃ ⋅ ⊂〉 ⇐″≡ ♠↓ ♦∂↔• ↔•≡ ←↔♠≈ƒ →♠≡←↔∂°±∑ ⊂〉 ⊄°÷≡↔•≡↑ ♦∂↔• ∧√∇∇∉∨⇐ …°≥≥≡…↔≡≈ ↔•≡ ↓∫
↔∂≡±↔ ″↔≡↑∂≥ ±≈ ↓↑°♥∂≈≡≈ ↔•≡ …≥∂±∂…≥ ≈↔←≡∑ ⋅〉
⊆≡≠≡↑≡±…≡←
〉 ∂± ∅⌠ ⊆°≡↑↔← ∏  ⇐°±↔≡″↓°↑↑ƒ …°±…≡↓↔← °≠ ↔•≡ ↓↔•°÷≡±≡←∂← ±≈ ″±÷≡″≡±↔ °≠ ↓↑≡∫
≡…≥″↓←∂〉 ∏⇒⇒ ∑ 〉 ∉√⇔∑ 
〉 ⇑≡≥≥″ƒ ⌠ ⇐←← ∏∉⌠ ⋅∂±÷°↑±∂ ⇒⇔⌠ ∪∂≥≥∂″← ⇔∏  ∉↑≡∫≡…≥″↓←∂ ±≈ ↑∂←× °≠ …↑≈∂°♥←…♠≥↑ ≈∂←∫
≡←≡ ±≈ …±…≡↑ ∂± ≥↔≡↑ ≥∂≠≡∑ ⊂ƒ←↔≡″↔∂… ↑≡♥∂≡♦ ±≈ ″≡↔∫±≥ƒ←∂←〉 ⇑∏ ∑ 〉 ≈°∂∑ 〉ñ″∝〉
〉〉⇑∨ ∉√⇔∑ 
⇐∉ ∂± ∉↑≡≡…≥″↓↔∂… ∉↑≡÷±±…∂≡←
∉∠⊂ ∠∇∨ ≤ ⇔∠√∑〉ñ∝°♠↑±≥〉↓°±≡〉 ∧≡↑♠↑ƒ ⌠   ñ 
〉 ⇑↑×≡↑ ⇔∏⌠ ∠←″°±≈ ⇐⌠ ∧°↑←≡± ⊄∏⌠ ∝±↔∂≡ ∨⌠ ∨↑∂×←←°± ∏¬  ⊄↑∝≡…↔°↑∂≡← °≠ ÷↑°♦↔• ″°±÷ …•∂≥∫
≈↑≡± ♦•° •♥≡ …°↑°±↑ƒ ≡♥≡±↔← ← ≈♠≥↔←〉 ∇ ∨±÷≥ ∏ ≡≈ ∑ 〉 ≈°∂∑ 〉ñ
∇∨∏° ∉√⇔∑ 
〉 ⇔≡↑∞←ƒ ⊕⌠ ∉↑°•←∞× ⊕⌠ ⊆∂÷° ∏ ∏↑⌠ ∧♠←↔ ¬⌠ °≥♥↑≡… ⇒  ⇒…↔∂♥↔∂°± °≠ ↔•≡ …°″↓≥≡″≡±↔ ←ƒ←↔≡″ ∂±
±°↑″≥ ↓↑≡÷±±…ƒ ±≈ ↓↑≡≡…≥″↓←∂〉 °≥ √″″♠±°≥ ∑ 〉 ≈°∂∑ 〉ñ∝〉″°≥∂″″〉〉〉
 ∉√⇔∑ 
〉 ⇐←♠× ⇔⌠ °≥♥↑≡… ⇒⌠ ⇔≡↑∞←ƒ ⊕⌠ ⊃↑÷ ⌠ ∧#←↔ ¬⌠ ≡↔ ≥〉  ∧♠±…↔∂°±≥ ±≥ƒ←∂← °≠ ↔•≡ ″±±°←≡∫∂±≈∫
∂±÷ ≥≡…↔∂± …°″↓≥≡″≡±↔ ↓↔•♦ƒ ∂± ±°↑″≥ ↓↑≡÷±±…ƒ ±≈ ↓↑≡≡…≥″↓←∂〉 ∏ ⊆≡↓↑°≈ √″″♠±°≥ ∑ 〉
≈°∂∑ 〉ñ∝〉∝↑∂〉〉〉 ∉√⇔∑ 
〉 ⊃≡↑÷±≡← ∏  ⊂↔♠≈∂≡← ←♠÷÷≡←↔ ± ←←°…∂↔∂°± ≡↔♦≡≡± ″↔≡↑±≥ ↓≡↑∂°≈°±↔≥ ≈∂←≡←≡ ±≈ ↓↑≡∫
≡…≥″↓←∂〉 ∨♥∂≈∫←≡≈ ⇔≡±↔ ∑ 〉 ⇒♥∂≥≥≡∑ •↔↔↓∑ññ≈♣〉≈°∂〉°↑÷ñ〉ñ←∝〉≡≈〉 ♥∂ ↔•≡ √±∫
↔≡↑±≡↔〉 ⇒……≡←←≡≈  ∏± 〉 ≈°∂∑ 〉ñ←∝〉≡≈〉 ∉√⇔∑ 
〉 ⇐←°″°↑ ∉⌠ ⊂∞≥″>← ⇒⌠ ,±ƒ ∏⌠ ⊂∞∂×≥∂ √⌠ ↑°←∂ ⊄  ⊆≡←↔↑∂…↔∂°± ±≥ƒ←∂← °≠ °↔°←…≥≡↑°←∂←∫←←°…∂↔∫
≡≈ ⇐⇔ ←↓≥∂…∂±÷ ♥↑∂±↔←〉 ∨♠↑°↓≡± ⇒↑…•∂♥≡← °≠ ∠↔°∫⊆•∂±°∫↑ƒ±÷°≥°÷ƒ ∑ 〉 ≈°∂∑ 〉ñ
←∫∫∫ ∉√⇔∑ 
〉 ,↓≡∞∫∏↑″∂≥≥° ∉⌠ ⋅≡↑↑≡↑ ∏⇒⌠ ⇒↑≡±←∫±↔∂≥≥ ⌠ ∏>♠↑≡÷♠∂ √⌠ ∨〉⌠ ≡±≈°∞ ⇒  ⊂♠…≥∂±∂…≥ ∂±∫
≠≡…↔∂°± ←  …♠←≡ °≠ ∂±≠≥″″↔∂°± ∂± ↓↑≡≡…≥″↓←∂〉 ⇒″ ∏ ⊄•≡↑ 〉 ⇒♥∂≥≥≡∑ •↔↔↓∑ññ∝°♠↑±≥←〉≥♦♦〉…°″ñ
″≡↑∂…±↔•≡↑↓≡♠↔∂…←ñ∧♠≥≥↔≡♣↔ñññ⊂♠…≥∂±∂…≥ℵ√±≠≡…↔∂°±ℵ←ℵℵ⇐♠←≡ℵ°≠ℵ√±≠≥″″↔∂°±〉〉
←↓♣ ⇒……≡←←≡≈  ∏± 〉 ≈°∂∑ 〉ñ∏⊄〉≡≡≈ ∉√⇔∑ 
〉 ∞°↑∫⇔↑ƒ ∨⌠ ≡♥ƒ ⇒⌠ ⊂…•≥≡≠≠≡↑ ∧⌠ ⊂•≡∂±≡↑ ∨  ↔≡↑±≥ ♠↑∂±↑ƒ ↔↑…↔ ∂±≠≡…↔∂°±∑ √← ∂↔ ∂±≈≡↓≡±≈≡±↔∫
≥ƒ ←←°…∂↔≡≈ ♦∂↔• ≈♥≡↑←≡ ↓↑≡÷±±…ƒ °♠↔…°″≡◊ ∏ ↔≡↑± ∧≡↔≥ ∇≡°±↔≥ ≡≈ ∑ 〉 ⇒♥∂≥≥≡∑
•↔↔↓∑ññ≈♣〉≈°∂〉°↑÷ñ〉ñ ⇒……≡←←≡≈  ∏± 〉 ≈°∂∑ 〉ñ
 ∉√⇔∑ 
〉 ° ⇔⌠ ∪♠ ∩⌠ ⇔≡↓↓°±÷ ⇐⌠ ∧↑∂≡±≈ ⇔⌠ ⇔°≥≡…×∂ ¬⌠ ≡↔ ≥〉  ∇≡÷≥∂÷∂≥≡ ↑°≥≡ °≠ ±↔∂°≈∂≡← ±≈ ⇐ ∂±
↓↑≡÷±±…ƒ ≥°←← ←←°…∂↔≡≈ ≡♣…≥♠←∂♥≡≥ƒ ♦∂↔• ⇐∫≈≡↓≡±≈≡±↔ ″≡…•±∂←″← ↔•↑°♠÷• …°″↓≥≡″≡±↔ ≥↔≡↑±∫
↔∂♥≡ ↓↔•♦ƒ〉 √″″♠±∂↔ƒ ∑ 〉 •↔↔↓∑ññ≈♣〉≈°∂〉°↑÷ñ〉ñ⊂∫∫ ⇒……≡←←≡≈
 ∏± 〉 ∉√⇔∑ 
〉 ⋅°≠≠″± ⇐⌠ ⊆♠″≡↑ ⌠ ↑″≡↑ ⇒⌠ ƒ±…• ⇒⌠ ∪∂±± ⊃⇔  ↔≡↑±≥ ±≈ ≠≡↔≥ ≥↔≡↑±↔∂♥≡ …°″↓≥≡∫
″≡±↔ ↓↔•♦ƒ …↔∂♥↔∂°± ∂± ≡↑≥ƒ ←≡♥≡↑≡ ↓↑≡≡…≥″↓←∂〉 ⇒″ ∏ ⊆≡↓↑°≈ √″″♠±°≥ ∑ 〉 ≈°∂∑ 〉ñ
∝∂〉 ∉√⇔∑ 
〉 ⊂≥″°± ∏∨⌠ ⋅≡♠←≡↑ ⇐⌠ ⊄↑∂≡♦←←≡↑ ⌠ ∂←∞≡♦←×∂ ⌠ ♥±÷• ⇔⌠ ≡↔ ≥〉  ♠↔↔∂°±← ∂± …°″↓≥≡∫
″≡±↔ ↑≡÷♠≥↔°↑ƒ ↓↑°↔≡∂±← ↓↑≡≈∂←↓°←≡ ↔° ↓↑≡≡…≥″↓←∂∑ ⇒ ÷≡±≡↔∂… ±≥ƒ←∂← °≠ ↔•≡ ∉⊆∠√⊂⊂∨ …°•°↑↔〉
∉°⊂ ≡≈ ∑ ≡〉 ⇒♥∂≥≥≡∑ •↔↔↓∑ññ≈♣〉≈°∂〉°↑÷ñ〉∧∝°♠↑±≥〉↓″≡≈〉 ⇒……≡←←≡≈
 ∏± 〉 ≈°∂∑ 〉ñ∝°♠↑±≥〉↓″≡≈〉 ∉√⇔∑ 
〉 ⊂∝)≡↑÷ ⇒∉⌠ ⊄↑°♠♦ ⇒⌠ ⇑≥°″ ⇒  ⇐°″↓≥≡″≡±↔ …↔∂♥↔∂°± ±≈ ∂±•∂∂↔∂°±∑ ⇒ ≈≡≥∂…↔≡ ≥±…≡〉
⊄↑≡±≈← √″″♠±°≥ ∑ 〉 ⇒♥∂≥≥≡∑ •↔↔↓∑ññ♦♦♦〉←…∂≡±…≡≈∂↑≡…↔〉…°″ñ←…∂≡±…≡ñ↑↔∂…≥≡ñ↓∂∂ñ
⊂ ⇒……≡←←≡≈  ∏± 〉 ≈°∂∑ 〉ñ∝〉∂↔〉〉〉 ∉√⇔∑ 
〉 ⇑↑∂≥≥∫⇑↑… ⌠ ∂←∞≡♦←×∂ ⌠ ″↑∂← ∏⇔⌠ ⋅°♠↑…≈≡ ⇔⌠ ⇒↔×∂±←°± ∏∉  ⊆°≥≡ °≠ ″≡″↑±≡ …°∫
≠…↔°↑ ↓↑°↔≡∂± ⇐⇔ ∂± ↑≡÷♠≥↔∂°± °≠ ⇐ ±≈ ⇐ ≈≡↓°←∂↔≡≈ °± …≡≥≥←〉 ⊄•≡ ∏°♠↑±≥ °≠ √″″♠±°≥°÷ƒ ∑
〉 ∉√⇔∑ 
〉 ∉°←↔ ⊄∪⌠ ∂←∞≡♦←×∂ ⌠ ⇒≈″← ∨⌠ ⊄≡≈∝ √⌠ ∂≥≥≡↑ ∨⇒⌠ ≡↔ ≥〉  ≡″↑±≡ …°≠…↔°↑ ↓↑°↔≡∂± °≠ ↔•≡
…°″↓≥≡″≡±↔ ←ƒ←↔≡″∑ ⇒≥↔≡↑±↔∂♥≡ ←↓≥∂…∂±÷ °≠ ⊂≡↑∂±≡ñ⊄•↑≡°±∂±≡ñ∉↑°•±≡∫↑∂…• ≡♣°±← ±≈ …ƒ↔°↓≥←″∂… ↔∂≥←
↓↑°≈♠…≡← ″♠≥↔∂↓≥≡ ∂←°≠°↑″← ↔•↔ …°↑↑≡≥↔≡ ♦∂↔• ↓↑°↔≡∂± ↓•≡±°↔ƒ↓≡〉 ∏°♠↑±≥ °≠ ∨♣↓≡↑∂″≡±↔≥ ≡≈∂…∂±≡
∑ 〉 ∉√⇔∑ 
〉 ∇°↑″± ⇔¬⌠ ⇑↑≥°♦ ∉∇⌠ ⇑↑°± ⌠ ⇔ƒ ⇒∏⌠ ⊂∂″ ⊆⇑⌠ ≡↔ ≥〉  ⊄•↑≡≡∫≈∂″≡±←∂°±≥ ←↔↑♠…↔♠↑≡ °≠  …°″∫
↓≥≡″≡±↔ …°±↔↑°≥ ↓↑°↔≡∂± ″°≈♠≥≡ ∂± ←°≥♠↔∂°±〉 ∏ °≥ ⇑∂°≥ ∑ 〉 ⇒♥∂≥≥≡∑ •↔↔↓∑ññ♦♦♦〉
←…∂≡±…≡≈∂↑≡…↔〉…°″ñ←…∂≡±…≡ñ↑↔∂…≥≡ñ↓∂∂ñ⊄ ⇒……≡←←≡≈  ∏± 〉 ∉√⇔∑ 
〉 ±…•≡←↔≡↑ ⌠ ⊃≥←″×∂← ⇒⌠ ♠≠″± ⊆⌠ ∂←∞≡♦←×∂ ⌠ ⇒≥♥↑≡∞ ∏⌠ ≡↔ ≥〉  ≡←≥≡← ♥∂↑♠← ±≈ ⇐
∂±≈∂±÷ ←∂↔≡← ↑≡ ≈∂←↔∂±…↔ °±″≡″↑±≡ …°≠…↔°↑ ↓↑°↔≡∂± ⇐⇔〉 ∉↑°…≡≡≈∂±÷← °≠ ↔•≡ ∇↔∂°±≥ ⇒…≈≡″ƒ
°≠ ⊂…∂≡±…≡← ∑ 〉 ∉√⇔∑ 
〉 °↑∂ ∅⌠ ⊂≡ƒ ⊄⌠ ⋅♠±÷ ⋅⌠ ⇒××↓∂°°± ∉⌠ ⇔•≡↓×←°± ∉⌠ ≡↔ ≥〉  ⋅♠″± •≡↑↓≡←♥∂↑♠←  ♥↑∂±↔ ⇒
♠↔ ±°↔ ♥↑∂±↔ ⇑ ∂±≈♠…≡← ≠♠←∂°± ≠↑°″ ♦∂↔•°♠↔ ∂±  ♥↑∂≡↔ƒ °≠ •♠″± …≡≥≥← ↔•↑°♠÷•  •♠″± •≡↑↓≡←♥∂↑♠← 
≡±↔↑ƒ ↑≡…≡↓↔°↑⌠ ⇐⇔〉 ∏ ⊃∂↑°≥ ∑ 〉 ∉√⇔∑ 
〉 ≥≥←↔↑°″ ⋅⌠ ∂←∞≡♦←×∂ ⌠ ⇒↔×∂±←°± ∏∉⌠ ∏°±←←°± ⇒⇑  ≡″↑±≡ …°≠…↔°↑ ↓↑°↔≡∂± ⇐∉ °↑
⇐⇔ ∂←  …≡≥≥♠≥↑ ↓∂≥♠← ↑≡…≡↓↔°↑ ≠°↑ ↓↔•°÷≡±∂… ±≡∂←←≡↑∂〉 °≥ ∂…↑°∂°≥ ∑ 〉 ∉√⇔∑ 
〉 ⊆∂≥≡ƒ ⊆⇐⌠ ≡″↓≡↑ ⇐⌠ ≡♠±÷ ⌠ ⇒↔×∂±←°± ∏∉  ⇐•↑…↔≡↑∂∞↔∂°± °≠ •♠″±″≡″↑±≡ …°≠…↔°↑ ↓↑°∫
↔≡∂± ⇐∉ ⇐⇔ °± ←↓≡↑″↔°∞°〉 °≥ ⊆≡↓↑°≈ ⇔≡♥ ∑ 〉 ≈°∂∑ 〉ñ″↑≈〉 ∉√⇔∑

〉 ∧↑≡″≡♠♣∫⇑……•∂ ⊃⌠ °♠≥↔°± ∨⇒⌠ ♥±÷•⇔⌠ ⇔↑÷°±∫⇔♠↑≡ƒ ⌠ ⇑≥°♠∂± ∏⌠ ≡↔ ≥〉  ¬≡±≡↔∂… ±≈
≠♠±…↔∂°±≥ ±≥ƒ←≡← °≠ ″≡″↑±≡ …°≠…↔°↑ ↓↑°↔≡∂± ⇐⇔ ″♠↔↔∂°±← ∂± ↔ƒ↓∂…≥ •≡″°≥ƒ↔∂… ♠↑≡″∂…
⇐∉ ∂± ∉↑≡≡…≥″↓↔∂… ∉↑≡÷±±…∂≡←
∉∠⊂ ∠∇∨ ≤ ⇔∠√∑〉ñ∝°♠↑±≥〉↓°±≡〉 ∧≡↑♠↑ƒ ⌠   ñ 
←ƒ±≈↑°″≡〉 ∏°♠↑±≥ °≠ ↔•≡ ⇒″≡↑∂…± ⊂°…∂≡↔ƒ °≠ ∇≡↓•↑°≥°÷ƒ ∑ 〉 ≈°∂∑ 〉ñ⇒⊂∇〉
 ∉√⇔∑ 
〉 ∧±÷ ⇐∏⌠ ∧↑≡″≡♠♣∫⇑……•∂ ⊃⌠ ∂←∞≡♦←×∂ ⌠ ∉∂±≡↔↔∂ ¬⌠ ∇°↑∂← ⌠ ≡↔ ≥〉  ≡″↑±≡ …°≠…↔°↑ ↓↑°∫
↔≡∂± ″♠↔↔∂°±← ∂± ↔ƒ↓∂…≥ •≡″°≥ƒ↔∂… ♠↑≡″∂… ←ƒ±≈↑°″≡ ⋅⊇⊂⌠ ≠↔≥ ←↔♣∫⋅⊇⊂⌠ ⇐ ÷≥°″≡↑♠≥°±≡↓•↑∂↔∂←⌠
±≈ ↔•≡ ⋅∨∉ ←ƒ±≈↑°″≡〉 ⇑≥°°≈ ∑ 〉 ≈°∂∑ 〉ñ≥°°≈∫∫∫ ∉√⇔∑ 
〉 ∉∂•×≥ ∏⌠ ⋅×≥ ⊄⌠ ⊃°♠↔∂≥∂±≡± ∉⌠ ⊆∂♥∂°   ⇐•↑…↔≡↑∂←↔∂… °≠ ↑≡…≡±↔ ≠≡↔≥ ÷↑°♦↔• …♠↑♥≡← ∂± ≠∂±∫
≥±≈〉 ⇔♠°≈≡…∂″ ∑ 〉 ⇒♥∂≥≥≡∑ •↔↔↓∑ññ♠×↓″…〉…〉♠×ñ←↔↑…↔ñ∨⇔ñ ⇒……≡←←≡≈
 ∏± 〉 ∉√⇔∑ 
〉 ⊆°∞≡± ⊂⌠ ⊂×≥≡↔←×ƒ ⋅∏〉 ∉↑∂″≡↑ °± ↔•≡ ∪∪∪ ≠°↑ ÷≡±≡↑≥ ♠←≡↑← ±≈ ≠°↑ ∂°≥°÷∂←↔ ↓↑°÷↑″″≡↑←〉 ∂±∑ ↑∫
♦≡↔∞ ⊂⌠ ″∂←≡±≡↑ ⊂ ≡≈← ∂°∂±≠°↑″↔∂…← ″≡↔•°≈← ±≈ ↓↑°↔°…°≥←∑ ≡↔•°≈← ∂± ″°≥≡…♠≥↑ ∂°≥°÷ƒ〉 √±∑ ⇒±°±∫
ƒ″°♠← ⊄°↔°♦⌠ ∇∏∑ ⋅♠″± ∉↑≡←←〉 ↓↓〉 〉
〉 ⇒±≈↑≡←°± ⊆⌠ ⊆≡↓↓° ∨⌠ ↓≥∂±←×∂ ⌠ ⊆≡″″   ¬∨∇∠∨⇒⊂∨⊆ ↓…×÷≡ ≠°↑ ≈≡←∂÷±∂±÷ ♠±∂→♠≡
÷≡±°″∂… ∉⇐⊆ ↓↑∂″≡↑←〉 ⇑⇐ ⇑∂°∂±≠°↑″↔∂…← ∑ 〉 ≈°∂∑ 〉ñ∫∫∫ ∉√⇔∑ 
〉 ⊆∂♥ ⇒⌠ °•±≡ √⊂  ⊂∇∉↓≡↑∑ ⊆≡↔↑∂≡♥≥ ±≈ ±≥ƒ←∂← °≠ •♠″± ⊂∇∉←〉 ⇑∂°∂±≠°↑″↔∂…← ∑
〉 ≈°∂∑ 〉ñ∂°∂±≠°↑″↔∂…←ñ〉〉 ∉√⇔∑ 
〉 ∉♠↑…≡≥≥ ⊂⌠ ∇≡≥≡ ⇑⌠ ⊄°≈≈∫⇑↑°♦± ⌠ ⊄•°″← ⌠ ∧≡↑↑≡∂↑ ⇒⌠ ≡↔ ≥〉  ∉√∇∑ ⇒ ↔°°≥ ←≡↔ ≠°↑ ♦•°≥≡∫÷≡∫
±°″≡ ←←°…∂↔∂°± ±≈ ↓°↓♠≥↔∂°±∫←≡≈ ≥∂±×÷≡ ±≥ƒ←≡←〉 ⇒″ ∏ ⋅♠″¬≡±≡↔ ∑ 〉 ≈°∂∑ 〉
ñ ∉√⇔∑ 
〉 ⇒≈∞•♠≡∂ √⇒⌠ ⊂…•″∂≈↔ ⊂⌠ ∉≡←•×∂± ⌠ ⊆″≡±←×ƒ ⊃∨⌠ ¬≡↑←∂″°♥ ⇒⌠ ≡↔ ≥〉  ⇒ ″≡↔•°≈ ±≈ ←≡↑♥≡↑
≠°↑ ↓↑≡≈∂…↔∂±÷ ≈″÷∂±÷ ″∂←←≡±←≡ ″♠↔↔∂°±←〉 ∇↔ ≡↔•°≈← ∑ 〉 ≈°∂∑ 〉ñ±″≡↔•∫
∉√⇔∑ 
〉 ∇÷ ∉⇐⌠ ⋅≡±∂×°≠≠ ⊂  ∉↑≡≈∂…↔∂±÷ ≈≡≥≡↔≡↑∂°♠← ″∂±° …∂≈ ←♠←↔∂↔♠↔∂°±←〉 ¬≡±°″≡ ⊆≡← ∑ 〉
≈°∂∑ 〉ñ÷↑〉 ∉√⇔∑ 
〉 ∇÷ ∉⇐⌠ ⋅≡±∂×°≠≠ ⊂  ⊂√∧⊄∑ ∉↑≡≈∂…↔∂±÷ ″∂±° …∂≈ …•±÷≡← ↔•↔ ≠≠≡…↔ ↓↑°↔≡∂± ≠♠±…↔∂°±〉 ∇♠…≥≡∂…
⇒…∂≈← ⊆≡← ∑ 〉 ∉√⇔∑ 
〉 ⊂↔≠≠ ⇒⇐⌠ ⇑≡±↔°± ⊂∏⌠ ♥°± ⇔≈≡≥←∞≡± ∉⌠ ⊆°≡↑↔← ∏⌠ ⊄ƒ≥°↑ ⊆∇⌠ ≡↔ ≥〉  ⊆≡≈≡≠∂±∂±÷ ↓↑≡≡…≥″↓←∂
♠←∂±÷ ↓≥…≡±↔∫≈≡↑∂♥≡≈ ∂°″↑×≡↑←〉 ⋅ƒ↓≡↑↔≡±←∂°± ∑ 〉 ≈°∂∑ 〉ñ⋅∅∉∨⊆⊄∨∇⊂√∠∇⇒⋅⇒〉
〉 ∉√⇔∑ 
〉 ⊆∂…•↑≈← ⇒⌠ ≡″↓ ∨∏⌠ ∂←∞≡♦←×∂ ⌠ ¬°°≈←•∂↓ ∏⇒⌠ ″↓≡ ⇒⌠ ≡↔ ≥〉  ♠↔↔∂°±← ∂± •♠″± …°″∫
↓≥≡″≡±↔ ↑≡÷♠≥↔°↑⌠ ″≡″↑±≡ …°≠…↔°↑ ↓↑°↔≡∂± ⇐⇔⌠ ↓↑≡≈∂←↓°←≡ ↔° ≈≡♥≡≥°↓″≡±↔ °≠ ≠″∂≥∂≥ •≡″°≥ƒ↔∂…
♠↑≡″∂… ←ƒ±≈↑°″≡〉 ∉↑°…≡≡≈∂±÷← °≠ ↔•≡ ∇↔∂°±≥ ⇒…≈≡″ƒ °≠ ⊂…∂≡±…≡← ∑ 〉 ≈°∂∑ 〉
ñ↓±←〉 ∉√⇔∑ 
〉 ∂←∞≡♦←×∂ ⌠ ≡♠±÷ ⌠ ⇐♠∂ ∪⌠ ⊂♠↑″±∂± ⊃⇑⌠ ∉↑×∂±←°± ∏⌠ ≡↔ ≥〉  ⇔∂←←≡…↔∂±÷ ←∂↔≡← ∂″↓°↑↔±↔
≠°↑ …°″↓≥≡″≡±↔ ↑≡÷♠≥↔°↑ƒ …↔∂♥∂↔ƒ ∂± ″≡″↑±≡ …°≠…↔°↑ ↓↑°↔≡∂± ⇐∉ ⇐⇔〉 ∏°♠↑±≥ °≠ ⇑∂°≥°÷∂…≥
⇐•≡″∂←↔↑ƒ ∑ 〉 ≈°∂∑ 〉ñ∝…〉 ∉√⇔∑ 
⇐∉ ∂± ∉↑≡≡…≥″↓↔∂… ∉↑≡÷±±…∂≡←
∉∠⊂ ∠∇∨ ≤ ⇔∠√∑〉ñ∝°♠↑±≥〉↓°±≡〉 ∧≡↑♠↑ƒ ⌠   ñ 
ƒ  ≤ ⊃°≥♠″≡  ≤ ⇒↑↔∂…≥≡ 
∠⊆√¬√∇⇒ ⊆∨⊂∨⇒⊆⇐⋅
↓♠≥∂←•≡≈∑  ƒ 
∧↑°±↔∂≡↑← ∂± √″″♠±°≥°÷ƒ ≤ ♦♦♦〉≠↑°±↔∂≡↑←∂±〉°↑÷
∨≈∂↔≡≈ ƒ∑ 
♠…∂≡±±≡ ⇐•↔≡±°♠≈⌠  
⊇±∂♥≡↑←∂↔6 ∉↑∂← ⇔≡←…↑↔≡←⌠ ∧↑±…≡
⊆≡♥∂≡♦≡≈ ƒ∑ 
↑∂≡∫⇐≥♠≈≡ ¬♠≈↑≡♠⌠  
≡≈√″″♠±≡⌠ ⊇±∂↔≡≈ ⊂↔↔≡←  
∇↔≥∂° ¬↑∂⌠  
⊇±∂♥≡↑←∂↔ƒ °≠ ⇑°±±⌠ ¬≡↑″±ƒ
⌡⇐°↑↑≡←↓°±≈≡±…≡∑
⇒〉 √±×≡↑∂ °××∂ 
⊂≡↓↓° ≡↑∂ 
⊂↓≡…∂≥↔ƒ ←≡…↔∂°±∑ 
⊄•∂← ↑↔∂…≥≡ ♦← ←♠″∂↔↔≡≈  
↔° √″″♠±°≥°÷∂…≥ ⊄°≥≡↑±…≡  
±≈ ⊆≡÷♠≥↔∂°±⌠  ←≡…↔∂°±  






⇒±≥ƒ←∂← °≠ ⇐°″↓≥≡″≡±↔ ⇐  
¬≡±≡ ⊆≡♥≡≥← ⊂♠←…≡↓↔∂∂≥∂↔ƒ ↔°  
⊂≡♥≡↑≡ ∉↑≡≡…≥″↓←∂〉 
∧↑°±↔〉 √″″♠±°≥〉 ∑〉 
⇒±≥ƒ←∂← °≠ ⇐°″↓≥≡″≡±↔ ⇐ ¬≡±≡ 
⊆≡♥≡≥← ⊂♠←…≡↓↔∂∂≥∂↔ƒ ↔° ⊂≡♥≡↑≡ 
∉↑≡≡…≥″↓←∂
⇒〉 √±×≡↑∂ °××∂⌠⌠⌡⌠ ⊄≡ ↑↔°×≥≥∂°⌠ ⊃∂≥≥≡ ⋅°≥″≡↑÷ ⌠⌠ ∉;∂♥∂ ∠±×″° ⌠ 
⌠ ∉;∂♥∂ ⊂♥≥∂±≡±⌠ ⊂≡↓↓° ⋅≡∂±°±≡±⌠ ∨≡↑° ∝±↔∂≡⌠⌠⌠ 
⌠⌠⌠ ↔∝ ∂♥∂±≡±⌠ ⇒±±≡≥∂ ∉°♠↔⌠⌠ ∉∂ 〉 ⊃∂≥≥ ⌠⌠ ≡≡± ⋅∂≥↔♠±≡±⌠ 
⌠⌠ ±≈ ⊂≡↓↓° ≡↑∂⌠⌡
 √″″♠±°∂°≥°÷ƒ⌠ ⊆≡←≡↑…• ∉↑°÷↑″← ⊇±∂↔⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈⌠  ≡≈∂…≥ ±≈ ⇐≥∂±∂…≥ ¬≡±≡↔∂…←⌠ ⊇±∂♥≡↑←∂↔ƒ 
°≠ ⋅≡≥←∂±×∂ ±≈ ⋅≡≥←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈⌠  ⇑…↔≡↑∂°≥°÷ƒ ±≈ √″″♠±°≥°÷ƒ⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ⋅≡≥←∂±×∂⌠ 
∧∂±≥±≈⌠  ⌠ ⋅≡≥←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ⋅≡≥←∂±×∂⌠ 
∧∂±≥±≈⌠  ⇔≡↓↑↔″≡±↔ °≠ ⇑∂°←…∂≡±…≡←⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈⌠  ⇔≡↓↑↔″≡±↔ °≠ ∠←↔≡↔↑∂…← ±≈ ¬ƒ±≡…°≥°÷ƒ⌠ 
⋅≡≥←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈⌠  ⇐•↑°±∂… ⇔∂←≡←≡ ∉↑≡♥≡±↔∂°± ⊇±∂↔⌠ ⇔≡↓↑↔″≡±↔ °≠ ⋅≡≥↔•⌠ 
∇↔∂°±≥ √±←↔∂↔♠↔≡ ≠°↑ ⋅≡≥↔• ±≈ ∪≡≥≠↑≡⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈⌠  ⇐•∂≥≈↑≡±← ⋅°←↓∂↔≥⌠ ⋅≡≥←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ 
⋅≡≥←∂±×∂⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈⌠  ∉∨⇔∨¬∠ ⊆≡←≡↑…• ⊇±∂↔⌠ ⊆⇐ ∠♠≥♠⌠ ∠♠≥♠ ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ∠♠≥♠⌠ ∠♠≥♠⌠ ∧∂±≥±≈⌠ 
 ⇔≡↓↑↔″≡±↔ °≠ ⇑∂°←…∂≡±…≡← ±≈ ∇♠↔↑∂↔∂°±⌠ ↑°≥∂±←× √±←↔∂↔♠↔≡↔⌠ ⋅♠≈≈∂±÷≡⌠ ⊂♦≡≈≡±⌠  ∧°≥×•;≥←± √±←↔∂↔♠↔≡ °≠ ¬≡±≡↔∂…←⌠ 
⋅≡≥←∂±×∂⌠ ∧∂±≥±≈⌠  °≥≡…♠≥↑ ∇≡♠↑°≥°÷ƒ⌠ ⊆≡←≡↑…• ∉↑°÷↑″← ⊇±∂↔⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈⌠  ⇔∂♥∂←∂°± °≠ 
⇐↑≈∂°♥←…♠≥↑ ≡≈∂…∂±≡⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⇐″↑∂≈÷≡⌠ ⇐″↑∂≈÷≡⌠ ⊇⌠  ⇔≡↓↑↔″≡±↔ °≠ ¬°♥≡↑±″≡±↔ ⊂≡↑♥∂…≡←⌠ ∇↔∂°±≥ √±←↔∂↔♠↔≡ 
≠°↑ ⋅≡≥↔• ±≈ ∪≡≥≠↑≡⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈⌠  ∧∂±±∂←• ⊆≡≈ ⇐↑°←← ⇑≥°°≈ ⊂≡↑♥∂…≡⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈⌠  √±←↔∂↔♠↔≡ ≠°↑ °≥≡…♠≥↑ 
≡≈∂…∂±≡ ∧∂±≥±≈⌠ ⋅∂√∧∨⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈
∉↑≡≡…≥″↓←∂ ∉∨ ∂←  …°″″°± ♥←…♠≥↑ ≈∂←≡←≡ °≠ ↓↑≡÷±±…ƒ ♦∂↔• ÷≡±≡↔∂… ↓↑≡≈∂←↓°←∂↔∂°±〉 
⇔ƒ←↑≡÷♠≥↔∂°± °≠ ↔•≡ …°″↓≥≡″≡±↔ ←ƒ←↔≡″ •← ≡≡± ∂″↓≥∂…↔≡≈⌠ ♠↔ ″°≥≡…♠≥↑ ″≡…•±∂←″← 
↑≡ ∂±…°″↓≥≡↔≡≥ƒ ♠±≈≡↑←↔°°≈〉 √± ↔•∂← ←↔♠≈ƒ⌠ ♦≡ ≈≡↔≡↑″∂±≡≈ ↔•≡ ↓°↔≡±↔∂≥ ≥∂±×÷≡ °≠ ←≡♥≡↑≡ ∉∨ ↔° 
↔•≡ ″°←↔ …≡±↔↑≥ …°″↓≥≡″≡±↔ ÷≡±≡⌠ ⇐〉 ⊄•↑≡≡ …°•°↑↔← °≠ ∧∂±±∂←• ↓↔∂≡±↔← ±≈ …°±↔↑°≥← ♦≡↑≡ 
↑≡…↑♠∂↔≡≈ ≠°↑  ÷≡±≡↔∂… …←≡∫…°±↔↑°≥ ←↔♠≈ƒ〉 ∉↑↔∂…∂↓±↔← ♦≡↑≡ ÷≡±°↔ƒ↓≡≈ ♠←∂±÷ ⊂≡→♠≡±°″ 
÷≡±°↔ƒ↓∂±÷ ±≈ ⊂±÷≡↑ ←≡→♠≡±…∂±÷〉 √±∂↔∂≥≥ƒ⌠ ♦≡ ←↔♠≈∂≡≈  ∧∂±±∂←• ↓↔∂≡±↔← ♦∂↔• ←≡♥≡↑≡ 
∉∨ ±≈  …°±↔↑°≥← ≠↑°″ ↔•≡ ⊂°♠↔•≡↑± ∧∂±≥±≈ ∉∨ ±≈ ↔•≡ ∧∂±±∂←• ↓°↓♠≥↔∂°±∫←≡≈ ∉∨ 
…°•°↑↔←〉 ∪≡ ♠←≡≈  …♠←↔°″∫″≈≡ ←∂±÷≥≡ ±♠…≥≡°↔∂≈≡ ↓°≥ƒ″°↑↓•∂←″ ⊂∇∉ ÷≡±°↔ƒ↓∂±÷ ←←ƒ 
…°±←∂←↔∂±÷ °≠  ⊂∇∉← ∂±  ÷≡±≡← ↔•↔ ≡±…°≈≡ …°″↓°±≡±↔← °≠ ↔•≡ …°″↓≥≡″≡±↔ ←ƒ←↔≡″〉 
∧°≥≥°♦∂±÷ ↔•≡ ↓↑∂″↑ƒ ←…↑≡≡±∂±÷⌠ ⇐ ♦← ←≡≥≡…↔≡≈ ← ↔•≡ …±≈∂≈↔≡ ÷≡±≡ ±≈ …°±←≡→♠≡±↔≥ƒ 
⊂±÷≡↑ ←≡→♠≡±…≡≈〉 ∧°♠↑↔≡≡± ⊂∇∉← ≠↑°″ ⇐ ♦≡↑≡ ≥←° ÷≡±°↔ƒ↓≡≈ ƒ  ⊂≡→♠≡±°″ ↓±≡≥ 
∂±  ↓↔∂≡±↔← ♦∂↔• ←≡♥≡↑≡ ∉∨ ±≈  …°±↔↑°≥←⌠ ∂±…≥♠≈∂±÷ ≥↑≡≈ƒ ←≡→♠≡±…≡≈ ∂±≈∂♥∂≈♠≥←〉 
⊄•↑≡≡ °≠  ↔•≡  ⊂∇∉← °←≡↑♥≡≈ ♦∂↔•∂± ⇐ ♦≡↑≡ ←←°…∂↔≡≈ ♦∂↔• ←≡♥≡↑≡ ∉∨∑ ↑← 
↓   ↓   ↓ 

∂± ↔•≡ ″∂≈≈≥≡ °≠ ↔•≡ ÷≡±≡ ♦∂↔•  ↓↑°↔≡…↔∂♥≡ ↓  
↓  
∫
″≡±↔ ←ƒ←↔≡″ ♦∂↔• ± ←←°…∂↔∂°± ↔°  …≥∂±∂…≥≥ƒ ↑≡≥≡♥±↔ ∉∨ ←♠↓•≡±°↔ƒ↓≡⌠ ←≡♥≡↑≡ ∉∨〉 ⊄•≡ 
↑≡←♠≥↔ •∂÷•≥∂÷•↔←  ↓°↔≡±↔∂≥ ↑°≥≡ ≠°↑ ↔•≡ …°″↓≥≡″≡±↔ ←ƒ←↔≡″ ∂± ↔•≡ ↓↔•°÷≡±≡←∂← °≠ ∉∨ ±≈ 
≡ƒ♦°↑≈←∑ ↓↑≡≡…≥″↓←∂⌠ …°″↓≥≡″≡±↔⌠ ⇐⌠ ←←°…∂↔∂°± ←↔♠≈ƒ⌠ ÷≡±≡ ↑≡÷♠≥↔∂°±⌠ ÷≡±≡↔∂… ↑∂←×⌠ ↓↑≡÷±±…ƒ 
…°″↓≥∂…↔∂°±⌠ ∂±±↔≡ ∂″″♠±∂↔ƒ

°××∂ ≡↔ ≥〉 ⇐ ¬≡±≡ ±≈ ∉∨
∧↑°±↔∂≡↑← ∂± √″″♠±°≥°÷ƒ ≤ ♦♦♦〉≠↑°±↔∂≡↑←∂±〉°↑÷ ƒ  ≤ ⊃°≥♠″≡  ≤ ⇒↑↔∂…≥≡ 
√∇⊄⊆∠⇔⊇⇐⊄√∠∇
∉↑≡≡…≥″↓←∂ ∉∨ ∂←  ←≡↑∂°♠← ♥←…♠≥↑ …°″↓≥∂…↔∂°± °≠ ↓↑≡÷±±…ƒ⌠ 
♦•∂…• ″ƒ ≥≡≈ ↔°  ≥∂≠≡∫↔•↑≡↔≡±∂±÷ ″♠≥↔∂∫°↑÷± ≈ƒ←≠♠±…↔∂°± 
±≈    …°±♥♠≥←∂♥≡  …°±≈∂↔∂°±⌠  ≡…≥″↓←∂  
∫
←∂°± °≠ ↔•≡ ≈∂←≡←≡ ↑≡ ♠±↓↑≡≈∂…↔≥≡ ♦∂↔• ≈≡≥∂♥≡↑ƒ ≡∂±÷ ↔•≡ °±≥ƒ 
∉↑≡≡…≥″↓←∂ •← ≡≡± ↔•≡ ←♠∝≡…↔ °≠ ±♠″≡↑°♠← ÷≡±≡↔∂… ←↔♠≈∂≡← 
±≈ ←≡♥≡↑≥ ←←°…∂↔∂±÷ ←∂±÷≥≡ ±♠…≥≡°↔∂≈≡ ↓°≥ƒ″°↑↓•∂←″← ⊂∇∉← 
•♥≡ ≡≡± ≈≡←…↑∂≡≈ ↑≡ ÷≡±≡← ≥∂±×≡≈ ↔° •ƒ↓≡↑↔≡±←∂°± ±≈ ♥←…♠≥↑ 
±≈ ″≡↔°≥∂… ≈∂←≡←≡ ⌠ ≥≥ ≈∂←≡←≡← ♦•°←≡ ↑∂←× ∂← ∂±…↑≡←≡≈ 
∂± ↔•≡ ≥↔≡↑ ≥∂≠≡ °≠ ∉∨ ↓↔∂≡±↔← 〉 ∧♠↑↔•≡↑″°↑≡⌠ ÷≡±≡← ≡±…°≈∂±÷ 
≠°↑ ↓↑°↔≡∂±← ∂±♥°≥♥≡≈ ∂± ↔•≡ ∂″″♠±°≥°÷∂…≥ ↓↑°…≡←←≡← •♥≡ ≥←° 
≡≡± ≠°♠±≈ ↔° •↑°↑ ⊂∇∉← ↔•↔ ↓↑≡≈∂←↓°←≡ ↓↔∂≡±↔← ↔° ∉∨ ⌠ 〉
∉↑≡÷±±…ƒ ∂← ↔•≡ ♠≥↔∂″↔≡ ∂″″♠±°≥°÷∂…≥ ↓↑≈°♣⌠ ♦•≡↑≡ 
↔•≡ ″↔≡↑±≥ ∂″″♠±≡ ←ƒ←↔≡″ ″♠←↔ ……°″″°≈↔≡ ↔° ↓↑°↔≡…↔ ↔•≡ 
″°↔•≡↑ ±≈ ÷↑°♦∂±÷ ≠≡↔♠← ≠↑°″ ↓↔•°÷≡±← ♦•∂≥≡ ≥≥°♦∂±÷ ↔•≡ 
↔•↔ ∂±♥°≥♥≡← ↓°°↑ ↓≥…≡±↔↔∂°± ⌠ ≡←↓≡…∂≥≥ƒ ∂± ↔•≡ ←≡♥≡↑≡ ±≈ñ°↑ 
≡↑≥ƒ °±←≡↔ ≈∂÷±°←∂← °↑ ≈≡≥∂♥≡↑ƒ 
°≠ ↔•≡ ≈∂←≡←≡⌠ ♦•≡↑≡ ∂″″♠±°≥°÷∂…≥ ″≡…•±∂←″← •♥≡ ≡≡± 
∂″↓≥∂…↔≡≈  ⌠  ∫
±∂←″←⌠  ∂±≈≡→♠↔≡  …°±↔↑°≥  °≠  ↔•≡  ″↔≡↑±≥  …°″↓≥≡″≡±↔  ←ƒ←↔≡″  
•← ≡≡± ←♠÷÷≡←↔≡≈ ↔° …°±↔↑∂♠↔≡ ↔° ↔•≡ ≡↔∂°≥°÷ƒ °≠ ∉∨ ⌠ 〉
°≠ ″∂…↑°≡← ±≈ ∂±∝♠↑≡≈ ↔∂←←♠≡ ″↔≡↑∂≥←〉 √↔ …± ≡ …↔∂♥↔≡≈ ƒ 
↔•≡ …≥←←∂…≥⌠ ↔•≡ ≥≡…↔∂±⌠ °↑ ↔•≡ ≥↔≡↑±↔∂♥≡ ↓↔•♦ƒ⌠ ♦•∂…• ↓↑°…≡≡≈ 
←↔≡↓♦∂←≡ ∂±  …°±↔↑°≥≥≡≈ …←…≈≡ °≠ ∂±↔≡↑…↔∂°±← ≡↔♦≡≡± ←♠↑≠…≡∫
°♠±≈ ±≈ ←°≥♠≥≡ ↓↑°↔≡∂±← ∂± ↔•≡ ←≡↑♠″〉 ⇐°″↓≥≡″≡±↔ ⇐ ∂← ↔•≡ 
…≡±↔↑≥  …°″↓°±≡±↔  °≠  ≥≥  …↔∂♥↔∂°±  ↓↔•♦ƒ←〉  √↔  ∂←  ″°±÷  ↔•≡  
″°←↔ ±…∂≡±↔ …°″↓°±≡±↔← °≠ ∂±±↔≡ ∂″″♠±∂↔ƒ ↔•↔ •← ≡♥°≥♥≡≈ 
°♥≡↑ ⌠ ″∂≥≥∂°± ƒ≡↑← ÷° 〉 √±≈≡≡≈⌠ ↔•≡ ≠♠±…↔∂°±≥ ≈°″∂±← 
°≠ ↔•≡ •♠″± ⇐ ↑≡ …°±←≡↑♥≡≈ ∂± …°↑≥← ±≈ ⇐±∂≈↑∂±← ⌠ 〉 
•♠″± ←≡↑♠″ ∂±≈∂…↔≡ ∂↔← ∂″↓°↑↔±↔ ↑°≥≡ ← ↔•≡ ×≡ƒ …°″↓°±≡±↔ 
°≠ ∂″″♠±∂↔ƒ ÷∂±←↔ ∂±≠≡…↔∂°± ±≈ ∂± ↔•≡ ≈∂←…↑∂″∂±↔∂°± ≡↔♦≡≡± 
←≡≥≠ ±≈ ±°±∫←≡≥≠ 〉
∫ ±≈ 
∫…•∂±← ±≈  ∂±≈∂♥∂≈♠≥ ≈°″∂±←〉 √± ←•↓≡⌠ ∂↔ ∂←  ↑°°↔∫≥∂×≡ 
″°≥≡…♠≥≡ ↔•↔ •← ≡∂÷•↔ ″…↑°÷≥°♠≥∂± ≈°″∂±← ↔•≡ °≈ƒ⌠ 
 ≥∂±×≡↑ ∇⌠ ↔•≡ ⇐ ±↓•ƒ≥↔°♣∂±⌠ ± ↑″∫≥∂×≡ ↑≡÷∂°± 
♦∂↔• ↔•≡ ⇐↑ñ←⌠ ⊇∨¬∧⌠ ⇑∉ ⇐⊇⇑⌠  ↔•∂°≡←↔≡↑∫…°±↔∂±∂±÷ 
≈°″∂± ⊄∨⇔⌠  ± ∇∫↔≡↑″∂±≥  ≈°″∂±  ∇⊄⌠ ±≈ ↔•≡ •≡≈ 
⇐⇐ ≥∂±×≡≈ ↔° ↔•≡ °≈ƒ ♦∂↔• ± ±…•°↑ 
↑≡ ≡±…°≈≡≈ ƒ  ≡♣°±← °≠ ↔•≡ ⇐ ÷≡±≡〉 ∪•≡± ⇐ ∂← …↔∂♥↔≡≈ 
↔° ⇐⌠ ± ∂±↔≡↑±≥ ↔•∂°≡←↔≡↑ °±≈ ∂← ≈∂←↑♠↓↔≡≈ ≥≥°♦∂±÷ …°♥≥≡±↔ 
↔↔…•″≡±↔ °≠ ⇐ ↔° ↔↑÷≡↔ ←♠↑≠…≡←〉 ⊂♠←≡→♠≡±↔≥ƒ⌠ ≠…↔°↑ ⇑ ∂±≈← 
↔°  ↔•≡  ¬  ±≈  ⇐⊇⇑  ≈°″∂±←  °≠  ⇐  〉 ⇒ ⇐ …°±♥≡↑↔←≡⌠ 
⇐⇑⌠ ∂← ≠°↑″≡≈ ♦•≡± ≠…↔°↑ ⇔ …↔∂♥↔≡← ⇐∫°♠±≈ ≠…↔°↑ ⇑ ↔° 
↔° ⇐ ↔° ↑≡≥≡←≡ ±↓•ƒ≥↔°♣∂… ⇐ ≠↑÷″≡±↔← ↔° ↔•≡ …∂↑…♠≥∫
↔∂°± 
……≡≥≡↑↔∂±÷ ≠…↔°↑ ⇐⇔⌠ ±≈ ⇐⊆ ∂±≈ ↓↑↔∂≥≥ƒ ↔° ↔•≡ ≠…↔°↑ 
⇑∫∂±≈∂±÷ ←∂↔≡ ↔° ↓↑≡♥≡±↔ °↑ ≈∂←↑♠↓↔ ⇐⇑ ≠°↑″↔∂°± ⌠ 〉
 
…↔∂♥↔∂°± ∂← ↔•≡ ×≡ƒ ″≡…•±∂←″ ≠°↑ ↑≡↓↑°≈♠…↔∂♥≡ ≠∂≥♠↑≡ ∂± 
⇐↑↑ƒ ñ   ″∂…≡  〉 ⊆≡…≡±↔≥ƒ⌠ 
∂↔ ♦← ←•°♦± ↔•↔ ≥↔≡↑±↔∂♥≡ …°″↓≥≡″≡±↔ ↓↔•♦ƒ ≡…°″≡← 
…↔∂♥↔≡≈ ≥←° ∂± •♠″± ↓↑≡÷±±…∂≡←⌠ ♦•≡↑≡ ←≡♥≡↑≡ ∉∨ ≈≡♥≡≥°↓← 

←ƒ±≈↑°″≡ •≡″°≥ƒ←∂←⌠ ≡≥≡♥↔≡≈ ≥∂♥≡↑ ≡±∞ƒ″≡←⌠ ≥°♦ ↓≥↔≡≥≡↔ …°♠±↔⌠ 
 ≥∂≠≡∫↔•↑≡↔≡±∂±÷ …°″↓≥∂…↔∂°± °≠ ∉∨⌠ ƒ ≡…♠≥∂∞♠″⌠  ↔↑÷≡↔≡≈ 
∂±•∂∂↔°↑ °≠ …°″↓≥≡″≡±↔ ↓↑°↔≡∂± ⇐⌠ ≈≡″°±←↔↑↔≡≈ ↔•↔ ↔•≡ 
…°″↓≥≡″≡±↔  ←ƒ←↔≡″  …°♠≥≈  ↓↑°♥∂≈≡    ↓↑°″∂←∂±÷  ↔↑÷≡↔  ≠°↑  ≈↑♠÷  
≈≡♥≡≥°↓″≡±↔ ∂± ←≡♥≡↑≡ ∉∨ 
←↔÷≡← °≠ …°″↓≥≡″≡±↔ …↔∂♥↔∂°±⌠ ∂〉≡〉⌠ ↔•≡ ≥ƒ↔∂… ↔≡↑″∂±≥ ↓↔•♦ƒ〉
∪≡ •♥≡ ≥°°×≡≈ ≠°↑ ⊂∇∉ ←←°…∂↔∂°± ♦∂↔• ←≡♥≡↑≡ ∉∨ ″°±÷  
←←°…∂↔∂°±← ♦≡↑≡ ≠°♠±≈ ∂± ⇐⌠ ♦•≡↑≡ ≥∂±×÷≡ °↔• ↔° ∂±≈∂♥∂≈♠≥ 
⊂∇∉←  ±≈  ↔°    ≈∂←↔∂±…↔  •↓≥°↔ƒ↓≡⌠  ♦←  °←≡↑♥≡≈〉  ⇐ ♦← ↔•♠← 
←♠←≡→♠≡±↔≥ƒ …•°←≡± ≠°↑ ≈≡↔∂≥≡≈ …↓∂≥≥↑ƒ ←≡→♠≡±…∂±÷ °≠ ∂↔← ≡♣°±← 
±≈ ↓↑°″°↔≡↑  ↑≡÷∂°±←  ∉⊆∠← ∂±  ♦°″≡± ♦∂↔• ←≡♥≡↑≡  ∉∨ ±≈ 
…°±↔↑°≥← ♦∂↔• ±°±∫∉∨ ↓↑≡÷±±…∂≡←〉
⇒⊄∨⊆√⇒⊂ ⇒∇⇔ ∨⊄⋅∠⇔⊂
≡≈∂…≥ ±≈ ⇐≥∂±∂…≥ ¬≡±≡↔∂…← ±≈ √±←↔∂↔♠↔≡ ≠°↑ °≥≡…♠≥↑ ≡≈∂…∂±≡ 
″≡↔•°≈←  °≠  ÷≡±°↔ƒ↓∂±÷  ∂±  ≡…•  ←↔÷≡  °≠  ↔•≡  ←↔♠≈ƒ  ↑≡  ≈≡←…↑∂≡≈  
〉 ⇒≥≥ ←♠∝≡…↔← ↓↑°♥∂≈≡≈ 
 ♦↑∂↔↔≡± ∂±≠°↑″≡≈ …°±←≡±↔ ∂± ……°↑≈±…≡ ♦∂↔• ↔•≡ ⇔≡…≥↑↔∂°± 
°≠ ⋅≡≥←∂±×∂〉 ⊂↔♠≈ƒ ↓↑°↔°…°≥← ♦≡↑≡ ↓↓↑°♥≡≈ ƒ ↔•≡ ≥°…≥ ∨↔•∂…≥ 
•← ≡≡± °↔∂±≡≈ ≠↑°″ ↔•≡ ⇐°°↑≈∂±↔∂±÷ ∨↔•∂…← ⇐°″″∂↔↔≡≡⌠ 
⋅°←↓∂↔≥ ⇔∂←↔↑∂…↔ °≠ ⋅≡≥←∂±×∂⌠ ±≈ ⊇♠←∂″⌠ ≠°↑ ↔•≡ ∧∂±±∂←• 
↓°↓♠≥↔∂°±∫←≡≈ ∉∨ …°•°↑↔ ♦← ↓↓↑°♥≡≈ ƒ ↔•≡ ≡↔•∂…← …°″″∂↔∫
↔≡≡ °≠ ↔•≡ ∧∂±±∂←• ⊆≡≈ ⇐↑°←← ⇑≥°°≈ ⊂≡↑♥∂…≡ ±≈ ƒ ↔•≡ ∂±∂←↔↑ƒ °≠ 
↓↓↑°♥≡≈ ƒ ↔•≡ ∨↔•∂…← ⇐°″″∂↔↔≡≡ °≠ ↔•≡ ⇔≡↓↑↔″≡±↔ °≠ ∠←↔≡↔↑∂…← 
±≈ ¬ƒ±≡…°≥°÷ƒ ↔ ⋅≡≥←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ ⇐≡±↔↑≥ ⋅°←↓∂↔≥〉
⊂≡≥≡…↔∂°± °≠ ⊂↔♠≈ƒ ⊂♠∝≡…↔← ±≈ 
⇔∂÷±°←↔∂… ⇐↑∂↔≡↑∂
∧∂±±∂←• ↓°↓♠≥↔∂°±∫←≡≈ ∉∨ …°•°↑↔ 
∉∨  …°•°↑↔  ⌠  ±≈  ↔•≡  ∧∂±±∂←•  ¬≡±≡↔∂…←  °≠  ∉∨  ⇐°±←°↑↔∂♠″  
∧√∇∇∉∨⇐ …°•°↑↔   ⊄≥≡  ⊂ ∂±  ⊂♠↓↓≥≡″≡±↔↑ƒ  ↔≡↑∂≥〉  
∠±≥ƒ ♦°″≡± ♦∂↔•  ←∂±÷≥≡↔°± ↓↑≡÷±±…ƒ ♦≡↑≡ ∂±…≥♠≈≡≈ ∂± ↔•≡ 
←↔♠≈ƒ〉  ∨♣…≡↓↔  ≠°↑  ↔•↑≡≡  ♦°″≡±  ≠↑°″  ↔•≡  ⊂°♠↔•≡↑±  ∧∂±≥±≈  ∉∨  
…°•°↑↔⌠ ♦•≡↑≡ ≈↔ °± ←♠∝≡…↔∂♥≡ ←ƒ″↓↔°″← ♦≡↑≡ ±°↔ ♥∂≥≥≡⌠ ≥≥ 
♦°″≡± ♦∂↔• ∉∨ ″≡↔ ↔•≡ …↑∂↔≡↑∂ °≠ ←≡♥≡↑≡ ∉∨ 〉 ⊂≡♥≡↑≡ ∉∨ ♦← 
°↑ ↓↑°↔≡∂±♠↑∂ 
♦°″± ≈∂÷±°←≡≈ ♦∂↔• ∉∨ ……°↑≈∂±÷ ↔° ↔•≡ ⇒″≡↑∂…± ⇐°≥≥≡÷≡ °≠ 
∠←↔≡↔↑∂…∂±← ±≈ ¬ƒ±≡…°≥°÷∂←↔← 〉
♠←≡≈ ≠°↑ ←≡→♠≡±…∂±÷ ±≈ ⊂≡→♠≡±°″ ÷≡±°↔ƒ↓∂±÷ ↑≡ ≈≡←…↑∂≡≈ 
∂± 
∧√¬⊇⊆∨  ≤ ⇐ ↓↑°∝≡…↔ ♦∂↔• ↔•≡ ±≥ƒ←∂← ↓↑°…≡←← ±≈ ↓↓↑°↓↑∂↔≡ ″≡↔•°≈ ∂± ↓↑≥≥≡≥〉 ⊄•≡ ←∂±÷≥≡ ±♠…≥≡°↔∂≈≡ ↓°≥ƒ″°↑↓•∂←″← ⊂∇∉← ↔•↔ 
〉 ⊂∉∨⌠ ←≡♥≡↑≡ ↓↑≡≡…≥″↓←∂〉
⊄⇒⇑∨  ≤ ⇐≥∂±∂…≥ …•↑…↔≡↑∂←↔∂…← °≠ ↔•≡ ⊂°♠↔•≡↑± ∧∂±≥±≈ …°•°↑↔ ∇  ¬≡±≡↔∂…← °≠ ∉↑≡≡…≥″↓←∂ 
∧√∇∇∉∨⇐ …°•°↑↔ ↓↑↔∂…∂↓±↔← ∂± ⇐ ←≡→♠≡±…∂±÷ ±≈ ÷≡±°↔ƒ↓∂±÷〉





⊂≡♥≡↑≡ ∉∨ ↓∫⊃≥♠≡⌡ 
…°″↓↑≡≈ 
↔° …°±↔↑°≥←⊄•≡ ⊂±÷≡↑ ←≡→♠≡±…∂±÷ 
←↔÷≡ ∇ 
↔•⌠ ↔• ↓≡↑…≡±↔∂≥≡
⇒÷≡⌠ ƒ≡↑← 〉 ⌠   ⌠  ∇  〉  ⌠  〉
∉↑≡∫↓↑≡÷±±…ƒ °≈ƒ ″←← ∂±≈≡♣⌠ ×÷ñ″  〉⌠ 〉  〉⌠  ∇  〉 〉 〉⌠  〉
⋅∂÷•≡←↔ ←ƒ←↔°≥∂… ≥°°≈ ↓↑≡←←♠↑≡ ⇑∉⌠ ″″⋅÷  ⌠   ⌠  〉  ⌠  〉
⋅∂÷•≡←↔ ≈∂←↔°≥∂… ⇑∉⌠ ″″⋅÷  ⌠   ⌠  〉  ⌠  〉
∉↑°↔≡∂±♠↑∂ ⇔⊇∫↓↑°↔⌠ ≈∂♠↑±≥ …°≥≥≡…↔∂°± ←″↓≥≡⌠ ÷ñ≈ 〉 〉⌠ 〉 ∇  ∇⇒  〉⌠ 〉 〉
∉↑°↔≡∂±♠↑∂ ⊇∫↓↑°↔⌠ ←∂±÷≥≡ ←″↓≥≡⌠ ÷ñ≥⌠ ″≡≈∂± ″♣⌠ ″∂± 〉 〉⌠ 〉⌠ ∇  〉 ∇⇒ ∇⇒
∉↑°↔≡∂±♠↑∂ ″≡←♠↑≡≈ ƒ ≈∂↓←↔∂♣ ∇  ↓°←∂↔∂♥≡∑  
⌠ ⌠ 
   〉 〉 ∇⇒ ∇⇒
∉↑∂″∂↓↑ ∇      〉   〉
⇑∂↑↔• ♦≡∂÷•↔ ⊂⇔ ←…°↑≡   〉⌠ 〉 ∇  〉  〉⌠ 〉 ∇  〉 〉  〉⌠ 〉 〉
¬≡←↔↔∂°±≥ ÷≡ ↔ ∂↑↔•⌠ ♦≡≡×←  ⌠   ⌠  〉  ⌠  〉
⌡±±∪•∂↔±≡ƒ ⊇ …°±↔∂±♠°♠← °↑  
⇒″°±÷ ↔•°←≡ ♦∂↔• ±° ≈∂♠↑±≥ ↓↑°↔≡∂± ♥∂≥≥≡〉
⇒″°±÷ ↔•°←≡ ♦∂↔• ±° →♠±↔∂↔↔∂♥≡ ≈∂♠↑±≥ °↑ ←∂±÷≥≡ ←″↓≥≡ ↓↑°↔≡∂± ″≡←♠↑≡″≡±↔〉
⊃≥♠≡← ≠°↑ …°±↔∂±♠°♠← ♥↑∂≥≡← ↑≡ ″≡≈∂± ⌠  ↓≡↑…≡±↔∂≥≡← ♠±≥≡←← °↔•≡↑♦∂←≡ ∂±≈∂…↔≡≈⌠ ↔•≡ ±♠″≡↑ °≠ ←♠∝≡…↔← ∂← ∂±≈∂…↔≡≈ ♦•≡↑≡ ≈↔ ↑≡ ±°↔ ♥∂≥≥≡ ≠°↑ ≥≥ ↓↑↔∂…∂↓±↔←〉
∉↑°↔≡∂±♠↑∂ ♦← ≥←° °←≡↑♥≡≈ ∂±  …°±↔↑°≥←⌠ ♦•° ≈∂≈ ±°↔ ″≡≡↔ ↔•≡ ≈∂÷±°←↔∂… …↑∂↔≡↑∂ °≠ ∉∨〉

°××∂ ≡↔ ≥〉 ⇐ ¬≡±≡ ±≈ ∉∨
∧↑°±↔∂≡↑← ∂± √″″♠±°≥°÷ƒ ≤ ♦♦♦〉≠↑°±↔∂≡↑←∂±〉°↑÷ ƒ  ≤ ⊃°≥♠″≡  ≤ ⇒↑↔∂…≥≡ 
♦≡∂÷•↔ ∂± ×∂≥°÷↑″← ≈∂♥∂≈≡≈ ƒ •≡∂÷•↔ ∂± ″≡↔≡↑← ←→♠↑≡≈ ×÷ñ″〉 
∉↑≡÷±±…ƒ ♦≡∂÷•↔ ±≈ •≡∂÷•↔ ″≡←♠↑≡← ♦≡↑≡ °↔∂±≡≈ ≠↑°″ ↔•≡ 
±↔≡±↔≥ …•↑↔←〉 ⊆≡≥↔∂♥≡ ∂↑↔• ♦≡∂÷•↔ ⊂⇔ ♠±∂↔← ⊕∫←…°↑≡ ♦≡↑≡ 
…≥…♠≥↔≡≈ ……°↑≈∂±÷ ↔° ∧∂±±∂←• ←↔±≈↑≈← 〉
⊂♠∝≡…↔← ∂± ⇐°″↓≥≡″≡±↔ ¬≡±°↔ƒ↓∂±÷
≠↑°″ ↔•≡ ∧∂±±∂←• ↓°↓♠≥↔∂°±∫←≡≈ ∉∨ …°•°↑↔ ±≈ ↔•≡ ⊂°♠↔•≡↑± 
∧∂±≥±≈ ∉∨ …°•°↑↔ ♦∂↔• ↓↑≡≠≡↑≡±…≡ °± ←≡♥≡↑∂↔ƒ °≠ ↔•≡ ≈∂←≡←≡〉
⊂♠∝≡…↔← ∂± ⇐ ⊂≡→♠≡±…∂±÷ ±≈ ∂…↑°←↔≡≥≥∂↔≡ 
⇒±≥ƒ←∂←
∪≡ ↓≡↑≠°↑″≡≈ ⇐ ←≡→♠≡±…∂±÷ ±≈ ↔•≡ ″∂…↑°←↔≡≥≥∂↔≡ ±≥ƒ←∂← °≠ 
↔•≡ ♠↓←↔↑≡″ ↑≡÷♠≥↔°↑ƒ ″°↔∂≠ ∂±  ←≡♥≡↑≡ ∉∨ ♦°″≡± ≠↑°″ ↔•≡ 
⊂°♠↔•≡↑± ∧∂±≥±≈ ∉∨ …°•°↑↔    ±≈  ±°±∫∉∨ …°±↔↑°≥← 
∧√¬⊇⊆∨  ≤ ⊄•≡ •↓≥°≥°…× ←↔↑♠…↔♠↑≡ ♦∂↔•∂± ⇐ ≈≡↔≡↑″∂±≡≈ ƒ ⊂±÷≡↑ ←≡→♠≡±…∂±÷ ±≈ ↑≡↓≥∂…↔∂°± ←↔♠≈∂≡←〉 ⊄•≡ ∂±↔≡±←∂≠ƒ∂±÷ ÷↑≈∂≡±↔ °≠ ↑≡≈ ↑≡↓↑≡←≡±↔← ↔•≡ 
″♠≥↔∂≥≥≡≥∂… ⇔
↔•↔ …°↑↑≡←↓°±≈ ↔° …°≥°↑← ∂± ↔•≡ ″↔≡↑∂≥ ↓±≡≥ ∂± 〉 ⊄•≡ ∂±≈≡↓≡±≈≡±↔≥ƒ ←←°…∂↔∂±÷ ⊂∇∉← ↑≡ ∂±≈∂…↔≡≈ ƒ ←↔↑←〉 ⇒≥≥ ⊂∇∉← ∂± ↔•∂← ∂″÷≡ ↑≡ ≥∂←↔≡≈ ∂± ⊄≥≡ ⊂ 
∂± ⊂♠↓↓≥≡″≡±↔↑ƒ ↔≡↑∂≥〉

°××∂ ≡↔ ≥〉 ⇐ ¬≡±≡ ±≈ ∉∨
∧↑°±↔∂≡↑← ∂± √″″♠±°≥°÷ƒ ≤ ♦♦♦〉≠↑°±↔∂≡↑←∂±〉°↑÷ ƒ  ≤ ⊃°≥♠″≡  ≤ ⇒↑↔∂…≥≡ 
 
↑≡≥↔∂♥≡ ≡♣↔≡±≈≡≈ •↓≥°↔ƒ↓≡ •°″°∞ƒ÷°←∂↔ƒ ⊆∨⋅⋅ ←↔↔∂←↔∂…←〉
⊂♠∝≡…↔← ∂± ⇐ ⊆≡↓≥∂…↔∂°± ƒ ⊂≡→♠≡±…∂±÷
♦≡↑≡ ←≡≥≡…↔≡≈ ≠°↑ ↔•≡ ←≡…°±≈ ←↔÷≡ °≠ ←≡→♠≡±…∂±÷⌠ ♦•∂…• ∂±♥°≥♥≡≈ 
↑≡∫←≡→♠≡±…∂±÷ ↔•≡ ″∂≈≈≥≡ ↓↑↔ °≠ ↔•≡ ÷≡±≡ ∂±≈∂…↔≡≈ ƒ ≥♠≡ ∂± 
←↔↔∂←↔∂…←〉
⊂♠∝≡…↔← ∂± ⊆≡↓≥∂…↔∂°± ƒ ⊂≡→♠≡±°″ ¬≡±°↔ƒ↓∂±÷
∧°♠↑↔≡≡± ⊂∇∉← ♦≡↑≡ ♥≥∂≈↔≡≈ ∂±  ♦°″≡± ♦∂↔• ←≡♥≡↑≡ ∉∨ ±≈ 
  ±°±∫∉∨  …°±↔↑°≥←  ≠↑°″  ↔•≡  ∧√∇∇∉∨⇐  …°•°↑↔  ∂±…≥♠≈∂±÷  ≥≥  
°≠ ↔•≡ ∧√∇∇∉∨⇐ ↓↑↔∂…∂↓±↔← ∂±…≥♠≈≡≈ ∂± ↔•≡ ∂±∂↔∂≥ ≡♣↓≥°↑∫
←≡→♠≡±…≡≈ ÷≡±°↔ƒ↓≡← °≠ ⇐ ∂± ↔•≡ ∂±∂↔∂≥ ↓•←≡ ±≈ ↑≡↓≥∂…↔∂°± 
↑≡ ≈≡←…↑∂≡≈ ∂± 〉
⇐°″↓≥≡″≡±↔ ¬≡±°↔ƒ↓∂±÷
⇒ …♠←↔°″ ⊂∇∉ ÷≡±°↔ƒ↓∂±÷ ♦← ↓≡↑≠°↑″≡≈ ♠←∂±÷ ⊂≡→♠≡±°″← 
←←⇒⊆⊆⇒∅ ⇒⇔√∫⊄∠∧ ←← ⊂↓≡…↔↑°″≡↔↑ƒ ⇐°″↓…↔ ↓≥↔≠°↑″ 
±≈ ∂∉∨∩ ¬°≥≈ …•≡″∂←↔↑ƒ ⊂≡→♠≡±°″ √±…〉⌠ ⊂± ⇔∂≡÷°⌠ ⇐⇒⌠ ⊇⊂⇒ 
♦∂↔• ←↔±≈↑≈ ↓↑°↔°…°≥← ← ≈≡←…↑∂≡≈ ≡≥←≡♦•≡↑≡ 
÷≡±≡← …°≈∂±÷ ≠°↑ …°″↓°±≡±↔← °≠ ↔•≡ …°″↓≥≡″≡±↔ ←ƒ←↔≡″ ♦≡↑≡ …•°∫
←≡± ≠°↑ ÷≡±°↔ƒ↓∂±÷ ±≈ ≠°↑ ≡…• ÷≡±≡⌠ ⊂∇∉← ♦∂↔• ←←♠″≡≈ ↑≡≥≡♥±…≡ 
♦≡↑≡ ←≡≥≡…↔≡≈ ←≡≈ °± ↓♠≥∂←•≡≈ ≈↔ °± ↓↑°↔≡∂± ≠♠±…↔∂°±⌠ …↔∂♥∫
∂↔ƒ⌠  °↑  ≈∂←≡←≡  ←←°…∂↔∂°± ⊄≥≡  ⊂ ∂±  ⊂♠↓↓≥≡″≡±↔↑ƒ  ↔≡↑∂≥〉  
∧♠↑↔•≡↑″°↑≡⌠ ♦≡ ∂±…≥♠≈≡≈ ↓°↔≡±↔∂≥≥ƒ ≠♠±…↔∂°±≥ ±°±←≡±←≡ ±≈ ″∂←∫
°↑   ≡±≈ ⊂∇∉← ← ″↑×≡↑← °≠ ←←°…∂↔∂°±〉 ⇒ ↔°↔≥ °≠  ⊂∇∉← ♦≡↑≡ 
←←ƒ≡≈ ∂± ≠°♠↑ ″♠≥↔∂↓≥≡♣≡← °≠  ″↑×≡↑← ≡…•〉 ∪≡ ≠°…♠←≡≈ °± 
⊂∇∉← ♦∂↔• ″∂±°↑ ≥≥≡≥≡ ≠↑≡→♠≡±…∂≡← 〈〉 ∂± ∨♠↑°↓≡± ↓°↓♠≥↔∂°±← 
←≡≈ °± ↔•≡ ⋅↓↓ ≈↔ 〉 ¬≡±°↔ƒ↓≡← ♦≡↑≡ ±≥ƒ∞≡≈ ♠←∂±÷ 
∂…↑°←↔≡≥≥∂↔≡ ⇒±≥ƒ←∂←
± ↑≡↓≡↔ ↓°≥ƒ″°↑↓•∂←″ ¬∧ ∂± ↔•≡ 
↓↑°″°↔≡↑ ↑≡ °≠ ↔•≡ ⇐ ÷≡±≡ ♦← ≈≡↔≡↑″∂±≡≈ ƒ ≠↑÷″≡±↔ 
≥≡≥≡≈ ≠°↑♦↑≈ ↓↑∂″≡↑ ±≈ ±°±∫≥≡≥≡≈ ↑≡♥≡↑←≡ ↓↑∂″≡↑ ⊄≥≡ ⊂  
∂± ⊂♠↓↓≥≡″≡±↔↑ƒ ↔≡↑∂≥ ∂± ∉⇐⊆ …°±≈∂↔∂°±← °≠ ± ∂±∂↔∂≥ ≈≡±∫
∫
″∂±≡≈ ♠←∂±÷ ± ♠↔°″↔≡≈ …↓∂≥≥↑ƒ ←≡→♠≡±…≡↑ ⇒⇑√♣≥ ⇔∇⇒ 
⇒±≥ƒ∞≡↑ ⇒↓↓≥∂≡≈ ⇑∂°←ƒ←↔≡″←〉 ¬≡±≡⊂…±  √⊕ ⊂∂∞≡ ⊂↔±≈↑≈ 

°××∂ ≡↔ ≥〉 ⇐ ¬≡±≡ ±≈ ∉∨
∧↑°±↔∂≡↑← ∂± √″″♠±°≥°÷ƒ ≤ ♦♦♦〉≠↑°±↔∂≡↑←∂±〉°↑÷ ƒ  ≤ ⊃°≥♠″≡  ≤ ⇒↑↔∂…≥≡ 
±♠″≡↑ °≠ ⇐⇒ ↑≡↓≡↔← ♦← ≈≡↔≡↑″∂±≡≈ ♦∂↔• ¬≡±≡ ↓↓≡↑ ♥〉 
∫
⌠ ″≡≈∂♠″ ≥≡±÷↔• ⇐⇒⌠ °↑ ≥°±÷ 
⇐⇒ ≠°↑ ↔•≡ ↓♠↑↓°←≡ °≠ ±≥ƒ←∂←〉
⇐ ⊂≡→♠≡±…∂±÷
⇐
←≡→♠≡±…≡≈  ♠←∂±÷  ←↔±≈↑≈  ⊂±÷≡↑  ←≡→♠≡±…∂±÷  ♦∂↔•  ↓↑∂″≡↑←  
≈≡↔∂≥≡≈  ∂±  ⊂〉  ⇒″↓≥∂↔→  ¬°≥≈  ⇒↓↓≥∂≡≈  ⇑∂°←ƒ←↔≡″←  ≡±∞ƒ″≡  
↔•≡ ⇑∂÷⇔ƒ≡ 〉 ↔≡↑″∂±↔°↑ ⇒↓↓≥∂≡≈ ⇑∂°←ƒ←↔≡″← ← ∂±←↔↑♠…↔≡≈ 
♦∂↔• ↔•≡ ∂≥≥∂↓°↑≡ ♠≥↔∂←…↑≡≡± ↓≥↔≡← ∂≥≥∂↓°↑≡⌠ ⊇⊂⇒ ♦∂↔• 
⊂♦≡≈≡±〉  ∨≥≡…↔↑°↓•°↑≡←∂←  ♦←  ↓≡↑≠°↑″≡≈  ♦∂↔•  ±  ⇒⇑√    
⇔∇⇒ ⇒±≥ƒ∞≡↑ ⇒↓↓≥∂≡≈ ⇑∂°←ƒ←↔≡″← ±≈ ←≡ …≥≥∂±÷ ♠←∂±÷ 
⇒↓↓≥∂≡≈ ⇑∂°←ƒ←↔≡″← ±≈ ↔•≡ ↑≡↓°↑↔≡≈ ↑≡←♠≥↔← ♦≡↑≡ …•≡…×≡≈ ƒ 
⊆≡↓≥∂…↔∂°± ƒ ⊂≡→♠≡±°″ ¬≡±°↔ƒ↓∂±÷
∧°♠↑↔≡≡± ⊂∇∉← …°♥≡↑∂±÷ ↔•≡ ≥≡±÷↔• °≠ ↔•≡ ÷≡±≡ ∂±≈∂…↔≡≈ ƒ 
↑≡≈ ↑≡…↔±÷≥≡← ∂±  ♦≡↑≡ ∂±…≥♠≈≡≈ ∂±  ←∂±÷≥≡ ⊂≡→♠≡±°″ 
±≈ ↔•≡ ÷≡±°↔ƒ↓∂±÷ ♦≡↑≡ ↓≡↑≠°↑″≡≈ ♦∂↔• ⊂≡→♠≡±°″ ←←⇒↑↑ƒ 
←ƒ←↔≡″ ↔ ↔•≡ ∧√ ⊄≡…•±°≥°÷ƒ ⇐≡±↔↑≡⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂〉 
↔° ≡±←♠↑≡ •∂÷• →♠≥∂↔ƒ °≠ ↔•≡ ÷≡±°↔ƒ↓∂±÷〉
∈♠≥∂↔ƒ ⇐°±↔↑°≥
¬≡±°↔ƒ↓∂±÷ ↑≡←♠≥↔← ≠↑°″ ≥≥ ″≡↔•°≈← ♦≡↑≡ ↔≡←↔≡≈ ≠°↑ ≈≡♥∂↔∂°±← 
≠↑°″ ↔•≡ ⋅↑≈ƒ∪≡∂±≡↑÷ ≡→♠∂≥∂↑∂♠″ ↓ 
♦≡↑≡ ≈∂←…°♥≡↑≡≈ ∂± ↔•≡ …°±↔↑°≥←〉 ⇔↔ °± ↔•↑≡≡ ∂±≈∂♥∂≈♠≥← ♦≡↑≡ 
↑≡″°♥≡≈ ≈♠≡ ↔° ♠±↑≡←°≥♥≡≈ ≈∂←…↑≡↓±…ƒ ≡↔♦≡≡± ↔•≡ ←≡→♠≡±…≡≈ 
±≈  ↔•≡  ÷≡±°↔ƒ↓≡≈  ↑≡←♠≥↔←  ±≈  ≈↔  ≠↑°″    ∂±≈∂♥∂≈♠≥←  ♦≡↑≡  
↑≡″°♥≡≈ ≈♠≡ ↔° 〈 ≠∂≥≡≈ ÷≡±°↔ƒ↓∂±÷ ƒ ↔•≡ ⊂≡→♠≡±°″ ⊄≥≡ 
⊂ ∂± ⊂♠↓↓≥≡″≡±↔↑ƒ ↔≡↑∂≥〉
√± ⊂∂≥∂…° ⇒±≥ƒ←∂← °≠ ∧♠±…↔∂°±≥∂↔ƒ
〉 ⊆∇⇒←±↓ ƒ ⇐≡±↔≡↑ ≠°↑ ±°±∫
←↔↑♠…↔♠↑≡  …•±÷≡←⌠  ♦•∂…•  ″∂÷•↔  ≡  ∂±↔↑°≈♠…≡≈  ƒ  ≡♣°±∂…  ⊂∇∉←  
±≈ …°♠≥≈ ≥≡≈ ↔° …•±÷≡← ∂± ↓°←↔↔↑±←…↑∂↓↔∂°±≥ ↓↑°…≡←←≡← °≠ ± 
°↔•≡↑♦∂←≡ ≠♠±…↔∂°±≥ ÷≡±≡ ⌠ 〉 °≈≡  °≠ ↔•≡ ↓↑°÷↑″ ♦← 
♠←≡≈⌠ ← ∂↔ ∂← ↓↓≥∂…≥≡ ≠°↑ ≥↑÷≡ ″⊆∇⇒← 〈⌠ ±♠…≥≡°↔∂≈≡←〉 
∧°≥≥°♦∂±÷ ↔•≡ ←♠÷÷≡←↔≡≈ ≥∂″∂↔←⌠  ↓∫♥≥♠≡ 〉 ♦← …°±←∂≈≡↑≡≈ 
∂±≈∂…↔∂♥≡ °≠ ± ⊂∇∉ ∂±≈♠…≡≈ …•±÷≡ ∂± ←≡…°±≈↑ƒ ←↔↑♠…↔♠↑≡〉
⊄•≡ ⊆≡≥↔∂♥≡ ∨♣↔≡±≈≡≈ ⋅↓≥°↔ƒ↓≡ 
⋅°″°∞ƒ÷°←∂↔ƒ
⊄° ↓↑≡≈∂…↔ ←≡≥≡…↔∂°± ↓↑≡←←♠↑≡ ↔°♦↑≈ ↔•≡ ≈∂←…°♥≡↑≡≈ •↓≥°↔ƒ↓≡ 
±≈  ↓∂±↓°∂±↔  ∂↔←  ←↔↑♠…↔♠↑≡⌠  ♦≡  …°″↓≥≡↔≡≈    ⊆∨⋅⋅  ±≥ƒ←∂←  
♠←∂±÷ ↔•≡ ←←°…∂↔∂±÷ ↑← ←  ≠°…≥ ⊂∇∉ 〉 ⊆∨⋅⋅ ♦← 
…°±≈♠…↔≡≈ ∂±  ⊆ ≠°≥≥°♦∂±÷ ↔•≡  ≈≡♥≡≥°↓≡↑←  ∂±←↔↑♠…↔∂°±←  ↔°  ↑≡♥≡≥  
↔•≡ ≡♥°≥♠↔∂°±↑ƒ ←≡≥≡…↔∂°± ↓↑≡←←♠↑≡← ♠±≈≡↑≥ƒ∂±÷ ↔•≡ •↓≥°↔ƒ↓≡ 
←↔↑♠…↔♠↑≡〉  ⇒≥≥  ⊂±÷≡↑  ←≡→♠≡±…≡≈  ∂±≈∂♥∂≈♠≥←  ∂±∂↔∂≥  …°•°↑↔  ±≈  
↑≡↓≥∂…↔∂°± …°•°↑↔ ∇ 
⌠ 〉
⊂↔↔∂←↔∂…≥ ⇒±≥ƒ←≡←
∉√∇  ⇐ ←≡→♠≡±…∂±÷ ↑≡←♠≥↔← ♦≡↑≡ ±≥ƒ∞≡≈ ≠°↑ ←←°…∂∫
↔∂°± ∂±  ÷∉√∇ ±≈ ∉√∇〉  ⊂∂±÷≥≡  ⊂∇∉ ←←°…∂↔∂°± ↔°  ≈∂←≡←≡  
∂±  ⋅↓≥°♥∂≡♦ 〉 ⋅↓≥°↔ƒ↓≡ ±≥ƒ←∂← ♦← …°±≈♠…↔≡≈ ♦∂↔• ↔•≡ 
〉 ⇒←←°…∂↔∂°± ±≥ƒ←∂← °≠ ∂±≈∂♥∂≈♠≥ ⊂∇∉← 
±≈ ↔•≡ ≈∂←…°♥≡↑≡≈ •↓≥°↔ƒ↓≡ ≥°…×← ♦← ≈°±≡ ♠←∂±÷  ↔≡←↔ ∂± ↔•≡ 
⋅↓≥°♥∂≡♦ ↓↑°÷↑″〉
⊆∨⊂⊇⊄⊂
⊂∇∉ ¬≡±°↔ƒ↓≡← °≠ ⇐°″↓≥≡″≡±↔ ¬≡±≡←
⊄° ±≥ƒ∞≡ ↓°↔≡±↔∂≥ ←←°…∂↔∂°±← ≡↔♦≡≡± ∉∨ ±≈ …°″↓≥≡″≡±↔ 
÷≡±≡←⌠ ♦≡ ÷≡±°↔ƒ↓≡≈ ←≡≥≡…↔≡≈ ⊂∇∉← ∂±  ÷≡±≡← …°≈∂±÷ …°″↓°∫
∂± ñ ⊂∇∉← ≡↔♦≡≡±  ∉∨ ♦°″≡± ±≈  ±°±∫∉∨ …°±↔↑°≥← 
≈↔ ±°↔ ←•°♦±〉 ∠♠↔ °≠ ↔•≡ ↑≡″∂±∂±÷ ≡∂÷•↔ ⊂∇∉←⌠ ↔•↑≡≡ ←←°…∂∫
↔≡≈ ↔° ⇐ ∂± ÷≡±°↔ƒ↓∂… ″°≈≡≥ ±≥ƒ←∂← ±≈ ∂± ⇐⌠ ↑←⌠ ±≈ 
〉 ↑← ∂± ↔•≡ 
↓↑°♣∂″∂↔ƒ °≠ ⇐ ≡♣°±  ♦← ″°←↔ ≥∂×≡≥ƒ ↔° •♥≡ ± ∂±≈≡↓≡±≈≡±↔ 

  ↓ 
⇐ ⊂≡→♠≡±…≡←
√± ↔•≡ ⇐
 〉 ↑← ∂← ≥°…↔≡≈ ∂±  ↓↑≡≈∂…↔≡≈ ↔↑±←…↑∂↓↔∂°± 
≠…↔°↑∫∂±≈∂±÷ ←∂↔≡〉 √↔ ∂←  ″∂←←≡±←≡ ⊂∇∉ ↔•↔ …♠←≡← ± ″∂±° …∂≈ 
…•±÷≡ ⊆〉 √↔ ♦← ↓↑≡≈∂…↔≡≈ ƒ ⊂√∧⊄ ±≈ ∉∠∅∉⋅∨∇ ↔° ≡ 
♦≡≥≥ ↔°≥≡↑↔≡≈ ±≈ ≡±∂÷±⌠ ↓↓↑≡±↔≥ƒ⌠ ≡…♠←≡ ↔•≡↑≡ ∂← ±° …•±÷≡ 
∂± ↔•≡ …•↑÷≡ °≠ ↔•≡ ″∂±° …∂≈ °↔• ≥ƒ←∂±≡ñ ±≈ ↑÷∂±∂±≡ñ⊆ 
↑≡ ←∂… ↑≡←∂≈♠≡←〉 ∠↔•≡↑ ♥↑∂±↔← ♦≡↑≡ ≡∂↔•≡↑ ←ƒ±°±ƒ″°♠← 
°↑ ∂±↔↑°±∂…〉 ⊂∂♣ ⊂∇∉← ♦≡↑≡ ∂±≈≡↓≡±≈≡±↔≥ƒ ←←°…∂↔≡≈ ↔° ←≡♥≡↑≡ 
∉∨〉 ↑←    ≠↑°″  ≡♣°±    •≈  ↔•≡  ←↔↑°±÷≡←↔  ←←°∫


↓   〉 
∪•∂≥≡  ♦≡  •≈  ↓↓↑°↓↑∂↔≡  ↓°♦≡↑  ↔°  ←←≡←←  ↔•↑≡≡  °≠  ←∂♣  ⊂∇∉←  
♦∂↔• ←∂±÷≥≡  ⊂∇∉ ←←°…∂↔∂°±∑  ↑← ⊗″∂±°↑  ≥≥≡≥≡  ≠↑≡→♠≡±…ƒ 
 ↓   
 ↓   
 ↓  

↑≡ °±≥ƒ ←♠÷÷≡←↔∂♥≡  〉
∧√¬⊇⊆∨  ≤ ⇐ ∂← ≥°…↔≡≈ ∂± …•↑°″°←°″≡  ∂± ↔•≡ ↑≡♥≡↑←≡ ←↔↑±≈〉 ⊄•≡ ≈∂←…°♥≡↑≡≈ ←∂±÷≥≡ ±♠…≥≡°↔∂≈≡ ↓°≥ƒ″°↑↓•∂←″ ⊂∇∉ ←←°…∂↔∂°±←⌠ ↔•≡∂↑ ↓°←∂↔∂°±←⌠ ±≈ 
←←°…∂↔∂±÷ •↓≥°≥°…×← ↑≡ ≈≡↓∂…↔≡≈ ∂± ⇒〉 ⊄•≡ ←←°…∂↔∂±÷ ⊂∇∉← ±≈ ↔•≡∂↑ ≥°…↔∂°±← ∂± ↔•≡ ≈°″∂±← °≠ ↔•≡ ≠♠±…↔∂°±≥ ⇐ ↑≡ ←•°♦± ∂± ↔•≡ ←…•≡″↔∂… ←↔↑♠…↔♠↑≡ ∂± 
⇑〉 ⇒≥≥ ←←°…∂↔∂±÷ ⊂∇∉← ↑≡ ≥°…↔≡≈ ∂± ∂±↔↑°±← ♦∂↔• ↔•≡ ≡♣…≡↓↔∂°± °≠ ↑←⌠ ♦•∂…• ∂← ≥°…↔≡≈ ∂± ↔•≡ ∉⊆∠〉 ⊄•≡ ≈°″∂±← ↑≡ ⊄∨⇔↔•∂°≡←↔≡↑∫…°±↔∂±∂±÷ 
≈°″∂± ⇐≈ ⇐⊇⇑…°″↓≥≡″≡±↔ ⇐↑ñ⇐←⌠ ⊇≡÷≠⌠ ⇑″↓ ¬″…↑°÷≥°♠≥∂± ≈°″∂±←  ∇⊄∇∫↔≡↑″∂±≥ ↑≡÷∂°± °≠ ↔•≡ …≥≡♥≡≈ ∫…•∂± ∂± ↔•≡ ≥∂±×≡↑ 
≈°″∂± ⇒±±↓•ƒ≥↔°♣∂… ↑≡÷∂°± ⇐ ∇ ∫←↔↑±≈ °≠ ↔•≡ ≥∂±×≡↑ ≈°″∂± ∉⊆∠↓↑°″°↔≡↑ ↑≡÷∂°±〉
⊄⇒⇑∨  ≤ ⊄•≡ ↑≡÷∂°± …°♥≡↑≡≈ ƒ •↓≥°≥°…×  •≈ ↔♦° •↓≥°↔ƒ↓≡← °≠  ⊂∇∉← ♦∂↔• ←♠÷÷≡←↔∂♥≡ ←←°…∂↔∂°± ↔° ↓↑≡≡…≥″↓←∂〉
⋅↓≥°≥°…×  ∧↑≡→♠≡±…ƒ …←≡←ñ…°±↔↑°≥← ∉↑°↓°←≡≈ ≡≠≠≡…↔  ↓∫⊃≥♠≡ ∠≈≈← ↑↔∂° ↔⌠ ∪≥≈ ↔≡←↔
⇐⇐⇐⇐⇐⇐⇐¬⇐⊄⇐¬⇒⇐¬⇐ 〉ñ〉 ∉↑°↔≡…↔∂♥≡ 〉 〉 〉 〉
⇐⊄⊄⊄⊄⇐⊄¬¬⇐⇐¬⇐¬⇒⇐ 〉ñ〉 ∉↑≡≈∂←↓°←∂±÷ 〉 〉 〉 〉
⊄•≡ ≠°…≥ ⊂∇∉ ↑← ∂± ↑≡≥↔∂♥≡ ≡♣↔≡±≈≡≈ •↓≥°↔ƒ↓≡ •°″°∞ƒ÷°←∂↔ƒ ±≥ƒ←∂←   ∂← ∂±≈∂…↔≡≈ ∂± °≥≈〉
⊄⇒⇑∨  ≤ ⊂∂♣ ±°±∫…°≈∂±÷ ←∂±÷≥≡ ±♠…≥≡°↔∂≈≡ ↓°≥ƒ″°↑↓•∂←″ ⊂∇∉ •♥≡ ∂±≈≡↓≡±≈≡±↔ ≥≥≡≥∂… ←←°…∂↔∂°± ↔° ←≡♥≡↑≡ ↓↑≡≡…≥″↓←∂〉
¬≡±°″∂… ↓°←∂↔∂°± ⇑♠∂≥≈  ⊂∇∉ ∂±°↑ ≥≥≡≥≡ ≠↑≡→♠≡±…ƒ ∂± …←≡←ñ…°±↔↑°≥← ∇  ↓∫⊃≥♠≡ ∠≈≈← ↑↔∂° ⇐√
∑ ↑← 〉ñ〉 ⌠ 〉 〉 〉 〉⌠ 〉
∑ ↑← 〉ñ〉 ⌠ 〉 〉 〉 〉⌠ 〉
∑ ↑← 〉ñ〉 ⌠ 〉 〉 〉 〉⌠ 〉
∑ ↑← 〉ñ〉 ⌠ 〉 〉 〉 〉⌠ 〉
∑ ↑← 〉ñ〉  〉 〉 〉 〉⌠ 〉
∑ ↑← 〉ñ  〉 〉 ∇⇒

°××∂ ≡↔ ≥〉 ⇐ ¬≡±≡ ±≈ ∉∨
∧↑°±↔∂≡↑← ∂± √″″♠±°≥°÷ƒ ≤ ♦♦♦〉≠↑°±↔∂≡↑←∂±〉°↑÷ ƒ  ≤ ⊃°≥♠″≡  ≤ ⇒↑↔∂…≥≡ 
⇒ ←≡↔ °≠ ≥≥≡≥≡← ←↓±±∂±÷ ≠↑°″   ∂±↔↑°± ↓↑°♣∂″≥ ↔° ≡♣°±  ↔° 
↔•≡   ∂±↔↑°± ↓↑°♣∂″≥ ↔° ≡♣°±  ±≈ …°±←∂←↔∂±÷ °≠  ⊂∇∉← ♦← 
≠°♠±≈ ↔° ≡ ←←°…∂↔≡≈ ♦∂↔• ←≡♥≡↑≡ ∉∨〉 ∠±≡ •↓≥°↔ƒ↓≡ ←•°♦≡≈ ± 
←←°…∂↔∂°± ∂±  ↓↑°↔≡…↔∂♥≡ ≠↑≡→♠≡±…ƒ ∂± ←≡♥≡↑≡ ∉∨ ♦°″≡± ±≈ 
±°±∫∉∨ …°±↔↑°≥← 〉 ±≈ 〉⌠ ↑≡←↓≡…↔∂♥≡≥ƒ⌠ ↓ 
±°↔•≡↑ °±≡ ∂±  ↓↑≡≈∂←↓°←∂±÷ ″±±≡↑ ≠↑≡→♠≡±…ƒ ∂± ←≡♥≡↑≡ ∉∨ 

↓  〉  ↓↓∂±÷  ↔•≡    ⊂∇∉←  …°±↔↑∂♠↔∂±÷  ↔°  
↔•≡ •↓≥°↔ƒ↓≡ ≥°±÷ ↔•≡ ⇐ ÷≡±≡ ←•°♦≡≈ ↔•↔ ↔•≡ ↔÷÷∂±÷ ⊂∇∉ 
↑← ∂← ≥°…↔≡≈ ↓ ∂±   ≈∂↑≡…↔∂°± °≠ ≡♣°± ⌠ ♦•∂…• …°↑∫
↑≡←↓°±≈← ↔°  ↔•≡  ≥↓•∫…•∂± °≠  ↔•≡  ÷≡±≡ ↓↑°≈♠…↔  ↔  ↔•≡  ≡≈÷≡ °≠  
¬ ±≈ ≈∂↑≡…↔≥ƒ ≡≠°↑≡   ↔•≡ ⇐⊇⇑ ≈°″∂± 
∧√¬⊇⊆∨  ≤ ⊄•≡ ≡♣↔≡±≈≡≈ •↓≥°↔ƒ↓≡ •°″°∞ƒ÷°←∂↔ƒ ∨⋅⋅ ≈∂÷↑″ °≠ ⇒ ♦°″≡± ♦∂↔• ←≡♥≡↑≡ ↓↑≡≡…≥″↓←∂ ∉∨ ±≈ ⇑ ±°±∫∉∨ …°±↔↑°≥← ♠←∂±÷ 
↑← ←  ≠°…≥ ←∂±÷≥≡ ±♠…≥≡°↔∂≈≡ ↓°≥ƒ″°↑↓•∂←″ ⊂∇∉ ↑≡↓↑≡←≡±↔↔∂♥≡ °≠ ↔•≡ •↓≥°≥°…× ←↔↑♠…↔♠↑≡〉 ⊄•≡ ±…≡←↔↑≥ ≥≥≡≥≡ …♠↑♥≡ ∂± ↑≡≈ ∂← …≥°←≡ ↔°  ≠°↑ 
 ≥°±÷ ←↔↑≡↔…• ∂± ±°±∫∉∨ …°±↔↑°≥← ↓↑↔∂…♠≥↑≥ƒ ∂± ↔•≡   ♠↓←↔↑≡″ ≈∂↑≡…↔∂°± ∂±≈∂…↔∂±÷ ↔•↔ ↔•≡ •↓≥°↔ƒ↓≡ ←♠↑↑°♠±≈∂±÷ ↔•≡ ≠°…≥ ⊂∇∉ ∂±≈∂…↔≡≈ ƒ ←≡♥≡↑≡≈ ♥≡↑↔∂…≥ ≥∂±≡ ∂← 
♠±≈≡↑ ←≡≥≡…↔∂°± ∂± ↔•∂← …°•°↑↔〉 ∝°↑ ≥≥≡≥≡ ±…≡←↔↑≥⌠ ∂± ↑≡≈ ⇐⌠ ″∂±°↑ ≥≥≡≥≡ ≈≡↑∂♥≡≈⌠ ∂± ≥♠≡ ⊄〉

°××∂ ≡↔ ≥〉 ⇐ ¬≡±≡ ±≈ ∉∨
∧↑°±↔∂≡↑← ∂± √″″♠±°≥°÷ƒ ≤ ♦♦♦〉≠↑°±↔∂≡↑←∂±〉°↑÷ ƒ  ≤ ⊃°≥♠″≡  ≤ ⇒↑↔∂…≥≡ 
↓↑°↓°←≡≈ •↓≥°↔ƒ↓≡ ←↓±← …↑°←← ↔•≡ ″∂≈≈≥≡ °≠ ↔•≡ ÷≡±≡ ≠↑°″ ↔•≡ 
  ∂±↔↑°± °≠ ≡♣°±  ←∂↔♠↔≡≈ ↔ ↔•≡   ≡±≈ °≠ ↔•≡ ⇒∇⇒ ≈°″∂± ↑∂÷•↔ 
≡≠°↑≡ ↔•≡ ∇⊄ ≈°″∂± ±≈ ↔   ≈∂↑≡…↔∂°± ↑≡…•∂±÷ ↓←↔ ↔•≡ ⇐⊇⇑ 
↑←⌠ ↑←⌠ ±≈ ↑← ↑≡ ≥°…↔≡≈ ∂± ↔•≡ ∂±↔↑°±← 
∫
↔°↑ƒ ″∂…↑°←↔≡≥≥∂↔≡ ↑≡÷∂°± ♦← ±°↔ ←←°…∂↔≡≈ ♦∂↔• ←≡♥≡↑≡ ∉∨〉
√± ⊂∂≥∂…° ∧♠±…↔∂°±≥ ⇒±≥ƒ←∂←
∫
≡±…≡≈ ƒ ≠°♠↑ °≠ ↔•≡ ←←°…∂↔∂±÷ ⇐ ⊂∇∉←∑ ↑←⌠ ↑←⌠ 
↑←⌠ ±≈ ↑←〉 ↑←⌠ ↑←⌠ ±≈ ↑← 
♦≡↑≡ ↓↑≡≈∂…↔≡≈ ↔° …↑≡↔≡ ± ≡♣°±∂… ←↓≥∂…∂±÷ ≡±•±…≡↑ ∨⊂∨ ←∂↔≡ 
♦∂↔•∂± ± ∂±↔↑°±⌠ ♦•≡↑≡← ↑← ♦← ≠°♠±≈ ↔° …↑≡↔≡  ±°♥≡≥ 
∨⊂∨ ←∂↔≡ ← ♦≡≥≥ ← ↔° …♠←≡ ± ≥↔≡↑↔∂°± °≠ ± ≡♣∂←↔∂±÷ ∨⊂∨ ←∂↔≡〉 √± 
⊆∇⇒←±↓⌠ ↑← •≈  ↓∫♥≥♠≡ °≠ 〉 ∂±≈∂…↔∂±÷  ≈∂←↑♠↓∫
↔∂°± ∂± ≥°…≥ ⊆∇⇒ ≠°≥≈∂±÷ ±≈ ↑← •≈  ↓∫♥≥♠≡ °≠ 〉 
∫
∂±÷ ⊂∇∉← ♦∂↔•∂± ↔•≡ •↓≥°≥°…× ↑≡÷∂°± ↑←⌠ ↑←⌠ ±≈ 
↑← •≈ ⊆∇⇒←±↓ ↓∫♥≥♠≡← 〈
←↔↑♠…↔♠↑≥ …•±÷≡ …♠←≡≈ ƒ ↔•≡←≡ ♥↑∂±↔←〉
⊄•≡ ⊆≡≥↔∂♥≡ ∨♣↔≡±≈≡≈ ⋅↓≥°↔ƒ↓≡ 
⋅°″°∞ƒ÷°←∂↔ƒ
•↓≥°↔ƒ↓≡ ↔° ↔•≡   ≈∂↑≡…↔∂°± °± ↔•≡ ⇐ ÷≡±≡ ←♠÷÷≡←↔∂±÷ ↔•↔ ↔•∂← 
←↔↑♠…↔♠↑≡ ♦∂↔• ↔∂÷•↔ ≥∂±×÷≡ ≈∂←≡→♠∂≥∂↑∂♠″ ∂± ↔•≡ ″∂≈≈≥≡ °≠ ↔•≡ 
÷≡±≡ ↑≡←♠≥↔← ≠↑°″  ↓°←∂↔∂♥≡ ←≡≥≡…↔∂°± ↓↑≡←←♠↑≡  〉
⇔√⊂⇐⊇⊂⊂√∠∇
√± ↔•∂← ←↔♠≈ƒ⌠ ♦≡ •♥≡ ≈≡←…↑∂≡≈ ÷≡±≡↔∂… ♥↑∂±↔← °≠ ↔•≡ ×≡ƒ …°″∫
↓≥≡″≡±↔  …°″↓°±≡±↔  ⇐  ∂±  ♦°″≡±  ♦∂↔•  ←≡♥≡↑≡  ∉∨  ±≈  …°±↔↑°≥  
•↓≥°↔ƒ↓≡ ←∂÷±↔♠↑≡ ∂± ↔•≡ •∂÷•≥ƒ …°±←≡↑♥≡≈ ″∂≈≈≥≡ ↑≡÷∂°± °≠ 
↔•≡ ″↔≡↑±≥ ⇐ ÷≡±≡ ♦∂↔• ↔•↑≡≡ ←←°…∂↔∂±÷ ⊂∇∉← ↑←⌠ 
←≡♥≡↑≡ ∉∨〉
⇐ ⊂∇∉← ↔•↔ ←←°…∂↔≡ ♦∂↔• ←≡♥≡↑≡ ∉∨ ↑≡ ≥°…↔≡≈ ∂± 
↔•≡ ↑≡ °≠ ″°←↔ ∂±↔≡±←≡ ≥∂±×÷≡ ≈∂←≡→♠∂≥∂↑∂♠″ ∂± ↔•≡ ″∂≈≈≥≡ °≠ 
♦∂↔•∂±  ↔•≡  •↓≥°≥°…×  ←↔↑♠…↔♠↑≡  ←♠↓↓°↑↔←    ↓°←←∂≥≡  ≠♠±…↔∂°±≥  
↑°≥≡ ≠°↑ ↔•≡ •↓≥°≥°…×∫≡±…°≈≡≈ ÷≡±≡ ↓↑°≈♠…↔〉 ∧♠↑↔•≡↑″°↑≡⌠ 
 ≈°♦±←↔↑≡″ °≠ ≡♣°± 
 ↔•↔ ∂← ∂± ↔∂÷•↔ ≥∂±×÷≡ ≈∂←≡→♠∂≥∂↑∂♠″ ♦∂↔• ↔•≡ •↓≥°≥°…× 
←↔↑♠…↔♠↑≡ ∂± ↔•≡ ″∂≈≈≥≡ °≠ ↔•≡ ÷≡±≡〉 ↑← •←  ↓≡↑≠≡…↔ ⇔  
←…°↑≡ °≠  ≠°↑ ↔•≡ ↔÷÷∂±÷ ⊂∇∉ ↑←  〉 ⇒″°±÷ 
 °←≡↑♥≡≈ ⊂∇∉←⌠ ↑← •≈ ↔•≡ ≡←↔ ≥≥≡≥∂… ←←°…∂↔∂°± 
←∂∞≡⌠ ↔•≡ ∂±≈≡↓≡±≈≡±↔ ←←°…∂↔∂°± °≠ ↑← ♦∂↔• ←≡♥≡↑≡ 
∉∨  ←♠↓↓°↑↔←  ↔•≡  ↑°≥≡  °≠  ↔•≡  •↓≥°≥°…×  ∂±  ←≡♥≡↑≡  ∉∨〉  ∪∂↔•  ↔•≡  
♥∂≥≥≡ ÷≡±°↔ƒ↓≡← ≠°↑ ↔•≡ ↑≡″∂±∂±÷ ↔♦° °≠ ↔•≡ ←∂♣ ←←°…∂↔∂±÷ 
⊂∇∉← ♦∂↔•∂± ⇐
←∂∞≡ ↑← ±≈ ↑↑∂↔ƒ °≠ ↔•≡ ♥↑∂±↔← ↑← ±≈ 
♦∂↔• …♠↔∂°±〉
√± ←♠↓↓°↑↔ °≠ ↔•≡ …♠←≥∂↔ƒ °≠ …•±÷≡← ∂± ↔•≡ •↓≥°≥°…×  
↑≡ °≠ ↔•≡ ⇐ ÷≡±≡⌠ ↔♦° °≠ ↔•≡ ↔•↑≡≡ ←←°…∂↔∂±÷ ⊂∇∉← ♦∂↔•∂± 
↔•≡  •↓≥°≥°…× ≈≡←…↑∂≡≈ ∂±  °♠↑  ←↔♠≈ƒ •♥≡ ≡≡± ∂″↓≥∂…↔≡≈ ∂±  
↓↑∂°↑ ←↔♠≈∂≡← ∂± °↔•≡↑ ↓•≡±°↔ƒ↓≡←〉 ↑←⌡⇐ •← ≡≡± ←•°♦± 
←♠↑÷∂…≥ ↑≡←≡…↔∂°± 〉 ↑← ∂←  ↓↑°≥≡ ←↓≥∂…∂±÷ ♥↑∂±↔ 
↔•↔ •← ≡≡± ≥∂±×≡≈ ↔° ←↔•″ ±≈ ↑≡≥↔≡≈ ↓•≡±°↔ƒ↓≡← ∂± ↔♦° 
∂±≈≡↓≡±≈≡±↔ ←↔♠≈∂≡← ⌠ 〉  ∇°±≡ °≠  ↔•≡←≡  ←↔♠≈∂≡←  ≥°°×≡≈ ≠°↑  
 •↓≥°↔ƒ↓≡ ←←°…∂↔∂°± ♦∂↔•∂± ⇐〉 √±↔↑°±∂… ♥↑∂±↔← …♠←∂±÷ 
⇐ ←↓≥∂…∂±÷ ″♠↔↔∂°±←  •♥≡ ≡≡± ≈≡←…↑∂≡≈ ∂±  ↓↔∂≡±↔←  ♦∂↔• ⇐ 
⌠ 
 ≈∂←≡←≡  ←←°…∂↔∂°± ∂±  ⇐ ♦∂↔•   •↓≥°↔ƒ↓≡∫←≡≈ ″≡…•±∂←″ 
∂±←↔≡≈  °≠  ↔•≡  …°±♥≡±↔∂°±≥  ←∂±÷≥≡  ⊂∇∉  ←←°…∂↔∂°±〉  √±≈≡≡≈⌠  ∂↔  
•← ≡…°″≡ ↓↓↑≡±↔ ↔•↔ ♦•∂≥≡ ″♠↔↔∂°±← ≥≡≈∂±÷ ↔° …•±÷≡← ∂± 
″∂±° …∂≈ ←≡→♠≡±…≡← ↑≡ ↑≡≈∂≥ƒ ≈≡↔≡…↔≡≈⌠ ″°↑≡ ←♠↔≥≡ …•±÷≡← 
∂± ÷≡±≡ ↑≡÷♠≥↔°↑ƒ ≡≥≡″≡±↔← ↑≡ ″°←↔ ≥∂×≡≥ƒ ……°♠±↔≥≡ ≠°↑ ″♠…• 
°≠ ↔•≡ ↓•≡±°↔ƒ↓∂… ♥↑∂↔∂°± ♦≡ °←≡↑♥≡ ∂± …°″↓≥≡♣ ≈∂←≡←≡←  
⌠ 〉 ⊂♠…• ↑≡÷♠≥↔°↑ƒ ≠≡↔♠↑≡← ↑≡″∂± …↑ƒ↓↔∂… ∂± ±≥ƒ←≡← ↔ ↔•≡ 
↔↑±←≥↔∂°±≥ ±≈ ↓°←↔↔↑±←≥↔∂°±≥ ≥≡♥≡≥〉

°××∂ ≡↔ ≥〉 ⇐ ¬≡±≡ ±≈ ∉∨
∧↑°±↔∂≡↑← ∂± √″″♠±°≥°÷ƒ ≤ ♦♦♦〉≠↑°±↔∂≡↑←∂±〉°↑÷ ƒ  ≤ ⊃°≥♠″≡  ≤ ⇒↑↔∂…≥≡ 
√±  °↔•≡↑  ÷≡±≡←⌠  ∂±↔↑°±∂…  ≈∂←≡←≡  ←←°…∂↔∂°±←  ♦∂↔•  …♠←↔∂♥≡  
←↓≥∂…∂±÷ ≈≡≠≡…↔← •♥≡ ≡≡± ≈≡←…↑∂≡≈ ⌠ 
↑≡↓↑°≈♠…↔∂♥≡ ∂″″♠±°≥°÷ƒ ∂±  ←≡↔∫♠↓ ←∂″∂≥↑ ↔° °♠↑ ←↔♠≈ƒ⌠ 
±  ∂±↔↑°±∂…  •↓≥°↔ƒ↓≡  ♦←  ≠°♠±≈  ↔°  ↑≡←♠≥↔  ∂±  √∫  ←≡…↑≡↔∂°±  
…•±÷≡← ∂± ♦°″≡± ♦∂↔• ∂≈∂°↓↔•∂… ↑≡…♠↑↑≡±↔ ″∂←…↑↑∂÷≡ 〉 
∧♠↑↔•≡↑″°↑≡⌠ ∂↔ ♦← ↑≡…≡±↔≥ƒ ←•°♦± ↔•↔ ″≡…•±∂…≥ ±♠…≥≡°←°″≡ 
∂±≈∂±÷ °……♠↑← ≡♥≡± °± ↔°↓ °≠ ÷≡±≡← 
↔•↔  ±°±∫…°≈∂±÷  ⊂∇∉←  ″ƒ  •♥≡  ±  ∂″↓°↑↔±↔  ↑≡÷♠≥↔°↑ƒ  ↑°≥≡⌠  
⇐°″↓≥≡″≡±↔ ⇐ ↓≥ƒ←  …≡±↔↑≥ ↑°≥≡ ∂±  ←♠……≡←←≠♠≥ ↓↑≡÷±±…ƒ〉 
√±↓↓↑°↓↑∂↔≡ …°″↓≥≡″≡±↔ …↔∂♥↔∂°± ″ƒ ↓≥ƒ  ↑°≥≡ ∂± ↔•≡ ∂±∂↔∂≥ 
←↔÷≡← °≠ ∉∨ ↓↑≡÷±±…∂≡← …°±↔↑∂♠↔∂±÷ ↔° ∂±≈≡→♠↔≡ ↓≥…≡±↔↔∂°± 
≡…♠≥∂∞♠″ ∂± ↔•≡ ↔↑≡↔″≡±↔ °≠  ≠♠≥≥∫≥°♦± ≈∂←≡←≡ ∂±≈∂…↔≡ ↔•↔ 
↔•≡ …°″↓≥≡″≡±↔ ←ƒ←↔≡″ ∂← ≥←° ∂±♥°≥♥≡≈ ∂± ↔•≡ ≥↔≡↑ ←↔÷≡← °≠ ↔•≡ 
⌠ 〉 ∉↑°≥≡″← ″ƒ ≡″≡↑÷≡ ∂≠ ≈∂←↔♠↑±…≡← ∂± ↔•≡ ↑≡″°♥≥ °≠ 
∂←…•≡″∂… °↑ ∂±∝♠↑≡≈ ↓≥…≡±↔≥ …°″↓°±≡±↔← ƒ …°″↓≥≡″≡±↔ ±≈ 
↓•÷°…ƒ↔≡← °……♠↑ 〉  …×  °≠  ≠♠±…↔∂°±∂±÷  ⇐  ∂±  ″∂…≡  ≥≡≈  ↔°  
≠≡♦≡↑ ↓↑≡÷±±…∂≡← ±≈ ↔°  •∂÷•≡↑ ≠≡↔≥ ↑≡←°↑↓↔∂°± ↑↔≡⌠ ♦•∂≥≡ 
≠≡↔≥ ±≈ ↓≥…≡±↔≥ ♦≡∂÷•↔← ♦≡↑≡ ≥°♦≡↑ 〉 ∠± ↔•≡ °↔•≡↑ •±≈⌠ 
⇐∫″≡≈∂↔≡≈  °♥≡↑∫…↔∂♥↔∂°±  °≠  ↔•≡  …°″↓≥≡″≡±↔  ←ƒ←↔≡″  ♦←  
←•°♦± ↔° ∂±≈♠…≡ •ƒ↓≡↑↔≡±←∂°± ≠°≥≥°♦∂±÷ ↓≥…≡±↔≥ ∂←…•≡″∂ ∂± ↑↔← 
〉 ∧♠↑↔•≡↑″°↑≡⌠ …°″↓≥≡″≡±↔ …↔∂♥↔∂°± ↔ ↔•≡ ≠≡↔°∫″↔≡↑±≥ 
∂±↔≡↑≠…≡ °≠ ⇐↑↑ƒ ñ  ″∂…≡  ↔•↔  ≥…×   ×≡ƒ …°″↓≥≡″≡±↔  ↑≡÷♠≥↔°↑  
⇐↑↑ƒ ñ  ″∂…≡  ♦≡↑≡  ↑≡≈ ↔°  ⇐ ñ  ″∂…≡  
♠±≈≡↑≥∂±≡ ↔•≡ ∂″↓°↑↔±…≡ °≠ ≥±…≡≈ …↔∂♥↔∂°± ±≈ ↑≡÷♠≥↔∂°± 
°≠ ↔•≡ …°″↓≥≡″≡±↔ ←ƒ←↔≡″ ≠°↑  •≡≥↔•ƒ ↓↑≡÷±±…ƒ〉
⇑≡…♠←≡ ⇐ …↔∂♥↔∂°± ƒ ↔•≡ ⇐ …°±♥≡↑↔←≡← ↑≡→♠∂↑≡← ≡♣↔≡±←∂♥≡ 
…°±≠°↑″↔∂°±≥ …•±÷≡← ±≈ ↔↑±←≥°…↔∂°± °≠ ↔•≡ ⇐⊇⇑ñ⊄∨⇔ ±≈ 
∇⊄ ≈°″∂±← ⌠ ↓↑°↔≡∂± …•±÷≡← …♠←≡≈ ƒ ♥↑∂±↔← ∂± ↔•≡ 
″∂≈≈≥≡ °≠ ↔•≡ ⇐ ÷≡±≡  ″ƒ  •∂±≈≡↑  ∂±≈∂±÷  °≠  ≠…↔°↑  ⇑  ↔°  ⇐  
〉 
←♠÷÷≡←↔≡≈ ƒ ∂↔← …↑∂↔∂…≥ ≥°…↔∂°±⌠ ∂↔ ∂← ↓°←←∂≥≡ ↔•↔ ⇐ …↔∂♥↔∂°± 
∂± ↔•≡ ∂±≈∂♥∂≈♠≥← ♦∂↔• ↔•≡ ↓↑°↔≡…↔∂♥≡ •↓≥°↔ƒ↓≡ ∂← ↓↑°↓≡↑≥ƒ ↑≡÷♠∫
″↔≡↑±≥ ↔∂←←♠≡ ≈♠↑∂±÷ ↓≥…≡±↔↔∂°± ♦°♠≥≈ ±°↔ ≡±…°♠±↔≡↑  ♥∂÷°↑∫
↔•≡ ♠↔≡↑∂±≡ ←↓∂↑≥ ↑↔≡↑∂≡← ↑≡←♠≥↔∂±÷ ∂±  ±°±∫∉∨ ↓↑≡÷±±…ƒ ♦∂↔•  
〉 ⇐°±…♠↑↑≡±↔≥ƒ⌠ 
↔•≡ ↓↑≡≈∂←↓°←∂±÷ •↓≥°↔ƒ↓≡ ″ƒ ↑≡←♠≥↔ ∂± ± ∂±…↑≡←≡≈ ≥≡♥≡≥ °≠ 
…°″↓≥≡″≡±↔  …↔∂♥↔∂°±  ←  ∂±≈∂…↔≡≈  ƒ  ∂±…↑≡←≡≈  ≠…↔°↑  ⇑  ⇑  
≥≡♥≡≥← ≡↑≥ƒ ∂± ↔•≡ ↓↑≡÷±±…ƒ〉 ⇐°″↓≥≡″≡±↔ ↔↔…× …°♠≥≈ …°″↓↑°∫
″∂←≡ ↔•≡ ∨⊃⊄ ∂±♥←∂°± ±≈ …°±←≡→♠≡±↔≥ƒ ↔•≡ ↓≥…≡±↔≥ ≠♠±…↔∂°± 
↑≡←♠≥↔∂±÷ ∂± ± ∂±…↑≡←≡≈ °……♠↑↑≡±…≡ °≠ ←≡♥≡↑≡ ∉∨ ⌠ 〉
⇐ ↓↑°″°↔≡↑ …↔∂♥∂↔ƒ ∂← ≈≡↓≡±≈≡±↔ °± ↔•≡ ≈∂±♠…≥≡°↔∂≈≡ ↑≡↓≡↔ 
↓°≥ƒ″°↑↓•∂←″ ¬∧ ←♠…• ↔•↔ ↔•≡ ≥°±÷≡↑ ↔•≡ ⇐⇒ ↑≡↓≡↔ 
↑≡÷∂°±⌠ ↔•≡ ≥°♦≡↑ ↔•≡ ↔↑±←…↑∂↓↔∂°±≥ …↔∂♥∂↔ƒ °≠ ⇐ 〉 ⇒ ←•°↑↔≡↑ 
≡↓∂≥≡↓←∂≡← ±≈ ≠≡↑∂≥≡ ←≡∂∞♠↑≡←〉 ⋅°♦≡♥≡↑⌠ ∂± ↔•≡ ↓↑≡←≡±↔ ←↔♠≈ƒ⌠ ♦≡ 
←≡♥≡↑≡ ∉∨ ∂±  ←″≥≥ ↓↔∂≡±↔ …°•°↑↔〉
⇐ ∂←  ×±°♦± ←  
≡≥≡…↔↑°↓•°↑≡←∂← ÷≡≥←〉 ⇐∧ •← ≡≡± ≈≡←…↑∂≡≈ ← ↓↑≡≈∂←↓°←∂±÷ ↔° 
∉∨ 
∉∨〉 ∠♠↑ ↑≡←♠≥↔ …°±…♠↑← ♦∂↔• ± ≡↑≥ƒ ←↔♠≈ƒ °≠ ⇐ ≥≥°↔ƒ↓≡← ↔•↔ ≈∂≈ 
〉
″∂≈≈≥≡ °≠ ⇐ ∂← ↔∂÷•↔≡←↔ ≠°↑ ↔•≡ ±…≡←↔↑≥ ↑← ≥≥≡≥≡ ∂± ±°±∫
∉∨ …°±↔↑°≥← ←♠÷÷≡←↔∂±÷ ↔•↔ ↔•≡ ←↔↑♠…↔♠↑≡ ↑≡←♠≥↔← ≠↑°″  ↓°←∂↔∂♥≡ 
≡♥°≥♠↔∂°±↑ƒ ←≡≥≡…↔∂°± ↓↑≡←←♠↑≡  〉 ⇒ ←∂″∂≥↑ ↓↔↔≡↑± 
∂←  °←≡↑♥≡≈ ≠°↑  ↔•≡  ±…≡←↔↑≥  ≥≥≡≥≡  °≠  ↑← ∂±  ∉∨ ♦°″≡±〉  
⋅°♦≡♥≡↑⌠ ∂± ←≡♥≡↑≡ ∉∨⌠ ↔•≡ •↓≥°≥°…× ←↔↑♠…↔♠↑≡ ≈∂←∂±↔≡÷↑↔≡← 
±°↔∂…≡≥ƒ  ←°°±≡↑  ↔•± ∂±  …°±↔↑°≥←⌠  ∂±≈∂…↔∂±÷   ≥°°←≡±≡≈ ≠°↑…≡  
°≠ …↔∂♥≡ ←≡≥≡…↔∂°±  〉 √↔ ♦°♠≥≈ ≠°≥≥°♦ ↔•↔ ≈♠≡ ↔°  ↓°←∫
←∂≥≡ ↑≡÷♠≥↔°↑ƒ ≠≡↔♠↑≡ …♠←≡≈ ƒ ←≡≡″∂±÷≥ƒ ≡±∂÷± ♥↑∂±↔← ↔•↔ 
•♥≡ ≡≡± ∂±↔↑°≈♠…≡≈ ∂±↔° ↔•≡ ″∂≈≈≥≡ °≠ ⇐⌠ ↔•≡ ↑∂←× ≠°↑ ←≡♥≡↑≡ 
∉∨ ∂±…↑≡←≡←⌠ ♦•∂≥≡ •↓≥°↔ƒ↓≡← ♦∂↔• ↔•≡ ±…≡←↔↑≥ ÷≡±°↔ƒ↓≡ ↑≡ 
↓↑°↔≡…↔∂♥≡ ≠↑°″ ←≡♥≡↑≡ ∉∨ ±≈⌠ ……°↑≈∂±÷≥ƒ⌠ ♠±≈≡↑ ←↔↑°±÷≡↑ ↓°←∂∫
↔∂♥≡ ±↔♠↑≥ ←≡≥≡…↔∂°±〉
∂± ⇒⊂∉ ∂←  ←←°…∂↔≡≈  ↔°  ≥↔≡∫°±←≡↔  ♠↔  ±°↔  ↔°  ≡↑≥ƒ∫°±←≡↔  
∉∨⌠ ±≈ ±°″∂±≥≥ƒ ↔° ←≡♥≡↑≡ ∉∨ ∂±  ⇐•∂±≡←≡ ↓°↓♠≥↔∂°± 〉 
∫
≡±↔ …°″↓≥≡″≡±↔ ↓↔•♦ƒ← …°±↔↑∂♠↔≡ ↔° ≡↑≥ƒ∫°±←≡↔ ∉∨ ±≈ 
≥↔≡∫°±←≡↔ ∉∨ ±≈ ↔•≡ ″≡…•±∂←″ °≠ ↔•≡←≡ ♥↑ƒ∂±÷ ←←°…∂↔∂°±← 
″≡↑∂↔ ″°↑≡ ←↔♠≈∂≡←〉
∫
↔∂≡← ≠°↑ ∉∨ ↑∂←× ←←≡←←″≡±↔ ±≈ ≈∂÷±°←∂←⌠ ″ƒ≡ ≡♥≡± ≠♠↔♠↑≡ ≈↑♠÷ 
≈≡♥≡≥°↓″≡±↔  ∫
≡±…≡← ≡↔♦≡≡± ∉∨ ±≈ •≡≥↔•ƒ ↓↑≡÷±±↔ ♦°″≡± ♠↔ ↔•≡ ↑°≥≡← °≠ 
∂±≈∂♥∂≈♠≥ ⊂∇∉← ←•°♠≥≈ ≡ …°±←∂≈≡↑≡≈ ←♠÷÷≡←↔∂♥≡ ±≈ ↔↑≡↔≡≈ ♦∂↔• 
⇐
↓↔∂≡±↔← ♦∂↔• ↔•≡ •∂÷•≡←↔ ↑∂←× °≠ ←≡♥≡↑≡ ∉∨〉
∨⊄⋅√⇐⊂ ⊂⊄⇒⊄∨∨∇⊄
⇒≥≥ ←♠∝≡…↔← ↓↑°♥∂≈≡≈  ♦↑∂↔↔≡± ∂±≠°↑″≡≈ …°±←≡±↔ ∂± ……°↑≈±…≡ 
♦∂↔• ↔•≡ ⇔≡…≥↑↔∂°± °≠ ⋅≡≥←∂±×∂〉 ⊂↔♠≈ƒ ↓↑°↔°…°≥← ♦≡↑≡ ↓↓↑°♥≡≈ 
←↔♠≈ƒ⌠ ≡↔•∂…≥ ↓↓↑°♥≥ •← ≡≡± °↔∂±≡≈ ≠↑°″ ↔•≡ ⇐°°↑≈∂±↔∂±÷ 
∨↔•∂…← ⇐°″″∂↔↔≡≡⌠ ⋅°←↓∂↔≥ ⇔∂←↔↑∂…↔ °≠ ⋅≡≥←∂±×∂ ±≈ ⊇♠←∂″⌠ 
≠°↑ ↔•≡ ∧∂±±∂←• ↓°↓♠≥↔∂°± ←≡≈ ↓↑≡∫≡…≥″↓←∂ …°•°↑↔ ♦← 
↓↓↑°♥≡≈ ƒ ↔•≡ ≡↔•∂…← …°″″∂↔↔≡≡ °≠ ↔•≡ ∧∂±±∂←• ⊆≡≈ ⇐↑°←← ⇑≥°°≈ 
⊂°♠↔•≡↑± ∧∂±≥±≈ ↓↑≡∫≡…≥″↓←∂ ←↔♠≈ƒ ♦← ↓↓↑°♥≡≈ ƒ ↔•≡ ∨↔•∂…← 
⇐°″″∂↔↔≡≡ °≠ ↔•≡ ⇔≡↓↑↔″≡±↔ °≠ ∠←↔≡↔↑∂…← ±≈ ¬ƒ±≡…°≥°÷ƒ ↔ 
⋅≡≥←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ ⇐≡±↔↑≥ ⋅°←↓∂↔≥〉
⇒⊇⊄⋅∠⊆ ⇐∠∇⊄⊆√⇑⊇⊄√∠∇⊂
⇒√ ≈≡←∂÷±≡≈ ↔•≡ ←↔♠≈ƒ ♦∂↔• ⊂ ±≈ ⋅〉 ⇒√ ±≈ ⊄ ≈≡←∂÷±≡≈ 
↓↑↔ °≠ ↔•≡ ↓↑∂″≡↑← ≠°↑ ←≡→♠≡±…∂±÷⌠ ⇒√ ←♠↓≡↑♥∂←≡≈ ≥°↑↔°↑ƒ 
♦°↑×⌠ ←≡→♠≡±…≡≈ ≥≥ ←″↓≥≡← ≠↑°″ ↓↔∂≡±↔← ±≈ ←°″≡ …°±↔↑°≥←⌠ ↑≡≈ 
↔•≡ ↑≡←♠≥↔←⌠ …°±≈♠…↔≡≈ ←←°…∂↔∂°± ±≥ƒ←≡← °≠ ↔•≡ ⇐ ←≡→♠≡±…∂±÷ 
↓↑°∝≡…↔⌠ ↓≡↑≠°↑″≡≈ 
⊄ …°±≈♠…↔≡≈ ≥°↑↔°↑ƒ ♦°↑× ≠°↑ ↔•≡ ↑≡÷♠≥↔°↑ƒ ↑≡÷∂°±← ↑±…• 
°≠ ↔•≡ ←↔♠≈ƒ⌠ ±≥ƒ∞≡≈ ↔•≡←≡ ≈↔⌠ ±≈ ↓↑↔∂…∂↓↔≡≈ ∂± ″∂± ≈↔ 

°××∂ ≡↔ ≥〉 ⇐ ¬≡±≡ ±≈ ∉∨
∧↑°±↔∂≡↑← ∂± √″″♠±°≥°÷ƒ ≤ ♦♦♦〉≠↑°±↔∂≡↑←∂±〉°↑÷ ƒ  ≤ ⊃°≥♠″≡  ≤ ⇒↑↔∂…≥≡ 
±≥ƒ←∂←〉 ⊃⋅ ≈≡←∂÷±≡≈ ↔•≡ …°″↓≥≡″≡±↔ ÷≡±°↔ƒ↓∂±÷ ⊂≡→♠≡±°″ 
…•∂↓〉 ∉∠ ±≥ƒ∞≡≈ ↔•≡ ÷≡±°↔ƒ↓∂±÷ ≈↔〉  ↓≡↑≠°↑″≡≈ ±≈ 
∂±↔≡↑↓↑≡↔≡≈ ↔•≡  ⊆∨⋅⋅ ±≥ƒ←∂←  ♦∂↔• ⇒√ ±≈ ∉⊂〉  ∉⊃ ≈≡←…↑∂≡≈ 
↓↔∂≡±↔ …°•°↑↔←〉 ⋅⌠ ⊂⋅⌠ ∨⌠ ∏⌠ ⌠ ±≈ ⇒∉ ≠°↑″ ↔•≡ °↑≈ °≠ 
↔•≡ ∧√∇∇∉∨⇐ …°•°↑↔ ±≈ ↑≡ ↑≡←↓°±←∂≥≡ ≠°↑ ↔•≡ …≥∂±∂…≥ ≈↔ 
±≈ ∂°≥°÷∂…≥ ←″↓≥≡← ♠←≡≈ ∂± ↔•∂← ←↔♠≈ƒ〉 ⋅ ↓↑°♥∂≈≡≈ ←″↓≥≡← 
±≈ ∂← ♦∂↔• ⋅ ↑≡←↓°±←∂≥≡ ≠°↑ ↔•≡ …≥∂±∂…≥ ≈↔ °≠ ↔•≡ ∧∂±±∂←• 
↓°↓♠≥↔∂°±∫←≡≈ ↓↑≡≡…≥″↓←∂ …°•°↑↔〉 ⋅ ↓↑°♥∂≈≡≈ ↔•≡ ←″↓≥≡← 
⇒⇐∇∠∪∨⇔¬∨∇⊄⊂
∪≡ ↔•±× ∏± ∠∂××°±≡± ∉•〉⇔〉⌠ ♦•° ↓↑°♥∂≈≡≈ ∂°∂±≠°↑″↔∂…← 
←←∂←↔±…≡ ∂± ″↓↓∂±÷ ↔•≡ ↓↑°″°↔≡↑ ±≈ ↑≡÷♠≥↔°↑ƒ ↑≡÷∂°±← °≠ 
⇐〉 ∪≡ ↔•±× ∉≡×× ∨≥≥°±≡± ≠°↑ ≈≡←∂÷±∂±÷ ↓↑↔ °≠ ↔•≡ ←≡→♠≡±…∫
∂±÷ ↓↑∂″≡↑← ±≈ ⋅±± ∏↑♥ ≠°↑ •≡↑ ≡♣↓≡↑↔∂←≡ ∂± …°″↓≥≡″≡±∫
↔°≥°÷ƒ〉 ⊄∂ ⇒≥↔°∫⊃∂≥∝×∂±≡±⌠ ⇔⌠ ≈≡←…↑∂≡≈ ↔•≡ ↑≡↓≥∂…↔∂°± 
≈↔←≡↔ ≠°↑ ♦•∂…• ♦≡ ↑≡ ÷↑↔≡≠♠≥〉 ⊆∂∂↔↔ ≡•↔∂±≡±⌠ ⊂♠←±± 
≡•↔;≥;⌠ ±≈ ∨∂∝ °↑↔≡≥∂±≡± ↑≡ ↔•±×≡≈ ≠°↑ ↔•≡∂↑ ↔≡…•±∂…≥ 




⇒…≈≡″ƒ °≠ ∧∂±≥±≈ ⌠ ⌠ ±≈ ⌠ ⋅⌠ ∉;∂♥∂××∂ ±≈ 
⊂×↑∂ ⊂°•≥≡↑÷ ∧°♠±≈↔∂°± ⋅⌠ ⊂∂÷↑∂≈ ∏♠←6≥∂♠← ∧°♠±≈↔∂°± ⊂⌠ 
⇔°…↔°↑≥ ∉↑°÷↑″″≡ ∂± ⇑∂°″≡≈∂…∂±≡⌠ ⇐≥∂±∂…≥ ¬↑≈♠↔≡ ∉↑°÷↑″ 
⊄⌠ ⊆≡←≡↑…• ∧°♠±≈↔∂°± °≠ ↔•≡ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂ ⊄ ±≈ 
⇑∂°″≡≈∂…♠″ ⋅≡≥←∂±×∂ ∧°♠±≈↔∂°± ⊄〉 ∧∂±←× ;×↑≡←;≥≥←×↓≡↔⌠ 
∨″∂≥ ⇒≥↔°±≡± ∧°♠±≈↔∂°±⌠ ∧∂±±∂←• ≡≈∂…≥ ∧°♠±≈↔∂°±⌠ ⊇±∂♥≡↑←∂↔ƒ 
°≠ ⋅≡≥←∂±×∂ ∧♠±≈←⌠ ⊂↓≡…∂≥ ⊂↔↔≡ ⊂♠←∂≈ƒ ≠°↑ ⋅≡≥↔• ⊆≡←≡↑…• ∨⊃∠ 
≠♠±≈∂±÷⌠ ∇°♥° ∇°↑≈∂←× ∧°♠±≈↔∂°±⌠ ⊂∂÷±≡ ±≈ ⇒±≡ ¬ƒ≥≥≡±≡↑÷ 
∧°♠±≈↔∂°±⌠ ±≈ ∧°♠±≈↔∂°± ≠°↑ ∉≡≈∂↔↑∂… ⊆≡←≡↑…• …°±↔↑∂♠↔≡≈ ↔° 
∫




〉  ⊆°≡↑↔←  ∏⌠  ∉≡↑←°±  ¬⌠  ⇐♠↔≥≡↑  ∏⌠  ∂±≈•≡∂″≡↑    ∇⋅⇑√  ∪°↑×∂±÷  ¬↑°♠↓  
°± ⊆≡←≡↑…• °± ⋅ƒ↓≡↑↔≡±←∂°± ⇔♠↑∂±÷ ∉↑≡÷±±…ƒ〉 ⊂♠″″↑ƒ °≠ ↔•≡ ∇⋅⇑√ 
♦°↑×∂±÷ ÷↑°♠↓ °± ↑≡←≡↑…• °± •ƒ↓≡↑↔≡±←∂°± ≈♠↑∂±÷ ↓↑≡÷±±…ƒ〉 ⋅ƒ↓≡↑↔≡±←∂°± 
 ∑〉 ≈°∂∑〉ñ〉⋅∅∉〉〉〉∨ 
〉  ⇒±≈↑♦≡≡↑  ∉⋅⌠  ¬↔≠°↑≈  ⌠  ⇔≡××≡↑  ¬⇒⌠  ≡≡″→∞  ⊂⌠  ∏ƒ←≡×↑  ⊆∪⌠  
  ÷≡±≡↔∂…  ↑∂←×  ≠…↔°↑  ≠°↑  ♥←…♠≥↑  ±≈  ″≡↔°≥∂…  ≈∂←≡←≡⌠  ←←°…∂↔≡←  ♦∂↔•  
↓↑≡∫≡…≥″↓←∂〉 ⊆≡↓↑°≈ ⇑∂°″≡≈ ∠±≥∂±≡  ∑〉 ≈°∂∑〉ñ∝〉
↑″°〉〉〉 
〉 
↓°←←∂≥≡ ±°♥≡≥ ↓↑°↔≡…↔∂♥≡ ≥°…♠← ≠°↑ ↓↑≡≡…≥″↓←∂〉 ∏ ⋅ƒ↓≡↑↔≡±←  ∑〉 
≈°∂∑〉ñ⋅∏⋅〉 
〉  ∪±  ∏∉⌠  ⊕•°  ⋅⌠  ∂  ⊄⌠  ∂  ⇐⊕⌠  ∪±÷  ∩⊄⌠  ⇐•≡±  ⊕∏〉  
↑← ∂← ←←°…∂↔≡≈ ♦∂↔• ↓↑≡≡…≥″↓←∂ ∂± ⋅± ⇐•∂±≡←≡ ♦°″≡±〉 ∉°⊂ ∠±≡ 
 ∑≡〉 ≈°∂∑〉ñ∝°♠↑±≥〉↓°±≡〉 
〉 
∉↑≡÷±±…ƒ ±≈ ≥°±÷∫↔≡↑″ ″↔≡↑±≥  …↑≈∂°♥←…♠≥↑  •≡≥↔•∑  ↓↑°÷↑≡←←  ↔•↑°♠÷• 
•↑″°±∂∞↔∂°± °≠ ↑≡←≡↑…• …°•°↑↔← ±≈ ∂°±×←〉 ⋅ƒ↓≡↑↔≡±←∂°±  
∑〉 ≈°∂∑〉ñ⋅∅∉∨⊆⊄∨∇⊂√∠∇⇒⋅⇒〉〉 
〉 ⇑≡←↔ ¬⌠ ∇≈≡♠ ⌠ ⇔♥∂← ⌠ ″ ∧⌠ ⇑≡↑…∂≡↑ ⊂⌠ ⇒±≈≡↑←°± ⇐〉 ¬≡±≡↔∂… ♥↑∂∫
±↔←⌠ ∂″″♠±≡ ≠♠±…↔∂°±⌠ ±≈ ↑∂←× °≠ ↓↑≡∫≡…≥″↓←∂ ″°±÷ ⇒″≡↑∂…± √±≈∂±←〉 
⇒″ ∏ ⊆≡↓↑°≈ √″″♠±°≥  ∑〉 ≈°∂∑〉ñ∝〉∫〉〉〉♣ 
〉  ∈♠…•  ⌠  ¬↑°♥≡↑  ⊂⇒⌠  ≡±∂÷←≡↑÷  ⊂⌠  ∂↑…•  ⇐〉  ⇒  …°″∂±↔∂°±  °≠  ←∂±÷≥≡  
±♠…≥≡°↔∂≈≡  ↓°≥ƒ″°↑↓•∂←″←  ∂±  ↔•≡   ♠±↔↑±←≥↔≡≈  ↑≡÷∂°±  °≠  ⋅⇒∫¬  ∂←  ←←°∫
…∂↔≡≈ ♦∂↔• ↓↑≡≡…≥″↓←∂〉 ⋅♠″ √″″♠±°≥  ∑〉 ≈°∂∑〉ñ∝〉
•♠″∂″″〉〉〉 
〉 
↓↑≡÷±±…ƒ∑ ≠…↔← ±≈ …°±↔↑°♥≡↑←∂≡←〉 ∉≥…≡±↔  ∑〉 ≈°∂∑〉ñ∝〉
↓≥…≡±↔〉〉〉 
〉 °××∂ ⇒√⌠ ⋅≡∂××∂±≡±∫∨≥°↑±↔ ∏⌠ ∏↑♥ ⋅⌠ ⊂∂←↔° ⊄⌠ °××∂ ⌠ ∂♥♠°↑∂ ⋅⌠ 
∧↑°±↔ 
√″″♠±°≥
〉  ⊄±÷  ∩⌠  ⊕•±÷  ∅⋅⌠  ⋅♠  ⌠  ♦×∫∂″  ∏⌠  ∂°  ⇒⋅〉  ⇐⇔ ⇐⇔ 
⋅⇒∫⇔⊆ ″°±°…ƒ↔≡← ∂± ↓≡↑∂↓•≡↑≥ ≥°°≈ ↑≡ →♠±↔∂↔↔∂♥≡≥ƒ …°↑↑≡≥↔≡≈ 
♦∂↔• ↔•≡ ←≡♥≡↑∂↔ƒ °≠ ↓↑≡∫≡…≥″↓←∂〉 ⇒″ ∏ ⊆≡↓↑°≈ √″″♠±°≥  ∑〉 
≈°∂∑〉ñ∝∂〉 
〉 
≠≡↔≥ ≥↔≡↑±↔∂♥≡ …°″↓≥≡″≡±↔ ↓↔•♦ƒ …↔∂♥↔∂°± ∂± ≡↑≥ƒ ←≡♥≡↑≡ ↓↑≡≡…≥″↓←∂〉  
⇒″ ∏ ⊆≡↓↑°≈ √″″♠±°≥  ∑〉 ≈°∂∑〉ñ∝∂〉 
〉 ⇑°∂∝ ⊆⌠ ⊂♥≡±←←°± ∏⌠ ∇∂≥←←°±∫∨×≈•≥ ⌠ ⊂±≈•°≥″ ⌠ ∂±≈•≥ ⊄⌠ ∉≥°±≡× ∨⌠  
∂±≈≡↓≡±≈≡±↔≥ƒ ←←°…∂↔≡≈ ♦∂↔• ↓↑≡≡…≥″↓←∂〉 ⇒″ ∏ ⊆≡↓↑°≈ √″″♠±°≥  
∑〉 ≈°∂∑〉ñ∝〉∫〉〉〉♣ 
〉  ∇°±∫× ⌠ ∂″♠↑ ⇒〉  ¬≡±°″∂… ♥∂≡♦ °≠  ↔•≡ ≡♥°≥♠↔∂°± °≠  ↔•≡ …°″↓≥≡″≡±↔ 
←ƒ←↔≡″〉 √″″♠±°÷≡±≡↔∂…←  ∑〉 ≈°∂∑〉ñ←∫∫∫ 
〉 ∇°±∫× ⌠ ∅°←•∂∞×∂ ∧〉 ∨♥°≥♠↔∂°± °≠ ↔•≡ …°″↓≥≡″≡±↔ ←ƒ←↔≡″〉 °≥ √″″♠±°≥ 
 ∑〉 ≈°∂∑〉ñ∝〉″°≥∂″″〉〉〉 
〉  ∇°±∫×  〉  ∨♥°≥♠↔∂°±  °≠  ↔•≡  …°″↓≥≡″≡±↔  ←ƒ←↔≡″〉  ⊂♠…≡≥≥ ⇑∂°…•≡″  
∑〉 ≈°∂∑〉ñ∫∫∫∫ℵ 
〉  ≡↑∂  ⊂〉  ⊂≡≥≠∫±°±∫←≡≥≠  ≈∂←…↑∂″∂±↔∂°±  ƒ  ↔•≡  …°″↓≥≡″≡±↔  ←ƒ←↔≡″〉  ∧∨⇑⊂ ≡↔↔ 
 ∑〉 ≈°∂∑〉ñ∫〉 
〉  ∏±←←≡± ⇑∏⌠  ⇐•↑∂←↔°≈°♠≥∂≈°♠ ⇒⌠  …⇐↑↔•ƒ ⇒⌠  ″↑∂←  ∏⇔⌠  ¬↑°← ∉〉  ⊂↔↑♠…↔♠↑≡  
°≠  ⇐  ↑≡♥≡≥←  …°±≠°↑″↔∂°±≥  …•±÷≡←  ↔•↔  ♠±≈≡↑≥∂≡  …°″↓≥≡″≡±↔  …↔∂♥∂↔ƒ〉  
∇↔♠↑≡  ∑〉 ≈°∂∑〉ñ±↔♠↑≡ 
〉 
⊂↔↑♠…↔♠↑≡← °≠ ⇐ ∂± …°″↓≥≡♣ ♦∂↔• ≠…↔°↑← ⇑ ±≈ ⇔ ÷∂♥≡ ∂±←∂÷•↔ ∂±↔° …°″∫
↓≥≡″≡±↔ …°±♥≡↑↔←≡ ≠°↑″↔∂°±〉 ⊂…∂≡±…≡  ∑〉 ≈°∂∑〉ñ
←…∂≡±…≡〉 
〉 ∏±←←≡± ⇑∏⌠ ¬↑°← ∉〉 ⊂↔↑♠…↔♠↑≥ ∂±←∂÷•↔← ∂±↔° ↔•≡ …≡±↔↑≥ …°″↓≥≡″≡±↔ …°″↓°±≡±↔ ⇐〉  
°≥ √″″♠±°≥  ∑〉 ≈°∂∑〉ñ∝〉″°≥∂″″〉〉〉 
〉 ⊄±∂÷♠…•∂∫⊂∂≈≥≡ ⇒⌠ √←≡±″± ⇔∨〉 √±↔≡↑…↔∂°±← °≠ •♠″± …°″↓≥≡″≡±↔ …°″↓°∫
±≡±↔ ⇐ ♦∂↔• ≠…↔°↑ ⇑ ±≈ ♦∂↔• …°″↓≥≡″≡±↔ ↑≡…≡↓↔°↑← ↔ƒ↓≡  ⇐⊆⌠ ⇐⇔ ±≈ 
↔ƒ↓≡  ⇐⊆⌠ ⇐⇔ñ⇐⇔ ∂±♥°≥♥≡ ± …∂≈∂… ←≡→♠≡±…≡ ↔ ↔•≡ ∇∫↔≡↑″∂±♠← °≠ 
⇐ ≥↓•∫…•∂±〉 ∏ √″″♠±°≥  ∑〉 
〉 
∇≡÷≥∂÷∂≥≡ ↑°≥≡ °≠ ±↔∂°≈∂≡← ±≈ ⇐ ∂± ↓↑≡÷±±…ƒ ≥°←← ←←°…∂↔≡≈ ≡♣…≥♠←∂♥≡≥ƒ 
♦∂↔• ⇐∫≈≡↓≡±≈≡±↔ ″≡…•±∂←″← ↔•↑°♠÷• …°″↓≥≡″≡±↔ ≥↔≡↑±↔∂♥≡ ↓↔•♦ƒ〉 
√″″♠±∂↔ƒ  ∑〉 ≈°∂∑〉ñ⊂∫∫ 
〉 ⇑♠↑♦∂…× ⊆⌠ ∧≡∂±≡↑÷ ⇑⇑〉 ∨…♠≥∂∞♠″ ≠°↑ ↔•≡ ↔↑≡↔″≡±↔ °≠ ↓↑≡∫
≡…≥″↓←∂ñ⋅∨∉ ←ƒ±≈↑°″≡〉 ∉≥…≡±↔  ∑〉 ≈°∂∑〉ñ∝〉
↓≥…≡±↔〉〉〉 
〉  °××∂  ⇒√⌠  ≥≡″≡↔↔∂  ⌠  ⋅≡∂±°  ⊂⌠  ⋅∂≥↔♠±≡±  ⌠  ⋅≡∂±°±≡±  ⊂⌠  ∂♥♠°↑∂  ⋅〉  
⇒←←°…∂↔∂°± °≠ ↔•≡ ↑← ↓°≥ƒ″°↑↓•∂←″ °≠ ↔•≡ ⇒⇐⊃⊆⇒ ÷≡±≡ ♦∂↔• ↔•≡ 
↑∂←× °≠ ↓↑≡∫≡…≥″↓←∂ ∂← ±°↔ ↑≡↓≥∂…↔≡≈ ∂±  ∧∂±±∂←• ←↔♠≈ƒ ↓°↓♠≥↔∂°±〉 ⇑⇐ ⊆≡← 
∇°↔≡←  ∑〉 ≈°∂∑〉ñ∫∫∫ 

°××∂ ≡↔ ≥〉 ⇐ ¬≡±≡ ±≈ ∉∨
∧↑°±↔∂≡↑← ∂± √″″♠±°≥°÷ƒ ≤ ♦♦♦〉≠↑°±↔∂≡↑←∂±〉°↑÷ ƒ  ≤ ⊃°≥♠″≡  ≤ ⇒↑↔∂…≥≡ 
〉 
⇑∏ ∠↓≡±  ∑≡〉 ≈°∂∑〉ñ″∝°↓≡±∫∫ 
〉 ⇒⇐∠¬ ⇐°″″∂↔↔≡≡ °± ∠←↔≡↔↑∂… ∉↑…↔∂…≡〉 ⇒⇐∠¬ ↓↑…↔∂…≡ ♠≥≥≡↔∂±〉 ⇔∂÷±°←∂← 
±≈ ″±÷≡″≡±↔ °≠ ↓↑≡≡…≥″↓←∂ ±≈ ≡…≥″↓←∂〉 ∇♠″≡↑ ⌠ ∏±♠↑ƒ 〉 
⇒″≡↑∂…± ⇐°≥≥≡÷≡ °≠ ∠←↔≡↔↑∂…∂±← ±≈ ¬ƒ±≡…°≥°÷∂←↔←〉 √±↔ ∏ ¬ƒ±≡…°≥ ∠←↔≡↔ 
 ∑〉 ≈°∂∑〉ñ⊂∫∫
〉  ∉∂•×≥  ∏⌠  ⋅×≥  ⊄⌠  ⊃°♠↔∂≥∂±≡±  ∉⌠  ⊆∂♥∂°  〉  ⇐•↑…↔≡↑∂←↔∂…  °≠  ↑≡…≡±↔  ≠≡↔≥  
÷↑°♦↔• …♠↑♥≡← ∂± ∧∂±≥±≈〉 ⇔♠°≈≡…∂″  ∑〉 
〉 ⋅°≥″≡↑÷ ⊃⌠ ∠±×″° ∉⌠ •↔≡≥ ∨⌠ •≡↑″° ∉⌠ ⇑≡≈♠∫⇒≈≈° ¬⌠ 
⇑ ±≈ ⇒⊂∉ ←←°…∂↔≡≈ ♦∂↔• ↓≥…≡±↔≥ ″≥↑∂〉 ≥↑ ∏  ∑〉 
≈°∂∑〉ñ∫∫∫ 
〉 
∇↔♠↑≡  ∑〉 ≈°∂∑〉ñ±↔♠↑≡ 
〉 ⇔≡←″≡↔ ∧∠⌠ ⋅″↑°♠± ⇔⌠ ≥±≈≡ ⌠ ⇐°≥≥°≈∫⇑≡↑°♠≈ ¬⌠ ⇐≥♠←↔↑≡← ⌠ ⇑≡↑°♠≈ ⇐〉  
⋅♠″± ⊂↓≥∂…∂±÷ ∧∂±≈≡↑∑ ± °±≥∂±≡ ∂°∂±≠°↑″↔∂…← ↔°°≥ ↔° ↓↑≡≈∂…↔ ←↓≥∂…∂±÷ 
←∂÷±≥←〉 ∇♠…≥≡∂… ⇒…∂≈← ⊆≡←  ∑≡〉 ≈°∂∑〉ñ±↑ñ÷×↓ 
〉 ⊂↑∂±↔•± ⊆⌠ ⊄≠≡↑ ⋅⌠ ⊂≡≡″±± ⊂∨⌠ ⋅°≠…×≡↑ √⌠ ⊂↔≈≥≡↑ ∉∧⌠ ¬°↑°≈×∂± ∏〉  
←↔↑♠…↔♠↑≡〉 ∇♠…≥≡∂… ⇒…∂≈← ⊆≡←  ∑∪〉 ≈°∂∑〉ñ±↑ñ÷×↔ 
〉 ⊂↑∂±↔•± ⊆⌠ ⊄≠≡↑ ⋅⌠ ⊂≡≡″±± ⊂∨⌠ ⋅°≠…×≡↑ √⌠ ⊂↔≈≥≡↑ ∉∧⌠ ¬°↑°≈×∂± ∏〉  
∂±≈♠…≡≈ ƒ ⊂∇∉←〉 ⋅♠″ ♠↔↔  ∑〉 ≈°∂∑〉ñ•♠″♠〉 
〉  ¬♠↔∂≡↑  ⌠  ⊃∂↔≥∂←  ⊆〉  ↑≡••∑  ±  ⊆  ↓…×÷≡  ↔°  ≈≡↔≡…↔  ≠°°↔↓↑∂±↔←  °≠  ←≡≥≡…↔∂°±  
∂± ÷≡±°″≡∫♦∂≈≡ ⊂∇∉ ≈↔ ≠↑°″ •↓≥°↔ƒ↓≡ ←↔↑♠…↔♠↑≡〉 ⇑∂°∂±≠°↑″↔∂…←  
∑〉 ≈°∂∑〉ñ∂°∂±≠°↑″↔∂…←ñ↔← 
〉 ⊂↔≡↓•≡±← ⌠ ⇔°±±≡≥≥ƒ ∉〉 ⇒ …°″↓↑∂←°± °≠ ⇑ƒ≡←∂± ″≡↔•°≈← ≠°↑ •↓≥°↔ƒ↓≡ 
↑≡…°±←↔↑♠…↔∂°± ≠↑°″ ↓°↓♠≥↔∂°± ÷≡±°↔ƒ↓≡ ≈↔〉 ⇒″ ∏ ⋅♠″ ¬≡±≡↔  
∑〉 ≈°∂∑〉ñ 
〉 
↓°↓♠≥↔∂°± ÷≡±°↔ƒ↓≡ ≈↔∑ ↓↓≥∂…↔∂°±← ↔° ∂±≠≡↑↑∂±÷ ″∂←←∂±÷ ÷≡±°↔ƒ↓≡← ±≈ 
•↓≥°↔ƒ↓∂… ↓•←≡〉 ⇒″ ∏ ⋅♠″ ¬≡±≡↔  ∑〉 ≈°∂∑〉ñ 
〉 
∉√∇∑  ↔°°≥ ←≡↔ ≠°↑ ♦•°≥≡∫÷≡±°″≡ ←←°…∂↔∂°± ±≈ ↓°↓♠≥↔∂°±∫←≡≈ ≥∂±×÷≡ 
±≥ƒ←≡←〉 ⇒″ ∏ ⋅♠″ ¬≡±≡↔  ∑〉 ≈°∂∑〉ñ 
〉  ⇑↑↑≡↔↔  ∏⇐⌠  ∧↑ƒ  ⇑⌠  ≥≥≡↑  ∏⌠  ⇔≥ƒ  ∏〉  ⋅↓≥°♥∂≡♦∑  ±≥ƒ←∂←  ±≈  ♥∂←♠≥∂∞↔∂°±  
°≠ ⇔ ±≈ •↓≥°↔ƒ↓≡ ″↓←〉 ⇑∂°∂±≠°↑″↔∂…←  ∑〉 ≈°∂∑〉ñ
∂°∂±≠°↑″↔∂…←ñ↔• 
〉 
↓°≥ƒ″°↑↓•∂←″ ≠°↑ ↔•≡ ↓↑≡≈∂…↔∂°± °≠ ↓↑°÷±°←∂← ∂± ↓↔∂≡±↔← ♦∂↔• ≡↑≥ƒ ←↔÷≡ ±°±∫
∉°⊂ ∠±≡  ∑≡〉 
≈°∂∑〉ñ∝°♠↑±≥〉↓°±≡〉 
〉 
∂± ↔•≡ ÷≡±≡ ≡±…°≈∂±÷ ⇐ ↑≡ ←←°…∂↔≡≈ ♦∂↔• ←↔•″ ±≈ ↑≡≥↔≡≈ ↓•≡±°↔ƒ↓≡← 
″°±÷ ⇒≠↑∂…± ⇐↑∂≡± ≠″∂≥∂≡←〉 ¬≡±≡← √″″♠±  ∑〉 ≈°∂∑〉ñ
←∝〉÷≡±≡〉 
〉 ∉♠↑♦↑ ⊆⌠ ±÷≡↑ ⌠ ∪≡↑≠≡≥ ⊄〉 ∉°≥ƒ″°↑↓•∂←″← ♦∂↔•∂± ↔•≡ ⇐ ÷≡±≡ ↑≡ 
∫
↔∂÷≡±← ″°±÷ ↔°↓∂… ≈≡↑″↔∂↔∂← ↓↔∂≡±↔←〉 ∨♣↓ ⇔≡↑″↔°≥  ∑〉 
≈°∂∑〉ñ∝〉∫〉〉〉♣ 
〉 ⊂∂≥♥ ⊆⌠ ∧↑÷ ⊄⊆⌠ ♠…↔≡≥≥∂ ∏∧⌠ ¬↑♠″…• ⇒⊂⌠ √←… 〉 ⊂×∂↓↓∂±÷ °≠ ≡♣°±  ∂± 
∫
…∂≡±…ƒ〉 √″″♠±°∂°≥°÷ƒ  ∑〉 ≈°∂∑〉ñ∝〉∂″∂°〉〉〉 
〉  ⊄←♠×″°↔°  ⋅⌠  ⋅°↑∂♠…•∂  ⊄⌠  °×♠  ⋅⌠  ∇÷≡  ⊂⌠  ∇∂←•∂∞×  ⋅⌠  ⊂♦≡  ⊄⌠  
≥♠↓♠← ≡↑ƒ↔•≡″↔°←♠←〉 ⇑∂°…•≡″ ⇑∂°↓•ƒ← ⊆≡← ⇐°″″♠±  ∑〉 
≈°∂∑〉ñ∝〉↑…〉〉〉 
〉  ⇑↑≡←↔  ∉⌠  ↓→♠≡↔↔≡  ∉⌠  ⊂°♠∂≈∂  ⌠  ≡↑∂÷±≈ ⌠  ⇐≡←↑° ⇒⌠  ⊃°♠↑≡↔∫⇐↑♥∂↑∂  ⊃⌠  
…♠←≡← ≈≡↑≡÷♠≥↔∂°± °≠ √⊆¬∫≈≡↓≡±≈≡±↔ ♣≡±°↓•÷ƒ ∂± ⇐↑°•±← ≈∂←≡←≡〉 ∇↔ 
¬≡±≡↔  ∑〉 ≈°∂∑〉ñ±÷〉 
〉 
⇐°″↓↑≡•≡±←∂♥≡  ←↓≥∂…∂±÷ ≠♠±…↔∂°±≥  ±≥ƒ←∂←  °≠  ⇔∇⇒ ♥↑∂±↔←  °≠  ↔•≡ ⇑⊆⇐⇒ 
÷≡±≡ ƒ •ƒ↑∂≈ ″∂±∂÷≡±≡←〉 ⇑↑≡←↔ ⇐±…≡↑ ⊆≡←  ∑⊆〉 ≈°∂∑〉ñ
…↑ 
〉 
∏↓±≡←≡ ↓↔∂≡±↔← ♦∂↔• ↔♣∂∫↔≡≥±÷∂≡…↔←∂〉 ⋅♠″ ♠↔↔  ∑〉 
≈°∂∑〉ñ•♠″♠〉 
〉 
≡÷≥≡±…≡↓•≥∂… ≥≡♠×°≡±…≡↓•≥°↓↔•ƒ ♦∂↔• ←♠…°↑↔∂…≥ …ƒ←↔← ↔ƒ↓≡  ⇐ 
〈 ∫
÷↔≡≈  ♠←∂±÷ ± ±↔∂←≡±←≡ ″°↑↓•°≥∂±° °≥∂÷°±♠…≥≡°↔∂≈≡〉 ∇≡♠↑°÷≡±≡↔∂…← 
 ∑〉 ≈°∂∑〉ñ←∫∫∫∞ 
〉 ∈≈≈°♠↑• ⊆⋅⌠ ÷≈°♠≈ ⌠ ⊂≥≈±• ∧⌠ •″°°≈ ∇⌠ ♠←↔≠ ∧∨⌠ 
∂±  √∫  ←≡…↑≡↔∂°±  ∂±  ♦°″≡±  ♦∂↔•  ∂≈∂°↓↔•∂…  ↑≡…♠↑↑≡±↔  ″∂←…↑↑∂÷≡〉  ⋅♠″ 
⊆≡↓↑°≈  ∑〉 ≈°∂∑〉ñ•♠″↑≡↓ñ≈≡♠ 
〉 ∨←≥″∂∫°←←≥≥″ ⇑⌠ ⊂…•↑″ ⊆⇔⌠ ⊄°″↓∂↔× ⌠ ♥± ∇°°↑↔ ∏⌠ ⊂…•∂≡←←≡≥ ⋅〉 
♠≥↔∂↓≥≡♣∂±÷ ÷≡±≡↔∂… ±≈ ±♠…≥≡°←°″≡ ↓°←∂↔∂°±∂±÷ …°≈≡←∑  …°″↓♠↔↔∂°±≥ 
↓↓↑°…•〉 ∉°⊂ ∠±≡  ∑≡〉 ≈°∂∑〉ñ∝°♠↑±≥〉↓°±≡〉 
〉 
⊆≡↓↑°≈♠…↔∂°± 
 ∑⊆〉 ≈°∂∑〉ñ⊆∨∉∫∫ 
〉  ⊆≡∂…••↑≈↔  ∉⌠  ∏↑♥  ⋅⌠  °××∂  ⇒√⌠  ∂♥♠°↑∂  ⋅  ∧√∇∇∉∨⇐  ⊂↔♠≈ƒ  ¬↑°♠↓⌠  
…°″↓≥∂…↔≡≈ ↓↑≡÷±±…ƒ〉 ∉°⊂ ∠±≡  ∑≡〉 ≈°∂∑〉ñ∝°♠↑±≥〉
↓°±≡〉 
〉 ∫
…∂≡±…ƒ ∂″↓∂↑← ≡↑≥ƒ ↓↑≡÷±±…ƒ ∂± ″∂…≡〉 °≥ ⊆≡↓↑°≈ ⇔≡♥  ∑〉 
≈°∂∑〉ñ″↑≈〉 
〉  ∂≥≥≡÷↑≈  ∨⌠  ∏°•±←°±  ⇒⇐⌠  °∝°♥∂…•  ⊂∏⌠  ⇑♠≡↑  ⇒∏⌠  ↑←•  ⋅⇐⌠  ¬∂≥≡↑↔  ∏⊂⌠  
•ƒ↓≡↑↔≡±←∂°± ∂± ↔•≡ ↑↔〉 °≥ √″″♠±°≥  ∑〉 ≈°∂∑〉ñ∝〉
″°≥∂″″〉〉〉 
〉 ∩♠ ⇐⌠ ° ⇔⌠ ⋅°≥≡↑← ⊃⌠ ∉≥±… ⇑⌠ ⇐•≡±÷ ⇒⌠ °≥∂± ⋅〉 ⇒ …↑∂↔∂…≥ ↑°≥≡ ≠°↑ 
″♠↑∂±≡ …°″↓≥≡″≡±↔ ↑≡÷♠≥↔°↑ …↑↑ƒ ∂± ≠≡↔°″↔≡↑±≥ ↔°≥≡↑±…≡〉 ⊂…∂≡±…≡  
∑〉 ≈°∂∑〉ñ←…∂≡±…≡〉〉〉 
〉 
⇐°″↓≥≡″≡±↔ ≠…↔°↑ ⇑ …↔∂♥↔∂°± ∂± ↓↔∂≡±↔← ♦∂↔• ↓↑≡≡…≥″↓←∂〉 ∏ ⊆≡↓↑°≈ 
√″″♠±°≥  ∑〉 ≈°∂∑〉ñ∝〉∝↑∂〉〉〉 
〉 
∧♠±…↔∂°±≥ ♥↑∂±↔ ∂± …°″↓≥≡″≡±↔ ⇐ ÷≡±≡ ↓↑°″°↔≡↑ ±≈ ÷≡±≡↔∂… ←♠←…≡↓↔∂∂≥∫
∂↔ƒ ↔° ↔≡″↓°↑≥ ≥°≡ ≡↓∂≥≡↓←ƒ ±≈ ≠≡↑∂≥≡ ←≡∂∞♠↑≡←〉 ∉°⊂ ∠±≡  ∑≡〉 
≈°∂∑〉ñ∝°♠↑±≥〉↓°±≡〉 
〉 
÷≡±≡ ″♠↔↔∂°± ∂← ∂±♥°≥♥≡≈ ∂± ↔•≡ ←♠←…≡↓↔∂∂≥∂↔ƒ ↔° ↓↑≡∫≡…≥″↓←∂〉 ⇒↑…• ¬ƒ±≡…°≥ 
∠←↔≡↔  ∑〉 ≈°∂∑〉ñ←∫∫∫ƒ 
〉 ⇐°°↓≡↑ ⇔∪⌠ ⇔≡±≡ ∨⌠ ↑←•≥≥ ∉⌠ ¬≥≥≡↑ƒ ∨⇔〉 ⇐ ≥≥°↔ƒ↓≡← ∂± 
↓↑≡÷±±…ƒ •ƒ↓≡↑↔≡±←∂°± ±≈ ≡…≥″↓←∂〉 ⋅♠″ ⋅≡↑≡≈  ∑〉 
≈°∂∑〉ñ 
〉 
…°″↓≥≡″≡±↔ ÷≡±≡← ±≈ ↑∂←× °≠ ↓↑≡≡…≥″↓←∂ ∂± ⊄∂ƒ♠±⌠ ⇐•∂±〉  
 ∑〉 ≈°∂∑〉ñ←∫∫∫ 
〉 
↓↑°≥∂≠≡↑↔∂°±  ±≈  ″∂÷↑↔∂°±  °≠  •♠″±  ≡♣↔↑♥∂≥≥°♠←  ↔↑°↓•°≥←↔  ≈≡↑∂♥≡≈  
⋅⊄⊆∫ñ⊂⊃±≡° …≡≥≥← ♥∂ ≈°♦±∫↑≡÷♠≥↔∂±÷ …ƒ…≥∂± ⇔〉 ∉≥…≡±↔  ∑〉 
≈°∂∑〉ñ∝〉↓≥…≡±↔〉〉〉 
⇐°↓ƒ↑∂÷•↔ ϖ  °××∂⌠ ↑↔°×≥≥∂°⌠ ⋅°≥″≡↑÷⌠ ∠±×″°⌠ °←×∂±≡±⌠ ⊂♥≥∂±≡±⌠ 
⋅≡∂±°±≡±⌠  ∝±↔∂≡⌠  ≡↑≡⌠  ∂♥∂±≡±⌠  ∉°♠↔⌠  ⊃∂≥≥⌠  ⋅∂≥↔♠±≡±⌠  ∂♥♠°↑∂  ±≈  ≡↑∂〉  
∂←  ↓≡↑″∂↔↔≡≈⌠  ↓↑°♥∂≈≡≈  ↔•≡  °↑∂÷∂±≥  ♠↔•°↑←  °↑  ≥∂…≡±←°↑  ↑≡  …↑≡≈∂↔≡≈  ±≈  ↔•↔  ↔•≡  
°↑∂÷∂±≥  ↓♠≥∂…↔∂°± ∂± ↔•∂←  ∝°♠↑±≥  ∂←  …∂↔≡≈⌠  ∂± ……°↑≈±…≡ ♦∂↔• ……≡↓↔≡≈ …≈≡″∂… 
↓↑…↔∂…≡〉 ∇° ♠←≡⌠ ≈∂←↔↑∂♠↔∂°± °↑ ↑≡↓↑°≈♠…↔∂°± ∂← ↓≡↑″∂↔↔≡≈ ♦•∂…• ≈°≡← ±°↔ …°″↓≥ƒ 
♦∂↔• ↔•≡←≡ ↔≡↑″←〉

∉↑≡≡…≥″↓←∂ ∂←  …°″″°± ♥←…♠≥↑ ≈∂←°↑≈≡↑ ↔•↔ ≠≠≡…↔←  °≠ ↓↑≡÷±±↔ ♦°″≡±〉 ∪°↑≥≈♦∂≈≡⌠ ∂↔ ±±♠≥≥ƒ ……°♠±↔← ≠°↑ 
  ″↔≡↑±≥ ±≈   ↓≡↑∂±↔≥ ≈≡↔•←〉⌠ ⊄•≡ …≥∂±∂∫
…≥ …•↑…↔≡↑∂←↔∂…← ↑≡ ≈∂♥≡↑←≡⌠ ±≈ ↔•≡ …°♠↑←≡ °≠ ↔•≡ ≈∂←≡←≡ 
∂← ♠±↓↑≡≈∂…↔≥≡〉 ⇑°↔•  ↓↑≡≡…≥″↓↔∂… ″°↔•≡↑ ±≈  …•∂≥≈ °↑± 
≠↑°″  ↓↑≡≡…≥″↓↔∂… ↓↑≡÷±±…ƒ ↑≡ ↔ •∂÷•≡↑ ↑∂←× ≠°↑ ≥↔≡↑∫≥∂≠≡ 
…↑≈∂°♥←…♠≥↑ ≈∂←≡←≡← ±≈ ↔ƒ↓≡  ≈∂≡↔≡← ″≡≥≥∂↔♠←〉
⇒±÷∂°÷≡±≡←∂← ∂← ↔∂÷•↔≥ƒ ∂±♥°≥♥≡≈ ∂± ↔•≡ ↓↔•°↓•ƒ←∂°≥°÷ƒ 
°≠ ↓↑≡≡…≥″↓←∂〉 ⇒ •∂÷• ↑↔∂° °≠ ←∧⊄ ←°≥♠≥≡ ∧″← ↑≡≥↔≡≈ 
↔ƒ↑°←∂±≡ ×∂±←≡  ↔° ↓≥…≡±↔≥ ÷↑°♦↔• ≠…↔°↑ ∂← ″°±÷ ↔•≡ 
″°←↔ ↓↑°″∂←∂±÷ ∂°″↑×≡↑← ≠°↑ ↓↑≡≈∂…↔∂±÷ ↔•≡ °±←≡↔ °≠ ↔•≡ ≈∂←∫
≡←≡〉 ⊂≡♥≡↑≥ ←♠←…≡↓↔∂∂≥∂↔ƒ ≥°…∂ ≠°↑ ↓↑≡≡…≥″↓←∂ •♥≡ ≡≡± 
⌠ ⋅°♦≡♥≡↑⌠ ≥∂±×∫
÷≡ ±≈ …±≈∂≈↔≡ ÷≡±≡ ←↔♠≈∂≡← •♥≡ ≡≡± ↓≥÷♠≡≈ ♦∂↔• ↓°°↑ 
↑≡↓↑°≈♠…∂∂≥∂↔ƒ〉
⊄•≡ ↓°↓♠≥↔∂°± °≠ ∧∂±≥±≈ ∂← ÷≡±≡↔∂…≥≥ƒ ♠±∂→♠≡ ∂± 
∨♠↑°↓≡〉 ⊄•≡ ↑≡↓≡↔≡≈ °↔↔≥≡±≡…× ≡♥≡±↔← ↔•↔ …♠←≡≈ ←↔↑°±÷ 
≠°♠±≈≡↑ ≡≠≠≡…↔← ±≈ ÷≡°÷↑↓•∂… ∂←°≥↔∂°± °♥≡↑ …≡±↔♠↑∂≡← •♥≡ 
↑≡←♠≥↔≡≈ ∂± ↔•≡ ≡±↑∂…•″≡±↔ °≠ ♥↑∂±↔← ↔•↔ ↑≡ ↑↑≡ °↑ ←≡±↔ 
∂± °↔•≡↑ ↓°↓♠≥↔∂°±←〉 ⊄•≡←≡ ≠≡↔♠↑≡← ↓↑°♥∂≈≡ ± °↓↓°↑↔♠±∂↔ƒ 
⇒←↔↑…↔
↓↑°↔≡∂±♠↑∂ ≈♠↑∂±÷ ↔•≡ ←≡…°±≈ •≥≠ °≠ ↓↑≡÷±±…ƒ〉 ∉↑≡≈∂←↓°←∂↔∂°± ↔° ↓↑≡≡…≥″↓←∂ ∂← ∂± ↓↑↔ •≡↑∂↔≥≡〉 √↔ ∂← ←←°…∂↔≡≈ ♦∂↔• ± 
∂±…↑≡←≡≈ ↑∂←× °≠ …↑≈∂°♥←…♠≥↑ ≈∂←≡←≡ ≥↔≡↑ ∂± ≥∂≠≡〉 ∪≡ •♥≡ ←≡→♠≡±…≡≈  …±≈∂≈↔≡ ÷≡±≡← ∂″↓≥∂…↔≡≈ ∂± ↓↑≡≡…≥″↓←∂ 
↔° ↓∂±↓°∂±↔ ÷≡±≡↔∂… ♥↑∂±↔← …°±↔↑∂♠↔∂±÷ ↔° ↓↑≡≈∂←↓°←∂↔∂°± ↔° °↑ ↓↑°↔≡…↔∂°± ≠↑°″ ↓↑≡≡…≥″↓←∂〉 ∧∂↑←↔⌠ ↔↑÷≡↔≡≈ ≡♣°″∂… 
←≡→♠≡±…∂±÷ ♦← ↓≡↑≠°↑″≡≈ ∂±  ↓↑≡≡…≥″↓↔∂… ♦°″≡± ±≈  …°±↔↑°≥← ≠↑°″ ↔•≡ ∧√∇∇∉∨⇐ …°•°↑↔ ∧∂±±∂←• ¬≡±≡↔∂…← 
°≠ ∉↑≡≡…≥″↓←∂ ⇐°±←°↑↔∂♠″〉 ⊄•≡±  ♦°″≡± ♦∂↔•  •∂←↔°↑ƒ °≠ ↓↑≡≡…≥″↓←∂ ±≈  ↓↑°♠← ♦°″≡± ♦∂↔• ±° ←♠…• 
•∂←↔°↑ƒ ≠↑°″ ↔•≡ ∇↔∂°±≥ ∧√∇⊆√⊂ ⊂↔♠≈ƒ  ≥↑÷≡ ∧∂±±∂←• ↓°↓♠≥↔∂°± ←♠↑♥≡ƒ °± ↑∂←× ≠…↔°↑← °≠ …•↑°±∂…⌠ ±°±…°″″♠±∂…≥≡ 
≈∂←≡←≡← ♦≡↑≡ ∂±…≥♠≈≡≈ ∂± ↔•≡ ±≥ƒ←≡←〉 ∪≡ ↔≡←↔≡≈  ↑↑≡ ±≈ ≥°♦∫≠↑≡→♠≡±…ƒ ♥↑∂±↔← ±≈ ≠°♠±≈ ± ≡♣…≡←← °←≡↑♥≡≈ 
 ♥≡↑←♠← ≡♣↓≡…↔≡≈ 〉 ±°″∂±≥≥ƒ ←←°…∂↔≡≈ ♦∂↔• ↓↑≡≡…≥″↓←∂ ∉
♥↑∂±↔← ♦≡↑≡ ↓↑°↔≡…↔∂♥≡ ♥↑∂±↔← ↑← ∨⇒ ∉〉∨∫ °≈≈← ↑↔∂°〉 ±≈ ↑← ⊆⊂ ∉〉 
°≈≈← ↑↔∂°〉 ∂± ∧″← ↑≡≥↔≡≈ ↔ƒ↑°←∂±≡ ×∂±←≡ 〉 ⊄•≡←≡ ♥↑∂±↔← ↑≡ ≡±↑∂…•≡≈ ∂± ↔•≡ ∧∂±±∂←• ↓°↓♠≥↔∂°± ♦∂↔• ″∂±°↑ ≥≥≡≥≡ 
≠↑≡→♠≡±…∂≡← 〉 ±≈ 〉⌠ ↑≡←↓≡…↔∂♥≡≥ƒ〉 ⊄•≡ƒ ″ƒ ≥←° ≡ ←←°…∂↔≡≈ ♦∂↔•  ≥°♦≡↑ ↑∂←× °≠ •≡↑↔ ≠∂≥♠↑≡ ∂±   ∧√∇⊆√⊂ 
♦°″≡±〉   ⋅ƒ↓≡↑↔≡±←∂°±〉 
∑∫〉 ⇔∠√∑ 〉ñ⋅∅∉∨⊆⊄∨∇⊂√∠∇⇒⋅⇒〉〉〉  ∠±≥∂±≡ ⇔↔ ⊂♠↓↓≥≡″≡±↔
≡ƒ ∪°↑≈←∑ …↑≈∂°♥←…♠≥↑ ≈∂←≡←≡←  ∧∂±≥±≈  •≡↑↔ ≠∂≥♠↑≡  ↓↑≡≡…≥″↓←∂  ↓↑°↔≡∂±♠↑∂
∧↑°″ ↔•≡ √″″♠±°∂°≥°÷ƒ⌠ ⊆≡←≡↑…• ∉↑°÷↑″← ⊇±∂↔ ⇒〉√〉〉⌠ ⊂〉〉⌠ °≥≡…♠≥↑ ∇≡♠↑°≥°÷ƒ⌠ ⊆≡←≡↑…• ∉↑°÷↑″← ⊇±∂↔ ∏〉〉⌠ ±≈ √±←↔∂↔♠↔≡ ≠°↑ °≥≡…♠≥↑ 
≡≈∂…∂±≡ ∧∂±≥±≈ñ⋅∂√∧∨ ⊇±∂↔ ∉〉⋅〉⌠ 〉⇒〉⌠ 〉∉〉⌠ ⋅〉〉⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈ ≡≈∂…≥ ±≈ ⇐≥∂±∂…≥ ¬≡±≡↔∂…← ⇒〉√〉〉⌠ ⋅〉〉⌠ ⇑…↔≡↑∂°≥°÷ƒ ±≈ 
√″″♠±°≥°÷ƒ ⇒〉√〉〉⌠ ⊂〉〉⌠ ∠←↔≡↔↑∂…← ±≈ ¬ƒ±≡…°≥°÷ƒ 〉⇒〉⌠ ⊂〉⋅〉⌠ ⋅〉〉⌠ ±≈ ⇐•∂≥≈↑≡±← ⋅°←↓∂↔≥ ∨〉⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂ ±≈ ⋅≡≥←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ 
⋅°←↓∂↔≥⌠ ∧∂±≥±≈ ∧°≥×•;≥←± √±←↔∂↔♠↔≡ °≠ ¬≡±≡↔∂…← ∏〉〉⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈ ⊂↔±≥≡ƒ ⇐≡±↔≡↑ ≠°↑ ∉←ƒ…•∂↔↑∂… ⊆≡←≡↑…•⌠ ⇑↑°≈ √±←↔∂↔♠↔≡ °≠ 
√⊄ ±≈ ⋅↑♥↑≈⌠ ⇐″↑∂≈÷≡⌠ ⇒ ∨〉⇔〉⌠ 〉√〉〉⌠ 〉⇔〉 ⇔≡↓↑↔″≡±↔ °≠ ≡≈∂…∂±≡⌠ ⇔∂♥∂←∂°± °≠ ⊆•≡♠″↔°≥°÷ƒ 〉⊄〉⌠ ∨〉⇔〉∠〉⊆〉⌠ ∏〉∉〉⇒〉 ±≈ ⇔≡↓↑↔″≡±↔ 
°≠ ¬≡±≡↔∂…← ∨〉⇔〉∠〉⊆〉⌠ ∪←•∂±÷↔°± ⊇±∂♥≡↑←∂↔ƒ ⊂…•°°≥ °≠ ≡≈∂…∂±≡⌠ ⊂↔〉 °♠∂←⌠ ∠  ∇≡♠↑°←♠↑÷≡↑ƒ °≠ ∇≡♠↑° ⇐≡±↔≡↑⌠ ♠°↓∂° ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥⌠ ∧∂±≥±≈ 
〉√〉〉 ∉←ƒ…•∂↔↑∂… ±≈ ∇≡♠↑°≈≡♥≡≥°↓″≡±↔≥ ¬≡±≡↔∂…← ⊇±∂↔⌠ ←←…•♠←≡↔↔← ¬≡±≡↑≥ ⋅°←↓∂↔≥ ±≈ ⋅↑♥↑≈ ≡≈∂…≥ ⊂…•°°≥⌠ ⇑°←↔°± 〉√〉〉 ⊇±∂↔ °≠ 
¬≡±≡↔∂…← ±≈ ⇑∂°″↑×≡↑← 〉⇒〉⌠ ⇔≡↓↑↔″≡±↔ °≠ ⋅≡≥↔• 〉∉〉⌠ ∨〉〉⌠ ⇐•↑°±∂… ⇔∂←≡←≡ ∉↑≡♥≡±↔∂°± ⊇±∂↔⌠ ⇔≡↓↑↔″≡±↔ °≠ ⋅≡≥↔• ∨〉〉⌠ ±≈ ⇔≡↓↑↔″≡±↔ °≠ 
¬°♥≡↑±″≡±↔ ⊂≡↑♥∂…≡← ⇒〉∉〉⌠ ∇↔∂°±≥ √±←↔∂↔♠↔≡ ≠°↑ ⋅≡≥↔• ±≈ ∪≡≥≠↑≡⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈ ⊄•≡ ∨←↔°±∂± ¬≡±°″≡ ⇐≡±↔≡↑⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⊄↑↔♠⌠ ∨←↔°±∂ 〉∉〉 
∉∨⇔∨¬∠ ⊆≡←≡↑…• ⊇±∂↔⌠ ⊆⇐ ∠♠≥♠⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ∠♠≥♠ ±≈ ∠♠≥♠ ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥⌠ ∧∂±≥±≈ ∨〉〉⌠ ⇒〉∉〉 ⇔≡↓↑↔″≡±↔ °≠ ⇑∂°←…∂≡±…≡← ±≈ ∇♠↔↑∂↔∂°±⌠ 
↑°≥∂±←× √±←↔∂↔♠↔≡↔⌠ ⊂°≥±⌠ ⊂♦≡≈≡± ∏〉〉 ⇔≡↓↑↔″≡±↔ °≠ ≡≈∂…≥ ±≈ °≥≡…♠≥↑ ¬≡±≡↔∂…←⌠ ∂±÷← ⇐°≥≥≡÷≡⌠ °±≈°±⌠ ⊇±∂↔≡≈ ∂±÷≈°″ ∏〉〉 ⇔∂♥∂←∂°± 
°≠ ⇐↑≈∂°♥←…♠≥↑ ≡≈∂…∂±≡⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⇐″↑∂≈÷≡⌠ ⊇±∂↔≡≈ ∂±÷≈°″ 〉〉 ⇔≡↓↑↔″≡±↔ °≠ ≡≈∂…∂±≡⌠ ⋅°←↓∂↔≥ ≠°↑ ⊂↓≡…∂≥ ⊂♠↑÷≡↑ƒ∪≡∂≥≥ ⇐°↑±≡≥≥ 
≡≈∂…∂±≡⌠ ∇≡♦ ∅°↑×⌠ ∇∅ ∏〉∨〉⊂〉 ±≈ ⇒±≥ƒ↔∂… ±≈ ⊄↑±←≥↔∂°±≥ ¬≡±≡↔∂…← ⊇±∂↔⌠ ←←…•♠←≡↔↔← ¬≡±≡↑≥ ⋅°←↓∂↔≥⌠ ⇑°←↔°± 〉⇔〉〉
⊄•≡ °±≥∂±≡∫°±≥ƒ ⇔↔ ⊂♠↓↓≥≡″≡±↔ ∂← ♥∂≥≥≡ ♦∂↔• ↔•∂← ↑↔∂…≥≡ ↔ •↔↔↓∑ññ•ƒ↓≡↑〉•∝°♠↑±≥←〉°↑÷ñ≥°°×♠↓ñ←♠↓↓≥ñ≈°∂∑〉ñ⋅∅∉∨⊆⊄∨∇⊂√∠∇⇒⋅⇒〉
〉ñ∫ñ⇔⇐〉
⇐°↑↑≡←↓°±≈≡±…≡ ↔° ⇒〉 √±×≡↑∂ °××∂ °↑ ⋅±±≡≥≡ ∂♥♠°↑∂⌠ ⇔≡↓↑↔″≡±↔ °≠ ≡≈∂…≥ ±≈ ⇐≥∂±∂…≥ ¬≡±≡↔∂…←⌠ ∧√∫ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ∉∠ ⇑°♣  
⋅↑↔″±∂±×↔♠ ⌠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈〉 ∨∫″∂≥ ∂±×
∉↑°↔≡…↔∂♥≡ °♦∫∧↑≡→♠≡±…ƒ ⊃↑∂±↔← ≠°↑ ∉↑≡≡…≥″↓←∂  
∂± ↔•≡ ∧″← ⊆≡≥↔≡≈ ⊄ƒ↑°←∂±≡ ∂±←≡  ¬≡±≡  
∂± ↔•≡ ∧∂±±∂←• ∉°↓♠≥↔∂°±
⇒〉 √±×≡↑∂ °××∂⌠ ∨″″ ⇔≥ƒ⌠ ∂…•≡≥ ⊄↑∂≡♦←←≡↑⌠ ∂↔∝ √〉 ♠↑×∂⌠ ∨≥∂←• ⇔〉∠〉 ⊆°≡↑←°±⌠  
∉♥° ⋅;↓↓)≥;⌠ ∂↑←∂ ⇒♠↑°⌠ ↑×♠← ∉≡↑°≥⌠ ⊂≡↓↓° ⋅≡∂±°±≡±⌠ ∨≡↑° ∝±↔∂≡⌠ ∏♠• ≡↑≡⌠ 
 ↔∝ ∂♥∂±≡±⌠ ⇒±±≡≥∂ ∉°♠↔⌠ ∏±≡ ∨〉 ⊂≥″°±⌠ ⊂≡↓↓° ≡↑∂⌠ ↑× ⇔≥ƒ⌠ ∏°•± ∉〉 ⇒↔×∂±←°±⌠  
⋅±±≡≥≡ ∂♥♠°↑∂
ϖ  ⇒″≡↑∂…± ⋅≡↑↔ ⇒←←°…∂↔∂°±⌠ √±…〉
⋅ƒ↓≡↑↔≡±←∂°± ∂← ♥∂≥≥≡ ↔ •↔↔↓∑ññ•ƒ↓≡↑〉•∝°♠↑±≥←〉°↑÷ ⇔∠√∑ 〉ñ⋅∅∉∨⊆⊄∨∇⊂√∠∇⇒⋅⇒〉〉
∉↑≡≡…≥″↓←∂
















































  ⋅ƒ↓≡↑↔≡±←∂°±  ⇒♠÷♠←↔ 
↔° °♥≡↑…°″≡ ″±ƒ °≠ ↔•≡ °←↔…≥≡← ∂± ←↔♠≈ƒ∂±÷ ↑↑≡ ≡±↑∂…•≡≈ 
♥↑∂±↔← ↔•↔ …°±↔↑∂♠↔≡ ↔° ↔•≡ ↑∂←× °≠ …°″↓≥≡♣ ≈∂←≡←≡←〉
∪≡ ≈≡←∂÷±≡≈  ↔↑÷≡↔≡≈ ÷≡±≡ ←≡→♠≡±…∂±÷ ↓↑°↔°…°≥ ↔° ←…↑≡≡± 
↔•≡ …°≈∂±÷ ±≈ ←↓≥∂…∂±÷ ↑≡← °≠ ÷≡±≡← °≠ ∂±↔≡↑≡←↔ ♦∂↔•∂± ±÷∂°∫
÷≡±∂… ±≈ ♥←…♠≥↑ ↓↔•♦ƒ← ±≈ °↔•≡↑ ↓♠↔↔∂♥≡ …±≈∂≈↔≡ 
÷≡±≡← ∂±  ←∂∞≡≥≡ …°•°↑↔ °≠ ↓↑≡≡…≥″↓←∂ …←≡← ±≈ …°±↔↑°≥← 
≠↑°″ ∧∂±≥±≈〉 ⋅≡↑≡⌠ ♦≡ ≡♣↓≥°↑≡ ↔•≡ ↓°↔≡±↔∂≥ …♠←≥ ↑°≥≡ °≠ 
♥↑∂↔∂°± ∂± …±≈∂≈↔≡ ÷≡±≡← ∂± ↓↑≡≡…≥″↓←∂〉
≡↔•°≈←
⇔∂÷±°←↔∂… ⇐↑∂↔≡↑∂ ±≈ ∉↔∂≡±↔ ⇐°•°↑↔←
⊄•≡ ←↔♠≈ƒ ≈≡←∂÷± ∂← °♠↔≥∂±≡≈ ∂± ∧∂÷♠↑≡〉 ⇒↔ ←↔÷≡ ⌠ ♦≡ ←↔♠≈∂≡≈  
±°±°≡←≡ °≈ƒ ″←← ∂±≈≡♣  ×÷ñ″ ♦°″≡± ♦∂↔• ↓↑≡≡…≥″↓↔∂… 
↓↑≡÷±±…∂≡← ±≈  ±°±↓↑≡≡…≥″↓↔∂… …°±↔↑°≥← ↔•↔ ♦≡↑≡ ″↔…•≡≈ 
÷≡°÷↑↓•∂…≥≥ƒ⌠ ∂± ÷≡⌠ ±≈ ∂± °≈ƒ ″←← ∂±≈≡♣ ≠↑°″ ↔•≡ ∧√∇∇∉∨⇐ 
…°•°↑↔ ∧∂±±∂←• ¬≡±≡↔∂…← °≠ ∉↑≡≡…≥″↓←∂ ⇐°±←°↑↔∂♠″⌠  …←≡
…°±↔↑°≥ …°•°↑↔ ↑≡…↑♠∂↔≡≈ ≠↑°″ ↔•≡  ∧∂±±∂←• ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥←〉
∇♠≥≥∂↓↑°♠← °↑ ″♠≥↔∂↓↑°♠← ♦°″≡± ♦∂↔•  ←∂±÷≥≡↔°± ↓↑≡÷±±…ƒ ♦≡↑≡ 
↓↑°↔≡∂±♠↑∂ °……♠↑↑∂±÷ ≠↔≡↑  ♦≡≡×← ÷≡←↔↔∂°±〉 ⋅ƒ↓≡↑↔≡±←∂°± ♦← 
 ″″ ⋅÷ °↑ ≈∂←↔°≥∂… ≥°°≈ 
↓↑≡←←♠↑≡  ″″ ⋅÷ ≠↔≡↑  ♦≡≡×← °≠ ÷≡←↔↔∂°±〉 ∉↑°↔≡∂±♠↑∂ ♦← 
〉 ÷ ↓↑°↔≡∂± ∂±  ∫•°♠↑ ←↓≡…∂∫
″≡±⌠ °↑ 〉 ÷ñ⌠ °↑   ↑≡≈∂±÷← °± ≈∂↓←↔∂…× ∂±  ↑±≈°″ ♠↑∂±≡ 
≈≡↔≡↑″∂±↔∂°± ♦∂↔• ±° ≡♥∂≈≡±…≡ °≠ ♠↑∂±↑ƒ ↔↑…↔ ∂±≠≡…↔∂°±〉 ⇒≥≥ ≈∂÷∫
∫
…∂±〉 ⊂≡♥≡± ↓↑≡≡…≥″↓↔∂…← ±≈  …°±↔↑°≥ ♦≡↑≡ ≡♣…≥♠≈≡≈ ≡…♠←≡ °≠ 
 ≠∂≥♠↑≡ ∂± ÷≡±°↔ƒ↓∂±÷⌠ ±≈ ≠♠↑↔•≡↑  …←≡← ♦≡↑≡ ≡♣…≥♠≈≡≈ ≡…♠←≡ 
°≠ ±°±∫∧∂±±∂←• ≡↔•±∂…∂↔ƒ ±≈ °♥♠″ ≈°±↔∂°± ↓↑≡÷±±…ƒ〉 ⊄•≡ …•↑∫
…↔≡↑∂←↔∂…← °≠ ↔•≡ ←↔♠≈ƒ ↓↑↔∂…∂↓±↔← ↑≡ ↓↑≡←≡±↔≡≈ ∂± ⊄≥≡ ⊂ ∂± 
↔•≡ °±≥∂±≡∫°±≥ƒ ⇔↔ ⊂♠↓↓≥≡″≡±↔〉 ⇒≥≥ ♦°″≡± ↓↑°♥∂≈≡≈  ♦↑∂↔↔≡± 
∂±≠°↑″≡≈ …°±←≡±↔⌠ ±≈ ↔•≡ ∧√∇∇∉∨⇐ ←↔♠≈ƒ ↓↑°↔°…°≥ ♦← ↓↓↑°♥≡≈ 
ƒ ↔•≡ …°°↑≈∂±↔∂±÷ ∨↔•∂…← ⇐°″″∂↔↔≡≡ °≠ ↔•≡ ⋅°←↓∂↔≥ ⇔∂←↔↑∂…↔ °≠ 
⋅≡≥←∂±×∂ ±≈ ⊇♠←∂″〉
⇒↔ ←↔÷≡ ⌠ ♦≡ ∂±…≥♠≈≡≈ ∂± ↔•≡ ±≥ƒ←≡← ♦•°≥≡∫≡♣°″≡ ←≡→♠≡±…∂±÷ 
≠↑°″ ± ≈≈∂↔∂°±≥  ♦°″≡± ♦∂↔•  •∂←↔°↑ƒ °≠ ↓↑≡≡…≥″↓←∂ ±≈ 
 ↓↑°♠← ♦°″≡± ♦∂↔• ±° ←♠…• •∂←↔°↑ƒ ≠↑°″ ↔•≡ ±↔∂°±≥ ∧√∇⊆√⊂ 
←↔♠≈ƒ …°•°↑↔ ∧√∇⊆√⊂ ≥∂…≡±←≡ ñ〉 ∧°↑ ∂≈≡±↔∂≠ƒ∂±÷ ↓↑≡≡…≥″↓∫
←∂ ±≈ ≡…≥″↓←∂ …←≡← ∂± ↔•≡ ∧√∇⊆√⊂ ←↔♠≈ƒ …°•°↑↔⌠ ♦≡ ♠←≡≈ ≠°≥∫
≥°♦∂±÷ ∧∂±±∂←• √⇐⇔ …°≈≡← 
∂± ↔•≡ …°″↓↑≡•≡±←∂♥≡ ∇↔∂°±≥ ⋅°←↓∂↔≥ ⇔∂←…•↑÷≡ ⊆≡÷∂←↔≡↑ …°♥≡↑∫
∂±÷ ƒ≡↑←  ↔° ∑ √⇐⇔∫ ∂± ♠←≡ ←∂±…≡ ∑ ∠〉⌠ ∠〉⌠ 
∠〉⌠ ∠〉⌠ ∠〉⌠ ∠〉⌠ ∠〉 √⇐⇔∫ ∂± ♠←≡ ≠↑°″  ↔° 
∑  ↔° ⌠ ⇒ ±≈ √⇐⇔∫ ∂± ♠←≡ ≠↑°″  ↔° ∑ 
〉⌠ 〉⌠ 〉⌠ 〉⌠ 〉〉 ⇐°±↔↑°≥← ≠↑°″ ∧√∇⊆√⊂ 
♦≡↑≡ ≥≥ ♦°″≡± ♦•° •≈ ÷∂♥≡± ∂↑↔• ↔ ≥≡←↔ °±…≡ ±≈ ≈∂≈ ±°↔ •♥≡ 
∂±…≥♠≈≡≈ ÷≡±°↔ƒ↓≡← °≠ ∧√∇∇∉∨⇐ ±≈ ∧√∇⊆√⊂ ♦•∂…• …°″∂±≡≈ ↔°∫
↔≥≡≈  …←≡← ±≈  …°±↔↑°≥←〉
⇒≥≥ ↓°≥ƒ″°↑↓•∂… ←∂↔≡← ∂± ↔•≡ ←↔÷≡ ↔↑÷≡↔≡≈ ←≡→♠≡±…∂±÷ ♦≡↑≡ 
→♠≡↑∂≡≈ ≠↑°″ ↔•≡ ↓°↓♠≥↔∂°± …°•°↑↔ ≡♣°″≡←〉 ⇒≥≥ °≠ ↔•≡ ∇↔∂°±≥ 
∧√∇⊆√⊂ ←↔♠≈ƒ ″≡↔•°≈°≥°÷ƒ ±≈ ≡↔•∂…≥ ↓↓↑°♥≥← ↑≡ ♥∂≥≥≡ 
°±≥∂±≡∑ 
〉
∉↑≡↓↑↔∂°± °≠ ¬≡±°″∂… ⇔∇⇒
¬≡±°″∂… ⇔∇⇒ ♦← ≡♣↔↑…↔≡≈ ≠↑°″ ♦•°≥≡ ≥°°≈ ♠←∂±÷ ↔•≡ ∇♠…≥≡°⊂↓∂± 
⇑≥°°≈ ∩ ⇔∇⇒ ≡♣↔↑…↔∂°± ×∂↔ …•≡↑≡ƒ∫∇÷≡≥ ¬″⋅  ⇐°〉 °↑ ↔•≡ 
⇐•≡″÷∂… ÷±≡↔∂… ⊂≡↓↑↔∂°± °≈♠≥≡ √″…•∂±≡ ⇐•≡″÷≡± ±≈ 
⊄↑÷≡↔≡≈ ⊂≡→♠≡±…∂±÷ ±≈ ⇐↓↔♠↑≡ ∨±↑∂…•″≡±↔
¬≡±≡← ∂″↓≥∂…↔≡≈ ∂± •♠″± ∂°″↑×≡↑ ←↔♠≈∂≡← ♦≡↑≡ …•°←≡± ← ↔↑∫
÷≡↔≡≈ …±≈∂≈↔≡ ÷≡±≡← ← ♦≡↑≡ ↔•≡∂↑ ←∂÷±≥∂±÷ ↓↑↔±≡↑← ±≈ ↓↑°↔≡∫
↓°≥ƒ″°↑↓•∂←″← ⊂∇∉← ±≈ ±ƒ ±≡∂÷•°↑∂±÷ °↑ ←←°…∂↔≡≈ ÷≡±≡ 
↔•↔ •♥≡ ≡≡± ≡±↑∂…•≡≈ ∂± ↓↑≡≡…≥″↓↔∂… ♦°″≡± ←≡≈ °± ″≡↔∫
±≥ƒ←∂←⌠ ÷≡±°″≡∫♦∂≈≡ ←←°…∂↔∂°± ←↔♠≈∂≡←⌠ °↑ ≠♠±…↔∂°±≥ ←↔♠≈∂≡← 
♦≡↑≡ ∂±…≥♠≈≡≈〉 ⊄•∂← ≥∂←↔ °≠ ≡♣∂←↔∂±÷ …±≈∂≈↔≡ ÷≡±≡← ♦← ←≡≈ °± 
↑≡♥∂≡♦ °≠ ≥∂↔≡↑↔♠↑≡ ∂± ∏±♠↑ƒ ⌠ ±≈ ∂↔ ∂±…≥♠≈≡≈ ÷≡±≡← ∂±♥°≥♥≡≈ 
∂± ±÷∂°÷≡±≡←∂←⌠ ←♠…• ← ∧⊄⌠ ±≈ ↓↑≡÷±±…ƒ⌠ ←♠…• ← ↓↑≡÷±±…ƒ∫
∞°±≡ ↓↑°↔≡∂±⌠ ″°±÷ °↔•≡↑ ↑≡≥≡♥±↔ ≠♠±…↔∂°±≥ ↓↔•♦ƒ←〉 ⊄•≡ ←↔♠≈∂≡≈ 
÷≡±≡← ↑≡ ≥∂←↔≡≈ ∂± ⊄≥≡ ⊂〉
∂↑↑∂≡← ≠↑°″ ÷≡±°″∂… ⇔∇⇒ ♦≡↑≡ ↓↑≡↓↑≡≈ ∂±∫•°♠←≡ ∪←•∂±÷↔°± 
⊇±∂♥≡↑←∂↔ƒ ⊂…•°°≥ °≠ ≡≈∂…∂±≡〉 ∨±∞ƒ″≡← ♦≡↑≡ ↓♠↑…•←≡≈ ≠↑°″ 
⇔∇⇒ ≠↑÷″≡±↔← ♦≡↑≡ ↑≡↓∂↑≡≈ ƒ ↔↑≡↔″≡±↔ ♦∂↔• ⊄ ⇔∇⇒ ↓°≥ƒ″≡↑←≡ 
±≈ ⊄ ⇔∇⇒ ↓°≥ƒ±♠…≥≡°↔∂≈≡ ×∂±←≡⌠ ♦•∂…• ↓•°←↓•°↑ƒ≥↔≡← ↔•≡   •ƒ∫
≈↑°♣ƒ≥ ÷↑°♠↓〉 ⇒± ≈≡±°←∂±≡ ♦← ↔•≡± ≈≈≡≈ ↔° ↔•≡   ↓°←∂↔∂°± ↔ ≡…• 
≡±≈ °≠ ↔•≡ ⇔∇⇒ ≠↑÷″≡±↔ ♦∂↔• ⊄→ ∉°≥ƒ″≡↑←≡〉 √≥≥♠″∂± ≈↓↔≡↑← 
♦∂↔• ± °♥≡↑•±÷∂±÷ ⊄ ♦≡↑≡ ≥∂÷↔≡≈ °±↔° ↔•≡ ⇔∇⇒ ≠↑÷″≡±↔ ≠°≥≥°♦≡≈ 
ƒ ≡≈∫←≡≈ ←∂∞≡ ←≡≥≡…↔∂°± ↓↑°…≡≈♠↑≡ ↔° ↑≡″°♥≡ ≈↓↔≡↑ ≈∂″≡↑← ±≈ 
≠↑÷″≡±↔← ≡≥°♦ ↔•≡ ≈≡←∂↑≡≈ ←∂∞≡〉 ⇒ ♠±∂→♠≡ ∂±≈≡♣ ←≡→♠≡±…≡ ♦← ≈≈∫
≡≈ ƒ ↓°≥ƒ″≡↑←≡ …•∂± ↑≡…↔∂°± ƒ ↔↑÷≡↔∂±÷ ↔•≡  ≥∂÷↔≡≈ ♠±∂♥≡↑←≥ 
≈↓↔≡↑← °± ≡…• ≠↑÷″≡±↔ ≡±≈〉
⊂≡→♠≡±…≡ …↓↔♠↑≡ ƒ •ƒ↑∂≈∂∞↔∂°± ♦← ↓≡↑≠°↑″≡≈ ……°↑≈∂±÷ ↔° ↔•≡ 
⋅ƒ↑∂≈∂∞↔∂°± ±≈ ∪←• ∂↔ ∇°〉 〉 ∪≡ ♠←≡≈ ≥°±÷≡↑ 
≥°…×∂±÷ °≥∂÷°← …°±↔∂±∂±÷ ± ≈≈∂↔∂°±≥  ↓ ∂±°←∂±≡ ←≡÷″≡±↔ ≠°↑ 
↓↑°″∂←…♠°♠← ↓∂↑∂±÷ ♦∂↔• ≈∂≠≠≡↑≡±↔ ∂±≈≡♣ ←≡→♠≡±…≡←〉 ⇒≠↔≡↑ •ƒ↑∂≈∂∞∫
↔∂°±⌠ …↓↔♠↑≡≈ ⇔∇⇒ ♦← ♦←•≡≈ ±≈ ≡≥♠↔≡≈ ……°↑≈∂±÷ ↔° ↔•≡ ″±♠∫
≠…↔♠↑≡↑← ∂±←↔↑♠…↔∂°±←〉
∧∂÷♠↑≡〉 ≡↔•°≈← ±≈ ←″↓≥≡← °≠ ←↔♠≈ƒ ≈≡←∂÷±〉 ⌡¬≡±°↔ƒ↓∂±÷ 
↓≡↑≠°↑″≡≈ ƒ ⇒÷∂≥≡±↔ 〉 ↑≡≠←≡→  …←≡← ±≈  …°±↔↑°≥←⌠ 
√≥≥♠″∂± …°≈∂±÷ ♥  …←≡← ±≈  …°±↔↑°≥←⌠ ±≈ ∇∂″≥≡÷≡± 
⊂≡→⇐↓ ∨⊕ ⊃⇐⊆°″≡  …←≡← ±≈  …°±↔↑°≥← ↓≥↔≠°↑″←〉 
∧√∇∇∉∨⇐ ∂±≈∂…↔≡← ∧∂±±∂←• ¬≡±≡↔∂…← °≠ ∉↑≡≡…≥″↓←∂ 
⇐°±←°↑↔∂♠″〉






°××∂ ≡↔ ≥  ∧⊄ √← ⇒←←°…∂↔≡≈ ∪∂↔• ∉↑≡≡…≥″↓←∂  
⊂≡→♠≡±…∂±÷ ±≈ ⇒±≥ƒ←∂←
⊂≡→♠≡±…∂±÷ ♦← ↓≡↑≠°↑″≡≈ °± ± √≥≥♠″∂± ⋅∂⊂≡→  ↔ ↔•≡ 
∪←•∂±÷↔°± ⊇±∂♥≡↑←∂↔ƒ ¬≡±°″≡ ⊄≡…•±°≥°÷ƒ ⇒……≡←← ⇐≡±↔≡↑ ♠←∂±÷ 
Η ↓⌠ Η ↓⌠ ±≈ Η ↓ ↑≡≈←〉 ∪≡ ≥∂÷±≡≈ ←≡→♠≡±…∂±÷ 
↔° ¬⊆⇐• ♠←∂±÷ ♦ ≥± ♥〉〉∫↑ ±≈ ÷≡±°↔ƒ↓≡≈ ↔•≡ ←″↓≥≡← 
¬≡±°↔ƒ↓≡↑〉
⊂↔↔∂←↔∂…≥ ⇒±≥ƒ←≡←
∈♠≥∂↔ƒ …°±↔↑°≥ ≡≠°↑≡ ″≡↔∫±≥ƒ←∂← ∂±…≥♠≈≡≈ ↑≡″°♥≥ °≠ ←∂±÷≥≡↔°± 
±≈ ″°±°″°↑↓•∂… ♥↑∂±↔←⌠ ↑≡″°♥≥ °≠ ←∂↔≡← ♦∂↔• 〈 ″∂←←∂±÷ ≈↔ 
∪≡∂±≡↑÷ ≡→♠∂≥∂↑∂♠″ ∂± …°±↔↑°≥← ∉〉〉 ⊄•≡ …°″∂±≡≈ ≈↔ ←≡↔ 
♦← ±≥ƒ∞≡≈ ♠←∂±÷ ∧∂←•≡↑ ≡♣…↔ ↔≡←↔ ↔•↔ ←≡↑♥≡≈ ← °♠↑ ↓↑∂″↑ƒ ←←°∫
…∂↔∂°± ↔≡←↔〉 ⊄•≡ ±≥ƒ←∂← ♦← ≈∂♥∂≈≡≈ ∂±↔°  …≥←←≡←∑ ≥°♦ ≠↑≡→♠≡±…ƒ 
±≈ ↑↑≡ ♥↑∂±↔← ″∂±°↑ ≥≥≡≥≡ ≠↑≡→♠≡±…ƒ ⊗⇒∧ℜ  °↑ …°″∫
″°± ♥↑∂±↔← ⇒∧〈〉 ⇒≠↔≡↑ →♠≥∂↔ƒ …°±↔↑°≥⌠  ♥↑∂±↔←  
♥↑∂±↔← ♦∂↔• ⇒∧ ±≈  ♥↑∂±↔← ♦∂↔• ⇒∧〈 ♦≡↑≡ 
≈♥±…≡≈ ↔° ↔•≡ …°″∂±≡≈ ↓↑∂″↑ƒ ±≥ƒ←∂←〉 ∠≠ ↔•≡←≡⌠  ♦≡↑≡ ∂± 
↓♠↔↔∂♥≡≥ƒ ≠♠±…↔∂°±≥ …↔≡÷°↑∂≡← ″∂←←≡±←≡⌠ ±°±←≡±←≡⌠ °↑ ←↓≥∂…≡ ↑≡÷∂°± 
♥↑∂±↔← ±≈  ♦≡↑≡ ∂± ≥∂×≡≥ƒ ≡±∂÷± …↔≡÷°↑∂≡← ←ƒ±°±ƒ″°♠←⌠ 
∂±↔↑°±∂…⌠ ±≈ ∂±↔≡↑÷≡±∂…〉
⊄•≡  ⊂∇∉← ♦∂↔• ←↔↑°±÷≡←↔ ←←°…∂↔∂°±← ♦≡↑≡ ≠♠↑↔•≡↑ …°″↓↑≡≈ 
•≡≥↔•…↑≡ ↑≡÷∂←↔↑∂≡← ♠←∂±÷ ∂″↓♠↔≡≈ ÷≡±°↔ƒ↓≡← °≠   ∧√∇⊆√⊂ 
♦°″≡±〉 ¬≡±°↔ƒ↓≡← ♦≡↑≡ ∂″↓♠↔≡≈ ♠←∂±÷  …°″∂±≡≈ ↓±≡≥ °≠ ∧∂±±∂←• 
♦•°≥≡∫÷≡±°″≡ ←≡→♠≡±…≡← ±≈  ¬≡±°″≡← ↓•←≡ √ ↑≡≠≡↑≡±…≡ ♦∂↔• 
⌠ ⇒←←°…∂↔∂°±← 
♦≡↑≡ …≥…♠≥↔≡≈ ♠←∂±÷ ≥°÷∂←↔∂… ↑≡÷↑≡←←∂°± ⊂∇∉⊄∨⊂⊄ ♥〉〉⌠ ∨ 
↔•≡ ↑↑∂↔ƒ °≠ ♥↑∂±↔← ±≈ ←≡♥≡↑≥ ≈∂÷±°←≡←〉 ⇑≡…♠←≡ °≠ ↔•≡ ≡♣↓≥°↑∫
↔∂♥≡ ±↔♠↑≡ °≠ ↔•∂← ↓↑↔ °≠ ↔•≡ ±≥ƒ←∂←⌠ ±° ″♠≥↔∂↓≥≡ ↔≡←↔∂±÷ …°↑↑≡…∫
…°≈≡← √⌠ ∩⌠ ±≈  ∂± ∧∂±±∂←• √⇐⇔∫⌠ √⇐⇔∫⌠ ±≈ √⇐⇔∫⌠ 
↑≡←↓≡…↔∂♥≡≥ƒ〉
⇔↔ ♦≡↑≡ ±≥ƒ∞≡≈ ♠←∂±÷ ∉≥∂±×⊂≡→⌠ ∉≥∂±×⌠ ±≈ ⊆〉 ♥∂↑⌠ ±≈ 
⊃∨∉ ⇑♠∂≥≈  ♦← ♠←≡≈ ∂± ≈≈∂↔∂°±≥ ±±°↔↔∂°±←〉 °←← °≠ ≠♠±…↔∂°± 
°∧ ±≥ƒ←≡← ♦≡↑≡ …°±≈♠…↔≡≈ ≠°↑ ≡…• ÷≡±≡ ♦∂↔• ←←°…∂↔∂±÷ ♥↑∂∫
±↔← ∂± ←∂≥∂…° ƒ ↔•≡ °∧ ↔°°≥ •↔↔↓←∑ññ÷∂↔•♠〉…°″ñ≡±←≡″≥∫♥↑∂↔∂°±ñ
⊃∨∉ℵ↓≥♠÷∂±←ñ≥°ñ″←↔≡↑ñ°∧↔°°≥〉↓″〉 ⊄•≡ ≠°≥≥°♦∂±÷ ±±°↔↔∂°±← 
♦≡↑≡ …≥…♠≥↔≡≈∑ °∧ ←…°↑≡ 〉 ∂← ↓↑°≥ƒ ≈″÷∂±÷⌠ °∧ ←…°↑≡ 
〉 ↔° 〉 ∂← ↓°←←∂≥ƒ ≈″÷∂±÷⌠ °∧ ←…°↑≡ 〉 ∂← ≡±∂÷±〉 √± ≈≈∂↔∂°± 
↔° ↓↓↑°↓↑∂↔≡ ←↔↔∂←↔∂…≥ ↓↑°∂≥∂↔ƒ ↔≡←↔←⌠ °≈≈← ↑↔∂°← ∠⊆ ♦∂↔•  
⊆≡←♠≥↔←
⊆≡←♠≥↔← °≠ ↔•≡ ←←°…∂↔∂°± ±≥ƒ←≡← ↑≡ ≥∂←↔≡≈ ∂± ⊄≥≡〉 ∧°↑ 
↔•≡←≡ ←↔♠≈∂≡←⌠ ÷≡±°↔ƒ↓≡← ≠↑°″ ←↔÷≡  ∧√∇∇∉∨⇐ ♦≡↑≡ …°″∫
∂±≡≈ ♦∂↔•  ↓°↓♠≥↔∂°± …°•°↑↔ ∂± ←↔÷≡  ∧√∇⊆√⊂ ≠°↑ ∝°∂±↔ 
±≥ƒ←∂←〉 ∧°↑↔ƒ∫°±≡ ♥↑∂±↔← ≈≡″°±←↔↑↔≡≈ ±°″∂±≥ ←←°…∂∫
↔∂°± ∉〉  ♠±…°″″°± ±≈  …°″″°±〉 ⊄•≡ ↔∂≥ °≠ ↔•≡ 
∉ ♥≥♠≡ ≈∂←↔↑∂♠↔∂°± °≠ ≡±∂÷± ♥↑∂±↔← ♦← ← ≡♣↓≡…↔≡≈  
↑≡←♠≥↔← ♦∂↔• ∉〉 ≡♣↓≡…↔≡≈  ±≈  ↑≡←♠≥↔← ♦∂↔• ∉〉 
≡♣↓≡…↔≡≈ 〉⌠ ←♠÷÷≡←↔∂±÷ ↔•↔ ↔•≡ °♥≡↑≥≥ ←↔♠≈ƒ ≈≡←∂÷± ±≈ 
→♠≥∂↔ƒ …°±↔↑°≥ ♦≡↑≡ ←♠……≡←←≠♠≥〉 ⇒″°±÷ ↔•≡  ↓♠↔↔∂♥≡≥ƒ 
≠♠±…↔∂°±≥ ♥↑∂±↔←⌠ °±≡ •≈ ∉〉  〉 …°″↓↑≡≈ ♦∂↔• 
↔•≡  °≠  °←≡↑♥≡≈ ″°±÷ ≡±∂÷± ♥↑∂±↔←〉 ⊄•≡ ≥…× °≠ 
∉ ∫
…↔∂°±⌠ ↑≡ ±°↔ …♠←∂±÷ ≠≥←≡ ↓°←∂↔∂♥≡←〉
∧°…♠←∂±÷ °±  ↓♠↔↔∂♥≡≥ƒ ≠♠±…↔∂°±≥ ″∂←←≡±←≡ °↑ ↔↑♠±∫
…↔∂±÷ ↑↑≡ ±≈ ≥°♦∫≠↑≡→♠≡±…ƒ ♥↑∂±↔←⌠ ♦≡ °←≡↑♥≡≈ ± 
≡♣…≡←← °←≡↑♥≡≈ ⌠ ≡♣↓≡…↔≡≈ 〉 °≠ ±°″∂±≥≥ƒ ←←°…∂↔≡≈ 
♥↑∂±↔← ∉〉〉 ⊄•≡ ←↔↑°±÷≡←↔ ←←°…∂↔∂°±← °←≡↑♥≡≈ ♦≡↑≡ 
∂± ∧⊄⌠ ♦∂↔•  ″∂←←≡±←≡ ♥↑∂±↔← ←←°…∂↔≡≈ ↔° ↓↑≡≡…≥″↓←∂∑ 
∇ℵ〉∑↓〉∨⇒ ↑← ∉〉∨∫ ∠⊆〉⌠ 
♦∂↔•←↔±≈← …°↑↑≡…↔∂°± ≠°↑ ″♠≥↔∂↓≥≡ ↔≡←↔∂±÷ ≠°↑ ↔•≡  ↑↑≡ 
±≈ ≥°♦∫≠↑≡→♠≡±…ƒ …°≈∂±÷ ♥↑∂±↔← ±≈ ∇ℵ〉∑↓〉
⊆⊂ ↑← ∉〉 ∠⊆〉〉 ⊄•≡←≡ ♥↑∂±↔← ↑≡ 
≡±↑∂…•≡≈ ∂± ↔•≡ ∧∂±±∂←• ↓°↓♠≥↔∂°± ♦∂↔• ⇒∧← ≡∂±÷ 〉 
 ¬≡±°″≡← ⇒∧〉 ±≈ 〉  ¬≡±°″≡← 
⇒∧〉⌠ ↑≡←↓≡…↔∂♥≡≥ƒ  〉
∨⇒ ±≈ ⊆⊂ ♦≡↑≡ ≡♣″∂±≡≈ …↑°←← ↑≡÷∂←↔↑ƒ∫
≈≡↑∂♥≡≈ ≈∂←≡←≡ ≡±≈ ↓°∂±↔←〉 ⇑°↔• °≠ ↔•≡ ←←≡←←≡≈ ⊂∇∉← ↓↑°∫
↔≡…↔≡≈ ≠↑°″ •≡↑↔ ≠∂≥♠↑≡ ∧∂←•≡↑ ≡♣…↔ ∉〉 ≠°↑ °↔•⌠ 
…←≡←ñ…°±↔↑°≥←ñ  ″∂±°↑ ≥≥≡≥≡ ⊗¬ℜ …°♠±↔ ∂± …←≡←ñ
∫
♥≥〉〉 …←≡←ñ…°±↔↑°≥←ñ  ″∂±°↑ ≥≥≡≥≡ 
⊗¬ℜ …°♠±↔ ∂± …←≡←ñ…°±↔↑°≥←ñ〉
⇔∂←…♠←←∂°±
∪≡ ≈∂←…°♥≡↑≡≈ ≥°♦∫≠↑≡→♠≡±…ƒ ↓↑°↔≡…↔∂♥≡ ÷≡±≡↔∂… ♥↑∂±↔← ∂± 
∧⊄ ↔•↔ …°±↔↑∂♠↔≡≈ ↔° ≥°♦≡↑ ↓↑≡≡…≥″↓←∂ ↑∂←×〉 ∪≡ ≥←° 
≠°♠±≈ ←←°…∂↔∂±÷ ÷≡±≡↔∂… ♥↑∂±↔← ∂± ×±°♦± …±≈∂≈↔≡ ÷≡±≡← 
♠←∂±÷  ↔↑÷≡↔≡≈ ←≡→♠≡±…∂±÷ ↓↓↑°…•〉 ⊄•≡←≡ ∧⊄ ♥↑∂±↔← 
″ƒ ≥←° ≡ ←←°…∂↔≡≈ ♦∂↔• ≥°♦≡↑ ↑∂←× °≠ •≡↑↔ ≠∂≥♠↑≡〉
∧⊄ …°≈≡← ≠°↑ ⊃∨¬∧⊆ ♥←…♠≥↑ ≡±≈°↔•≡≥∂≥ ÷↑°♦↔• ≠…∫
↔°↑ ↑≡…≡↓↔°↑ 〉 √↔ …°±←∂←↔← °≠  ∂″″♠±°÷≥°♠≥∂±∫≥∂×≡ ≈°″∂±← 
∂± ± ≡♣↔↑…≡≥≥♠≥↑ ≥∂÷±≈∫∂±≈∂±÷ ↑≡÷∂°±⌠  ↔↑±←″≡″↑±≡ 
←≡÷″≡±↔⌠ ±≈  …ƒ↔°↓≥←″∂… ↑≡÷∂°± …°±↔∂±∂±÷  ↔ƒ↑°←∂±≡ 
×∂±←≡ ≈°″∂±〉 ⊃∨¬∧⊆ ∂← ≡←←≡±↔∂≥ ≠°↑ ←♠↑♥∂♥≥ ƒ ±≡÷∫
↔∂♥≡≥ƒ ↑≡÷♠≥↔∂±÷ ↔•≡ ≥≡♥≡≥← °≠ ≡±≈°÷≡±°♠← ♥←…♠≥↑ ≡±≈°↔•≡∫
≥∂≥ ÷↑°♦↔• ≠…↔°↑〉 √±↔≡↑±≥∂∞↔∂°± ±≈ ←∂÷±≥∂±÷ °≠ ≠♠±…↔∂°±≥ 
⊃∨¬∧⊆← ♦∂≥≥ ≡±•±…≡ ±÷∂°÷≡±∂… ÷↑°♦↔• °≠ ≥°°≈ ♥≡←←≡≥←〉
⊂♠←↔∂±∂±÷ ±÷∂°÷≡±≡←∂← ∂← ±≡…≡←←↑ƒ ≠°↑ …∂↑…♠≥↔∂°±⌠ ±≈ ±↔∂∫
±÷∂°÷≡±∂… ↔↑≡↔″≡±↔ …♠←≡← …↑≈∂°♥←…♠≥↑ ″°↑∂≈∂↔ƒ〉 ⊄•≡↑≡ 
↑≡ ″♠≥↔∂↓≥≡ ∂←°≠°↑″← °≠ ⊃∨¬∧⊆ °≠ ♦•∂…• ↔•≡ ←°≥♠≥≡ ≠°↑″← 
•♥≡ ≡≡± ∂″↓≥∂…↔≡≈ ∂± ↓↑≡≡…≥″↓←∂〉 ⊄•≡ ←°≥♠≥≡ ≠°↑″← 
°≠ ⊃∨¬∧⊆ °±≥ƒ …°±↔∂± ↔•≡ ≡♣↔↑…≡≥≥♠≥↑ ↓↑↔← °≠ ↔•≡ ↓↑°∫
≡♣…≡←← °≠ ⊃∨¬∧⊆ °≠ ↓≥…≡±↔≥ °↑∂÷∂± •← ≡≡± ↑≡…°↑≈≡≈〉
∧♠↑↔•≡↑″°↑≡⌠ ≠↔≡↑ •≡≥↔•ƒ ≡±≈°↔•≡≥∂♠″ ∂← ↑≡←↔°↑≡≈⌠ ≡≥≡♥↔≡≈ 
≥≡♥≡≥← °≠ ←°≥♠≥≡ ⊃∨¬∧⊆ ↑≡ °←≡↑♥≡≈ ∂± ♦°″≡± ♦∂↔•  •∂←∫
↔°↑ƒ °≠ ↓↑≡≡…≥″↓←∂〉
√±…↑≡←≡≈ ≥≡♥≡≥← °≠ ←∧⊄ñ←⊃∨¬∧⊆ •♥≡ ≥←° ≡≡± 
∂±≈∂…↔≡≈ ∂± ↓≡↑∂↓↑↔♠″ …↑≈∂°″ƒ°↓↔•ƒ ♦•≡↑≡ •∂÷• ≥≡♥≡≥← 
°≠ ←∧⊄ …°↑↑≡≥↔≡ ♦∂↔• ↔•≡ ←ƒ″↓↔°″← ←≡♥≡↑∂↔ƒ〉 ⊂∂″∂≥↑≥ƒ⌠ 
•≡↑↔ ≠∂≥♠↑≡ ≠↔≡↑ ″ƒ°…↑≈∂≥ ∂±≠↑…↔∂°± ∂±≈≡↓≡±≈≡±↔ °≠ ↓↑≡÷∫
 ⊆•≡≡ ≡↔ ≥ 
↑≡↓°↑↔ ≡♣↔↑≡″≡ ←∧⊄ ≥≡♥≡≥← ∂± ↔ ≥≡←↔ ↔•≡ ↔• ↓≡↑…≡±↔∂≥≡ 
∂±  …←≡← °≠ •≡↑↔ ≠∂≥♠↑≡ ≈♠↑∂±÷ ↓↑≡÷±±…ƒ〉 ⇒≥↔•°♠÷• ≠♠↑∫
↔•≡↑ ↑≡←≡↑…• ∂← ↑≡→♠∂↑≡≈ ↔° ←←≡←← ↔•≡ ≡≠≠≡…↔ °≠ ♠±≈≡↑≥ƒ∂±÷ 
•≡↑↔ ≠∂≥♠↑≡ ∂± ≥↔≡↑ ≥∂≠≡⌠ ∂↔ ♦← ↑≡…≡±↔≥ƒ ←•°♦± ∂±  ″≡↔∫
±≥ƒ←∂← °≠ ↑≡←♠≥↔← ≠↑°″  ←↔♠≈∂≡← ↔•↔ 〉∫≠°≥≈ ∂±…↑≡←≡ ∂± ↑∂←× 
°≠ •≡↑↔ ≠∂≥♠↑≡ ∂← ←←°…∂↔≡≈ ♦∂↔• ↓↑≡≡…≥″↓←∂⌠ ↓↑↔∂…♠≥↑≥ƒ 
≈♠↑∂±÷ ↔•≡ ↔∂″≡ ↓≡↑∂°≈ °≠  ↔°  ƒ≡↑← ≠↔≡↑ ↓↑≡≡…≥″↓←∂〉
∉↑≡≡…≥″↓←∂ ∂±…↑≡←≡← ↔•≡ ↑∂←× °≠ ↓≡↑∂↓↑↔♠″ …↑≈∂°″ƒ°↓∫
↔•ƒ⌠ ±≈ ∂↔ •← ≡≡± ←♠÷÷≡←↔≡≈ ↔•↔ ←∧⊄ ″ƒ ≡ ↔°♣∂… ↔° ↔•≡ 
•≡↑↔〉 ⇒≥←° ↔•≡ ≈↑∂♥≡↑ °≠ ↔•≡ …↑≈∂… ≈ƒ←≠♠±…↔∂°± ∂± ←♠←…≡↓↔∂≥≡ 
↓↑≡≡…≥″↓↔∂…← ∂← ≥∂×≡≥ƒ ″≡≈∂↔≡≈ ƒ ±↔∂±÷∂°÷≡±∂… ≠…↔°↑←〉
∠♠↑ ↑≡←♠≥↔← ∂±≈∂…↔≡ ↔•↔ ∧⊄ ♥↑∂±↔← ↔•↔ ↓↑°↔≡…↔ ≠↑°″ 
↓↑≡≡…≥″↓←∂ ″ƒ ≥←° ↓↑°↔≡…↔ ≠↑°″ •≡↑↔ ≠∂≥♠↑≡⌠ ↔•≡↑≡ƒ 
≈≈∂±÷ ↔° ↔•≡ ÷↑°♦∂±÷ °≈ƒ °≠ ≡♥∂≈≡±…≡ ↔•↔ ∂″≥±…≡ °≠ 
±÷∂°÷≡±∂… ≠…↔°↑← ″ƒ ≡ ↔•≡ ≥∂±× ≡↔♦≡≡± ↓↑≡≡…≥″↓←∂ 






  ⋅ƒ↓≡↑↔≡±←∂°±  ⇒♠÷♠←↔ 
⊄≥≡〉 ⊄•≡ ∠←≡↑
⊆⊂√⇔ ∇♠″≡↑ ¬≡±≡ ∇″≡ ∉ ⊃≥♠≡⌡









 ∧√∇∇∉∨⇐ ∂±°↑ ⇒≥≥≡≥≡ 
⇐°♠±↔ ∂± ∉↑≡±↔•≡←≡← 
⇐←≡←ñ⇐°±↔↑°≥← ⋅∪∨
⇐°±←≡→♠≡±…≡ ⇔∂←↔±…≡ 
∧↑°″ ∨♣°±⌠ ⇑←≡ ∉∂↑← °∧ ⊄°°≥
↑← ∧⊄ 〉∨∫ 〉 〉〉 〉 ñ ñ  ∂←←≡±←≡ ♥↑∂±↔⌠ ∨⇒ 〉
↑← ∧⊄ 〉 〉 〉〉 〉 ñ ñ  ∂←←≡±←≡ ♥↑∂±↔⌠ ⊆⊂ 〉
↑←









↑← ⇐∠⊆√∇ 〉 〉 〉〉 〉 ñ ñ  ∂←←≡±←≡ ♥↑∂±↔⌠ ∅⊄ 〉
↑← ∏⇒¬ 〉 〉 〉〉 〉 ñ ñ
↑← ¬∉⊆ 〉 〉 〉〉 〉 ñ ñ 〉 √±↔↑°± ♥↑∂±↔  〉
↑←




↑← ⇐∠⊆√∇ 〉 〉 〉〉 〉 ñ ñ 〉 √±↔↑°± ♥↑∂±↔  〉
↑← ⇒⇔⇒ 〉 〉 〉〉 〉 ñ ñ 〉 ∂←←≡±←≡ ♥↑∂±↔⌠ ∉ 〉
↑← ⇒⇐⊃⊆ 〉 〉 〉〉 〉 ñ ñ 〉 ∂←←≡±←≡ ♥↑∂±↔⌠ ⇒¬ 〉
↑← ⇒⇔⇒ 〉 〉 〉〉 〉 ñ ñ 〉 ∂←←≡±←≡ ♥↑∂±↔⌠ ⊆⊂ 〉
↑← √∇⋅⇑∨ 〉 〉 〉〉 〉 ñ ñ 〉 ∂←←≡±←≡ ♥↑∂±↔⌠ ∉ 〉
↑←






























∉⊕∉ 〉 〉 〉〉 〉 ñ ñ 
⊂ƒ±°±ƒ″°♠← ♥↑∂±↔⌠ 
⌠ ←↓≥∂…≡ ↑≡÷∂°± 
♥↑∂±↔
〉
↑← ⇐⊄ 〉 〉 〉〉 〉 ñ ñ 〉 ∂←←≡±←≡ ♥↑∂±↔⌠ ⇔∨ 〉
↑←









↑← √∇⋅⇑⇒∫⇒⊂ 〉 〉 〉〉 〉 ñ ñ  ∂←←≡±←≡ ♥↑∂±↔⌠ ⊆∈ 〉
↑← ⇒⇔⇒ 〉 〉 〉〉 〉 ñ ñ 〉 √±↔↑°± ♥↑∂±↔  〉
↑←





















°××∂ ≡↔ ≥  ∧⊄ √← ⇒←←°…∂↔≡≈ ∪∂↔• ∉↑≡≡…≥″↓←∂  
±≈ …↑≈∂°♥←…♠≥↑ ″°↑∂≈∂↔ƒ ∂± ≥↔≡↑ ≥∂≠≡ ∂± ←♠←…≡↓↔∂≥≡ ∂±≈∂∫
♥∂≈♠≥←〉 ∇°♥≡≥ ↔•≡↑↓≡♠↔∂… °↓↔∂°±← ≠°↑ ↔•≡←≡ ∂±≈∂♥∂≈♠≥← ″ƒ 
∂±…≥♠≈≡ ≥°…×∂±÷ ←∧⊄ ↓↑°≈♠…↔∂°± °↑ ±≡♠↔↑≥∂∞∂±÷ ±↔∂°≈∂≡← 
÷∂±←↔ ±÷∂°÷≡±∂… ↓↑°↔≡∂±←〉⌠
∧↑°″ ↔•≡ °←≡↑♥≡≈ ←←°…∂↔∂±÷ ♥↑∂±↔← ∂± ∧⊄⌠ 
↑← …♠←∂±÷ ⊆⊂ ∂← ″°↑≡ ≥∂×≡≥ƒ °≠ ≠♠±…↔∂°±≥ 
∂″↓°↑↔±…≡〉 ⊄•∂← ∂← ≡…♠←≡ ∂↔ ↑≡←♠≥↔← ∂±  ↓°≥↑ …•±÷≡ 
↓°← ±≡♠↔↑≥ ♦∂↔•∂± ↔•≡ ∂″″♠±°÷≥°♠≥∂±∫≥∂×≡ ≈°″∂± ⌠  
≠♠±…↔∂°±≥ ↓↑↔ °≠ ↔•≡ ↓↑°↔≡∂±〉 ⊆← ∂← ≥°…↔≡≈ ∂± ↔•≡ 
≥←↔ ±♠…≥≡°↔∂≈≡ °≠ ± ≡♣°±〉 ⊄•≡↑≡≠°↑≡⌠ ↔•≡ ♥↑∂±↔ ″ƒ ≠≠≡…↔ 
←↓≥∂…∂±÷⌠ ← ♦≡≥≥ ← ↔•≡ …°≈≡≈ ″∂±° …∂≈ ←≡→♠≡±…≡〉
∨↓∂≈≡″∂°≥°÷∂…≥ ←↔♠≈∂≡← ♦∂↔• ″±ƒ °≠ ↔•≡ ↓↑°↔≡…↔∂♥≡ ←←°∫
…∂↔∂°±← ≠↑°″ ←≡♥≡↑≡ …↑≈∂°♥←…♠≥↑ ≈∂←≡←≡← ↑≡ ←↔↑°±÷≡←↔ ≠°↑ 
⊄•≡ °↔•≡↑ ♥↑∂±↔ ↑≡←♠≥↔∂±÷ ∂± ↔•≡ ″∂±° …∂≈ ←♠←↔∂↔♠↔∂°± 
∨⇒ ∂← ±°↔ ∂±…≥♠≈≡≈ ∂± ↔•≡ ←∧⊄ °↑ ↔•≡ ⊃∨¬∧⊆ ∂←°≠°↑″ 
⌠ ♦•∂…• ∂← ↔•≡ ≈°″∂±±↔ ∂←°≠°↑″ ∂± ↔•≡ ↓≥…≡±↔〉 ∨♥≡± ←°⌠ 
≡…♠←≡ ⊃∨¬∧⊆ ∂←°≠°↑″  …±°±∂…≥ ←≡→♠≡±…≡ ∂← ≡♣↓↑≡←←≡≈ 
∂± ♥←…♠≥↑ ≡±≈°↔•≡≥∂♠″⌠ ∨⇒ ″∂÷•↔ •♥≡ ± ∂″↓°↑↔±↔ ↑°≥≡ 
∫
≡≥∂±÷ ↔•≡ ←↓∂↑≥ ↑↔≡↑∂≡←〉
∪≡ ≥←° ≠°♠±≈ ←♠↓↓°↑↔ ≠°↑ ↔•≡ ↑°≥≡ °≠ ←≡♥≡↑≥ °↔•≡↑ 
…±≈∂≈↔≡ ÷≡±≡← ∂± ↓↑≡≡…≥″↓←∂〉 ⇐°↑∂± •← ≡≡± ↓↑≡♥∂∫
♥↑∂±↔←〉 ⊂↔≡↓±∂± ≡↔ ≥ ↑≡↓°↑↔ ←∂″∂≥↑ ∠⊆← °≠ 〉 ↔  
↑← ±≈ ↑←〉 ⊆← ±≈ ↑← 
∂± …↔∂♥∂± ⇒ ↑≡…≡↓↔°↑ ↔ƒ↓≡ ⇐ •♥≡ ≡≡± ↓↑≡♥∂°♠←≥ƒ ≥∂←↔≡≈ 
↔° ↓↑≡≡…≥″↓←∂ ♦← ≡←↔≥∂←•≡≈ ∂±  ∇°↑♦≡÷∂± ↓°↓♠≥∫
↔∂°±〉 √±↔≡↑≡←↔∂±÷≥ƒ⌠ ↑← ≠≡↔♠↑≡← ∂± ±♠″≡↑°♠← ←↔♠≈∂≡← 
↔•↔ ↓∂±↓°∂±↔ ↔•≡ ←←°…∂↔∂°± °≠ ±∂↔↑∂… °♣∂≈≡ ←ƒ±↔•←≡  ↔°  
←↓≡…↔↑♠″ °≠ ″♠≥↔∂≠…↔°↑∂≥ ≈∂←≡←≡←〉 °←↔ ↑≡≥≡♥±↔≥ƒ⌠  •↓∫
≥°↔ƒ↓≡ ∂±…≥♠≈∂±÷ ↑← ♦← ≠°♠±≈ ↔° ↓↑°↔≡…↔ ♦°″≡± ≠↑°″ 
↓↑≡÷±±…ƒ •ƒ↓≡↑↔≡±←∂°± ±≈ ↓↑≡≡…≥″↓←∂〉 ⊆← 
∂± ∂±↔≡↑≥≡♠×∂±  •← ≡≡± ←•°♦± ↔° ≡≥°±÷ ↔° ± ∂±↔↑°±∂… 
•↓≥°↔ƒ↓≡⌠ ♦•∂…• ←↔↑°±÷≥ƒ ↓↑≡≈∂←↓°←≡← ♦°″≡± °≠ ⇑•↑∂±∂ 
⇒↑ ↓°↓♠≥↔∂°± ↔° ∂≈∂°↓↔•∂… ↑≡…♠↑↑≡±↔ ″∂←…↑↑∂÷≡←〉 ∠♠↑ 
↓↔•°÷≡±≡←∂← ″ƒ ≡ ←•↑≡≈ ≡↔♦≡≡± ↑≡…♠↑↑≡±↔ ″∂←…↑↑∂÷≡← 
±≈ ↓↑≡≡…≥″↓←∂〉⌠
∉≡↑←↓≡…↔∂♥≡←
″↔≡↑±≥ ∧⊄ ←≡→♠≡±…≡ ♥↑∂±↔← ←←°…∂↔≡ ♦∂↔• ≥°♦≡↑ ↓↑≡∫
≡…≥″↓←∂ ←♠←…≡↓↔∂∂≥∂↔ƒ〉 ∧♠↑↔•≡↑ ↑≡←≡↑…• ∂← ↑≡→♠∂↑≡≈ ↔° ↓∂±∫
↓°∂±↔ ↔•≡ ″≡…•±∂←″ °≠ ↓↑°↔≡…↔∂°± ≠↑°″ ↓↑≡≡…≥″↓←∂ ±≈ 
•≡↑↔ ≠∂≥♠↑≡ ±≈ ↔•≡ ≡≠≠≡…↔ °≠ ∧⊄ ♥↑∂±↔← °± ÷≡±≡ ↔↑±←…↑∂↓∫
↔∂°±〉 ¬≡±≡↔∂… ←←°…∂↔∂°±← ″ƒ °↓≡± ±≡♦ ♥≡±♠≡← °≠ ≈↑♠÷ 
↑≡ ≠♠↑↔•≡↑ ≈≡…∂↓•≡↑≡≈〉 ¬≡±≡↔∂… ↓↑°↔≡…↔∂°± ≠↑°″ ↓↑≡≡…≥″↓←∂ 
≡…♠←≡ °≠ ∧⊄ ♥↑∂±↔← ″ƒ ≥←° ↓↑°↔≡…↔ ↔•≡←≡ ♦°″≡± ≠↑°″ 
•≡↑↔ ≠∂≥♠↑≡ ∂± ≥↔≡↑ ≥∂≠≡〉
⇒…×±°♦≥≡≈÷″≡±↔←
∪≡ ↔•±× ↔•≡ ↓↑↔∂…∂↓±↔← °≠ ↔•≡ ∧√∇∇∉∨⇐ ←↔♠≈ƒ ∧∂±±∂←• ¬≡±≡↔∂…← °≠ 
∉↑≡≡…≥″↓←∂ ⇐°±←°↑↔∂♠″⌠ ← ♦≡≥≥ ← ↔•°←≡ ∂± ↔•≡ ∇↔∂°±≥ ∧√∇⊆√⊂ 
⊂↔♠≈ƒ〉 ⊄•≡ ∧∂±≡↔⊂≡→ ↓↑°∝≡…↔ ↓↑°♥∂≈≡≈ ″°←↔ °≠ ↔•≡ ∧√∇⊆√⊂ ÷≡±°∫
↔ƒ↓≡← ≠°↑ ♦•∂…• ♦≡ ↑≡ ÷↑↔≡≠♠≥〉
↑← ⇔⊆ 〉 〉 〉〉 〉 ñ ñ  √±↔↑°± ♥↑∂±↔  〉
↑← √ 〉 〉 〉〉 〉 ñ ñ 〉 √±↔↑°± ♥↑∂±↔  〉
↑← ∇∠⊄⇐⋅
↑←
⇐⊄ 〉 〉 〉〉 〉 ñ ñ 
⊂ƒ±°±ƒ″°♠← ♥↑∂±↔⌠ 
∇⇔ ↔↑±←…↑∂↓↔ ♥↑∂±↔⌠ 
⇒⇒
〉
↑← ⊄∨ 〉 〉 〉〉 〉 ñ ñ  ∂←←≡±←≡ ♥↑∂±↔⌠ ⊆⋅ 〉
↑← ∧⊄ 〉 〉 〉〉 〉 ñ ñ  √±↔↑°± ♥↑∂±↔  〉
↑← ∧⊄ 〉 〉 〉〉 〉 ñ ñ  ∂←←≡±←≡ ♥↑∂±↔⌠ ⊃ 〉
↑← ⇒∇¬∉⊄ 〉 〉 〉〉 〉 ñ ñ  ∂←←≡±←≡ ♥↑∂±↔⌠ ⊆⋅ 〉
↑← ∧⊄ 〉 〉 〉〉 〉 ñ ñ
↑←




↑← ∇∠⊂ 〉 〉 〉〉 〉 ñ ñ 〉 √±↔↑°± ♥↑∂±↔  〉
↑←




⇐°♠±↔← °≠ ″∂±°↑ ≥≥≡≥≡← ↑≡ ÷∂♥≡± ≠°↑ ↔•≡ …°″∂±≡≈ ≈↔  …←≡← ±≈  …°±↔↑°≥←⌠ ±≈ ↓≡↑ ∧√∇∇∉∨⇐ ≈↔ ←≡↔ ∂± ↓↑≡±↔•≡←≡←  °≠  ♦°″≡± ♦∂↔• ↓↑≡≡…≥″↓←∂ 
±≈  °≠  …°±↔↑°≥ ♦°″≡± ↓←←≡≈ →♠≥∂↔ƒ …°±↔↑°≥〉 ∧√∇∇∉∨⇐ ∂±≈∂…↔≡← ∧∂±±∂←• ¬≡±≡↔∂…← °≠ ∉↑≡≡…≥″↓←∂ ⇐°±←°↑↔∂♠″ ⋅∪∨⌠ ⋅↑≈ƒ∪≡∂±≡↑÷ ∨→♠∂≥∂↑∂♠″ °∧⌠ ≥°←← °≠ 
≠♠±…↔∂°± ⇒∧⌠ ″∂±°↑ ≥≥≡≥≡ ≠↑≡→♠≡±…ƒ ±≈ ⊆⊂√⇔⌠ ∂≈≡±↔∂≠ƒ∂±÷ ±♠″≡↑〉
⌡∇°±≈∝♠←↔≡≈ ∉ ♥≥♠≡←〉
⊄≥≡〉 ⇐°±↔∂±♠≡≈
⊆⊂√⇔ ∇♠″≡↑ ¬≡±≡ ∇″≡ ∉ ⊃≥♠≡⌡









 ∧√∇∇∉∨⇐ ∂±°↑ ⇒≥≥≡≥≡ 
⇐°♠±↔ ∂± ∉↑≡±↔•≡←≡← 
⇐←≡←ñ⇐°±↔↑°≥← ⋅∪∨
⇐°±←≡→♠≡±…≡ ⇔∂←↔±…≡ 
∧↑°″ ∨♣°±⌠ ⇑←≡ ∉∂↑← °∧ ⊄°°≥






  ⋅ƒ↓≡↑↔≡±←∂°±  ⇒♠÷♠←↔ 
⊂°♠↑…≡← °≠ ∧♠±≈∂±÷
⊄•∂← ←↔♠≈ƒ ♦← ←♠↓↓°↑↔≡≈ ƒ ∏±≡ ±≈ ⇒↔°← ∨↑××° ∧°♠±≈↔∂°±⌠ ⊄•≡ 
⇒…≈≡″ƒ °≠ ∧∂±≥±≈  ±≈ ⌠ ⊂∂÷↑∂≈ ∏♠←6≥∂♠← ±≈ ⇒≥≠↑≡≈ 
°↑≈≡≥∂± ∧°♠±≈↔∂°±←⌠ ±≈ ∇↔∂°±≥ √±←↔∂↔♠↔≡← °≠ ⋅≡≥↔• ÷↑±↔← ⊇ 
⋅ ∏〉∉〉 ⇒↔×∂±←°±⌠ ⊆∠ ¬∫⇒∏〉∉〉 ⇒↔×∂±←°±⌠ 
±≈ ∉ ⇒⊆ ∨〉⇔〉∠〉 ⊆°≡↑←°±〉 ∧∂±±∂←• ≡≈∂…≥ ∧°♠±≈↔∂°±⌠ 
⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂ ∧♠±≈←⌠ ⊂↓≡…∂≥ ⊂↔↔≡ ⊂♠←∂≈ƒ ≠°↑ ⋅≡≥↔• 
⊆≡←≡↑…• ∨⊃∠ ≠♠±≈∂±÷⌠ ⊂×↑∂ ±≈ ∉;∂♥∂××∂ ⊂°•≥≡↑÷ ∧°♠±≈↔∂°±⌠ 
∇°♥° ∇°↑≈∂←× ∧°♠±≈↔∂°±⌠ ⊂∂÷±≡ ±≈ ⇒±≡ ¬ƒ≥≥≡±≡↑÷ ∧°♠±≈↔∂°±⌠ 
±≈ ∧°♠±≈↔∂°± ≠°↑ ∉≡≈∂↔↑∂… ⊆≡←≡↑…• ←♠↓↓°↑↔≡≈ ↔•≡ ∧√∇∇∉∨⇐ ←↔♠≈ƒ 
∧∂±±∂←• ¬≡±≡↔∂…← °≠ ∉↑≡≡…≥″↓←∂ ⇐°±←°↑↔∂♠″〉 ∏〉 ≡↑≡ ∂←  ↑≡…∂↓∂≡±↔  
°≠ ↔•≡ ⊆°ƒ≥ ⊂°…∂≡↔ƒ ∪°≥≠←°± ⊆≡←≡↑…• ∨♣…≡≥≥≡±…≡ ♦↑≈〉 〉 





 〉 ∂←°±×°♥ ⊂⌠ ∏°←≡↓• ⊂〉 √±…∂≈≡±…≡ °≠ ↓↑≡≡…≥″↓←∂∑ ↑∂←× ≠…↔°↑← ±≈ 
°♠↔…°″≡← ←←°…∂↔≡≈ ♦∂↔• ≡↑≥ƒ∫ ♥≡↑←♠← ≥↔≡∫°±←≡↔ ≈∂←≡←≡〉 ⇒″ ∏ ∠←↔≡↔ 
¬ƒ±≡…°≥〉 ∑〉≡〉≡〉 ≈°∂∑ 〉ñ∝〉∝°÷〉〉〉〉
 〉 ∪°↑≥≈ ⋅≡≥↔• ∠↑÷±∂∞↔∂°±〉 ∪°↑≥≈ ⋅≡≥↔• ⊆≡↓°↑↔∑ ×≡ ∨♥≡↑ƒ °↔•≡↑ 
±≈ ⇐•∂≥≈ ⇐°♠±↔〉 ¬≡±≡♥⌠ ⊂♦∂↔∞≡↑≥±≈∑ ∪°↑≥≈ ⋅≡≥↔• ∠↑÷±∂∞↔∂°± 〉
 〉 ⇔♠≥≡ƒ 〉 ⊄•≡ ÷≥°≥ ∂″↓…↔ °≠ ↓↑≡∫≡…≥″↓←∂ ±≈ ≡…≥″↓←∂〉 ⊂≡″∂± 
∉≡↑∂±↔°≥〉 ∑〉 ≈°∂∑ 〉ñ∝〉←≡″↓≡↑∂〉〉〉〉
 〉 ⊂↔≠≠ ⇒⇐⌠ ⊆≡≈″± ⇐∪⌠ ∪∂≥≥∂″← ⇔⌠ ≡≡←°± ∉⌠ °≡ ⌠ ⊄•∂≥÷±↔•± ⇑⌠ 
÷±♠← ∉⌠ ⊂↔≡≡÷≡↑← ∨⇒⌠ ⊄←∂÷← ∨⊕⌠ ∇≡←← ⊆⇑⌠ ƒ↔↔ ⌠ ∉°←↔°± ⌠ ⊆°≡↑↔← 
∏ ¬≥°≥ ∉↑≡÷±±…ƒ ⇐°≥≥°↑↔∂°± ⇐°〉 ∉↑≡÷±±…ƒ ±≈ ≥°±÷∫
↔≡↑″ ″↔≡↑±≥ …↑≈∂°♥←…♠≥↑ •≡≥↔•∑ ↓↑°÷↑≡←← ↔•↑°♠÷• •↑″°±∂∞↔∂°± 
°≠ ↑≡←≡↑…• …°•°↑↔← ±≈ ∂°±×←〉 ⋅ƒ↓≡↑↔≡±←∂°±〉 ∑〉 ≈°∂∑ 
〉ñ⋅∅∉∨⊆⊄∨∇⊂√∠∇⇒⋅⇒〉〉〉
 〉 ⇒÷↑♦≥ √⌠ ↑♠″±…•∂ ⊂⇒〉 ∉↑≡≡…≥″↓←∂ ±≈ ↔•≡ ±↔∂∫±÷∂°÷≡±∂… ←↔↔≡〉 
∉↑≡÷±±…ƒ ⋅ƒ↓≡↑↔≡±←〉 ∑〉 ≈°∂∑ 〉ñ∝〉↓↑≡÷•ƒ〉〉〉〉
 〉 ⊕≡∂←≥≡↑ ⋅⌠ ≥♠↑ ∨⌠ ⇐•±↔↑∂±≡ ∧⌠ ⊃↔∂←• ⌠ ⊂↔≠≠ ⇒⇐⌠ ⊂≡±±←↔↑)″ ⌠ 
∠≥°♥←←°± ⌠ ⇑↑≡±±≡…×≡ ⊂∉⌠ ⊂↔≡↓± ⋅⌠ ⇒≥≥≡÷↑±∞ ⇔⌠ ⇔∂≥ ∉⌠ ⊂…•°≡≈≥ 
⌠ ⋅♠±≈ ⌠ ⊃≡↑≥°•↑≡± ⊂〉 ∉↑≡≈∂…↔∂♥≡ ♥≥♠≡ °≠ ↔•≡ ←∧≥↔∫∑∉≥¬∧ ↑↔∂° ∂± 
♦°″≡± ♦∂↔• ←♠←↓≡…↔≡≈ ↓↑≡≡…≥″↓←∂〉 ∇ ∨±÷≥ ∏ ≡≈〉 ∑〉 ≈°∂∑ 
〉ñ∇∨∏°〉
 〉 ∂♥♠°↑∂ ⋅⌠ •≡↑″° ∉⌠ ∠≥≥∂×∂±≡± ⊃⌠ ∪∂≈≡± ∨⌠ ⋅;∂♥;∫;≥≥∂±≡± ⌠ 
⊂♠±≈←↔↑)″ ⋅⌠ ∂↔∂±≡± ⊄⌠ ∝ ⊆⌠ ∅≥∂×°↑×≥ ∠⌠ ≡↑≡ ∏〉 ⊂♠←…≡↓↔∂∂≥∂↔ƒ 
≥°…∂ ≠°↑ ↓↑≡≡…≥″↓←∂ °± …•↑°″°←°″≡← ↓ ±≈ ↓ ∂± ∧∂±±∂←• ≠″∂≥∂≡←〉 
⇒″ ∏ ⋅♠″ ¬≡±≡↔〉 ∑〉 ≈°∂∑ 〉ñ〉
 〉 ⇐•↓↓≡≥≥ ⊂⌠ °↑÷± 〉 ⊂≡↑…•∂±÷ ≠°↑ ÷≡±≡↔∂… …≥♠≡← ↔° ↔•≡ …♠←≡← °≠ ↓↑≡∫
≡…≥″↓←∂〉 ⇐≥∂± ⊂…∂ °±≈〉 ∑〉 ≈°∂∑ 〉ñ⇐⊂〉
 〉 ♠±≈″↑× ∉∨⌠ ∂≥∝≡≈•≥ ⊇⌠ ⇑°°″←″ ⇔√⌠ ±±∂≥ ⋅⌠ ↑↔∂± ∇¬⌠ 
∉≥°↔∂≡ ⇒⌠ ∉≡≥↔°±≡± ⌠ ∉≡↑°≥ ⌠ ⊂↓≡…↔°↑ ⊄⇔⌠ ⊂ƒ♥;±≡± ⇒⇐〉 ∨♥≥♠↔∂°± °≠ 
⋅↓↓ ≈↔ ∂± ←∂♣ ↓°↓♠≥↔∂°±← °≠ ∨♠↑°↓≡± ≈≡←…≡±↔〉 ∨♠↑ ∏ ⋅♠″ ¬≡±≡↔〉 
∑〉 ≈°∂∑ 〉ñ≡∝•÷〉〉〉
 〉 ∇≡♥±≥∂±± ⋅⊆〉 ⊄•≡ ∧∂±±∂←• ↓°↓♠≥↔∂°± ←↔↑♠…↔♠↑≡〉 ⇒ ÷≡±≡↔∂… ±≈ ÷≡±≡∫
≥°÷∂…≥ ←↔♠≈ƒ〉 ⋅≡↑≡≈∂↔←〉 ∑〉
 〉 ∂″ ∨⊄⌠ ∪#↑↔∞ ∉⌠ ⋅♥♠≥∂±± ⇒⊂⌠ ≡↔ ≥ ⊂≡→♠≡±…∂±÷ √±∂↔∂↔∂♥≡ ⊂♠°″∂ ⊂√⊂♠ 
∉↑°∝≡…↔〉 ⇔∂←↔↑∂♠↔∂°± ±≈ ″≡≈∂…≥ ∂″↓…↔ °≠ ≥°←←∫°≠∫≠♠±…↔∂°± ♥↑∂±↔← ∂± 
↔•≡ ∧∂±±∂←• ≠°♠±≈≡↑ ↓°↓♠≥↔∂°±〉 ∉°⊂ ¬≡±≡↔〉 ∑≡〉 ≈°∂∑ 
〉ñ∝°♠↑±≥〉↓÷≡±〉〉
 〉 ∏;;←×≡≥;∂±≡± ⊄⌠ ⋅≡∂±°±≡± ⊂⌠ ∝±↔∂≡ ∨⌠ ≡↑≡ ∏⌠ ∂♥∂±≡± ⌠ ∉°♠↔ ⇒⌠ 
°≠ ∉↑≡∫≡…≥″↓←∂ ⇐°±←°↑↔∂♠″ ∧√∇∇∉∨⇐〉 ⇑∏ ∠↓≡±〉 ∑≡〉 
≈°∂∑ 〉ñ″∝°↓≡±∫∫〉
 〉 ⇑°↑°≈♠≥∂± ⌠ ⊃↑↔∂∂±≡± ∨⌠ ∉≡≥↔°±≡± ⌠ ∏°♠←∂≥•↔∂ ∉⌠ ∏♠°≥≡♥∂ ⇒⌠ ↔∂×∂±≡± 
⊄⌠ ;±±∂←↔) ⊂⌠ ⊂≥°″ ⊃⌠ ⊂♠±≈♥≥≥ ∏⌠ ∉♠←× ∉〉 ∧°↑↔ƒ∫ƒ≡↑ ↔↑≡±≈← ∂± …↑∫
≈∂°♥←…♠≥↑ ↑∂←× ≠…↔°↑← ∂± ∧∂±≥±≈〉 ∨♠↑ ∏ ∉♠≥∂… ⋅≡≥↔•〉 ∑
〉 ≈°∂∑ 〉ñ≡♠↑↓♠ñ…×♠〉
 〉 ⊄↑∂≡♦←←≡↑ 〉 ∨♣…≡←←∂♥≡ …°″↓≥≡″≡±↔ …↔∂♥↔∂°± ≈♠≡ ↔° ÷≡±≡↔∂… •↓∫
⊇±∂♥≡↑←∂↔ƒ ∂± ⊂↔〉°♠∂←⌠ ⇒↑↔←  ⊂…∂≡±…≡← ∨≥≡…↔↑°±∂… ⊄•≡←≡← ±≈ 
⇔∂←←≡↑↔↔∂°±← ∉↓≡↑ 〉 〉
 〉 ∂ ⋅⌠ ⇔♠↑∂± ⊆〉 ∧←↔ ±≈ ……♠↑↔≡ ←•°↑↔ ↑≡≈ ≥∂÷±″≡±↔ ♦∂↔• ⇑♠↑↑°♦←∫
∪•≡≡≥≡↑ ↔↑±←≠°↑″〉 ⇑∂°∂±≠°↑″↔∂…←〉 ∑〉 ≈°∂∑ 〉ñ
∂°∂±≠°↑″↔∂…←ñ↔↓〉
 〉 …≡±± ⇒⌠ ⋅±± ⌠ ⇑±×← ∨⌠ ⊂∂♥…•≡±×° ⇒⌠ ⇐∂♠≥←×∂← ⌠ ≡↑±ƒ↔←×ƒ ⇒⌠ 
¬↑∂″≡≥≥ ⌠ ⇒≥↔←•♠≥≡↑ ⇔⌠ ¬↑∂≡≥ ⊂⌠ ⇔≥ƒ ⌠ ⇔≡∉↑∂←↔° ⇒〉 ⊄•≡ ÷≡±°″≡ 
±≥ƒ←∂← ↔°°≥×∂↔∑  ↓⊆≡≈♠…≡ ≠↑″≡♦°↑× ≠°↑ ±≥ƒ∞∂±÷ ±≡♣↔∫÷≡±≡↑↔∂°± 
⇔∇⇒ ←≡→♠≡±…∂±÷ ≈↔〉 ¬≡±°″≡ ⊆≡←〉 ∑〉 ≈°∂∑ 〉ñ
÷↑〉〉〉
 〉  ⇔≡∉↑∂←↔°  ⇒⌠ ⇑±×←  ∨⌠  ∉°↓≥∂±  ⊆⌠  ≡↔  ≥〉  ⇒ ≠↑″≡♦°↑× ≠°↑  ♥↑∂↔∂°± ≈∂←∫
…°♥≡↑ƒ ±≈ ÷≡±°↔ƒ↓∂±÷ ♠←∂±÷ ±≡♣↔∫÷≡±≡↑↔∂°± ⇔∇⇒ ←≡→♠≡±…∂±÷ ≈↔〉 ∇↔ 
¬≡±≡↔〉 ∑〉 ≈°∂∑ 〉ñ±÷〉〉
 〉  ¬≡±°″≡← ∉↑°∝≡…↔ ⇐°±←°↑↔∂♠″⌠ ⇒≡…←∂← ¬⊆⌠ ⇒♠↔°± ⇒⌠ ⇑↑°°×← ⇔⌠ 
⇔≡∉↑∂←↔° ⇒⌠ ⇔♠↑∂± ⊆⌠ ⋅±≈←×≡↑ ⊆∨⌠ ±÷ ⋅⌠ ↑↔• ¬⊄⌠ …⊃≡± 
¬⇒〉 ⇒± ∂±↔≡÷↑↔≡≈ ″↓ °≠ ÷≡±≡↔∂… ♥↑∂↔∂°± ≠↑°″ ⌠ •♠″± ÷≡±°″≡←〉 
∇↔♠↑≡〉 ∑〉
 〉 ⇐••≡≈ ⋅⌠ ∉≥↔ ∉⌠ ∉∂↑∂±≡± ⌠ …⇐↑↔•ƒ ⊂⌠ ∪≥↔≡↑ ⌠ °←×∂±≡± ⊂⌠ 
⊂≥°″ ⊃⌠ ⇔≥ƒ ⌠ ⇔♠↑∂± ⊆⌠ ∉≥°↔∂≡ ⇒⌠ ⇒∂↔↔°×≥≥∂° ⊄⌠ ⊆∂↓↔↔∂ ⊂〉 ∪•°≥≡∫
÷≡±°″≡ ♥∂≡♦ °≠ ↔•≡ …°±←≡→♠≡±…≡← °≠  ↓°↓♠≥↔∂°± °↔↔≥≡±≡…× ♠←∂±÷  
÷≡±°″≡ ←≡→♠≡±…≡← ≠↑°″ ∧∂±≥±≈ ±≈ ⊇±∂↔≡≈ ∂±÷≈°″〉 ∨♠↑ ∏ ⋅♠″ ¬≡±≡↔〉 
∑〉 ≈°∂∑ 〉ñ≡∝•÷〉〉〉
 〉 ∉♠↑…≡≥≥ ⊂⌠ ∇≡≥≡ ⇑⌠ ⊄°≈≈∫⇑↑°♦± ⌠ ⊄•°″← ⌠ ∧≡↑↑≡∂↑ ⇒⌠ ⇑≡±≈≡↑ ⇔⌠ 
≥≥≡↑ ∏⌠ ⊂×≥↑ ∉⌠ ≈≡ ⇑××≡↑ ∉√⌠ ⇔≥ƒ ∏⌠ ⊂•″ ∉⇐〉 ∉√∇∑  ↔°°≥ ←≡↔ ≠°↑ 
♦•°≥≡∫÷≡±°″≡ ←←°…∂↔∂°± ±≈ ↓°↓♠≥↔∂°±∫←≡≈ ≥∂±×÷≡ ±≥ƒ←≡←〉 ⇒″ ∏ 
⋅♠″ ¬≡±≡↔〉 ∑〉 ≈°∂∑ 〉ñ〉
 〉 ¬≥♠←″± ¬⌠ ⇐≥≥≡↑° ∏⌠ ♠≥≈∂± ⇔∨⌠ ⋅°°≈ ⌠ ⊆°…• ∏⇐〉 ♥∂↑∑ ± 
……≡←←∂≥≡ ←ƒ←↔≡″ ≠°↑ ↔≡←↔∂±÷ ⊂∇⊃ ±°♥≡≥↔ƒ〉 ⇑∂°∂±≠°↑″↔∂…←〉 ∑
〉 ≈°∂∑ 〉ñ∂°∂±≠°↑″↔∂…←ñ↔↑〉
 〉 …↑≡± ∪⌠ ∉↑∂↔…•↑≈ ⇑⌠ ⊆∂°← ⇔⌠ ⇐•≡± ∅⌠ ∧≥∂…≡× ∉⌠ ⇐♠±±∂±÷•″ ∧〉 
⇔≡↑∂♥∂±÷ ↔•≡ …°±←≡→♠≡±…≡← °≠ ÷≡±°″∂… ♥↑∂±↔← ♦∂↔• ↔•≡ ∨±←≡″≥ ⇒∉√ ±≈ 
⊂∇∉ ≡≠≠≡…↔ ↓↑≡≈∂…↔°↑〉 ⇑∂°∂±≠°↑″↔∂…←〉 ∑〉 ≈°∂∑ 〉ñ
∂°∂±≠°↑″↔∂…←ñ↔→〉
 〉 ⊂•∂♠ƒ 〉 ⊂↔↑♠…↔♠↑≡ ±≈ ≈♠≥ ≠♠±…↔∂°± °≠ ♥←…♠≥↑ ≡±≈°↔•≡≥∂≥ ÷↑°♦↔• 
≠…↔°↑ ↑≡…≡↓↔°↑∫ ∧≥↔∫〉 √±↔ ∏ ⇑∂°…•≡″ ⇐≡≥≥ ⇑∂°≥〉 ∑〉
 〉 ⇑°♠≥±÷≡↑ ⇐〉 ∨±≈°↔•≡≥∂♠″〉 ⇒↑↔≡↑∂°←…≥≡↑ ⊄•↑°″ ⊃←… ⇑∂°≥〉 
∑≡≡〉 ≈°∂∑ 〉ñ⇒⊄⊃⇑⇒⋅⇒〉〉〉
 〉 ⇒≈≡≥∫∈≈∂↑ ⋅⌠ ∨↔•∂≡↑ ∏⌠ ≡≡ ⇔⊂⌠ ⊄•♥≡±≈∂↑±↔•± ∉⌠ ⇒″∂↑ ∨〉 
⇐↑≈∂°♥←…♠≥↑ ↔°♣∂…∂↔ƒ °≠ ±÷∂°÷≡±≡←∂← ∂±•∂∂↔°↑← ∂± ↔↑≡↔″≡±↔ °≠ 
″≥∂÷±±…ƒ∑  ←ƒ←↔≡″↔∂… ↑≡♥∂≡♦ ±≈ ″≡↔∫±≥ƒ←∂←〉 ⇐±…≡↑ ⊄↑≡↔ ⊆≡♥〉 
∑〉 ≈°∂∑ 〉ñ∝〉…↔↑♥〉〉〉〉
 〉 ƒ±↑≈ ⊂∨⌠ ∂± ∏∅⌠ ≡↑…•± ∏⌠ ∂″ ⋅⌠ ∂ ∏⌠ °±≈≥ ⊂⌠ ∂≡↑″±± 
⊄⇒⌠ °↑÷± ∏∉⌠ ⊂≡≥≥×≡ ∧∪⌠ ⊂↔∂≥≥″± √∨⌠ ∨↓←↔≡∂± ∧⋅⌠ ⊂♠×•↔″≡ ⊃∉⌠ 
↑♠″±…•∂ ⊂⇒〉 ∨♣…≡←← ↓≥…≡±↔≥ ←°≥♠≥≡ ≠″←∫≥∂×≡ ↔ƒ↑°←∂±≡ ×∂±←≡  
←∧≥↔ ″ƒ …°±↔↑∂♠↔≡ ↔° ≡±≈°↔•≡≥∂≥ ≈ƒ←≠♠±…↔∂°±⌠ •ƒ↓≡↑↔≡±←∂°±⌠ ±≈ ↓↑°∫
↔≡∂±♠↑∂ ∂± ↓↑≡≡…≥″↓←∂〉 ∏ ⇐≥∂± √±♥≡←↔〉 ∑〉 ≈°∂∑ 〉ñ 
∏⇐√〉
 〉 ⊄♠∞…♠ ⊕⇑⌠ ⇒←∂…∂°÷≥♠ ∨⌠ ⊂♠±♠≥ ⌠ ∠∞≡± ⇑⌠ ⇒↑∂×± ⋅⌠ °… 〉 ⇐∂↑…♠≥↔∂±÷ 
≡±≈°↔•≡≥∂≥ …≡≥≥ ±♠″≡↑ ±≈ ″↑×≡↑← °≠ ≡±≈°↔•≡≥∂≥ ≈ƒ←≠♠±…↔∂°± ∂± ↓↑≡♥∂∫
°♠←≥ƒ ↓↑≡≡…≥″↓↔∂… ♦°″≡±〉 ⇒″ ∏ ∠←↔≡↔ ¬ƒ±≡…°≥〉 ∑〉≡〉
≡〉 ≈°∂∑ 〉ñ∝〉∝°÷〉〉〉〉
 〉 ⇔″↓ ∏⌠ ¬∂♥≡↑↔∞ ⌠ ⊂≡″∂÷↑± ⌠ ≡↔ ≥ √∉⇒⇐ √±♥≡←↔∂÷↔°↑←〉 ⊆≡≥♣∂±∫ 
±≈ ←°≥♠≥≡ ∧≥↔ ≥≡♥≡≥← ∂± ↓≡↑∂↓↑↔♠″ …↑≈∂°″ƒ°↓↔•ƒ∑ ↑≡←♠≥↔← °≠ ↔•≡ ″♠≥∫
↔∂…≡±↔≡↑ √∉⇒⇐ ←↔♠≈ƒ〉 ∏⇒⇐⇐ ⋅≡↑↔ ∧∂≥〉 ∑〉 ≈°∂∑ 〉ñ∝〉
∝…•≠〉〉〉〉
 〉 ∠±°♠≡ ⌠ ⊇≡″♠↑ ⊂⌠ ⊄×≡≈ ∅⌠ ≡↔ ≥〉 ⊇←≡≠♠≥±≡←← °≠ ←°≥♠≥≡ ∧″←∫≥∂×≡ ↔ƒ↑°∫
←∂±≡ ×∂±←≡∫ ←  ∂°″↑×≡↑ °≠ …♠↔≡ ←≡♥≡↑≡ •≡↑↔ ≠∂≥♠↑≡ ∂± ↓↔∂≡±↔← ♦∂↔• 
…♠↔≡ ″ƒ°…↑≈∂≥ ∂±≠↑…↔∂°±〉 ⇒″ ∏ ⇐↑≈∂°≥〉 ∑〉 ≈°∂∑ 
〉ñ∝〉″∝…↑≈〉〉〉〉
 〉 ⊆•≡≡ ∏←⌠ ∅°♠±÷ ⇑⇐⌠ ⊆± ⊂〉 ⇒±÷∂°÷≡±∂… ≠…↔°↑← ±≈ ↑≡±≥ ≈∂←≡←≡ ∂± 
↓↑≡÷±±…ƒ〉 ⇐←≡ ⊆≡↓ ∠←↔≡↔ ¬ƒ±≡…°≥〉 ∑〉 ≈°∂∑ 〉ñ 
ñ〉
 〉 ∪♠ ∉⌠ ⋅↔•↔•°↔♠♦ ⊆⌠ ♦°× ⇐⊂⌠ ⇑♠ ⇒⌠ °↔↑°±∂← ⊆⇒⌠ ⊆♠←•↔°± 
⇐⌠ ⊕″± ⇒⌠ ∧↑ƒ≡↑ ⇒⇒⌠ ≈″ ⊇⌠ ⇐•≡♦∫¬↑•″ ⇐⇒⌠ ″← ⇒〉 
∉↑≡≡…≥″↓←∂ ±≈ ≠♠↔♠↑≡ …↑≈∂°♥←…♠≥↑ •≡≥↔•∑  ←ƒ←↔≡″↔∂… ↑≡♥∂≡♦ ±≈ 
″≡↔∫±≥ƒ←∂←〉 ⇐∂↑… ⇐↑≈∂°♥←… ∈♠≥ ∠♠↔…°″≡←〉 ∑≡〉 ≈°∂∑ 
〉ñ⇐√⊆⇐∠⊇⊄⇐∠∨⊂〉〉〉
 〉 ⊂••♠≥ ⊂⌠ ≡≈♥≡≈°≠←×ƒ ⇔⌠ ∪≡±÷≡↑ ∏⇑⌠ ∇∂∞″♠≈≈∂± ∏⌠ ⇑↑°♦± ⊂⌠ 
⇑∝↑…•↑ƒ ⊂⌠ ⊂≥•♠≈≈∂± ⊂⌠ ⊄•≈•±∂ ⊆⌠ ♠≡≥≥≡↑ ⇒⌠ ⊄♠±÷ ⇒⌠ ±÷ 
⊆⌠ ⇒↑±ƒ ⊕⌠ ⊄≥″°↑ ⇔⌠ ↑♠″±…•∂ ⊂⇒⌠ ⊆± ⊂〉 ⇐∂↑…♠≥↔∂±÷ ±↔∂±∫
÷∂°÷≡±∂… ≠…↔°↑← ±≈ ″ƒ°…↑≈∂≥ ≈ƒ←≠♠±…↔∂°± ∂± •ƒ↓≡↑↔≡±←∂♥≡ ≈∂←°↑∫
≈≡↑← °≠ ↓↑≡÷±±…ƒ〉 ⋅ƒ↓≡↑↔≡±←∂°±〉 ∑〉 ≈°∂∑ 〉ñ
⋅∅∉∨⊆⊄∨∇⊂√∠∇⇒⋅⇒〉〉〉
〉 ⊄•≈•±∂ ⊆〉 √±…•∂±÷ ↔°♦↑≈←  ↔↑÷≡↔≡≈ ↔•≡↑↓ƒ ≠°↑ ↓↑≡≡…≥″↓←∂〉 
⋅ƒ↓≡↑↔≡±←∂°±〉 ∑〉 ≈°∂∑ 〉ñ⋅∅∉∨⊆⊄∨∇⊂√∠∇⇒⋅⇒〉 
〉〉
 〉 ƒ±↑≈ ⊂∨⌠ ↑♠″±…•∂ ⊂⇒〉 ⇒±÷∂°÷≡±∂… ≠…↔°↑← ±≈ ↓↑≡≡…≥″↓∫
←∂〉 ⊂≡″∂± ∇≡↓•↑°≥〉 ∑〉 ≈°∂∑ 〉ñ∝〉←≡″±≡↓•↑°≥〉〉 
〉〉
 〉 ⇐•↑∂←↔∂±÷≡↑ ⋅∪⌠ ∧♠• ¬⌠ ≈≡ ⊃°← ⇒⌠ ∪∂≡←″±± ⇐〉 ⊄•≡ …↑ƒ←↔≥ ←↔↑♠…↔♠↑≡ 
°≠ ↓≥…≡±↔≥ ÷↑°♦↔• ≠…↔°↑ ∂± …°″↓≥≡♣ ♦∂↔• ≈°″∂±  °≠ ♥←…♠≥↑ ≡±≈°↔•≡∫
≥∂≥ ÷↑°♦↔• ≠…↔°↑ ↑≡…≡↓↔°↑∫〉 ∏ ⇑∂°≥ ⇐•≡″〉 ∑〉 ≈°∂∑ 
〉ñ∝…〉〉






°××∂ ≡↔ ≥  ∧⊄ √← ⇒←←°…∂↔≡≈ ∪∂↔• ∉↑≡≡…≥″↓←∂  
 〉 ⊂↔≡↓±∂± ⇒⌠ ⇒≥…0← ⇒⌠ ≈≡ ∉↑°←↔ ⇔⌠ ⊄←↔←↑∂← ⊃⌠ ⇔↑≡ƒ≠♠← ⌠ ⊄↑≡≥♠ƒ≡↑ ∏⌠ 
≡↔♦≡≡± ↔♦° …°″″°± ←∂±÷≥≡ ±♠…≥≡°↔∂≈≡ ↓°≥ƒ″°↑↓•∂←″← ∂± ⇐∠⊆√∇ ÷≡±≡ 
±≈ ↓↑≡≡…≥″↓←∂ ∂± ⇐♠…←∂± ♦°″≡±〉 ∉°⊂ ∠±≡〉 ∑≡〉 ≈°∂∑ 
〉ñ∝°♠↑±≥〉↓°±≡〉〉
 〉 ⊆°↔≡± ⊄⌠ ∏°•±←°± ∉⌠ ∧°↑←″° ⊂⌠ ∧∂↔∞↓↔↑∂…× ∨⌠ ⇔ƒ≡↑ ⊄⇔⌠ ⇑↑≡±±≡…×≡ ⊂∉⌠ 
⇑≥±÷≡↑° ∏⌠ °←≡← ∨⌠ ⇒♠←↔÷♠≥≡± ⊆〉 ⇒←←°…∂↔∂°± ≡↔♦≡≡± ↔•≡ …±≈∂≈↔≡ 
←♠←…≡↓↔∂∂≥∂↔ƒ ÷≡±≡ ⇒⇐⊃⊆⇒ °± …•↑°″°←°″≡ → ±≈ ↓↑≡∫≡…≥″↓←∂ ∂± 
 ≥↑÷≡ ∇°↑♦≡÷∂± ↓°↓♠≥↔∂°±∫←≡≈ ←↔♠≈ƒ ↔•≡ ⋅⊇∇⊄ ←↔♠≈ƒ〉 ∨♠↑ ∏ ⋅♠″ 
¬≡±≡↔〉 ∑〉 ≈°∂∑ 〉ñ≡∝•÷〉〉〉
 〉 ♠±∂∞ ⌠ ♠∂∞°± ⊆⌠ ∉≥≡∂ ⇒⇐⌠ ……•∂±∂ ⊆⌠ ⇔♠↑↔≡ ¬⌠ ⇐♥≥≥∂ ⊆⇐⌠ 
⊄±♠←∫⊂±↔°← ∏∨⌠ ⊂±≈↑∂″ ⊃⇐〉 ≡∇∠⊂ ↔÷ ⊂∇∉ •↓≥°↔ƒ↓≡← ∂± •ƒ↓≡↑↔≡±←∂♥≡ 
≈∂←°↑≈≡↑← °≠ ↓↑≡÷±±…ƒ〉 ⇔∇⇒ ⇐≡≥≥ ⇑∂°≥〉 ∑〉 ≈°∂∑ 〉ñ
≈±〉〉〉
 〉 ∈≈≈°♠↑• ⊆⋅⌠ ÷≈°♠≈ ⌠ ⊂≥≈±• ∧⌠ •″°°≈ ∇⌠ ♠←↔≠ 
∧∨⌠ •∝°♠ ⊄⌠ ⇒≥″♦∂ ∪∅〉 √∫ ÷≡±≡ ↓↑°″°↔≡↑ ±≈ ∂±↔↑°± ↓°≥ƒ∫
″°↑↓•∂←″← ±≈ …•±÷≡← ∂± √∫ ←≡…↑≡↔∂°± ∂± ♦°″≡± ♦∂↔• ∂≈∂°↓↔•∂… 
↑≡…♠↑↑≡±↔ ″∂←…↑↑∂÷≡〉 ⋅♠″ ⊆≡↓↑°≈〉 ∑〉 ≈°∂∑ 〉ñ
•♠″↑≡↓ñ≈≡♠〉
 〉 ⊆≡≈″± ⇐∪⌠ ⊂↑÷≡±↔ √〉 √″″♠±°≥°÷ƒ °≠ ↓↑≡∫≡…≥″↓←∂〉 ⇒″ ∏ ⊆≡↓↑°≈ 
√″″♠±°≥〉 ∑〉 ≈°∂∑ 〉ñ∝〉∫〉〉〉♣〉
 〉 ⊄↑≡″≡≥≥≡± ∉〉 ⊂≡″∂±≥ ↓↑∂″∂±÷ ≠°↑ ↓↑°∫
↔≡…↔∂°± ≠↑°″ ↓↑≡∫≡…≥″↓←∂∫ ♠±∂≠ƒ∂±÷ •ƒ↓°↔•≡←∂←〉 ∏ ⊆≡↓↑°≈ √″″♠±°≥〉 
∑〉
∪•↔ √← ∇≡♦◊
∪≡ •♥≡ ≡←↔≥∂←•≡≈  ÷≡±≡↔∂… ←←°…∂↔∂°± ≡↔♦≡≡± ↓↑≡≡…≥″↓↔∂… 
″°↔•≡↑← ±≈ ↔•≡ ∧⊄ ∧″← ↑≡≥↔≡≈ ↔ƒ↑°←∂±≡ ×∂±←≡  ÷≡±≡〉
⊄•≡ ←″≡ ♥↑∂±↔← ″ƒ ≥←° ↓↑°↔≡…↔ ∧∂±±∂←• ♦°″≡± ≠↑°″ •≡↑↔ ≠∂≥♠↑≡ 
∂± ≥↔≡↑ ≥∂≠≡〉
∪•↔ √← ⊆≡≥≡♥±↔◊
∉↑≡≡…≥″↓←∂ ∂←  …°″″°± •ƒ↓≡↑↔≡±←∂♥≡ ≈∂←°↑≈≡↑ °≠ ↔•≡ ↓↑≡÷±±…ƒ〉
∧⊄⌠  ×±°♦± …±≈∂≈↔≡ ÷≡±≡⌠ 
°↓≡±← ± °↓↓°↑↔♠±∂↔ƒ ≠°↑ ≈↑♠÷ ≈≡♥≡≥°↓″≡±↔ ↔° ↔↑÷≡↔ ↔•≡ ♦°″≡± ″°←↔ 
↔ ↑∂←× °≠ ↔•≡ ≈∂←≡←≡〉
⊂♠″″↑ƒ
¬≡±≡↔∂… ♥↑∂±↔← ♦∂↔•∂± ↔•≡ ″↔≡↑±≥ ∧⊄ ↓↑°↔≡…↔ ∧∂±±∂←• ♦°″≡± 
≠↑°″ ↓↑≡≡…≥″↓←∂〉







∂♥∂±≡±⌠ ⇒±±≡≥∂ ∉°♠↔⌠ ∏±≡ ∨〉 ⊂≥″°±⌠ ⊂≡↓↓° ≡↑∂⌠ ↑× ⇔≥ƒ⌠ ∏°•± ∉〉 ⇒↔×∂±←°± ±≈ ⋅±±≡≥≡
∉♥° ⋅;↓↓)≥;⌠ ∂↑←∂ ⇒♠↑°⌠ ↑×♠← ∉≡↑°≥⌠ ⊂≡↓↓° ⋅≡∂±°±≡±⌠ ∨≡↑° ∝±↔∂≡⌠ ∏♠• ≡↑≡⌠ ↔∝ 
⇒〉 √±×≡↑∂ °××∂⌠ ∨″″ ⇔≥ƒ⌠ ∂…•≡≥ ⊄↑∂≡♦←←≡↑⌠ ∂↔∝ √〉 ♠↑×∂⌠ ∨≥∂←• ⇔〉∠〉 ⊆°≡↑←°±⌠
 ¬≡±≡ ∂± ↔•≡ ∧∂±±∂←• ∉°↓♠≥↔∂°±
∉↑°↔≡…↔∂♥≡ °♦∫∧↑≡→♠≡±…ƒ ⊃↑∂±↔← ≠°↑ ∉↑≡≡…≥″↓←∂ ∂± ↔•≡ ∧″← ⊆≡≥↔≡≈ ⊄ƒ↑°←∂±≡ ∂±←≡
∉↑∂±↔ √⊂⊂∇∑ ∫∩〉 ∠±≥∂±≡ √⊂⊂∇∑ ∫ 
⇐°↓ƒ↑∂÷•↔ ϖ  ⇒″≡↑∂…± ⋅≡↑↔ ⇒←←°…∂↔∂°±⌠ √±…〉 ⇒≥≥ ↑∂÷•↔← ↑≡←≡↑♥≡≈〉
∂← ↓♠≥∂←•≡≈ ƒ ↔•≡ ⇒″≡↑∂…± ⋅≡↑↔ ⇒←←°…∂↔∂°±⌠  ¬↑≡≡±♥∂≥≥≡ ⇒♥≡±♠≡⌠ ⇔≥≥←⌠ ⊄∩ ⋅ƒ↓≡↑↔≡±←∂°±
≈°∂∑ 〉ñ⋅∅∉∨⊆⊄∨∇⊂√∠∇⇒⋅⇒〉〉
∑∫ °↑∂÷∂±≥≥ƒ ↓♠≥∂←•≡≈ °±≥∂±≡ ∏♠±≡ ⌠ ⋅ƒ↓≡↑↔≡±←∂°±〉
•↔↔↓∑ññ•ƒ↓≡↑〉•∝°♠↑±≥←〉°↑÷ñ…°±↔≡±↔ñññ
∪°↑≥≈ ∪∂≈≡ ∪≡ ↔∑ 
⊄•≡ °±≥∂±≡ ♥≡↑←∂°± °≠ ↔•∂← ↑↔∂…≥≡⌠ ≥°±÷ ♦∂↔• ♠↓≈↔≡≈ ∂±≠°↑″↔∂°± ±≈ ←≡↑♥∂…≡←⌠ ∂← ≥°…↔≡≈ °± ↔•≡
•↔↔↓∑ññ•ƒ↓≡↑〉•∝°♠↑±≥←〉°↑÷ñ…°±↔≡±↔ñ←♠↓↓≥ññññ⋅∅∉∨⊆⊄∨∇⊂√∠∇⇒⋅⇒〉〉〉⇔⇐
⇔↔ ⊂♠↓↓≥≡″≡±↔ ♠±≡≈∂↔≡≈ ↔∑

•↔↔↓∑ññ•ƒ↓≡↑〉•∝°♠↑±≥←〉°↑÷ññ←♠←…↑∂↓↔∂°±←ñ
∂← °±≥∂±≡ ↔∑ ⋅ƒ↓≡↑↔≡±←∂°± √±≠°↑″↔∂°± °♠↔ ←♠←…↑∂∂±÷ ↔° ⊂♠←…↑∂↓↔∂°±←∑

•↔↔↓∑ññ♦♦♦〉≥♦♦〉…°″ñ↑≡↓↑∂±↔←
 √±≠°↑″↔∂°± °♠↔ ↑≡↓↑∂±↔← …± ≡ ≠°♠±≈ °±≥∂±≡ ↔∑ ⊆≡↓↑∂±↔←∑

≈°…♠″≡±↔〉∉≡↑″∂←←∂°±← ±≈ ⊆∂÷•↔← ∈♠≡←↔∂°± ±≈ ⇒±←♦≡↑ ↔•∂← ↓↑°…≡←← ∂← ♥∂≥≥≡ ∂± ↔•≡
…≥∂…× ⊆≡→♠≡←↔ ∉≡↑″∂←←∂°±← ∂± ↔•≡ ″∂≈≈≥≡ …°≥♠″± °≠ ↔•≡ ∪≡ ↓÷≡ ♠±≈≡↑ ⊂≡↑♥∂…≡←〉 ∧♠↑↔•≡↑ ∂±≠°↑″↔∂°± °♠↔
∠≠≠∂…≡〉 ∠±…≡ ↔•≡ °±≥∂±≡ ♥≡↑←∂°± °≠ ↔•≡ ↓♠≥∂←•≡≈ ↑↔∂…≥≡ ≠°↑ ♦•∂…• ↓≡↑″∂←←∂°± ∂← ≡∂±÷ ↑≡→♠≡←↔≡≈ ∂← ≥°…↔≡≈⌠ 
 …± ≡ °↔∂±≡≈ ♥∂ ⊆∂÷•↔←∂±×⌠  ←≡↑♥∂…≡ °≠ ↔•≡ ⇐°↓ƒ↑∂÷•↔ ⇐≥≡↑±…≡ ⇐≡±↔≡↑⌠ ±°↔ ↔•≡ ∨≈∂↔°↑∂≥⋅ƒ↓≡↑↔≡±←∂°±∂±
 ⊆≡→♠≡←↔← ≠°↑ ↓≡↑″∂←←∂°±← ↔° ↑≡↓↑°≈♠…≡ ≠∂÷♠↑≡←⌠ ↔≥≡←⌠ °↑ ↓°↑↔∂°±← °≠ ↑↔∂…≥≡← °↑∂÷∂±≥≥ƒ ↓♠≥∂←•≡≈∉≡↑″∂←←∂°±←∑










∉⊆∠⊄∨⇐⊄√⊃∨ ∠∪ ∧⊆∨∈⊇∨∇⇐∅ ⊃⇒⊆√⇒∇⊄⊂ ∧∠⊆ ∉⊆∨∨⇐⇒∉⊂√⇒ √∇ ⊄⋅∨ ∧⊄ 
¬∨∇∨ √∇ ⊄⋅∨ ∧√∇∇√⊂⋅ ∉∠∉⊇⇒⊄√∠∇ 
∠±≥∂±≡ ←♠↓↓≥≡″≡±↔ 
⇒〉 √±×≡↑∂ °××∂⌠⌠⌠ ∨″″ ⇔≥ƒ⌠ ∂…•≡≥ ⊄↑∂≡♦←←≡↑⌠ ∂↔∝ √〉 ♠↑×∂⌠⌠⌠ ∨≥∂←• ⇔〉∠〉 
⊆°≡↑←°±⌠⌠ ∉♥° ⋅;↓↓)≥;⌠ ∂↑←∂ ⇒♠↑°⌠⌠⌠ ↑×♠← ∉≡↑°≥⌠⌠⌠ ⊂≡↓↓° ⋅≡∂±°±≡±⌠ ∨≡↑° 
∝±↔∂≡⌠⌠⌠ ∏♠• ≡↑≡⌠⌠⌠⌠ ↔∝ ∂♥∂±≡±⌠ ⇒±±≡≥∂ ∉°♠↔⌠⌠ ∏±≡ ∨〉 ⊂≥″°±⌠ 
⊂≡↓↓° ≡↑∂⌠⌠ ↑× ⇔≥ƒ⌠⌠ ∏°•± ∉〉 ⇒↔×∂±←°±⌠ ±≈ ⋅±±≡≥≡ ∂♥♠°↑∂⌠⌠  
√″″♠±°∂°≥°÷ƒ⌠ ⊆≡←≡↑…• ∉↑°÷↑″← ⊇±∂↔⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈ 
≡≈∂…≥ ±≈ ⇐≥∂±∂…≥ ¬≡±≡↔∂…←⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂ ±≈ ⋅≡≥←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥⌠ 
∧∂±≥±≈  
⇑…↔≡↑∂°≥°÷ƒ ±≈ √″″♠±°≥°÷ƒ⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂ ±≈ ⋅≡≥←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥⌠ 
∧∂±≥±≈ 
⊂↔±≥≡ƒ ⇐≡±↔≡↑ ≠°↑ ∉←ƒ…•∂↔↑∂… ⊆≡←≡↑…•⌠ ⇑↑°≈ √±←↔∂↔♠↔≡ °≠ √⊄ ±≈ ⋅↑♥↑≈⌠ ⊇⊂⇒〉 
∪←•∂±÷↔°± ⊇±∂♥≡↑←∂↔ƒ ⊂…•°°≥ °≠ ≡≈∂…∂±≡⌠ ⇔≡↓↑↔″≡±↔ °≠ ≡≈∂…∂±≡⌠ ⇔∂♥∂←∂°± °≠ 
⊆•≡♠″↔°≥°÷ƒ⌠ ⊇⊂⇒ 
∇≡♠↑°←♠↑÷≡↑ƒ °≠ ∇≡♠↑°⇐≡±↔≡↑⌠ ♠°↓∂° ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥⌠ ∧∂±≥±≈  
∉←ƒ…•∂↔↑∂… ±≈ ∇≡♠↑°≈≡♥≡≥°↓″≡±↔≥ ¬≡±≡↔∂…← ⊇±∂↔⌠ ←←…•♠←≡↔↔← ¬≡±≡↑≥ ⋅°←↓∂↔≥ ±≈ 
⋅↑♥↑≈ ≡≈∂…≥ ⊂…•°°≥⌠ ⊇⊂⇒ 
∪←•∂±÷↔°± ⊇±∂♥≡↑←∂↔ƒ ⊂…•°°≥ °≠ ≡≈∂…∂±≡⌠ ⇔≡↓↑↔″≡±↔ °≠ ¬≡±≡↔∂…←⌠ ⊂↔〉〉°♠∂←⌠ ⊇⊂⇒ 
√±←↔∂↔♠↔≡ ≠°↑ °≥≡…♠≥↑ ≡≈∂…∂±≡ ∧∂±≥±≈⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈ 
 ⊇±∂↔ °≠ ¬≡±≡↔∂…← ±≈ ⇑∂°″↑×≡↑←⌠ ∇↔∂°±≥ √±←↔∂↔♠↔≡ ≠°↑ ⋅≡≥↔• ±≈ ∪≡≥≠↑≡⌠ ∧∂±≥±≈ 
∠←↔≡↔↑∂…← ±≈ ¬ƒ±≡…°≥°÷ƒ⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂ ±≈ ±≈ ⋅≡≥←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥⌠ 
∧∂±≥±≈ 
⇔≡↓↑↔″≡±↔ °≠ ⋅≡≥↔•⌠ ∇↔∂°±≥ √±←↔∂↔♠↔≡ ≠°↑ ⋅≡≥↔• ±≈ ∪≡≥≠↑≡⌠ ∧∂±≥±≈ 
⊄•≡ ∨←↔°±∂± ¬≡±°″≡ ⇐≡±↔≡↑⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⊄↑↔♠⌠ ∨←↔°±∂〉 
⇐•↑°±∂… ⇔∂←≡←≡ ∉↑≡♥≡±↔∂°± ⊇±∂↔⌠ ⇔≡↓↑↔″≡±↔ °≠ ⋅≡≥↔•⌠ ∇↔∂°±≥ √±←↔∂↔♠↔≡ ≠°↑ ⋅≡≥↔• ±≈ 
∪≡≥≠↑≡⌠ ∧∂±≥±≈ 
 ±≈ ⋅≡≥←∂±×∂ ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥⌠ ⋅⊇⊂⌠ 
∧∂±≥±≈ 
∉∨⇔∨¬∠ ⊆≡←≡↑…• ⊇±∂↔⌠ ⊆⇐ ∠♠≥♠⌠ ∠♠≥♠ ⊇±∂♥≡↑←∂↔ƒ ⋅°←↓∂↔≥ ±≈ ⊇±∂♥≡↑←∂↔ƒ °≠ ∠♠≥♠⌠ 
∠♠≥♠⌠ ∧∂±≥±≈ 
°≥≡…♠≥↑ ∇≡♠↑°≥°÷ƒ ⊆≡←≡↑…• ∉↑°÷↑″⌠ ⊆≡←≡↑…• ∉↑°÷↑″← ⊇±∂↔⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ 
∧∂±≥±≈ 
∧°≥×•;≥←± √±←↔∂↔♠↔≡ °≠ ¬≡±≡↔∂…←⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈ 
⇔≡↓↑↔″≡±↔ °≠ ⇑∂°←…∂≡±…≡← ±≈ ∇♠↔↑∂↔∂°±⌠ ↑°≥∂±←× √±←↔∂↔♠↔≡↔⌠ ⊂♦≡≈≡±〉 
  
⇔∂♥∂←∂°± °≠ ⇐↑≈∂°♥←…♠≥↑ ≡≈∂…∂±≡⌠ ⊇±∂♥≡↑←∂↔ƒ °≠ ⇐″↑∂≈÷≡⌠ ⊇  
⇔≡↓↑↔″≡±↔ °≠ ¬°♥≡↑±″≡±↔ ⊂≡↑♥∂…≡←⌠ ∇↔∂°±≥ √±←↔∂↔♠↔≡ ≠°↑ ⋅≡≥↔• ±≈ ∪≡≥≠↑≡⌠ ⋅≡≥←∂±×∂⌠ 
∧∂±≥±≈ 
⇔≡↓↑↔″≡±↔ °≠ ≡≈∂…∂±≡⌠ ⋅°←↓∂↔≥ ≠°↑ ⊂↓≡…∂≥ ⊂♠↑÷≡↑ƒ∫∪≡∂≥≥ ⇐°↑±≡≥≥ ≡≈∂…∂±≡⌠ ⊇⊂⇒ 







⇐°↑↑≡←↓°±≈∂±÷ ♠↔•°↑∑  
⇒〉 √±×≡↑∂ °××∂⌠ ⇑⊂…⌠ ⊂…  °↑ 
⇔≡↓↑↔″≡±↔ °≠ ≡≈∂…≥ ±≈ ⇐≥∂±∂…≥ 
¬≡±≡↔∂…← 
∉〉∠〉 ⇑°♣  ⋅↑↔″±∂±×↔♠  
∧√∫ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈ 
↔≡≥〉     
≠♣〉   
∂±×≡↑∂〉≥°××∂⇓•≡≥←∂±×∂〉≠∂ 
 
⋅±±≡≥≡ ∂♥♠°↑∂⌠ ⇔⌠ ∉•⇔⌠ ⇒≈∝ ∉↑°≠〉 
⇔≡↓↑↔″≡±↔ °≠ ≡≈∂…≥ ±≈ ⇐≥∂±∂…≥ 
¬≡±≡↔∂…←⌠ 
∉〉∠〉 ⇑°♣  ⋅↑↔″±∂±×↔♠   
∧√∫ ⊇±∂♥≡↑←∂↔ƒ °≠ ⋅≡≥←∂±×∂⌠ ∧∂±≥±≈     
↔≡≥〉    















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































⊄≥≡ ⊂〉 ⊄•≡ …±≈∂≈↔≡ ÷≡±≡← ±≈ ∂±↔↑°±∂… °↑ ±≡↑∫÷≡±≡ ≥°…∂  
⇐±≈∂≈↔≡ ÷≡±≡← 
           ⇐±≈∂≈↔≡ ≥°…∂ 
¬≡±≡ ⊂∇∉ 
⇒⇐∨ ⇒¬⊄⊆ ∨⊆⇒∉ ∏⇒¬ ⊆∠⇐ ⇒¬⊄ ↑←    
⇒⇐⊃⊆ ⇒¬⊄⊆ ∨⊂⊆⊆¬ ⇔⊆ ⊂∠⇔ ⇒¬⊄ ↑←                  
⇒⇐⊃⊆⇑ ⇒∇¬∉⊄ ∧⇒ √⇒⇒ ⊂∠⇔ ⇒¬⊄⊆ ↑←                  
⇒⇐⊃⊆⇐ ⇒∇¬∉⊄ ∧⊄ √⇒⇒ ⊂⊄∠∩ ⇒∉∠∨ ↑←   
⇒⇐⊃⊆⇒ ⇒∇¬∉⊄ ∧⊄ ⇐⊄ ⊂⊄∠∩ ⇐⊄⇒ ↑←                  
⇒⇐⊃⊆⇑ ⇒∇¬∉⊄ ∧∇ √∉⇒ ⊂∪⇒∉ ∨⊂⊆⊆¬ ↑← 
⇒⇐⊃⊆ ⇒∇⊄∩⊆ ¬∉⊆ ⇐⇔ ⊄¬∧⇑ √∧⊄⇔ ↑← 
⇒⇔⇒ ⇐≈×±… ⋅∨∅ ∉ ⊄¬∧⇑ √ ↑←                 
⇒⇔⇒ ⇐∠⇔ ⋅∨∅ ⊆⊆∧√∉ ⊄¬∧⇑ √⇒⇒ ↑← 
⇒⇔⇒ ⇐∠⊄ √∧⊄⇔ ⇒¬√ ⊄¬∧⇑⊆ ⇐⇔ ↑← 
⇒⇔⇒ ⇐∠⊆√∇ √ ∨ ⊄¬∧⇑⊆ ∉ ↑←                 
⇒⇔⇒ ⇐⊄⇒ √∇⋅⇒ ∇∠⇔⇒ ⊄¬∧⇑⊆⇒∉ ∉ ↑←    
⇒⇔⇒ ⇔∨∧ √∇⋅⇑⇒ ∇∠⊂ ⊄√∨ ±≡↑ √∫ ↑← 
⇒⇔⇒ ⇔¬∨ √∇⋅⇑⇑ ∇∠⊄⇐⋅ ⊄√∨ ±≡↑ √∫ ↑← 
⇒⇔⇒ ∨⇔∇ √∇⋅⇑⇐ ∉⇔¬∧⇔ ⊄∇∧ ∇∠⊂ ↑←                 
⇒⇔⇒⊄⊂ ∨⇔∇ √∇⋅⇑∨ ∉⇔∩⇔⇐ ⊃∨¬∧⇒ ∇∠⊂ ↑←                 
⇒⇔ ∨⋅⇔ √∉ ∉¬∧ ⊃∨¬∧⇑ ∇∠⊂ ↑←  
⇒⇔ ∨⋅⇔ √⊄¬⇒ ∉⊂¬ ⊃∨¬∧⇐ ⊃∨¬∧⇒ ↑← 
⇒¬⊄ ∨∇¬ √⊄¬⇑ ⊆∠⇐ 
 
  
 
 
